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I Abstract 
The number of children globally who develop drug-resistant tuberculosis is unclear, in part due 
to diagnostic challenges and limited resistance testing, and in part because recording and 
reporting is not comprehensive . Large numbers of children, however, are exposed to drug-
resistant bacilli each year and it is clear that the very young and those immune-compromised 
are vulnerable to developing disease. 
Few studies have looked at the progression from exposure to infection or from infection to 
disease in the child contacts of adu lts with drug-resistant tuberculosis. It is uncertain which 
factors influence this progression and also whether any interventions can prevent it. Finally, 
few studies have analysed the presentation, treatment and outcome of children with disease. 
This thesis starts by reviewing what is published regarding drug-resistant tuberculosis in 
children. This includes systematic reviews of the management of children exposed to drug-
resistant tuberculosis as well as the management of those with multidrug-resistant 
tuberculosis disease. It reviews what is known regarding the second-line tuberculosis drugs in 
children and then clarifies the definitions that are used throughout the rest of the work. 
The thesis then systematically examines each of the stages from infection to disease with a 
series of inter-related studies. The first study attempts to quantify the burden of drug-
resistance in the context that the work is carried out. The following study investigates the risk 
factors for infection and prevalent disease in children exposed to a multidrug-resistant 
tuberculosis source case. This is followed by two studies which explore the transmission of 
drug-resistant bacilli from adults to children. The identification and referral patterns and 
obstacles to referral for exposed children are examined through operational studies that 
include qualitative and quantitative components. A descriptive cohort study assesses the 
toxicity and efficacy of a standardised preventive treatment regimen given to child contacts. 
The final part of the thesis includes a series of studies to investigate the treatment of drug-
resistant tuberculosis disease in children and the adverse effects of the second-line 
medications. 
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I Introduction 
The burden of drug-resistant tuberculosis infection and disease in children 
Determining the global burden of tuberculosis (TB) is difficult as reporting is inconsistent and 
tests for infection and disease are imperfect. Traditional estimates suggest that a third of the 
world population may be infected with TB1 and that each year nine million people develop the 
disease, with an estimated 1.7 million dying from it. 2-3 Challenges in determining the scale of 
the paediatric TB epidemic are compounded as the diagnosis of Mycobacterium tuberculosis 
infection and disease in children is even more problematic than in adults . The tuberculin skin 
test (TST) and commercial interferon gamma release assays (IGRAs) have limited sensitivity 
and specificity to detect M. tuberculosis infection in children4 and due to the paucibacillary 
nature of paediatric TB, together with difficulties in obtaining clinical samples, 
microbiologically confirmed TB disease is typically obtained in less than 30% of children with 
radiological/clinical evidence of intra-thoracic pathology.s The diagnosis of TB relies on a 
constellation of history, examination, immunology, radiology and bacteriology, all with limited 
sensitivity and specificity.6 As even children with culture-confirmed TB are frequently not 
recorded and reported in TB registers/ the total number of children reported with TB is likely 
an under-estimate of the actual burden . 
Drug-resistant (DR) TB presents a challenge to international public health. It is a man-made 
problem arising through ineffective treatment regimens and failures of health programming.s 
DR-TB is defined as M. tuberculosis resistant to any first-line TB medication but once the bacilli 
are resistant to rifampicin and isoniazid, they are said to be multidrug-resistant (MDR).9-10 
ExtenSively drug-resistant (XDR) TB is caused by bacilli that are, in addition, resistant to a 
fluoroquinolone and an injectable second-line TB medication.1l-12 The World Health 
Organization (WHO) estimates 650,000 prevalent cases of MDR-TB each year13 and cases have 
now been seen in most countries in the world;14 in some areas of Eastern Europe and Central 
Asia multidrug resistance is seen in more than 30% of all TB cases. Although in sub-Saharan 
Africa and Southern Asia the proportion is lower, the total number of cases is high due to high 
overall TB burden. South Africa has one of the highest incidences of TB in the world, with rates 
in the townships surrounding Cape Town exceeding 1,000 per 100,000.2 Over two percent of 
TB cases are MDR and this figure has risen in the last decade reflecting increasing drug 
resistance, increasing detection of drug resistance or a combination of the two. 2, 15 To diagnose 
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DR-TB either the bacilli must be demonstrated to grow in the presence of an antibiotic 
(phenotypic resistance) or to possess genetic mutations known to be associated with drug 
resistance (genotypic resistance). It is therefore not possible to diagnose DR-TB from sputum 
smear microscopy alone. In many regions of the world drug resistance testing is unavailable 
and DR-TB is therefore not diagnosed, reported or treated. 
As paediatric TB is under-reported and as DR-TB is challenging to determine, it is not a surprise 
that the number of reported cases of paediatric DR-TB is limited. Prior to the studies presented 
in this thesis, only two hundred children had been described with MDR-TB in the medical 
literature. As over half a million cases of MDR-TB are estimated to occur each year globally13 
and as children comprise up to 20% of the total TB burden in high TB incidence settings, 16-18 
the burden of children with DR-TB is significantly under-reported. 
Tuberculosis pathophysiology and immunology 
Following exposure to aerosolised M. tuberculosis some children will become infected. Once 
infection has occurred the adaptive immune system recognises the bacilli; it may clear the 
infection, fail to contain it or reach an equilibrium in which the immune system is unable to 
eradicate the infection but prevents it from progressing. For those with M. tuberculosis 
infection, a proportion will, at some pOint in the future, progress to TB disease.19 The risk for 
this is greatest in the first couple of years following infection20 and for young children, 90% of 
those progressing to disease do so in the first year.21 From data collected prior to the era of 
chemotherapy, it is clear that a proportion of children infected with M. tuberculosis will 
develop chest radiology changes that spontaneously resolve without treatment. However, 
throughout the thesis, TB disease is defined as either symptomatic illness or chest radiology 
changes consistent with TB. Children with M. tuberculosis infection, therefore, have no clinical 
symptoms or signs and radiology that is normal. Traditionally the only means of detecting M. 
tuberculosis infection was through a history of exposure and a positive TST such as the 
Mantoux or Tine test. The crude antigen mixture used, however, does not completely 
differentiate between Bacillus Calmette-Guerin (BCG), M. tuberculosis and environmental, 
non-tuberculous mycobacteria (NTM).22 It can take up to three months following infection for 
an individual to mount a response and the response is affected by human immunodeficiency 
virus (HIV) infection,23 malnutrition and other immunosuppressive states such as viral 
infections, steroid use or neoplastic disorders.20 Sensitivity and specificity are difficult to 
measure in the absence of a gold standard but when sensitivity is measured against confirmed 
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TB disease, results are variable. Newer tests, IGRAs, measure either the interferon-y released 
by T-cells or the number of T-cells which release interferon-v, after stimulation by M. 
tuberculosis-specific antigens such as early-secreted antigenic target 6-kDa protein (ESAT-6) 
culture filtrate protein 10 (CFP-10) or TB antigen TB7.7. Large numbers of studies have 
examined these in vitro tests and in some contexts they seem to show higher sensitivity in 
confirmed TB cases or against an exposure gradient.24 Specificity seems less affected by prior 
BCG vaccination or NTM exposure.25 IGRAs, like the TST, are unable to differentiate between 
M. tuberculosis infection and TB disease. The evidence base regarding the role of IGRAs in 
children is expanding26 but data from high-burden settings are limited, especially in HIV-
infected children.4 Few studies have included individuals exposed to MDR-TB.27 Meta-analyses 
of the existing data suggest that IGRAs currently offer little in addition to the TST for screening 
TB-exposed children, particularly in low resource settings.4 This is reflected in current 
international guidelines.2s-3o 
The epidemiology of drug-resistant tuberculosis in children 
The development ofTB requires exposure to M. tuberculosis, subsequent infection, and finally, 
progression to disease.31 The risk of moving from one state to the next is determined by 
multiple microbiological, immunological, social and cultural factors.31 In the absence of 
accurate tests of infection and disease, it is important to understand the epidemiology of each 
of the exposure, infection and disease stages, and risk factors determining progression 
between each stage. If these factors are identified, interventions can be targeted to those at 
the highest risk of progression to the next stage. As children serve as a sentinel marker of 
ongoing M. tuberculosis transmission and failing TB control, by identifying risk factors for 
infection and disease in children the broader epidemic can be better understood. 
Infection rather than just exposure is required for disease to develop. Exposed children with a 
positive TST are five times more likely to develop disease than those with a indeterminate or 
negative TST, suggesting that those with a positive TST were more likely to have been 
infected.32 This may also be the case for the IGRAs but so far there is little evidence to inform 
their predictive utility in children. Due to the limitations of these tests, as well as a time delay 
in hypersensitivity conversion, the results must be combined with a clinical assessment of the 
likelihood that infection has occurred. This will include an evaluation of the infectiousness of 
the source case as well as the risk of transmission. Although initial animal models implied that 
isoniazid-resistant mycobacteria were less infectious and pathogenic than drug-susceptible 
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organisms,33-34 studies in humans are less clear.21, 35-38 An association exists between certain 
strain types and drug resistance39 and different strains demonstrate different virulence 
patterns.40-41 The overall picture, however, remains uncertain. 
For drug-susceptible TB, patients with sputum microscopy smear-positive disease are between 
two and three times more likely to cause infection in contacts than those with sputum 
microscopy smear-negative disease,42-43 with higher bacterial loads more infectious.42, 44-45 
Although HIV-infected individuals with culture-confirmed TB are more often sputum smear-
negative than HIV-uninfected individuals,46 there is little evidence that they are less 
infectious.47-48 More extensive pulmonary disease, affecting multiple zones on a chest 
radiograph, is associated with increased infectiousness, independent of mycobacterialload.42, 
49-50 The implication, therefore, is that when assessing a contact it is vital to understand the 
extent of lung involvement in the source case. 
The risk of a contact becoming infected depends on the physical proximity of the source case 
to the contact, the daily extent of the interaction, environmental factors, as well as the 
duration of the exposure.51 First degree relatives are up to five times more likely to cause 
infection in the contact than more distant relatives,50 especially when the relative is female.45 
Those sleeping in the same room are up to three times more likely to infect contacts than 
those sleeping in different rooms,42,49-S0,S2-S4 with physical proximity of sleeping showing a 
graded response.49-50 The odds of infection in the contact is up to four times higher in families 
where smokers Iive,43,55 and is increased where rooms are crowded or where ventilation is 
poor.56 The length and frequency of cough of the source case has been shown to affect the risk 
of infection in the contact.S7 This is particularly relevant to MDR-TB as source cases have often 
been previously treated with ineffective first-line regimens and the diagnosis has been 
delayed, consequently increasing exposure time.s8-59 
From studies that examined the natural history of tuberculosis, conducted prior to the 
chemotherapy era, it is known that infected infants (i.e. <12 months) have a 50% life-time risk 
of progression to disease. Children from one to two years have a 20-30% risk, those from three 
to five a risk of 5%, those five to ten years only a 2% risk and adolescents an adult-like risk (5-
10%).60-61 Adults with HIV and TB infection have a 7-10% annual risk of developing TB,62 an 
effect modulated by combination antiretroviral therapy (cART) and immune status. Children 
with HIV are more than twenty times as likely to develop TB as those HIV-uninfected63 and 
children with malnutrition have been shown to be more vulnerable than those adequately 
nourished.43 
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The origin of infection in child contacts is dependent on background TB prevalence. A number 
of studies have demonstrated that TB contacts subsequently developing disease usually do so 
with the same strain as that of the identified source case. 21.37.64-65 Other studies, however, 
have shown that in high prevalence regions many contacts develop disease of a different strain 
to their identified source case implying infection from someone else within the community.66-69 
Older studies have shown that although household source cases are important, many children 
have evidence of infection without a known household source case.S3• 70 It is possible that in 
the same household there is more than one TB case, each with a different strain and it is also 
possible for a source case to be infected with mUltiple strains.71-72 In reality, in low prevalence 
regions the identified source case is likely to be the origin of the infection,73 whereas in high 
prevalence areas, a combination of household and community sources of infection is likely to 
occur.66 The nature of the interaction between the source case and the contact is also 
important and the more intense the interaction the more likely the strains will be concordant. 
Younger children are therefore more likely to be infected with the same strain as the known 
source case as opposed to older children who interact more with the community. When 
planning preventive treatment in the presence of mUltiple possible strains, however, a balance 
between the most likely and the most dangerous outcomes should be considered. 
The evolution of drug-resistance in M. tuberculosis strains 
At every division of M. tuberculosis there is a small probability of a genetic mutation arising 
that will confer resistance to a TB medication. Therefore, at anyone time, within a large 
untreated population of M. tuberculosis, mycobacteria will exist which possess such mutations. 
Monotherapy with only one drug will exert a selective advantage onto those strains, allowing 
them to prosper with drug-susceptible strains dying. Eventually, the entire population will 
possess that mutation and will be resistant to that medication. Isoniazid and rifampicin are the 
two most important medications used to treat M. tuberculosis and the rate of spontaneous 
mutation to create resistance to isoniazid is 1 in 106 cell divisions and rifampicin 1 in 108•74 The 
use of a multidrug regimen should ensure that those mutants resistant to one of the 
medications can be killed by one of the others in the regimen. A population of 1014 bacilli 
would be required to create the mathematical possibility of a mutation to both isoniazid and 
rifampicin. Even in cavitary TB, with high bacillary load, the number of organisms cannot reach 
this level. 
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Therefore, for resistance to develop to a multidrug regimen, monotherapy must be 
inadvertently given. This occurs when serum levels are sub-therapeutic, treatment is 
intermittent, chaotic or only some of the drugs in the regimen are taken. Resistance usually 
develops first to isoniazid as this medication is the most bactericidal and therefore causes the 
greatest selective advantage. In addition mutations to isoniazid occur more frequently than to 
rifampicin. This leads to isoniazid mono-resistant M. tuberculosis. If rifampicin is then given as 
monotherapy (or in combination with other medications given imperfectly) resistance to 
rifampicin will develop. Resistance to only rifampicin was rare prior to the HIV epidemic. 
However, and for reasons that are still not entirely clear, it is now see more frequently, 
especially in those HIV-infected. 
Drug resistance can be acquired as described above, through sequential, selective pressure in 
the face of inadequate therapy, where a previously drug-susceptible organism develops 
resistance within one human host. Alternatively, resistance can be transmitted where 
mycobacteria, already resistant, are transmitted to a new host. Additionally, a combination of 
the two can occur when one individual receives a mycobacterium already resistant to one or 
more medications and then in the face of inadequate treatment develops resistance to further 
antibiotics. It is unclear what proportion of drug resistance in tuberculosis is transmitted and 
what is acquired. Children usually have transmitted resistance as disease is normally 
paucibacillary, making acquired resistance less likely. 
The relationship between strain type, drug resistance and virulence is complex. One study has 
demonstrated a relationship between Beijing strain and both HIV infection and drug resistance 
in adults with tuberculous meningitis (TBM).75 However, another study found no association 
between strain type and either presentation or outcome in an investigation of children with 
TBM.76 Further investigations have demonstrated a relationship between strain type and 
disease phenotype in children77 and in adults41• 78 and a number of studies have demonstrated 
that strain type, and Beijing specifically, is associated with drug resistance. 39• 79-81 
The management of children with drug-resistant tuberculosis infection 
If a child with M. tuberculosis infection can be given effective treatment to prevent the 
progression to disease, the child is spared a TB disease episode. This has clinical implications 
for the individual, reducing morbidity, mortality and avoiding lengthy, unpleasant and 
potentially costly treatment with associated adverse events. It also has implications for the 
Drug-resistant tuberculosis in children James Seddon Page 120 
community as children provide a reservoir for future disease propagation, as well as direct 
onwards transmission in those children who develop infectious TB.82 The first trials of isoniazid 
as preventive therapy for TB were carried out over fifty years ago,83 and isoniazid has been 
demonstrated to reduce the risk of progressing from infection to disease in HIV-positive and 
HIV-negative children following exposure to drug-susceptible TB.84-86 The majority of 
international agencies and National TB Programmes advise providing children less than five 
years and all HIV-infected children with isoniazid daily for six months following exposure to an 
infectious case of drug-susceptible TB.16 
Following exposure to a source case with MDR-TB it is unclear how vulnerable children should 
be managed.87 Although concordance between putative source cases and child contacts is not 
complete, many clinicians are uncomfortable treating a child exposed to an MDR organism 
with isoniazid. Cases have been reported of children exposed to MDR-TB developing TB 
disease on isoniazid preventive therapy.88-89 Resistance caused by an inhA promoter region 
mutation may be overcome by giving isoniazid at a high dose (lS-20mg/kg) but this will not 
treat all strains.90-92 Drugs other than isoniazid and rifampicin have not been proved to be 
effective in preventing the progression from infection to disease and concerns exist regarding 
the potential toxicity of other agents, given to well children without TB disease. The Centers 
for Disease Control identified the need for a preventive therapy trial for contacts of MDR-TB in 
1992.93 Since then numerous international agencies and experts have recommended that 
studies assessing MDR-TB preventive therapy should be a global public health priority.6,94-98 
The management of children with drug-resistant tuberculosis disease 
A microbiologically confirmed diagnosis is only made in about 20% of children with clinical 
evidence of TB.s When extensive efforts are employed this figure can increase, but rarely to 
above 50%.99 It is therefore recommended that children should be treated for clinically 
presumed, as well as confirmed, TB, based on symptoms, signs and radiology.16 Many clinicians 
are wary of making a presumed diagnosis of MDR-TB in children, however, due to perceptions 
that the treatment is associated with significant adverse events, is long and traumatic for 
children, and may involve prolonged hospital admission. The balance between making a 
confirmed diagnosis (specific but not sensitive) vs. a presumed diagnosis (sensitive but perhaps 
not specific) is influenced by such assumptions. 
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Adults with TB usually have multibacillary disease with extensive tissue damage and lung 
cavities. Microbiological diagnosis is common. Treatment recommendations for adults with 
MDR-TS include an injectable medication for six to eight months and a total duration of 
therapy of 18-24 months.1OO Durations shorter than this are associated with increased risk of 
failure and relapse. Children, however, have a different spectrum of disease. Whilst older 
children (older than 8 years) may have adult-type disease,82 younger children commonly have 
limited, paucibacillary disease, including intra-thoracic or extra-thoracic lymph node disease.lOl 
Children metabolise drugs differently to adults, have a different spectrum of adverse effects 
and different psychosocial, developmental and educational needs. However, generally, the 
advice is for children to be treated in a similar way to adults. Some experts suggest that it may 
be possible to treat limited disease less aggressively but evidence to support this is Iimited.16, 
102-103 
Drugs used to treat drug-resistant tuberculosis infection and disease 
The treatment of DR-TS infection and disease necessitates the use of second-line TS agents. 
Despite their approval more than forty years ago, there are major gaps in our knowledge of 
the pharmacokinetics ofTB drugs in children, particularly ofthe second-line agents,l04 The 
pharmacokinetics of TB drugs is modulated by several factors. Age is an important variable as 
young children achieve lower serum concentrations for most first-line TB drugs compared to 
adults when given at the same mg/kg dosages. lOS-lOB Other potentially important determinants 
include malabsorption and immune-compromise resulting from HIV infection,l09-11o poor 
nutritional status111 and variable pharmacogenetics.106,112 Recent global interest in paediatric 
TB resulted in a critical review of existing treatment recommendations and a number of new 
recommendations have been made regarding the appropriate dosing of first-line TB drugs in 
children;l13 however, there is scant evidence on which to base dosing guidelines for the 
second-line TS drugs. Toxicity is a major concern, but paediatric data are limited. Co-
administration with cART may potentiate drug toxicity or result in drug-drug interactions that 
compromise the efficacy or safety of the TS regimen or cART. Knowledge of the effects of age, 
HIV co-infection and concomitant cART in children on the pharmacokinetics of second-line TS 
agents is limited. 
The challenges to treating MDR-TS in children are only partly due to the uncertainties 
surrounding the activity and safety of the available drugs. The second-line drugs are rarely 
produced in paediatric formulations or appropriate tablet sizes, necessitating breaking, 
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splitting, crushing or grinding. Hence dosing may be inaccurate and sub-therapeutic or toxic 
levels are possible. The taste of the medications is often unpalatable. A number of the drugs 
cause vomiting and diarrhoea which may affect the amount absorbed and causes further 
uncertainty about the dosing. The daily pill burden can be vast as the child may require 
multiple TB medications, cART, other antibiotics as well as supplements of vitamins and 
calories. Adherence can be challenging in children either too young to understand or not old 
enough to cooperate. Treatment for MDR-TB in children should always be given under directly 
observed therapy (DOT) but in reality, in many settings, responsibility is often given to the 
caregiver who is given a week or a month's supply of drugs. Caregivers may well be the source 
case, however, and may have chronic medical problems themselves, have defaulted 
treatment, or have additional problems such as drug or alcohol abuse. There is an established 
relationship between TB and alcohol in many contexts and populations114 and in treatment 
cohorts of MDR-TB alcohol and drugs are common and associated with both default1l5 and 
poor prognosis. 116 
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I Conceptual framework 
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Aims and structure of thesis 
The aim of this thesis was to examine each of the different stages from exposure to DR-TB 
through to the treatment of disease, as outlined in the conceptual framework. 
The first step was to carry out a review of literature relevant to the different components of 
the cascade. I have therefore examined the literature regarding the management of children 
exposed to DR-TB, the management of children with DR-TB disease and finally the 
characteristics of the second-line TB drugs. The next step was to define the terms that I 
proposed to use in the studies that were to be carried out. 
The main component of the thesis was to carry out original research to examine the different 
stages in the progression from exposure to disease treatment. Through a series of inter-related 
studies, the reasons for progression from one stage to the next in the cascade were explored 
and interventions examined. Within this, the first study aimed to quantify the burden of drug 
resistance in the context in which the research is to be carried out. Epidemiological risk factors 
for infection and disease were then explored in child contacts of MDR-TB. Investigations into 
transmission dynamics were examined in two studies and then two operational research 
studies explored what proportion of child contacts access care and why so many fail to do so. 
The toxicity, tolerability and efficacy of a multidrug preventive therapy regimen were studied 
and finally a series of investigations explored the treatment and adverse effects of DR-TB 
disease treatment. Following the original research, the final step in the thesis is to draw 
together conclusions from what had been discovered and identify suggestions for changes in 
policy and practice, together with areas for future research. 
The majority of the elements in the thesis, both the literature reviews and original research 
studies, have been written up as individual articles for submission to peer-review academic 
journals. However, to provide a coherent description of the body of work, one thesis has been 
produced. Where sections of the thesis are drawn from articles that have been written, this 
will be noted and published/submitted articles are available at the end . Text presented in the 
thesis is only drawn from articles that I have written myself. However, all articles benefitted 
from critical input from other authors. 
All research studies in the thesis were approved by the Ethics Committees of both the London 
School of Hygiene and Tropical Medicine and Stelienbosch University. 
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I Context and environment of work 
The Republic of South African is located at the southern tip of the African continent. The 
population was just over SO million in 2011117 and the country is comprised of Black African 
(Zulu, Xhosa, Basotho, Bapedi, Venda, Tswana, Tsonga, Swazi, Ndebele), White (mainly of 
European ancestry), Indian and Coloured (a heterogeneous group of mixed ancestry) ethnic 
groups. The antenatal HIV prevalence was 29.3% in 2008118 and the national T8 incidence was 
948 cases per 100,000 in 2007. 118 
South Africa is divided into nine provinces, of which the Western Cape is situated in the south-
west corner of the country. 
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The population of the Western Cape was 5.3 million in 2011.117 The HIV antenatal prevalence 
was 16.9%119 in 2009 and the TB notification rate was 976 per 100,000.118 Within the Western 
Cape, the province is divided into six health districts. The largest is the metropolitan health 
district called the City of Cape Town with a population of 3.4 million. 
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The City of Cape Town health district is further subdivided into eight sub-districts of roughly 
half a million population each. One of these, Khayelitsha, is a peri-urban township, and is 
located on the outskirts of the City. Khayelitsha is a poor sub-district and has a predominantly 
Xhosa-speaking population.12o In Khayelitsha the TB notification rate was nearly 1600 per 
100,000 in 2008 with an antenatal HIV seroprevalence of 31.1%.121 Medecins sans Frontieres 
(MSF), working with local health authorities in one township of Cape Town, Khayelitsha, since 
2007, are piloting a decentralized model for the identification and treatment of MDR-TB 
patients. This involves a package of care that includes counselling, support, sensitization, 
education, adherence support groups, active case finding of contacts and psychosocial care. 122 
Each year, there are about two hundred adults diagnosed with MDR-TB from the Khayelitsha 
sub-district. A paediatric outreach DR-TB clinic has been running since December 2008 in 
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Khayelitsha where, once a month, a specialist visits the community clinic. New patients are 
assessed and for those who can be managed in the community, follow-up of both exposed and 
diseased patients occurs. 
In all sub-districts, once an adult has been diagnosed with sputum positive MDR-TB, contact 
tracing should occur to identify any individuals at risk in the household. In practice this occurs 
inconsistently and many vulnerable children are not identified or referred. At the beginning of 
2010, a professional nurse was appointed in each of the eight sub-districts to oversee this 
process. One of their tasks is to carry out a household assessment on all new adu lts with MDR-
TB at diagnosis to discuss infection control, adherence and follow up. Another task is to 
identify any exposed children who are less than five years and those HIV-infected and refer 
them to their nearest clinic (roughly one hundred exist in the City of Cape Town Health district) 
to be seen by the local doctor before referral to the regional paediatric DR-TB clinic. This DR-TB 
clinic takes place at Tygerberg Children's Hospital (TCH), a large provincial, academic hospital, 
and as an outreach service, conducted within Khayelitsha on a monthly basis. The children are 
referred by faxing a standardised referral form and ringing to make an appointment. At the 
DR-TB clinic, the child is assessed by a specialist to rule out disease using history, examination 
and plain film chest radiography (CR; antero-posterior and lateral ). If the child is found to be 
well, but is deemed to have had significant exposure, they are started on preventive therapy. 
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The provincial policy is to provide ethambutol (20-25mg/kg daily), ofloxacin (15-20mg/kg daily) 
and high dose isoniazid (15-20mg/kg daily) for six months. Children are seen routinely at two, 
four, six and twelve months where they are examined and have a chest radiograph taken. 
Any children in the Western Cape who are confirmed or suspected of having MDR-TB disease, 
and children failing effective first-line therapy, are also referred to this specialist children's DR-
TB clinic. Children are assessed and, if necessary, started on treatment. If the child requires a 
daily injectable medication for the intensive phase they are admitted to Brooklyn Chest 
Hospital (BCH), a specialist residential TB hospital with a sixty bed paediatric capacity. 
Otherwise they are managed as outpatients. Children who are being followed-up after 
discharge from BCH to complete their treatment in the community return to the DR-TB clinic 
for appointments. 
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I Literature Review 
literature review 1: managing child contacts of drug-resistant tuberculosis 
Concepts from the following topic have been written as articles: 
• Seddon JA, Godfrey-Faussett P, Hesseling AC, Gie RP, Beyers N, Schaaf HS. Management of 
children exposed to multidrug-resistant Mycobacterium tuberculosis. Lancet Infect Dis. 
2012; 12: 469-479 
• Seddon JA, Godfrey-Faussett P, Hesseling AC, Schaaf HS, Enarson D. Should preventive 
treatment be provided to child contact of tuberculosis in high burden settings? (submitted) 
For this section of the thesis, the literature surrounding preventive therapy was systematically 
searched (Table 1) From the articles found, together with a synthesis of relevant themes and 
topics, a discussion of the relative merits of preventive therapy for contacts of DR-TB is 
provided. 
Preventive therapy 
TB control programmes have traditionally focused on case-finding and treatment of infectious 
patients with TB disease, usually adults. From a public health perspective, this must remain the 
priority as it will reduce population transmission and consequently the number of new 
infections. However, to decrease future disease burden and for individual clinical care, these 
strategies need to be complemented with the identification and treatment of exposed 
individuals who are at a high risk of becoming infected and then of progression to disease.123 
Those at the highest risk are young children and the immunosuppressed . Few studies have 
examined the management of children exposed to MDR-TB and in the field of preventive 
therapy there is no consensus in published articles and expert guidelines. 
The rationale for preventive therapy 
Preventive therapy regimens have been used since 1951 in an effort to prevent the 
progression from infection to disease.124 The WHO advises that those with M. tuberculosis 
infection who are at a high risk of progression, should be given daily isoniazid for at least six 
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months.l6 ln high burden settings high risk is considered children less than five years of age or 
those HIV-infected in household contact with an infectious TB case.12S Alternative preventive 
therapy options that have been proposed include rifampicin or combinations of rifampicin, 
isoniazid and pyrazinamide.126-129 A number of studies have demonstrated that when uptake 
and adherence to preventive therapy is good, there is a reduction in the likelihood of 
progression from infection to disease. The reduction is in the order of 60% for those without 
HIV infection83.8s.130 increasing to 90% in analysis restricted to patients with good 
adherence. l3l HIV-infected children, given preventive therapy, had a 72% reduction in disease 
progression in the era before cART.84• 132 However in a recent placebo-controlled trial of HIV-
infected and HIV-exposed, uninfected infants with no known exposure to a TB source case at 
the time of enrolment and universal access to cART, 96 weeks of isoniazid did not lead to a 
reduced incidence of TB disease.133 WHO has recently proposed an aggressive strategy for HIV-
infected patients, where all should be given preventive therapy, irrespective of age, contact 
with a TB source case, degree of immunosuppression or evidence of infection.134 Therapy is 
advised for up to 36 months. Prophylaxis refers to treatment given after exposure to prevent 
infection while treatment of latent infection implies that infection has been determined. 
Preventive therapy includes both these situations and will be used throughout the thesis (see 
definitions section later).6 
The assessment of child contacts of multidrug-resistant tuberculosis 
When presented with the child contact of an MDR-TB source case a number of decisions must 
be made. The first is to assess whether the child has TB disease. This is not always 
straightforward but giving preventive therapy to a patient with TB disease is not only 
inadequate but also runs the risk of promoting further resistance. Once TB disease is excluded, 
the attending physician must make a series of assessments which, in the absence of reliable 
diagnostic tests, will always be probability-based judgements. These are demonstrated in 
Figure 1. Initially the likelihood of infection must be evaluated. If the child is likely to be 
infected, the risk of disease progression must be determined. If the child is likely to be infected 
and has a high chance of disease progression then the final assessment is of the drug 
susceptibility of the infecting strain. Once all these factors are evaluated preventive therapy 
can be considered. In each individual case, the risks associated with preventive therapy must 
be carefully weighed against the risk of disease. 
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Evidence regarding the management of multidrug-resistant tuberculosis contacts 
Few studies have examined the management of child contacts of MDR-TB. My own review of 
the literature identified no randomised controlled trials investigating those exposed to MDR-
TB and only three studies that have looked at preventive therapy in contacts of MDR-TB. This 
was the same result as others who had systematically searched the literature.13S One study in 
Cape Town followed 105 children, of which 41 had been given a multi-drug preventive therapy 
regimen tailored to the drug susceptibility test (DST) pattern of the source case strain.21 This 
demonstrated a protective effect of the tailored regimen as only two out of the 41 treated 
children (5%) developed TB disease compared to 13 out of the 64 (20%) who had been 
observed carefully without intervention. The second study, in Rio de Janeiro, retrospectively 
assessed 218 adult and child contacts of MDR-TB source cases of whom 45 had been given 
isoniazid.65 This study showed a non-significant trend towards a protective effect of the 
preventive therapy. Finally, 110 infected adult and child contacts of 19 MDR-TB source cases 
were given a multi-drug preventive therapy regimen in Chuuk, Federated States of Micronesia. 
Twelve months of preventive therapy was given under DOT and no patients given preventive 
therapy developed TB disease.136 Although no definitive conclusions can be drawn from these 
studies, they would suggest that it may be beneficial to give some form of preventive therapy 
to child contacts of MDR-TB. 
Recommendations from international organisations and departments of health 
International guidelines vary regarding the management of MDR-TB contacts. The British 
National Institute for Health and Clinical Excellence (NICE) advocates careful follow-up of all 
contacts of infectious MDR-TB patients with no treatment as no medication has been 
demonstrated to be effective in preventing progression from infection to disease.137 The WHO 
recommends close observation as there are limited data supporting the use of drugs other 
than isoniazid and rifampicin. It does, however, imply that contacts of MDR-TB source cases 
may be infected with mUltiple strains, some of which might be susceptible to isoniazid. 16 The 
South African Department of Health suggests giving isoniazid to contacts of MDR-TB source 
cases.138 One Delphi survey failed to gain consensus, suggesting that it was up to the attending 
physician to make the decision and advocating the need for further studies.139 
The Centers for Disease Control and Prevention (CDC), the American Thoracic Society (ATS) 
and the Infectious Diseases Society of America (IDSA) have issued a joint statement suggesting 
that high-risk contacts of MDR-TB source cases should receive a regimen that includes two 
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drugs to which the source case's TB strain is susceptible.93 The American Academy of 
Paediatrics (AAP) suggest specialist referral. l40 Published expert opinions vary141-142 as does 
reported practice.89,143-148 Although treating with medications to which the source case's 
isolate is susceptible is intuitively convincing and biologically plausible, there are limited data 
to indicate if it is successful in preventing infection or the progression from infection to 
disease. The adverse effects of such treatments have also not been explored and the costs to 
the patient and to the health system have not been assessed. 
Available medications that might have a place in a preventive treatment strategy for child 
contacts of multidrug-resistant tuberculosis 
Whichever regimen is used, it is important that clinicians are familiar with the medications 
available, their mechanism of action and possible adverse effects149. The drugs in Table 2 have 
all been suggested as preventive therapy for MDR-TB. Although the individual drugs will be 
discussed later in the literature review on second-line drugs, they are discussed here in 
relation to their use in preventive therapy as drug characteristics are central to preventive 
therapy decision-making. In addition the use of first-line drugs, not covered in the later 
literature review, are discussed here. 
Delivering the correct amount of a drug to a child is problematic, both in terms of being 
confident of ingestion as well as knowing the correct drug dosage. Traditionally, paediatric 
dosing was extrapolated from adult pharmacokinetic studies. However, children generally 
metabolise medications more rapidly than adults with drug concentrations lower than adults 
given a corresponding dose for weight.15O This has been demonstrated in a number of recent 
studies assessing TB drug concentrations in children10s, 107, 110,112 resulting in a revision to WHO 
first-line TB drug dosing recommendations in 2009.113 The caveat to this, however, is that 
neonates and very young infants, with immature liver and enzyme development, seem to 
metabolise drugs less rapidly than older children. Care must be taken when prescribing for this 
sub-population.108,lSl Determining the optimal drug concentration to aim for in children is also 
problematic and the pharmacodynamic properties of drugs may not be the same for children 
and adults. Most of the second-line drugs have been minimally studied in children with TB. 
Isoniazid is effective when used alone as preventive therapy for drug-susceptible TB infection 
because it is highly bactericidal and leads to rapid bacterial clearance.1S2 Resistance has not 
been shown to develop in infected patients treated with this monotherapy when TB disease 
has been excluded prior to initiation. ls3 Its use in contacts of known MDR-TB is questionable, 
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however, as the contact is likely to be infected with an MDR strain. The majority of isoniazid 
resistance is coded for on one of two genes and so resistance can be detected using genetic 
tests. It can be divided into high-level or low-level resistance, the former being coded for on 
the katG gene and the latter on the inhA promoter region. 1S4 
Pyrazinamide is effective in killing M. tuberculosis but only in the acidic environment created 
by active inflammation responding to rapidly replicating mycobacteria. This situation is not 
usually found in M. tuberculosis infection and so its place in preventive therapy is uncertain.15S 
Pyrazinamide-containing preventive therapy regimens have been shown to have significant 
adverse effects in adults and adherence can be poor.1S6-158 However, studies in children being 
treated for TS disease demonstrate it to be well tolerated and rarely associated with adverse 
effects_1S9-160 Resistance to pyrazinamide is complicated to test as it requires conditions of very 
low pH which are difficult to replicate in vitro. Direct resistance testing, as well as surrogate 
and genetic techniques, have shown that levels of resistance can be high in strains already 
resistant to isoniazid and rifampicin.161-162 
Fluoroquinolones have good activity against M. tuberculosis163 but concerns had previously 
prevented their use in children due to the effect on the cartilage growth of immature 
beagles. l64 A growing body of experience has subsequently assessed their use in children and 
found no evidence to support these concerns.165 Fluoroquinolones have good bactericidal 
activity and seem to be well tolerated. Although effective in vitro, ciprofloxacin has poor early 
bactericidal activity; other fluoroquinolones are therefore likely to be more effective. 166 A 
recent study has demonstrated that although moxifloxacin has the best in vitro activity of the 
tested fluoroquinolones against M. tuberculosis in the exponential growth phase, levofloxacin 
was the most effective against those in the latent phase, suggesting it may be effective when 
used as preventive therapy. 
Ethambutol is effective but concerns regarding its effect on the optic nerve have limited its use 
in those for whom colour vision and visual acuity was not possible to test, essentially 
precluding its use from young children. Studies have subsequently shown that when used at 
modern doses, optic neuritis has rarely been seen.167 There is emerging evidence, however, 
that in MDR strains the frequency of ethambutol resistance is very high,161 suggesting that it 
may not be an effective choice. 
Ethionamide is a similar drug to isoniazid, inhibiting the synthesis of mycolic acid and 
consequently impairing the formation of the cell wall. If the mycobacteria have a mutation in 
Drug-resistant tuberculosis in children James Seddon Pagel34 
the inhA promoter region, the mutation that usually leads to low-level isoniazid resistance, 
then there will also be resistance to ethionamide. l54 However, if there is a katG gene mutation, 
the mutation that usually leads to high-level isoniazid resistance, there is no increased risk of 
resistance to ethionamide. Adverse effects are common and include nausea and vomiting. 
However, these usually lessen with time and can be reduced by initially splitting the daily dose 
or giving a reduced dose at the start of treatment and increasing over a couple of weeks to the 
full dose. 
Preventive treatment strategies for the management of drug-resistant contacts 
Contacts may be given a single drug, a standardised multidrug regimen, where all patients are 
given the same combination regardless of susceptibility, or an individualised, tailored 
multidrug regimen determined by the DST of the source case. 
Contacts of TB source cases with isolates resistant to only either rifampicin or isoniazid can 
usually be treated with the other agent alone. As both these drugs have been shown to be 
effective in reducing the risk of progression from infection to disease in contacts of drug-
susceptible disease, either drug should be effective. It must be noted, however, that with the 
increasing use of line probe assay (LPA) genotypic tests to diagnose MDR-TB a proportion of 
source cases labelled as having rifampicin-monoresistant (RMR) TB may, in fact, have MDR-TB 
as the genotypic tests only detect the katG and inhA mutations, missing a small but important 
proportion of isoniazid resistance. Contacts of XDR-TB may be infected with a strain that is 
resistant to multiple agents. Few treatment options are available and until new agents become 
available close follow-up remains a key component of management. 
Although good evidence exists for the efficacy of isoniazid in preventing disease progression in 
drug-susceptible infection, there are limited data to support its use alone in those exposed to 
MDR-TB. A rationale exists for using it alone at high dose as it is well tolerated, adverse effects 
are rare and it would treat drug-susceptible strains as well as strains with low-level 
resistance.90, 92,168 There have, however, been documented cases of children exposed to MDR-
TB progressing to disease whilst on isoniazid preventive therapy given at the previously 
recommended dose (Smg/kg).88 Using a fluoroquinolone on its own might also be effective as 
they are well-tolerated and have both bactericidal and sterilising activity. Fluoroquinolones 
are, however, used widely to treat non-tuberculosis bacterial infections and there is concern 
that widening their use still further and using them over long periods of time may promote 
resistance to this essential class of drug needed to treat MDR-TB. A number of drugs in the 
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research and development pipeline, TMC-207, OPC-67683, PA-824, may also be suitable for 
MDR-TB preventive therapy.169 
A standardised multi-drug regimen will have some operational advantages over a regimen 
tailored to the DST pattern of the isolate from the source case. It is simpler to implement and 
healthcare workers can become familiar with a small number of drugs, dosages, adverse 
effects and interactions. It is only necessary to have a limited DST on the strain of the source 
case, sufficient to know that they have MDR-TB. Fundamentally, the choice of agents must 
reflect the DST pattern of the prevailing organisms and so making universal recommendations 
may not be appropriate. What is suitable for one area may not be for another. Deciding at 
which level to provide guidance is also difficult, whether it be global, regional, country, district 
or at hospital level, as is often the case for antibiotic policy. Balancing the tensions between 
easy-to-follow unambiguous general policies and providing treatment that is most likely to be 
effective for the target population is a constant public health challenge. Proposed standardised 
regimens have included combinations of pyrazinamide, ethambutol and a fluoroquinolone.93, 
170 
The advantages of a tailored regimen include an increased likelihood of success and reduced 
promotion of resistance if a diagnosis of disease were missed at the beginning. However, it 
requires a health system that is able to perform DST to a variety of first- and second-line 
medications and requires extensive experience and expertise from front-line medical staff. By 
giving three or more medications to which the bacilli is susceptible, it could be argued that this 
is little different from a disease treatment regimen. Some would suggest close observation 
with rapid identification and treatment if TB disease develops as a more appropriate strategy 
in a we" child.125,137 
The Research Exce"ence to Stop TB Resistance Group (RESIST-TB) met in December 2009 to 
discuss research into MDR-TB. They produced three clinical trial protocols of which one 
examined the question of preventive therapy to adult and child contacts of MDR-TB. It was 
suggested that a trial be conducted comparing isoniazid with either a new drug or one used in 
combination with existing drugs.98 It would need to be a large trial as the endpoint ofTB 
disease is relatively infrequent and large numbers of patients would need to be recruited in 
both arms to demonstrate a difference. The composition of the new regimen is still under 
discussion. 
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Other factors which will affect which reg~men is employed in a given circumstance will be 
certain pragmatic considerations such as regulatory approval, often challenging in children, 
experiences of certain drugs in other diseases, cost and national programme policy. The 
optimal duration of treatment has not been explored. 
Adherence 
Almost all studies performed have demonstrated that, in routine clinical care, personal 
adherence to a course of isoniazid is singularly poor.l7l If the treatment needs to be given to a 
child who is clinically well and may not be compliant with the parents' wishes, it seems to be 
even worse.172•173 In a recent, prospective study in Cape Town, 180 child contacts of drug-
susceptible TB were started on isoniazid. Only 20% completed five months or more of 
preventive therapy and the assessment of adherence consisted of whether they came to the 
clinic monthly to collect the medications with no record of whether they were actually taken 
or not. As this is with isoniazid, which has a relatively benign adverse effect profile, there are 
concerns that with more complex regimens it may be even worse. 
However, with education, counselling and peer support, good levels of adherence can be 
achieved and TB programmes must consider the best ways of promoting good adherence to 
completion of treatment. Novel techniques are being employed including DOT by family 
members or non-medical treatment supporters, use of mobile telephone technology, 
incentives and decentralised care in the community.174-176 Preventive therapy has rarely been 
given under DOT and it is usually the responsibility ofthe parent to administer. The available 
resources and local prevalence ofTB in the community will also affect which model of 
supervision and support families receive. 
The influence of Human Immunodeficiency Virus 
As preventive therapy regimens given to those exposed to MDR-TB do not contain rifampicin 
many of the usual interactions with cART medications are less profound. limited work has 
been done on the interaction between second-line TB drugs and cART drugs.177 It is unclear if 
therapeutic levels are being achieved, especially in children where less data are available. In 
addition, chronic diarrhoea, a common consequence of HIV, may affect the absorption of both 
MDR-TB preventive therapy as well as those of cART.178 
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The other key question is the timing of the initiation of cART and MDR-TB preventive therapy. 
If the patient is already well established on cART it is probably safe to start preventive therapy 
immediately without stopping the cART. If the diagnosis of HIV is made whilst the patient is 
established on MDR-TB preventive therapy then cART should be initiated in accordance with 
the appropriate guidelines for initiation of cART based on clinical and immunological criteria. 
The problem arises if the two are diagnosed at the same time. If a patient is simultaneously 
diagnosed with HIV and TB disease, HIV is immediately classed as WHO clinical stage 3 or 4 
which necessitates immediate or imminent cART treatment.179 Often cART initiation is delayed 
for a couple of weeks to avoid the worst of the interactions and adverse effects. However, if 
the patient is diagnosed with HIV and M. tuberculosis infection it may be appropriate, 
dependent on other clinical and immunological circumstances, to start preventive therapy and 
wait until either the preventive therapy is well established or completed before starting cART. 
The debate about when to start cART is complex and little evidence is available.180 However, 
clinicians are treating HIV infection now at an earlier stage than previously and there is 
convincing evidence that early initiation of cART is associated with reduced TB incidence and 
mortality, particularly in children. l8l In fact, providing cART to these children may be more 
effective than any MDR-TB preventive therapy. Once HIV is diagnosed co-trimoxazole should 
be started according to appropriate guidelines, irrespective of whether cART or MDR-TB 
preventive therapy is initiated or not.182 
Immune Reconstitution Inflammatory Syndrome (IRIS) can be divided into paradoxical and 
unmasking IRIS and usually manifests in the first few weeks of cART.183-l85 Paradoxical IRIS 
occurs when currently treated TB disease becomes worse following the initiation of cART. 
Children with M. tuberculosis infection do not fall into this group. Unmasking IRIS, however, 
must be considered in any HIV-infected MDR-TB contact started on cART. The cART may lead 
to recognition of previously undetected TB disease as the immune system reconstitutes. 
Management would be to start full treatment for MDR-TB disease. The role of corticosteroids 
is still inconclusive but may give some protection in certain situations. ls6 
Conclusions 
MDR-TB is emerging as a significant challenge to international public health. The disease 
burden can be reduced by treating exposed patients who are at high risk of becoming infected 
and of progression to disease. Although the number of contacts will vary between populations, 
conservative estimates would suggest that in high burden regions, there are at least two 
contacts that are either less than five years or are HIV-infected for each MDR-TB source case.21, 
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65 This implies that over a million vulnerable contacts could be considered for preventive 
therapy each year. From a different perspective, of the half a million people who develop 
MDR-TB disease each year, a significant number are HIV-infected or less than five years old; for 
a proportion of these a source case may have been identified and preventive therapy initiated. 
A study from Peru has demonstrated that of households with a case of MDR- or XDR-TB, nearly 
a quarter have a contact that develops TB in the subsequent four years.187 MDR-TB disease is 
expensive to treaeS8-189 and treatment is associated with significant toxicity.190 Preventing 
MDR-TB disease may be a practical and cost-effective solution from both the individual and 
public health perspective. However, treating a well child with potentially toxic drugs also 
presents a challenge. For each child, the risk of preventive therapy must therefore be weighed 
against the risk of disease. A very young child, sleeping in the same room as a close family 
member with sputum smear-positive TB disease, or an HIV-infected child, is likely to benefit 
more from preventive therapy than an older child in contact with a neighbour with smear-
negative disease. Careful follow-up is essential regardless of the treatment decision. 
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Table 1 - Search strategy for literature review 
Search term CINAHL Africa NiPAD 
31/10/09 31/10/09 
1 TB 2651 14037 
2 Tuberculosis 9253 176033 
3 Mycobacter* 2274 43877 
4 MDR 327 1756 
5 XDR 36 216 
6 Drug-resist* 9930 19108 
7 M u Itid rug-resist * 1524 4686 
8 Prophylaxis 6868 5905 
9 Chemoprophylaxis 353 2221 
10 "Preventive therapy" 250 525 
11 "Preventive treatment" 279 439 
12 Latent 2158 3667 
13 lor 2 or 3 10271 178952 
14 4 or 5 or 6 or 7 10737 21283 
15 8 or 9 or 10 or 11 or 12 9666 11890 
16 13 and 14 and 15 71 379 
-
- ~ 
-- - - - -
When row 16 for all databases combined in Endnote 2394 references were produced. 
When duplicates were removed in Endnote th is left 1393 references. 
When duplicates were removed manually 1048 references were left. 
Embase 
31/10/09 
37494 
124042 
68558 
6874 
172 
62094 
29040 
101072 
13403 
1406 
2446 
62393 
167967 
83626 
176094 
455 
Elimination following review oftitles and abstracts left 173 of which 146 full text references (84%) were retrieved 
Of these 146 articles, 55 were found to be useful to the literature review 
Medline 
31/10/09 
15332 
161113 
70656 
8547 
207 
150533 
21943 
60493 
4070 
1506 
2477 
35422 
193782 
158906 
102141 
411 
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WOS Cochrane ASP Global Health 
3/11/09 3/11/09 3/11/09 3/11/09 
33252 1734 17240 6918 
>100000 2420 22720 51314 I I 
87558 887 14288 63121 
10667 137 3910 1602 
336 3 259 121 
>100000 3798 18246 46346 
32213 415 6944 4964 
80964 12157 12606 25195 
5282 585 745 6854 
1942 196 512 337 
2953 364 787 596 
65107 817 15958 10023 
>100000 4248 39674 71811 
>100000 4025 23774 47336 
>100000' 13715 30142 38300 
564 48 92 285 
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Figure 1- Decision algorithm for assessing child contacts of MDR-TB cases 
Child exposed to source case with MDR-
TB disease 
Does the child have TB disease? 
Is the chi ld likely to have TB infection? 
Is the child likely to progress to TB 
disease? 
Is the child likely to be infected with the 
same MDR-TB strain as the source 
case? 
Consider isoniazid 
preventive treatment 
Consider MDR-TB 
preventive treatment 
Assessments 
History 
Examination 
Chest radiology 
TST/IGRA 
Infectiousness of source case 
Proximity/intensity of contact 
Duration of contact 
Age 
HIV status and degree of 
immunosuppression 
Nutrition 
Other immunodeficiency 
Local prevalence of TB 
Intensity of interaction with 
MDR-TB source case 
Number of known source 
cases 
Age of child 
• requires evaluation for 
MDR-TB disease 
MDR-TB - multidrug-resistant tubercu losis; TST - tubercul in skin test ; IGRA - interferon-gamma release assay; HIV - human 
immunodeficiency virus 
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Table 2 - Drugs suggested in a preventive treatment regimen for MDR-TB 
Medication Drug Characteristics Dosage advised Formulations Adverse effects· Comments 
Isoniazid Bactericidal lS-20mg/kg Tablets (lOOmg & Peripheral neuropathy Give pyridoxine if malnourished or HIV-infected 
Rapidly absorbed and distributes widely once daily 300mg) Hepatit is Stop all hepatotoxic drugs if evidence of hepatit is 
Inhibition of ce ll wall synthesis via Syrup (lOmg/ml) Hypersensitivity Absorption greatest if taken on an empty stomach but acceptable levels with food 
inhibition of mycolic acid 
Pyrazinamide Bacteriostatic (bactericidal to rapidly 30-40mg/kg Tablets (SOOmg) Hepatitis Stop all hepatotoxic drugs if evidence of hepatitis 
growing mycobacteria) once daily Hyperuricaemia Reduce dose if evidence of any joint pa in 
Well absorbed and distributes widely Arthra lgia Absorption unaffected by food but adverse effects may be reduced if ta ken with foods 
Inhibit ion of Fatty Acid Synthase I Myalgia 
Active only at low pH Rash 
Photosensitivity 
Ethambutol Bacteriostatic (bactericidal at high dose) 10-2Smg/kg Tablets (lOOmg & Optic neuritis Assess colour vision and visual fields (dependant on child, possible from - f ive years) 
Well absorbed and distributes widely once dai ly 400mg) Peripheral neuropathy Can be taken with or without food 
(poor into the CSF) Hypersensitivity 
Inhibition of cell wa ll synthesis 
Ethionamide or Bacteriostatic lS-20mg/kg Tablets (2S0mg) Hepatitis Stop all hepatotoxic drugs if evidence of hepatit is 
prothionamide Inhibits cell wall synthesis via inh ibition of once daily Hypothyroidism If gastrointestinal disturbance severe, aim to give the full dose once daily with in two weeks 
mycolic acid Hypersensitivity but consider initially: 
Well absorbed and distributes widely Metall ic taste • giving separately from the other med icines (others in the morning, ethionamide in the 
Hypoglycaemia evening). 
• splitting the daily dose 
• giving a smaller dose and building up over t ime 
Monitor thyroid function every two months 
Absorption unaffected by food 
Ciprofloxacin Bactericidal (poor early bactericidal lS-20mg/kg Tablets (2S0mg & Insomnia Ciprofloxacin should not be used unless no other fluoroqu inolone is available 
activity) twice a day SOOmg) Arthralgia Can be taken with or without food 
Well absorbed and distributes widely Syrup (SOmg/ml & Restlessness Patients should be advised to drink plenty of fluids to avoid excessive urine alkalinity 
Inhibition of DNA gyrase l00mg/ml) Confusion 
Headache 
Ofloxacin Bactericidal 15-20mg/kg Tablets (200mg & As for ciprofloxacin Can be taken with or without food 
Well absorbed and distributes widely once daily 400mg) Patients should be advised to drink plenty of fluids to avoid excessive urine alkalinity 
Inhibition of DNA gyrase 
Levofloxacin As for ofloxacin 10mg/kg daily Tablets (2S0mg & As for ciprofloxacin Can be taken with or without food 
(twice daily for SOOmg) Patients should be advised to drink plenty of fluids to avoid excessive urine alkalinity 
ch ildren <5 Syrup (2Smg/ml) Possible photosensit ivity 
--------
years) 
- - -- ----- -
*Alliisted drugs have been associated with gastrointestinal disturbance 
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Literature review 2: management of drug-resistant tuberculosis disease in children 
Concepts from the following topic have been written as articles/guidelines: 
• Ettehad D, Schaaf HS, Seddon lA, Cooke GS, Ford N. Treatment outcomes for children with 
multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 
2012; 12: 449-456 
• Seddon lA, Furin 11, Gale M, Del Castillo Barrientos H, Amanullah F, Hurtado R, Ford N, 
Starke 1, Schaaf HS. Caring for children with drug-resistant tuberculosis: practice-based 
recommendations. Am 1 Resp Crit Care Med 2012; 186: 953-964 
• Schaaf HS, Seddon JA. Epidemiology and management of childhood multidrug-resistant 
tuberculosis. Clinical Practice (in press) 
• Furin Jl, Seddon lA, Perez-Velez C. Management of drug resistant tuberculosis in children: a 
field guide 
For this section of the thesis, the literature surrounding the treatment of children with DR-TS 
disease was searched. A systematic review was carried out, in which I assisted with the data 
collection and writing. However, as I was not the principle author, I have not included this 
review in the thesis but refer to it in the text. However, in addition to the systematic review, I 
have also been involved in a number of other reviews and for these have searched the 
literature thoroughly. A list ofthe studies that have described the management of MDR-TS in 
children is shown in Table 3. As with the chapter above, rather than simply presenting a list of 
the articles that have been found, I present an evidence-based discussion of the management 
of DR-TS in children. 
Treatment initiation 
The diagnosis of DR-TS in children is either confirmed or presumed. Confirmed disease occurs 
when M. tuberculosis is isolated from the child with either phenotypic or genotypic resistance. 
In published studies of children with MDR-TS the proportion culture-confirmed ranges from 
30%144 to 100%.58,191-196 Although a number of these investigations excluded presumed cases, 
it is clear from studies of drug-susceptible paediatric TS, that confirmation is usually achieved 
in only about 20% of cases with clinical evidence of disease.5 This suggests a significant 
proportion of children treated for DR-TS should be presumptively diagnosed. A presumptive 
diagnosis of DR-TS can be made on clinical symptoms, signs and radiology, in combination with 
Drug-resistant tuberculosis in children James Seddon Page 143 
risk factors for drug resistance, such as contact with a confirmed or presumed DR-TB source16. 
197 or the failure to respond to a first-line regimen. The operational definition of failure is 
challenging and includes ongoing microbiological positivity, non-resolving symptoms or signs 
of TB, persistent or deteriorating radiology and poor weight gain or weight IOSS.197 Although 
the time course is different for each child, all should be improving by two months, if therapy is 
effective. 
Children with presumed DR-TB should be started on effective therapy as soon as possible to 
avoid progression to severe disease, worse clinical outcome and ongoing transmission. 
However, empiric therapy for DR-TB may needlessly expose a child to toxic medications. 
Extensive efforts should, therefore, be made to confirm the diagnosis with intensive sampling 
from the child. Dependent on age of the child and health care resources, attempts can be 
made to obtain sputum samples, gastric aspirates, induced sputum samples, biologic fluid 
samples, nasopharyngeal aspirates, lymph node aspiration biopsy or tissue biopsy.5, 198-201 With 
extensive sampling the proportion of children with a confirmed diagnosis can rise to greater 
than 50%.99 Invasive methods, such as broncho-alveolar lavage, bronchoscopic biopsy or open 
lung biopsy may be in the child's best interest if a confirmed diagnosis can be made.202 All 
isolates confirmed as resistant to rifampicin should be sent for full second-line DST 
assessment. 
Regimen design and treatment duration 
The WHO has placed the drugs used in the treatment of DR-TB in five groups;197 drug 
characteristics will be discussed in the next section. Group 1 drugs are considered first-line 
with the remainder second-line. Few of the second-line drugs are produced in paediatric 
formulations, and the pharmacokinetics of most are incompletely studied in young children.203 
This means that optimal dosing is unknown for many of these medications and that tablets 
must be broken or cut, potentially leading to inaccurate dosages and blood concentrations 
that are sub-therapeutic or toxic. The taste of the medications is often unpalatable and a 
number of the drugs can cause vomiting and diarrhea.203 This may not only affect the amount 
of drug absorbed but also deter adherence. Daily injectable drugs are usually given for the first 
few months of treatmentS8.191-192, 204-205 and the pill burden can be vast; the child may require 
multiple TB medications, cART, antibiotics, as well as vitamin and calorie supplements. The 
number of tablets can be divided and spread over the course of the day which may improve 
tolerability but can make DOT challenging. Drugs can be mixed with different foods or drinks 
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and, in some situations, nasogastric or percutaneous endoscopic gastrostomy feeding may be 
appropriate. A programmatic dosing table is demonstrated in Table 4. 
Guidelines suggest that the decision on which drugs to include in a DR-TB treatment regimen 
should be guided by the DST of the child's isolate. Ifthis is not available, regimen composition 
should be guided by the DST pattern of the presumed source case.16, 140-141, 197,206 If DR-TB 
treatment is given for failure of a first-line regimen, the child should be assumed to have TB 
that is resistant to rifampin and isoniazid. For children with confirmed MDR-TB, or those with a 
clear MDR-TB source case, there is no role for rifampicin. However, if the child is either failing 
first-line therapy or there are multiple source cases, it may be appropriate to include 
rifampicin for the first six months to treat any potential drug-susceptible organisms. However, 
the drug-drug interactions seen with rifampicin must be considered, especially in those HIV-
infected/07 and there is some evidence that the fluoroquinolones are less effective in 
rifampicin-containing regimens.20s-209 
When designing a regimen to treat children with MDR-TB, the target should be to use at least 
four drugs which are likely to have activity against the infecting organism (Figure 1).16,140,142 As 
they are effective drugs, with few adverse effects,2l0 any first-line drugs to which the organism 
has not been shown to be resistant should still be used. Even though the organism is resistant 
to isoniazid, it is sometimes used at a high dose, in case of low-level resistance.91 High level 
resistance to isoniazid is usually caused by mutations in the katG gene, while low level 
resistance that may be overcome with higher doses (15-20 mg/kgJday) is usually caused by 
mutations in the inhA promoter region. InhA mutations usually confer resistance to 
ethionamide.90 With increasing use of genotypic diagnostics, the implications of different 
mutations will become increasingly important.92, 2l1-212 
The next step is to add a second-line injectable drug from group two and a fluoroquinolone 
from group three.142 The later generation fluoroquinolones (Ievofloxacin and moxifloxacin) are 
more effective than earlier generation (ofloxacin) in vitro,213-215 but are poorly studied in 
children. Further drugs from group four are then added. Either ethionamide or prothionamide 
should be used (if no inhA mutation is documented) as their metabolic pathways are similar 
and cross-resistance is total.214 The same is true for cycloserine and terizidone and only one of 
these two should be used.214 Para-aminosalicylic acid (PAS) can be added if there are not 
sufficient effective drugs at this stage but due to gastrointestinal intolerance, the other drugs 
from group four are usually used in preference. Finally, agents from group five can be added if 
required. Drugs from group five are described as having relatively weak or uncertain activity 
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against M. tuberculosis. 16,197 However, both clofazimine and Iinezolid have, in recent studies, 
demonstrated promising efficacy and can be considered useful drug options.216-m Novel 
agents such as delamanid,218 PA_824219 and bedaquiline220 are in advanced stages of clinical 
trials. However, as no child-friendly formulations have been produced or any paediatric 
pharmacokinetic studies conducted, it will be a number of years before these drugs are 
available for use in children. 
The decision on number of drugs and duration of therapy is dependent on both extent of 
disease and degree of drug resistance, as well as penetration to different body sites and 
treatment response, For children with cavitary or widespread disease, with resistance to only 
rifampicin and isoniazid, treatment is usually given for 18 months from the time of sampling of 
the first negative culture. Good outcomes have been reported in children treated with 
regimens of this duration, even with extensive disease.s8, 144,192,205 Treatment normally 
includes an injectable drug for the first four to six months; given daily, Limited evidence 
currently exists regarding the efficacy, and reduced toxicity, of giving three times a week.140 
The systematic review of MDR-TB treatment in children suggests that in those studies where 
injectable drug use was more common, treatment outcomes were better.221 WHO has recently 
recommended that injectable drugs should be given for eight months as longer durations are 
associated with better outcomes in adults.1°O For older children with extensive disease this 
may be appropriate, but for most children four to six months is likely to be sufficient.221 For 
children with limited, paucibacillary disease, such as isolated intra- or extra-thoracic lymph 
node involvement and with susceptibility to the second-line drugs, it may be possible to treat 
the child for 12-15 months in total, dependent on response. It may be possible in such 
situations to give a shorter duration of the injectable medication or omit the injectable 
medication altogether and treat only with oral drugs. Although evidence for such shorter 
regimens is lacking and these regimens are of unproven efficacy, good treatment outcomes 
have been seen in some studies.s8, 205, 222 If the isolate is XDR or pre-XDR, (see Table 9 for 
definitions) treatment relies on less effective drugs and in reported studies of children with 
extensive resistance, more drugs have been used and the treatment given for a minimum of 24 
months in total.192,196In the treatment of XDR-TB, consideration can be given to the inclusion 
of streptomycin, as cross-resistance between second-line injectables is incomplete.223 
There is limited available evidence to inform the management of TS in children caused by 
isolates resistant to isoniazid alone. A single study of children with isoniazid mono-resistant 
(HMR) TB describes good treatment outcomes using three to four drugs.224 Guidelines suggest 
treatment for six to twelve months with rifampicin, pyrazinamide and ethambutol.16,140,142In 
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cases of extensive disease or for TBM, a fluoroquinolone and one other drug can be added. A 
study assessing the treatment of 18 children with RMR-TB demonstrate good outcomes when 
treated with four months of amikacin and a total of 18 months using a further 4-5 drugs.225 
Guidelines suggest that RMR-TB can be treated with isoniazid, pyrazinamide, ethambutol and a 
fluoroquinolone for 12-15 months.16 In cases of extensive disease an injectable agent can be 
employed for the first few months, a further drug can be added and treatment extended to 18 
months. If genotypic tests are employed to perform DST, most national programs advise 
treating RMR-TB with an MDR-TB regimen as these tests do not identify all of the mutations 
conferring isoniazid resistance.226 
In addition to TB drugs, guidelines suggest children with TB should be given pyridoxine if they 
are HIV-infected, malnourished, breast-fed or are being given terizidone, cycloserine or high-
dose isoniazid/6 as pyridoxine deficiency is common.227 Most experts put all children being 
treated for DR-TB on multivitamin supplements. Steroids have been demonstrated to improve 
outcome in children with TBM228-BO and are additionally advised for airway obstruction and 
pericardial TB.16, 140 Nutritional and metabolic requirements should be assessed as these 
children are commonly malnourished 191-192,204 and have often been in a catabolic state prior to 
the diagnosis of DR-TB. They may also have high calorific requirements due to the ongoing 
tissue damage, repair and inflammation. 
Other adjunctive treatments include bronchoscopy and surgery. In cases of intra-thoracic 
lymph node disease, with external pressure on the airways leading to compression and 
respiratory compromise, assessment by bronchoscopy is advised.231-232 In cases of extensive 
resistance, where the disease is localized to one anatomical lobe or part of the lung, surgical 
resection may still have a place. If there is extensive destruction and fibrosis, it may be difficult 
for some drugs to penetrate into lesions with poor vascularization. Enucleation of the nodes 
may be required bronchoscopically or surgically, both to relieve the pressure on the airway 
and also to de-bulk the lymph node lesion.m . 233 
Management of co-morbid conditions 
Co-morbid medical conditions can increase the risk of TB and affect treatment outcomes. 
Examples include HIV infection,63 diabetes, 234 and malnutrition.43 Rates of HIV infection in 
paediatric MDR-TB cohorts range from 0%144.222 to 54%.l9l All children treated for DR-TB 
should be offered testing for HIV infection following counselling and consent from 
parents/guardians or, if old enough, the child. Important practical considerations in the co-
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treatment ofTB and HIV infection include the timing of initiation of cART, IRIS, drug-drug 
interactions97,177, and overlapping toxicities of cART and TB therapy.203 Generally, it is 
recommended that children with DR-TB and HIV infection be started on cART within two 
weeks of initiating TB therapy.15,197, 235 This will decrease the likelihood of adverse drug 
reactions while allowing rapid initiation of immunorestorative therapy. The management of 
TBM in this situation is complex and requires further investigation.236 IRIS occurs within the 
first few weeks of ART when a resurgent immune system begins to recognize M. tuberculosis 
antigens183-185 and, when severe, may respond well to corticosteroids. Differentiating IRIS from 
treatment failure can be challenging but decreasing HIV viral load and improving CD4 count 
should point to IRIS. Little data exist on the interactions between cART and second-line TB 
therapy in adults97,177 with even less for children.203 In general, stavudine should be avoided, 
and concomitant use of tenofovir and an injectable requires regular testing of renal function 
and electrolytes. 
For children with DR-TB and diabetes, more frequent glucose monitoring may be indicated as 
both TB disease and some TB drugs (rifampicin, ethionamide, PAS and fluoroquinolones) can 
disrupt glycemic control. Malnourished children should be treated according to established 
protocols237 and malnutrition should be prevented by the provision of nutritional support to 
children and their families. 
Morbidity associated with drug-resistant tuberculosis 
Chronic pulmonary disease may exist concurrent with pulmonary DR-TB or can occur later due 
to chronic lung inflammation and tissue damage. Peak flow testing or more extensive 
spirometry should be carried out with appropriate infection control precautions if the child is 
old enough to co-operate. Breathing exercises and physiotherapy are advised to improve 
function and as there is frequently a reversible component, a trial of bronchodilators is often 
merited. 
Little is published regarding osteo-articular DR-TB in children. The few case series of spinal 
disease describe relatively good treatment outcomes.238-239 It is advised that children should be 
followed by orthopaedic surgeons as deformities can deteriorate with the growth of the child. 
Spinal lesions particularly need to be monitored for many years as spinal growth can 
exaggerate any deformity, with the potential to compress the spinal cord and cause 
neurological damage. In settings where there are no orthopaedic specialists, nurses and 
community members can assist with limb and spine splinting and with physiotherapy, Reports 
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of DR-TBM in children describe very poor outcomes.193. 240 TBM can cause devastating 
neurological damage and affected children ideally should have access to intensive 
physiotherapy and occupational therapy during and after their illness. Developmental 
assessments and level of functioning should be determined at the end of therapy and children 
should be followed up to monitor progress and to provide support. The care of severely 
disabled children is challenging and parents should be supported with access to care services 
as well as assistance in funding applications for resources to which they are entitled. 
Although most of the adverse events of the drugs reverse on termination of therapy, the 
effects on hearing241 and vision are often permanent. These can have a significant impact on 
the child's development and quality of life.242-243 Hearing loss in adults treated for MDR-TB is 
common244 but in children is poorly described. One study assessing hearing loss documented 
ototoxicity in 7% of children treated for MDR-TB.204 Another study found hearing loss in 25% of 
children.245 Adverse effects on vision and hearing should be quantified and appropriate aids 
that will improve function should be given to the child. The child may need physical 
intervention, such as hearing aids, or they may need extra school support or financial 
assistance. A final area of morbidity that is seldom addressed is the psychological aspect of 
both the condition and its treatment.246 Children receive treatment for extended periods and 
TB is stigmatizing in some contexts. It may be necessary for the child to be admitted to hospital 
initially but for the majority, ambulatory treatment should be the norm, sparing the child 
separation from friends, families and communities. 
Treatment monitoring 
Children should be monitored for three reasons: to determine response to therapy; to identify 
adverse events early; and to promote adherence. A suggested monitoring schedule, which can 
be adapted to local conditions and resources, is demonstrated in Table S. Response to therapy 
includes clinical, microbiological and radiological monitoring.16 lt is advised that children are 
clinically assessed on a regular basis to identify symptoms or signs that might signal response, 
including activity levels, respiratory function and neurological development.16 Height and 
weight should be measured regularly and plotted on an appropriate percentile chart.247 For 
children with pulmonary disease, respiratory samples should be collected. For older children, 
able to expectorate, the adult schedule is suggested, with monthly sampling.197 For younger 
children, with an initial positive smear or culture result, samples can initially be taken monthly. 
After culture conversion this can be carried out every two to three months. Significant rates of 
'cure' rather than simply 'treatment completed' have been reported in children treated for 
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MDR-TB, implying that ongoing microbiological testing is possible, even in young children.58,192, 
195,204,222 For those with negative smear and culture samples at treatment initiation, samples 
are obtained if the clinical or radiological situation changes. All samples should be sent for 
culture and D5T, in addition to smear microscopy. Finally, regular radiological monitoring with 
CR is advised for children with pulmonary disease16 with additional radiology if clinically 
indicated. It can be useful to have a CR at the end of therapy to provide a baseline for follow-
up. Although CR improvement is an important indicator of successful treatment response, 
complete resolution may not occur and a normal CR is not required to complete therapy. In 
the majority of reported cases, however, significant CR resolution at the end of therapy was 
observed.58 
Adverse events 
In children treated for MDR-TB, toxicity is common, occurring in up to 40% of cases.221 
Significant adverse events, however, and ones that necessitated stopping or changing 
treatment, were less common. The toxicity of the first- and second-line TB drugs has been well 
described in other reviews and is summarized in Table 3.140,203.210 The toxicity of the second-
line drugs in children will be described later in the thesis. This section therefore focuses on the 
monitoring and management of adverse events, specifically in children. Due to renal, thyroid, 
auditory and visual adverse events possible with second-line TB drugs, it is advised that prior 
to initiating therapy, children should have their hearing and vision tested as well as their renal 
and thyroid function. Children old enough to co-operate (usually from about five years) can be 
assessed using Ishihara charts and by pure tone audiometry (PTA).248 Oto-acoustic emissions 
(OAE) can be used to test the hearing in younger children but visual testing is challenging for 
this age group. Clinicians should, however, be reassured that the incidence of ocular toxicity is 
very rare (0.05%) when ethambutol is given at the recommended dosage.249 
Children should be assessed clinically for adverse events on a regular basis by their healthcare 
provider and on a daily basis by DOT supporter and/or caregivers following training in the 
recognition of signs and symptoms of adverse events. Thyroid function should be checked 
regularly if on a potentially thyrotoxic drug. Renal function and hearing should also be tested 
while taking an injectable drug. There is no need to monitor full blood count or liver function 
routinely. Transient elevations in transaminase levels are common at the start of TB therapy 
and are rarely associated with significant adverse events.210 Due to the increased risk of 
myelosuppression, a regular full blood count is advised if the child is receiving Iinezolid.250 
Drugs to alleviate adverse events, such as analgeSiCS, anti-emetics, anti-pruritics and drugs to 
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manage diarrhoea, are likely to improve adherence if provided free of charge. TB drugs should 
also always be provided without cost to the family. A suggested monitoring schedule is shown 
in Table 5 with the management of adverse events described in Table 6. 
Promoting adherence 
DOT is a key component of successful treatment and the use of community health workers 
(CHW) or DOT supporters can be valuable for promoting adherence and identifying adverse 
events early.174. 251 DOT is a comprehensive package of support and assistance, rather than a 
paternalistic observation of ingestion.2S2 Although young children, in effect, always receive 
I 
their treatment under DOT, in a programmatic sense DOT implies treatment given under the 
supervision of someone outside the family. DOT should be made as easy as possible; CHWs 
and DOT supporters can be employed to give the medications at a convenient location such as 
at home or at a nearby c1inic.174 Long waiting times, peer pressure, unsympathetic staff and 
stigmatization at health facilities can deter attendance at clinic and impair overall adherence. If 
children are old enough to understand, it is important to invest time and effort in educating 
them about the disease and allow them to take responsibility for their illness and their 
treatment. Adolescents can be at high risk of severe disease and adherence can be challenging 
with associated poor treatment outcomes.197• 2S3 If the child is not old enough, the parents 
must be prepared appropriately. The child and family should be warned about the possibility 
of all adverse events and what to do if they occur.16 These adverse events should be managed 
proactively and promptly. Creative mechanisms should be employed to encourage adherence, 
with reward systems appropriate to the child's age; mobile telephone technology has been 
used successfully in adults and could play an important role in the adolescent age group.17S 
Infection control 
Children traditionally have been considered to pose a low infection control risk as they 
generally have paucibacillary disease and limited tussive force. However, as the diagnosis of 
DR-TB is frequently delayed in children,58. 204. 221 those with diagnosed DR-TB tend to be older 
than those with drug-susceptible disease 254-255 and have more severe pathology. In one 
paediatric MDR-TB cohort, over 60% of children were sputum smear-positive.192 Infection 
control should therefore form a vital part of any management strategy.256 
Children are a significant transmission risk if they have sputum smear-positive disease and a 
moderate risk whilst they still have sputum CUlture-positive disease. While smear-positive they 
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should sleep in a room separate from others. Those cUlture-positive should not sleep in the 
same room as the most vulnerable such as those HIV-infected or the very young. If the climate 
allows, children should be encouraged to spend as much of their time outside as possible. Play, 
eating and schooling areas should attempt to facilitate this. When outside, it is reasonable to 
allow children to play and eat without a mask. Where it is not possible to spend long periods of 
time outside, windows should be kept open, passive air extraction systems put in place and 
areas with sufficient resources should consider active air flow management systems. Those 
without pulmonary disease are unlikely to pose an infection risk unless there is pus 
discharging, uncovered from a body site. 
Staff should protect themselves when interacting with infectious children. If the child is 
sputum smear-positive, staff should wear a fit-tested respirator with a filter efficiency of 95% 
or greater (e.g., N95, N99, N100). More comprehensive guidance on infection control 
measures to employ in healthcare facilities has been documented by the WHO and the COC.257-
258 
Multidisciplinary care 
Multidisciplinary care is a cornerstone in the successful management of children with OR-TB. In 
addition, the child and caregiver should be engaged as active members of the health care 
team. Input from pharmacists can be invaluable in providing appropriate medications, 
formulations and advice concerning interactions and pharmacokinetics. Support from a 
dietician is important in monitoring and planning calorie intake and the correct balance of 
nutrients, vitamins and minerals. Physiotherapy and occupational therapy are of benefit not 
only for those with neurodevelopment involvement but also for those with respiratory and 
musculo-skeletal deficit. Social services should assess home circumstances and support the 
caregiver to look after a child who may have complex medical needs and must take mUltiple 
medications. They must also assist the family in securing any funding or grants that they are 
eligible for to assist in the process of home-based care. In cases of neglect, abuse or drug and 
alcohol use, child placement with alternative caregivers may be necessary. In areas of limited 
resources, many of these key tasks can be carried out by CHWs. Ongoing education is 
important and when no longer infectious, children should be encouraged to return to school. 
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Table 3 - Studies describing drug-resistant tuberculosis treatment in children 
First author Year of study Location Number of children included Number culture-confirmed Treatment success Adverse events 
(%) 
Seddonm 2003-2008 Cape Town, South Africa 111 111 88 (79) NS 
Fairl ie "~" 2008 Johannesburg, South Africa 13 13 7 (54) 2 
leimanezzz 1998-2006 latvia 76 NS 70 (92) 26 
Feja l44 1995-2003 New York, USA 20 6 16 (80) 4 
Mendez Echevarriazos 1994-2005 Madrid, Spain 8 5 8 (100) 4 
Granich~~Y 1994-2003 California, USA 10 NS 9 (90) NS 
DrobacLU4 1999-2003 Lima, Peru 38 28 36 (95) 16 
Schaaf~H 1998-2001 Cape Town, South Africa 39 39 21 (54) 20 
Padayatchim 1992-2003 Durban, South Africa 8 8 1 (13) NS 
Schluger l 94 1983-1993 New York, USA 2 2 2 (100) NS 
Suessmuthm 2005 Hannover, Germany 1 1 1 (100) NA 
PinonLbU 2010* Turin, Italy 2 NS 1 (50) 0 
Kj611erstrom 196 2011* Lisbon, Portugal 4 4 4(100) 3 
·year of publication as year of study unclear; NS: not stated 
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Table 4 - A proposed dosing table for the drugs used in the treatment of drug-resistant tuberculosis in children 
Isoniazid Pyrazinamide Ethambutol Ofloxacin Levofloxacln Moxlfloxacin Terizidone Ethionamide PAS 
Dosing range (mg/kg) 15-20 30-40 20-25 15-20 7.5-10 7.5-10 15-20 15-20 150 
Weight (kg) Tablet size (mg) 100 500 400 100 200 400 250 400 250 250 4000 
3-4.9 50 125 100 100 100 100 • • 62.5 62.5 500 
(1/2 tab) (1/4 tab) (1/4 tab) (1 tab) (1/2 tab) (1/4 tab) (1/4 cap) (1/4 tab) (1/8 sach) 
5-6.9 100 250 100 150 100 100 62.5 • 125 125 1000 
(1 tab) (1/2 tab) (1/4 tab) (HHab) (1/2 tab) (1/4 tab) (1/4 tab) (1/2 cap) (1/2 tab) (1/4 sach) 
7-9.9 150 250 200 200 150 200 125 • 187.5 187.5 1500 
(1 Y, tab) (1/2 tab) (1/2 tab) (2 tabs) (3/4 tab) (1/2 tab) (1/2 tab) (3/4 cap) (3/4 tab) (3/8 sach) 
10-13.9 200 500 300 300 200 200 125 100 250 250 2000 
(2 tabs) (1 tab) (3/4 tab) (3 tabs) (1 tab) (1/2 tab (1/2 tab) (1/4 tab) (1 cap) (1 tab) (1/2 sach) 
14-19.9 300 500 400 400 300 300 187.5 200 375 375 3000 
(3 tabs) (1 tab) (1 tab) (4 tabs) (1 Y, tab) (3/4 tab) (3/4 tab) (1/2 tab) (1 Y, caps) (1 Y, tab) (3/4 sach) 
20-29.9 400 750 600 600 400 400 250 200 500 500 4000 
(4 tabs) (1 Y, tab) (1 Y, tab) (6 tabs) (2 tabs) (1 tab) (1 tab) (1/2 tab) (2 caps) (2 tabs) (1 sach) 
30-39.9 400 1000 800 800 600 600 312.5 300 625 625 6000 
(4 tabs) (2 tabs) (2 tabs) (8 tabs) (3 tabs) (1 Y, tab) (1 X tabs) (3/4 tab) (2 Y, caps) (2 y, tabs) (1 Y, sach) 
>40 400 1500 1200 1200 800 800 375 400 750 750 8000 
(4 tabs) (3 tabs) (3 tabs) (12 tabs) (4 tabs) (2 tabs) (1 Y, tabs) (1 tab) (3 caps) (3 tabs) (2 sach) 
- ---
_._-
---------
·Unable to create an appropriate fraction of a tablet for a child of this weight 
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Table 5 - A proposed monitoring sched ule t o determine response and detect adverse events when treating drug-resistant tuberculosis in children 
Month 
All children Baseline 
1 2 3 4 5 6 9 12 15 
HIV status • 
Toxicity (symptoms, signs) • • • • • • • • • • 
Height and weight • • • • • • • • • • 
Aud iolog/ • • • • • • • 
Colour vision test ingL • • • • • • • • • • 
CR3 • • • 
TB cu lture and DS~ • • • • • • • 
Creatinine and potassium' • • • • • • • 
TSH, T/ • • • • • • 
Haematology (FBC with differential)b • • • • • • • • 
H IV-infected 
LFTs, Cholesterol • • • 
CD4 count and viral load • • • 
HIV: Human Immunodeficiency Virus; CR: chest radiograph; TB: tuberculosis; D5T: drug susceptibility test; TSH: thyroid stimulating hormone; FBC: full blood count; LFT: liver function tests; 
IMonthly whi lst on an injectable and at six months following termination of injectable 
21f on ethambutol 
'If any pulmonary involvement or at any point if cl inically indicated. To be repeated at the end of treatment 
18 
• 
• 
• 
• 
• 
Ongoing 
• 
• 
• 
• 
• 
• 
• 
'Monthly if old enough to expectorate. If unable to expectorate and initially smear or culture positive, monthly until culture-converted then three monthly. If initially smear and culture negative, to perform if clinically 
indicated. For extra-pulmonary TB, samples can be taken when cl inically indicated 
sif on ethionamide, prothionamide or PAS 
6if on Iinezolid or HIV-infected 
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Table 6 - The management of adverse events in the treatment of drug-resistant tuberculosis in children140-142,197, 203, 261 
Adverse event TB drugs possibly cART drugs Monitoring Management 
responsible possibly 
responsible 
Hearing lossz4l Amikacin, kanamycin, PTA or OAE assessed If any hearing loss is detected strong consideration should be given to stopping/switching 
capreomycin and classified using the injectable drug 
ASHA gu idelines 248 
Renal impairment'41 Amikacin, kanamycin, Tenofovir Blood testing 1. Evidence of mildly elevated creatinine should prompt re-testing 
capreomycin, 2. Markedly elevated creatinine or potassium should lead to the cessation of all nephrotoxic 
drugs 
Visual impairmentlbl Ethambutol Clinical or Ishihara Any deterioration in visual fields or colour vision should lead to stopping/switching the 
Chart ethambutol 
Hypothyroidism"b " Ethionamide, Blood testing 1. If T4 is low, continue medications and supplement with O.05mg thryoxine supplement daily 
prothionamide, PAS 2. Continue to monitor T4 and consider increasing supplementation to O.lmg daily 
Hepatitis"U Rifampicin, isoniazid, Nevirapine, Clinically and blood 1. Clinical suspicion of hepatitis (vomiting not directly associated with medications, 
pyrazinamide, ethionamide, efavirenz, Pis testing abdominal pain or jaundice) should lead to immediate cessation of all hepatotoxic drugs 
prothionamide 2. Investigation into non-drug aetiologies (hepatic viruses etc.) should take place 
3. Treatment should continue with medications that are less hepatotoxic (ethambutol, 
injectables, fluoroquinolones, terizidone/cycloserine and PAS) . 
4. The hepatotoxic TB drugs can be re-introduced one-by-one every two days 
5. Given that the child is on treatment for DR-TB the relative merits of re-introducing 
isoniazid, rifampicin and pyrazinamide should be considered . 
Rash All TB drugs Nevirapine, Clinical 1. Mild reactions - symptomatic relief 
efavirenz 2. Stevens Johnson reactions - immediate cessation of all drugs (including all TB and HIV 
medications) until the symptoms have resolved. 
3. Sequential re-introduction can then occur. Re-start the TB medications one by one every 
two days and monitor response. If the child was on cART, once TB treatment is re-
established all cART medications should be restarted at the same time to prevent the 
development of resistance. 
4. Once TB and cART drugs are established other agents can be added. Co-trimoxazole is an 
important, but rare, cause of severe skin reactions. 
- ---
-_._--- -
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Vomiting Ethionamide, Zidovudine, Pis Clinical If nausea and vomiting compromise drug delivery, it may be prudent to split the dose of 
prothionamide, PAS, ethionamide/prothionamide or give it at a separate time from the other drugs 
ethambutol 
Diarrhoea PAS, ethionamide, Zidovudine, Pis Clinical 1. PAS is usually given twice a day but if diarrhoea is severe, the dosage can be reduced or 
prothionamide the drug given in smaller quantities more frequently 
2. If diarrhoea is profuse, regular monitoring of hydration status and serum potassium should 
be conducted 
3. CHWs or DOT supporters can be trained to provide oral rehydration solutions for those 
with vomiting or diarrhoea. 
Peripheral Isoniazid, Stavudine, Clinical 1. Mild reactions - increase the dose of pyridoxine or reducing the dose of the offending TB 
neuropathl63 didanosine drug 
2. If severe or persisting in spite of above, the TB drug should be stopped. 
Neuropsychiatric Terizidone, cycloserine, Efavirenz Clinical 1. As a first step, it is important to verify that the child has been prescribed and is receiving 
effects264 isoniazid, fluoroquinolones the correct dose as over-dosing can be associated with adverse events 
2. The next step is to reduce the dosage of the drug felt most likely to be responsible and 
monitor the effect. 
3. If this does not help then the drug should be stopped. 
4. If no resolution then the drug should be re-introduced and the next most likely drug 
reduced in dose and then, if necessary, stopped. 
Joint problems.lb~ Pyrazinamide, Clinical 1. Analgesia 
fluoroquinolones 2. Reducing dose or stop one of potentially offending drugs 
Metabolic problems linezolid Stavudine, Clinical and blood tests Lactic acidosis is life-threatening and if determined, all potentially implicated drugs should 
didanosine, be stopped 
zidovudine 
Bone marrow Linezolid Zidovudine Clinical and blood tests The responsible drug should be switched or stopped 
,--suppression266 ---
--
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Figure 2 - An algorithm to aid in the construction of a drug-resistant tuberculosis treatment 
regimen for children 
DR-TB diagnosed 
Use any Group 1 drugs to which 
the isolate has not been shown to 
be resistant 
Add a drug from Group 2 
Add a drug from Group 3 
Add drugs from Group 4 until four 
active drugs prescribed 
Add drugs from Group 5 until four 
active drugs prescribed 
Pyrazinamide 
Ethambutol 
Rifampicin· 
Amikacin 
Kanamycin 
Capreomycin 
Streptomycin" 
Ofloxacin 
levofloxacin 
Moxifloxacin 
Ethionamide (or prothionamide) 
Terizidone (or cycloserine) 
PAS 
High-dose isoniazid 
Clofazimine 
Linezolid 
Amoxicilli n/ clavu la nate 
Imipenem/ cilastatin 
Thiacetazone (if confirmed HIV 
negative) 
Clarithromycin 
·Consider including rifampicin for six months if the child is treated for failure of first-line therapy or If there are multiple potential 
source cases 
"Consider streptomycin if the isolate is found to be resistant to amikacin, kanamycin or capreomycin but is demonstrated to be 
susceptible to streptomycin 
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Literature review 3: second-line tuberculosis drugs in children 
Concepts from the following topic have been written as articles: 
• Seddon JA, Hesseling AC, Marais Bl, Mcf/Jeron H, Peloquin CA, Donald PR, Schaaf HS. 
Paediatric use of second-line anti-tuberculosis agents: A review. Tuberculosis (Edinb) 2012; 
92: 9-17 
• Schaaf HS, Seddon lA, Caminero JA. Second-line antituberclosis drugs: current knowledge 
and controversies. Prog Respir Res 2011; 40: 81-95. 
• Seddon lA, Schaaf HS, Hesseling AC. Retooling existing tuberculosis drugs for children. Clin 
Infect Dis 2012 (in press) 
In this section, the literature surrounding the use of second-line TB drugs in children is 
reviewed. As with the two previous sections, the literature is presented as a discussion ofthe 
drugs and their use. The review starts by reviewing the properties of the drugs, moves to the 
toxicity of the drugs and concludes with a discussion of the interaction with cART medications. 
To search this literature systematically, a systematic review for each of the individual drugs 
would have needed to have been completed. This would have been a vast project and so 
although what follows is not a systematic review, it is comprehensive. Multiple data sources 
were accessed and references cross-checked to identify relevant articles. A summary of 
dosages and adverse effects is shown in Table 7. 
Characteristics of the second-line drugs in children 
Injectable medications used in the treatment of drug-resistant TB include the aminoglycosides, 
amikacin and kanamycin, as well as the cyclic polypeptide, capreomycin. Streptomycin, 
another aminoglycoside, was previously used widely in re-treatment TB cases in combination 
with first-line medications and this has led to high levels of resistance to streptomycin in 
strains already resistant to rifampicin and isoniazid. Hence, it is rarely used in the treatment of 
MDR-TB. However, streptomycin can be used in the treatment of XDR-TB, if the organism is 
found to be susceptible, as there is limited cross-resistance with the other injectable 
medications. High levels of cross-resistance between amikacin and kanamycin mean that if a 
strain is found to be resistant to one, the other is very unlikely to be of use.267 For children, 
amikacin is usually given in preference to kanamycin as it has a lower minimum inhibitory 
concentration (MIC) and the available ampoule sizes are smaller, preventing wastage. 
Amikacin and kanamycin are generally preferred to capreomycin as the first choice injectable 
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for MDR-TB in children with capreomycin reserved, in most programmes, for the treatment of 
XDR-TB. However, there is evidence that if a strain is resistant to an aminoglycoside it will 
already be resistant to capreomycin.268-269 Alternatively, if resistant to capreomycin there is a 
chance that it will still be susceptible to amikacin or kanamycin. The amikacin MIC for M. 
tuberculosis (strain type H37Rv) is 0.5-1.0jlg/mI214, 270-271 which compares to 2-4jlg/ml for both 
kanamycin and capreomycin.214, 270-271 Here, MIC in liquid broth culture refers to the 
concentration at which the drug inhibits mycobacterial growth as compared to a culture 
containing a 1:100 dilution of mycobacteria (i.e. 99% inhibition). Pharmacokinetic profiles have 
been studied in children receiving short-courses of aminoglycosides for bacterial infections 
given intravenously (IV}272 but not in prospective studies of children on prolonged courses of 
treatment, where it is typically given intramuscularly (1M). Half-lives (t 1/2) of 2.5-3.5 hours are 
reported for amikacin and kanamycin given IV.m As the maximum serum concentration (Cmax) 
is dose-dependent consideration should be given to therapeutic drug monitoring at the start of 
therapy to establish the ideal dose for each child.214 Time to maximum serum concentration 
(tmax) is at the end of the infusion for IV injections and is estimated to be between 30 and 60 
minutes for 1M injections. Elimination is by urinary excretion and doses should be reduced in 
patients with renal impairment. Guidelines recommend that the dose of amikacin in children 
should be from 15 to 22.5mg/kg dailyl6, 197 and kanamycin or capreomycin from 15 to 
30mg/kg. Oral absorption is very poor and so administration for all three agents is only 
possible via 1M or IV injection. 
The fluoroquinolones have a central role in the management of MDR-TB in children. Resistance 
to early generation fluoroquinolones (ofloxacin) may not necessarily imply resistance to later 
generations (moxifloxacin or levofloxacin}.274 The MICs and mutant prevention concentrations 
(MPCs) of the fluoroquinolones follow a sequential progression with lower concentrations 
required to prevent growth in the higher generation fluoroquinolones.21S MICs, on plates of 
7Hll media, of 0.5,0.71,0.35,0.177 and 0.125Ilg/ml were reported for ciprofloxacin, 
ofloxacin, levofloxacin, moxifloxacin and gatifloxacin respectively, using a definition of the 
lowest concentration required to inhibit any growth within four weeks.213-214 Few studies have 
assessed the pharmacokinetics of the fluoroquinolones in young children; the available data is 
largely from studies in older children with cystic fibrosis.27S-277 None have been conducted in 
children treated for MDR-TB.278 Caparelli et al279 studied children aged six months to sixteen 
years after single gatifloxacin doses of 5, 10 and 15mg/kg bodyweight (maximum 600mg). Drug 
clearance was more rapid than in adults and children required a higher mg/kg dosage to 
achieve similar blood concentrations. This was confirmed in a study by Chien et a 1280 who 
studied 85 children, also aged six months to sixteen years, given IV or orallevofloxacin. IV and 
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oral dosing led to comparable blood concentrations. They concluded that children younger 
than five years of age clear levofloxacin almost twice as fast as adults and consequently are 
exposed to approximately one half of the dose. They recommend that children older than five 
years receive 10mg/kg daily but children less than five should be given 10mg/kg twice daily. 
Early bactericidal activity (EBA) studies showed that ofloxacin, 152levofloxacin, moxifloxacin and 
gatifloxacin281 all have activity close to that of isoniazid and activity exceeding that of isoniazid 
after several days of treatment. Whether this later effect relates to sterilizing activity is 
uncertain. Although ciprofloxacin has a low MIC, it is not recommended in the treatment of 
MDR-TB due to its poor EBA.166 
Thioamides include ethionamide and prothionamide; as the mechanism of action for the two is 
similar and cross-resistance is complete only one of the two should be used. The thioamides 
share a number of biochemical pathways with isoniazid in their activation and, dependent on 
mutation, can show cross-resistance.91· 1S4 Ethionamide has a narrow therapeutic margin 
between efficacy and toxicity with a MIC in broth (99% growth inhibition) of O.25-0.5Ilg/ml.271 
In adults, absorption from the intestinal tract is almost complete and is little affected by food 
or antacids.282 Protein binding is 30%283 and ethionamide distributes with ease throughout the 
body, including to the cerebrospinal fluid (CSF). In adults, peak plasma concentrations occur 
approximately two hours post dose and Cmax has been found to be between 1.9 to 2.5Ilg/ml 
following an oral dose of SOOmg.282• 284-285 For adults, increasing the dosage above 7S0mg 
results in severe intolerance and so for clinical purposes, the recommended peak serum 
concentration for susceptible strains of M. tuberculosis is 2.5Ilg/ml. Studies in children are 
limited. Published data include an isolated case report and a study evaluating CSF levels of 
ethionamide in children with TBM.284.286 Recently, a study from South Africa has demonstrated 
that dosages of 15-20mg/kg achieve adequate serum concentrations in children.287 Younger 
children (S2 years of age) eliminated the drug more rapidly than older children and HIV co-
infection was associated with lower concentrations. 
Cycloserine is an analogue of D-alanine, is bacterostatic and acts by inhibition of peptidoglycan 
synthesis. The alternative drug, terizidone, comprises two molecules of cycloserine attached to 
a molecule of terephtalaldehyde. The MIC for terizidone is very variable.2BB Cycloserine has a 
MIC in broth (99% growth inhibition) between 25-75Ilg/mI.214. 271 Cycloserine is completely and 
rapidly absorbed after oral administration with a tmax of 2-4 hrs.288-289 Distribution is 
widespread, including to the CSF. Although unaffected by orange juice or antacids, absorption 
is significantly delayed when taken with a high fat meal.290 There are no pharmacokinetic data 
to guide paediatric dosing in different age groups for either drug. 
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PAS is produced in two formulations: free acid PAS (enteric-coated slow-release granules) and 
sodium salt PAS (granules and tablets). The mechanism of action is unclear but may be related 
to thymidylate synthesis or disruption of acquisition of iron. MIC for drug-susceptible strains in 
broth is <1Ilg/mI291 (using the Alamar blue colourimetric method) and slightly higher (4-
81lg/ml) for some MDR-TB strains.214 PAS is 50-60% protein bound and tl/2 of the free drug is 
45-60 minutes. Absorption is increased with food214 and CSF penetration is poor. Since PAS has 
no post-antibiotic effect, it is recommended that twice daily dosing is used to constantly keep 
its concentration above MIC.292 Treatment with either formulation results in similar blood 
concentrations. Despite being the oldest TB drug, only one small English language study of four 
children has reported paediatric pharmacokinetic data.293 Children were given 300mg/kg/day, 
in five divided doses of 60mg/kg. T max was at 60 minutes with Cmax between 6.25Ilg/ml and 
12Ilg/mJ. CSF peak concentrations were generally greater than 11lg/mJ. 
The group five medications have either uncertain efficacy against M. tuberculosis or an 
uncertain place in the treatment of MDR-TB. Clofazimine is an old drug, discovered in 1954. 
Used extensively to treat Mycobacterium leprae, it has only recently been used in the 
treatment of M. tuberculosis disease. The mechanism of action is unknown but it has an MIC in 
broth of Slilg/mi (99% growth inhibition)271,294 and may have a synergistic effect when used in 
combination with amikacin.295 Oral absorption is 45-62% and is increased with a high fat 
meaJ.296 Serum concentrations are often very low214, 296 but as the drug tends to concentrate 
inside macrophages it may be more effective at killing intracellular organisms than the 
concentrations in serum would suggest. A recent study from Bangladesh demonstrated that 
adults with MDR-TB benefit from the addition of clofazimine to their treatment regimens. 217 
No pharmacokinetic studies have been conducted in children. Linezolid is an oxazolidinone, a 
new class of antibiotic with a novel mechanism of action. Cross-resistance is therefore unlikely 
but it does appear that the MIC is increased in strains already resistant to other first-line 
drugs.214 The pharmacokinetics of linezolid has been studied in children of various ages297.298 
and children have more rapid clearance and shorter t1/2 than adults, indicating a need for more 
frequent dosing. However, the optimal dosing frequency in children with TB has not been 
established. It is well absorbed after oral administration and distributes widely, including good 
CSF penetration.299 EBA in an adult study was similar for once or twice daily dosing with 
600mg3OOand the limited clinical experience in children on treatment for XDR-TB has seen good 
outcomes with twice daily dosing in younger children and once daily in those older.301.302 
Thiacetazone was previously used extensively to treat TB and only fell out of favour with 
severe Stevens-Johnson reactions seen in association with HIV. The MIC (complete inhibition) 
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is O.4-1.0Ilg/mI303 and cross-resistance with ethionamide is 29-79%. In adults, it is well 
absorbed after oral administration with Cmax 1.591lg/ml, t max 3.3 hours and t1/2 15-16 hours.304 
There are no published pharmacokinetic studies in children. The final drugs in class five are the 
beta-Iactams and the macrolide clarithromycin. Amoxicillin and the carbapenems (imipenem 
and meropenem) have some activity against M. tuberculosis, but MICs are not achievable in 
serum. When combined with clavulanic acid, however, the MIC is lower and becomes possible 
to achieve in serum.30S-307 The addition of ethambutol seems to provide a synergistic effect, 
even if given at sub-inhibitory concentrations.30s Amoxicillin and clavulanic acid are rapidly 
absorbed orally but the carbapenems must be given parentrally. Meropenem has good CSF 
penetration and has also been shown to be active against 'persistent' strains grown in 
anaerobic media.30s Clarithromycin has been used extensively to treat bacterial infections, 
non-tuberculous mycobacteria as well as M.lepra. Although MICs are high using agar 7H10 at 
99% inhibition of growth (4 to ~16Ilg/ml)309-310 it may have a bi-directional synergistic role with 
some of the first-line drugs - improving the efficacy of the first-line drugs as well as the first-
line drugs reducing its MIC.311-312 Moreover, it works mainly intracellularly and so this high MIC 
may not accurately reflect its bactericidal activity. Studies in children (aged six months to ten 
years) have shown that it is well absorbed orally and reaches Cmax (3.591lg/ml) after about 3 
hours. High doses are tolerated and food seems to increase bioavailability.313 
Safety and toxicity 
Monitoring and describing adverse effects in children is challenging; young children cannot 
articulate pain, nausea, vertigo, peripheral neuropathy, anxiety or confusion. Rashes are 
common due to a variety of aetiologies and the testing of hearing and vision is more difficult 
than in adults. However, it is particularly important to detect adverse effects as, in addition to 
life-threatening and unpleasant effects, growth and neuro-cognitive development may be 
affected. Children treated for MDR-TB are usually on mUltiple medications and determining 
the drug responsible for an adverse effect can be difficult. This is of concern as HIV frequently 
complicates MDR-TB and overlapping drug toxicity should be considered.97,177 
In the treatment of MDR-TB any first-line drugs to which the organism is still susceptible are 
used. The adverse effects of the first-line medications have been well described and children 
seem to develop adverse effects less frequently than adults.16, 314-317 Isoniazid can cause 
peripheral neuropathy,263 while pyrazinamide and isoniazid can lead to hepatitis. All can cause 
rash, gastrointestinal upset and arthritis.16, 261, 317 Isoniazid used at high dose has not been well 
studied and adverse effects may be more pronounced than with the traditional dose. Although 
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the incidence of ethambutol-related optic neuritis is much lower in children than in adults, 
concerns remain regarding toxicity. 167,249 
The aminoglycosides and polypeptides can cause peripheral neuropathy, hypersensitivity and 
rash, but the main toxicities of concern are nephrotoxicity, ototoxicity and vestibular 
derangement. Fatal renal failure and electrolyte imbalances, particularly hypokalaemia, have 
been reported in adults treated with capreomycin. 318 Hearing loss is irreversible, usually 
developing first in the high frequencies and then progressing to the speech recognition 
frequencies. If high frequency loss is detected early and the drug can be stopped without 
compromising the child's health, communication may be preserved. Therefore, unless 
monitored regularly hearing loss is only detected once communication problems develop. No 
studies have assessed toxicity using these agents in children with TB. Studies in neonates319 
and children with cystic fibrosis320 demonstrate limited toxicitl3 but assessment of hearing 
loss in children receiving longer courses of aminoglycosides following liver transplantation, as 
occurs in MDR-TB treatment, found hearing loss in lS of 66 children evaluated, using a 3SdB 
loss at one frequency to define hearing loss. 321 Adult studies of MDR-TB treatment 
demonstrate high rates of hearing loss, vestibular dysfunction and renal impairment, the latter 
two often reversible.322-324 In adults the cumulative dose is the greatest indicator of ototoxicity 
with a mean onset time of nine weeks following treatment initiation.273 Certain familial 
mitochondrial mutations predispose patients to hearing loss325-328 and aspirin may offer some 
protection. These mutations and their relationship with hearing loss have not been studied in 
children, however. 
The fluoroquinolones were shown in the 19705 to cause cartilage damage in the joints of 
juvenile beagles164 and although multiple studies and reviews have subsequently 
demonstrated safe use in children,165, 329-335 concerns remain. They can also cause 
psychological/neurological disorders, sleep problems, gastrointestinal upset and peripheral 
neuropathy. The newer fluoroquinolones seem to be associated with fewer adverse effects 
than the older medications,26S but caution must be exercised with moxifloxacin due to possible 
QT interval prolongation.336 When used in the treatment of MDR-TB, they are generally well 
tolerated in both adults and in children with few significant adverse effects.33o However, a 
large number of adverse effects have been documented in adults receiving a fluoroquinolone 
and pyrazinamide for preventive therapy.146, 337 The reason for this is not clear. 
Few studies have assessed the adverse effects of the thioamides on children. Both 
ethionamide and prothionamide are commonly associated with adverse effects338-340 and can 
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cause profound gastrointestinal upset; severe nausea and vomiting can compromise 
adherence for both adults and children. The severity of symptoms usually subsides with time 
but symptoms can be reduced by initially splitting the daily dose or introducing the drug 
gradually with escalation of the dose over time. The full dose, given once daily, should, 
however, be aimed for within a few weeks of starting treatment. The thioamides show 
structural similarities to the potent thyrostatic drug methimazole, which seems to inhibit 
thyroid hormone synthesis by inhibition of organification.341 As a result, hypothyroidism can 
occur.262,342-346 Pellagra-like rash347, hepatitis340, 348-354 and hypoglycaemia355 have also been 
documented as well as rare central nervous system adverse effects including seizures, 
encephalopathy and acute psychosis.347 Prothionamide seems to be marginally better 
tolerated in adults.356 
Cycloserine and terizidone have been poorly studied in children. In adults, cycloserine has 
been widely implicated in neuropsychiatric adverse effects such as anxiety, depression, 
confusion, psychosis, irritability, tremor, convulsions and aggression.264, 357-359 It has also been 
associated with hypersensitivity reactions in those with HIV360 and with an episode of 
encephalitis.361 From the very limited data that are available, terizidone seems to be better 
tolerated. Emerging data suggest that terizidone has fewer adverse effects (1%) than 
cycloserine (11%).362 
The newer granular formulation of PAS is well tolerated and easily administered to children. 
PAS can cause hypothyroidism,262, 363-364 an effect which may be potentiated by the 
concomitant use of ethionamide. 262 Gastrointestinal problems,365-366 hepatitis,367 
thrombocytopenia,368-370 hypoglycaemia,371 vasculitis, arthralgia, eosinophilia, malabsorption 
372-373 and a lymphoma-like syndrome (lymphadenopathy, rash and hepatomegaly)374-377 are 
other potential adverse effects. Hypersensitivity reactions, characterised by fever, 
conjunctivitis and rash, may occur in up to 5-10% of patients on PAS, usually within the first 
couple of months.366-367, 375-376 It may be possible to desensitise those with hypersensitivity to 
PAS by starting with a low dose and slowly increasing. 378 However this is not recommended. 377 
Toxicity of the group five drugs is considerable but adverse effects are less common in children 
compared to adults. There is much experience in the use of c10fazimine as it has been given 
extensively in the treatment of leprosy. It commonly causes gastrointestinal symptoms such as 
diarrhoea, nausea, vomiting and abdominal pain. The majority of patients develop a red-brown 
hyperpigmentation of the skin and conjunctiva which is reversible but may take many months 
to revert. A recent leprosy trial in India and China included 422 children less than 15 years of 
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age. Clofazimine was very well tolerated and few drug reactions were noted. Skin 
discolouration was usually short-lived and felt to be acceptable to patients.379 Adverse effects 
in children on short courses of linezolid are rare but include headache and gastrointestinal 
disturbance.266, 298, 380-382 With prolonged use in adults withdrawal ofthe drug is frequently 
required due to myelosuppression (including pancytopenia) and peripheral and optic 
neuropathy; lactic acidosis has also been reported.383-389 Reports of linezolid use in children 
with MDR-TS have found it to be well tolerated.260, 302, 383-384 Thiacetazone was used widely to 
treat TS prior to the advent of HIV. Severe, life-threatening Stevens Johnson reactions were 
associated with thiacetazone use in HIV-infected adults390-391 and children.392 Although it is 
contraindicated only in HIV-infected individuals, it is now rarely available in most countries. 
Other adverse effects include gastrointestinal disturbances, skin reactions, hepatotoxicity, 
haemolytic anaemia and agranulocytosis.393 The most common adverse effects of the beta-
lactams are gastrointestinal and hypersensitivity reactions. Occasionally liver and renal 
derangement can occur. The macrolides can cause gastrointestinal disturbances, 
hepatotoxicity, prolonged QT syndrome and rash. 
Effect of Human Immunodeficiency Virus co-infection and Interaction with antiretroviral 
therapy 
Co-infection with both TS and HIV is common in areas where both diseases are widespread.394-
39S Rapid initiation of cART in children with MDR-TS is critical due to the advanced spectrum of 
TS disease observed in this paediatric subpopulation.192 The drug interactions between cART 
and first-line TS drugs have been extensively reviewed. 396-397 Rifampicin reduces the 
concentrations of many concomitantly administered drugs including the key antiretroviral non-
nucleoside reverse transcriptase inhibitors and protease inhibitors. Data describing the 
pharmacokinetic interactions between cART and the second-line TS drugs are incomplete and 
the metabolic pathways of some of the drugs are poorly characterized. Hence, unanticipated 
interactions might occur. However, the potential for clinically important changes in cART or TS 
drug concentrations is less for most second-line TS regimens compared to the rifampicin-
containing first-line regimens. cART and second-line TS drugs have many adverse effects in 
common. High rates of neuropathy, hypokalaemia, hypothyroidism and marked renal 
impairment have been reported in adult populations with MDR-TS and a high proportion of 
HIV infected patients. 398-399 Drug interactions between TS drugs and cART are therefore 
important to consider.97, m However, the risks attributable to the TS and cART drug 
combinations versus those due to potential confounding factors such as the extent of immune 
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suppression, co-morbidities (e.g. chronic viral hepatitis, or diabetes), concomitant medication 
or toxins and nutritional status, are uncertain. Table 8 summarises possible interactions and 
adverse effects that may be exacerbated. Few studies have assessed second-line drugs in 
combination with cART in adults and no studies have done so in children. 
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Table 7 - A summary of the dose and adverse effects of the second-line drugs used in the treatment of drug resistant tuberculosis 
Drug Dose recommended Formulation size Main adverse effects 
I 
Kanamycin 15-30mg/kg once daily 19vial Ototoxicity, nephrotoxicity 
Amikacin 15-25mg/kg once daily 100mg, 250mg, 500mg and 19 vials As for kanamycin 
Capreomycin 15-30mg/kg once daily 19vial As for kanamycin 
Ofloxacin 15-20mg/kg once daily 200mg, 400mg Sleep disturbance, gastrointestinal disturbance, arthritis, peripheral 
neuropathy, 
Levofloxacin 10mg/kg once daily 2S0mg, SOOmg As for ofloxacin 
(twice da ily for <5 years) 
Moxifloxacin 7.5-lOmg/kg once da ily 400mg As for ofloxacin, prolonged QT syndrome 
Ethionamide/Prothionamide 15-20mg/kg once da ily 12Smg and 2S0mg tablets GI disturbance, metallic taste, hypothyroidism 
Cycloserine/Terizidone 15-20mg/kg once daily 250mg capsules Neurological and psychological effects 
PAS 150mg/kg granules da ily in two or three Sachets of 4g GI intolerance, hypothyroidism, hepatitis 
divided doses 
Clofazimine 5mg/kg once daily 50mg, 100mg tablets/capsules Skin discoloration 
Linezol id 10mg/kg twice daily 600mg tablets and syrup Diarrhoea, headache, nausea, myelosuppression, neurotoxicity, lactic acidosis 
(once daily for >10 years) and pancreatitis 
Amoxicillin/clavulanate, As for bacterial infections Amoxicillin/clavulanate - various Gastrointestinal intolerance, hypersensitivity reactions, seizures, liver and renal 
Imipenem, Meropenem formulations dysfunction 
Meropenem - 500mg and 19 vials 
Imipenem - 250mg and 500mg vials 
Thiacetazone 5-8mg/kg once daily 150mg tablets Stevens Johnson Syndrome in HIV-infected patients, gastrointestinal 
intolerance, hepatitis, skin reactions 
Clarithromycin 7.5- 15mg/kg twice daily 500mg tablets GI intolerance, rash, hepatitis, prolonged QT syndrome, ventricular arrhythmias 
High dose isoniazid 15-20mg/kg once daily 100mg tablets Hepatitis, peripheral neuropathy 
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Table 8 - Potential interactions and combined toxicity between the second-line tuberculosis 
drugs and antiretroviral treatment95,96 
Drug Pharmacokinetlc interactions Increased risk of adverse effects 
Injectables Unlikely Nephrotoxicity with tenofovir 
Fluoroquinolones Moxifloxacin concentration may Psychiatric symptoms with efavirenz 
be reduced by ritonavir Hepatitis with nevirapine, efavirenz or protease 
Moxifloxacin concentration may inhibitors 
be increas~d by unboosted Prolongation QT interval with protease 
atazanavir inhibitors and efavirenz 
Buffered didanosine may reduce 
oral absorption of all 
fluoroquinolones 
Ethionamide/Prothionamide Unknown Peripheral neuropathy with stavudine or 
didanosine 
Psychiatric symptoms with efavirenz 
Hepatitis with nevirapine, efavirenz or protease 
inhibitors 
Gastrointestinal intolerance with zidovudine or 
protease inhibitors 
Cycloserine/Terizidone Renally cleared so interactions Peripheral neuropathy with stavudine or 
unlikely didanosine 
Nephrotoxicity caused by Psychiatric symptoms with efavi renz 
tenofovir' could affect serum Stevens Johnson Syndrome with nevirapine and 
concentrations efavirenz 
PAS Unlikely Hepatitis with nevi rapine, efavirenz or protease 
inhibitors 
Gastrointestinal intolerance with zidovudine or 
protease inhibitors 
Clofazimine May increase etravirine and Gastrointestinal intolerance with zidovudine or 
protease inhibitor protease inhibitors 
concentrations 
Linezol id Unlikely Peripheral neuropathy with stavudine or 
didanosine 
Gastrointestinal intolerance w ith zidovudine or 
protease inhibitors 
Lactic acidosis with stavudine, didanosine or 
zidovudine 
Bone marrow toxicity with zidovudine 
Amoxicillin/lmipenem/ Unlikely Nephrotoxicity with tenofovir 
Meropenem with clavulanic 
acid 
Thiacetazone Not advised in HIV-infected Not advised in HIV-infected patients due to risk 
patients due to risk of Stevens- of Stevens-Johnson Syndrome 
Johnson Syndrome 
Clarithromycin Concentrations increased by Combination with non-nucleoside reverse 
ritonavir transcriptase inhibitors not recommended due 
Concentrations reduced by to increased concentrations of the 14-hydroxy 
efavirenz and nevi rapine metabolite which is associated with rashes 
Clarithromycin reduces 
zidovudine concentrations 
Currently not advised for use in children 
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Standardised definitions for research 
Concepts from the following topic have been written as an article: 
• Seddon JA, Schaaf HS, Furin JJ, Marais BJ, Tebruegge M, Detjen A, Hesseling AC, Perez-Velez 
CM, Shah S, Adams LV, Starke JR, Becerra MC, 5waminathan 5. Consensus statement on 
research definitions for drug-resistant tuberculosis in children. (submitted) 
In this chapter, I set out the terms and definitions that I am to use throughout the thesis. This 
process of formulating these definitions was achieved in collaboration with 'The Sentinel 
Project on Pediatric Drug-Resistant Tuberculosis' - a group of researchers, healthcare 
providers and advocates committed to preventing child deaths from DR-TB.4°O I took the lead 
in formulating and writing a consensus statement of experts to consolidate and clarify the 
definitions used in research into paediatric DR-TB. The proposed definitions were revised 
through meetings, conference calls and written feedback in order to achieve clarity and 
consensus. As well as allowing me to be consistent throughout my own work for this thesis, 
the definitions provide a tool for others to use when carrying out research into paediatric DR-
TB. The few studies that have described children with DR-TB have used inconsistent 
definitions, making standardization and synthesis of data challenging. The current 
programmatic WHO definitions used to describe adults with DR-TB and children with drug-
susceptible TB are inadequate for research studies of children with DR-TB. More rigorous 
definitions are required for use in research recording the epidemiology of exposure, infection 
and disease, as well as research into diagnosis, treatment, prevention and outcome. 
Definitions need to be relevant for both prospective studies, where comprehensive data can 
be collected, and for retrospective studies. The distinction between definitions used in clinical 
management, programmatic reporting and research studies is complex; many research studies 
document clinical management or report programmatic data. Whilst the following definitions 
will hopefully strengthen programmatic reporting, these proposed definitions are intended for 
use in the research setting, rather than for clinical decision-making. 
Terminology and measures of exposure 
To facilitate comparisons between different studies it is vital that key terms be standardized. 
Table 9 provides a summary of the suggested consensus definitions regarding epidemiological 
terms, disease classification, type of treatment, and categories of drug resistance. Exposure is 
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a continuum, with no documented exposure at one extreme and extensive exposure at the 
other. Although any exposure to a DR-TB source case could potentially result in a child 
becoming infected, in reality this exposure must reach a significant threshold for the child to 
be deemed a contact. This necessitates the use of a binary definition. The issue is complex and 
incorporates elements of the infectiousness of the source case, the proximity and intensity of 
interaction between source case and contact, the daily duration of exposure, the length of 
exposure over time, as well as environmental factors such as air exchange. 31.401 Different 
definitions will provide different degrees of sensitivity and specificity and it is important that 
definitions are consistent and well described. Recent interactions are more likely to result in 
disease in the child compared with interactions that took place more than a year ago.61• 83. 402-
403 
A 'DR-TB contact' should be defined as a child exposed to an infectious DR-TB source case who, 
in the last twelve months, had either slept in the same household or had daily interaction with 
the child.404 If possible, enough data points are collected to provide an exposure 'score' (Table 
9) as this concept provides a more precise and comprehensive description of the likely 
infection risk and correlates well with tests of M. tuberculosis infection.401 
In the same way that exposure is a gradient, so too is the spectrum from exposure through 
infection to disease.19 Despite this continuum, it is necessary to assign children into distinct 
categories for research studies. The terminology used in the literature for children who 
demonstrate immunological evidence of infection with M. tuberculosis, in the absence of 
clinical symptoms, is confusing. Latent TB infection, latent TB, M. tuberculosis infection and TB 
infection have all been employed. The word "tuberculosis" implies a disease state and 
therefore it was felt that TB infection should not be used for a well child. For children who 
have been recently infected by M. tuberculosis, the use of the word latency is incongruous as it 
implies an established immunological equilibrium, which may not have been achieved. A child 
with a positive immunological test (e.g. TST or IGRA) should be classified as having "M, 
tuberculosis infection" to cover both recent and latent infection. This is consistent with other 
consensus definitions.40s In order for a child to be classified as having 'DR M, tuberculosis 
infection', the child must have a positive immunological test result as well as being a DR-TB 
contact. The terminology used for children with clinical, radiological or microbiological 
pathology is similarly inconsistent across the published literature. 'Active disease' is a term 
used widely to denote an ill child, but 'inactive disease' is not a useful concept. For consistency 
the term 'TB disease' should be used. 
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Terms used for the treatment given to those with DR-TB disease include 'curative treatment', 
'disease treatment', anti-TB treatment, and 'TB treatment'. To avoid ambiguity the term 'DR-
TB treatment' should be used. In the existing literature there is also inconsistency surrounding 
the terminology used to describe the treatment given to children without DR-TB disease. 
Primary prophylaxis refers to treatment given to a child before any known exposure to an 
infectious TB case. Post-exposure prophylaxiS, window prophylaxiS or preventive therapy 
refers to treatment given to a child after documented TB exposure. Treatment of TB infection 
and treatment of latent infection are both used to refer to drugs given following a positive 
immunological test result indicating infection. Secondary prophylaxis refers to treatment given 
to a child after a course of TB treatment. For consistency the use of the summative term 'DR-
TB preventive therapy' can be used to cover all of these circumstances. 
Definitions of drug resistance and testing methodology 
Although drug resistance is generally divided into the discrete categories of mono-, poly-, 
MDR- or XDR-TB, 197 (Table 9) it is more useful to view drug resistance as a continuum. For 
research into paediatric DR-TB, it is important to describe the precise DST pattern. It is also 
important to record the DST pattern ofthe likely source case(s), rather than their DST 
category, when the child has been diagnosed presumptively. 
Due to the wide variety of testing methodologies available to determine drug resistance, at a 
minimum, researchers should clearly state the laboratory techniques employed in determining 
drug resistance. It should be documented to which drugs DST was performed and which 
techniques were used for each of the drugs. If DST is determined by phenotypic testing, the 
Clinical and Laboratory Standards Institute standards should be employed.406 It is anticipated 
that more DST will be carried out using genotypic methods in the future. A number of 
genotypic tests exist using nucleic acid amplification to determine DST. Some assays only 
determine whether the organism belongs to the M. tuberculosis complex and whether 
mutations in the rpoB gene are present (associated with rifampicin resistance in >95% cases). 
The Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA) is one such test, which is currently 
being rolled out widely.407 lfthis test is employed and the rpoB mutation result is positive, the 
sample should be recorded as having resistance to rifampicin, as this test cannot confirm or 
refute MDR. The frequency of RMR strains is increasing in some settings,408 and samples found 
to be rifampicin-resistant should therefore not be assumed to be MDR. Conversely, HMR-TB is 
common in many regions; if a sample is found not to have an rpoB gene mutation, it should 
not be assumed to be fully drug-susceptible. Consequently, it is important to follow up results 
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determined from samples tested with the Xpert MTB/RIF assay with a cultured sample that can 
have DST determined to isoniazid. 
The genotypic testing of resistance to isoniazid usually involves testing for mutations in the 
inhA promoter region and the katG gene.226 A molecular line probe assay (e.g. GenoTypee 
MTBDRp/us; Hain Lifescience, Nehren, Germany) is frequently used for this purpose. As well as 
recording the presence of genotypic resistance to isoniazid, it is desirable to also record the 
mutation conferring resistance, as this has clinical and epidemiological significance.92 Other 
molecular tests are under development and in the future, genotypic testing to the second-line 
drugs is likely to become more widespread, as drug resistance to these agents is associated 
with known gene mutations.212 
Previous episodes and treatment 
A distinction should be made between a previous episode of disease and any previous 
treatment given (Table 10). Prior studies have employed a six-month symptom-free period 
following the completion of at least one month of previous treatment as a pragmatic 
differentiator of disease episodes .192 For a child newly diagnosed with DR-TB disease, it is 
important to distinguish between: (a) a child who was previously treated with first-line therapy 
for TB disease, had a favourable treatment outcome and has subsequently been re-infected 
with a DR-TB strain; (b) a child who was infected with a DR-TB strain and treated with first-line 
drugs before the diagnosis of DR-TB was made; and (c) a child who was infected with a DS-TB 
strain with resistance developing during first-line treatment. The first two types of drug 
resistance are referred to as transmitted or primary resistance, while the third is termed 
acquired resistance. Although clinically it is sensible to suspect the development of resistance 
in a child if treatment has been poorly adhered to and/or incorrectly prescribed/supplied, for 
this conclusion to be reached in a research context, it is necessary to have had an initial drug-
susceptible sample. Most children with DR-TB disease, however, have transmitted 
resistance.254 
To document treatment delay, a standard definition of when the DR-TB episode began should 
be used to determine the interval from the assumed start of the disease episode to the start of 
DR-TB treatment. Published studies have defined a DR-TB episode as beginning (in the event 
that DR-TB was subsequently confirmed) at either the child's initial documented presentation 
to the healthcare system, when a specimen was obtained that eventually confirmed DR-TB, or 
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alternatively, when the child commenced TB treatment for the current episode, based on 
whichever was the first documented event.192 
Certainty of diagnosis of disease 
When treating children for DR-TB disease, the decision is binary - the child is treated or not. 
For the clinician this diagnosis is either confirmed or presumed. This may be sufficient for 
clinical management and for recording and reporting purposes. For research purposes, 
however, it is important to document the degree of certainty for both the diagnosis of TB and 
the diagnosis of drug resistance. For the diagnosis of TB disease in children, the WHO first 
proposed categories of suspect, probable and confirmed TB for reporting and for research.409 
This classification has recently been refined by a National Institute of Health (NIH) expert 
panel, focusing specifically on intra-thoracic disease.4os (see Table 10). For extra-thoracic TB a 
similar system should be adopted; one has been proposed for TBM.410 A definition of 
'confirmed DR-TB disease' requires clinical evidence of TB disease together with the detection 
of M. tuberculosis from a specimen collected from the child with resistance demonstrated. All 
samples from children should be subjected to culture and DST. A definition of 'probable DR-TB 
disease' should be used when a diagnosis of probable TB disease has been made and the child 
is a DR-TB contact. Cases should be classified as 'possible DR-TB disease' if a diagnosis of 
probable TB disease has been made and either the child fails adherent first-line TB treatment 
or has been exposed to a source case with risk factors for drug resistance (failed therapy, 
death or default with no known DST). 
Site of disease and disease severity 
Site and severity of disease can have an impact on the choice and duration of treatment as 
well as treatment outcome. Disease severity, for example, has been shown to correlate with 
bacterial yield in children and culture conversion.99, 192, 411 TB programs usually report disease 
site using ICD-10 codes,412 and these codes should be used for reporting disease site in children 
with DR-TB. Defining the severity of disease in children is challenging and existing approaches 
are limited. Radiological findings can be used to describe the spectrum of intra-thoracic 
disease and can be an indicator of severity.413 A recently-proposed classification system divides 
different types of both intra- and extra-thoracic childhood TB into severe and non-severe 
disease based on known host-pathogen interaction and pathophysiology of disease.411 Where 
possible, this classification should be employed for research purposes. 
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Adverse events 
Second-line TB drugs are associated with increased risk of adverse events.414 For research, it is 
important to determine the type of adverse event, the severity, the relationship to the 
medications being given, any action taken and any associated risk factors. 146 The Division of 
Microbiology and Infectious Diseases (DMID) within the US National Institute of Allergy and 
Infectious Diseases (NIAID) has published tables to allow the grading of adverse events.415 
These tables are specific for children and should be used for research on paediatric DR-TB. 
However, a number of adverse events that are frequently encountered in the treatment of 
children with DR-TB disease and DR M. tuberculosis infection are not adequately covered in 
this classification system.204 These include thyroid dysfunction, hearing loss, arthralgia and 
arthritis. Proposed criteria for grading these adverse events are included in Table 11. 
It is important to note the action taken when an adverse event occurs.416 For each adverse 
event, data should be collected documenting whether any action was taken and if so, what 
type. Where possible other factors possibly associated with the adverse event should be 
recorded. These include co-morbidities such as HIV infection, diabetes, and asthma, as well as 
the nutritional status and the type and severity of TB disease. 
Disease outcome 
Adult guidelines typically use microbiological parameters to determine response to treatment. 
The outcome definitions currently recommended by WHO for adults with DR-TB disease, were 
first proposed by an expert consensus group for use in the analysis of retrospective data. Cure 
was defined as 'five consecutive negative cultures from samples collected at least 30 days 
apart in the final 12 months of treatment.'197. 417 For children with drug-susceptible TB disease, 
cure has been defined as a child who is 'sputum smear-negative in the last month of treatment 
and at least one previous occasion.'16 Neither of these definitions are appropriate for children 
with DR-TB disease. Instead, 'cure' should be the completion of treatment, with simultaneous 
evidence of clinical and radiological improvement, in conjunction with three or more negative 
sputum cultures in the last 12 months of treatment (in the absence of subsequent positive 
results). As only a relatively small proportion of children will have a confirmed diagnosis at the 
beginning of their treatment, S-6, 418 and as microbiological investigations are frequently not 
repeated during follow-up, the majority of children will not fulfil the definition for cure. 
'Probable cure' is defined as the presence of the same constellation, but without the 
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microbiological component. The proposed definitions for treatment outcome are summarized 
in Table 12. 
Treatment response can be divided into microbiological, radiological and clinical responses. A 
key component of clinical response is nutritional status, with poor status a risk for both the 
development of TB disease as well as poor treatment outcome.419-422 Nutritional variables that 
require monitoring, at a minimum, include height and weight. These parameters should be 
assessed at treatment initiation and then monthly, and should be plotted on standardized 
charts. An improvement in nutritional status should be included among the criteria used to 
define 'probable cure'. Radiological improvement encompasses partial or complete resolution 
of chest radiographic features. However, it is important to consider that some children with 
HIV infection who are started on cART may experience a radiological deterioration despite 
clinical improvement due to IRls.185• 423-424 Nevertheless, this phenomenon is unlikely to 
influence classification of final disease outcome, as IRIS typically presents early in the 
treatment course and resolves before final outcome is determined. 
Other treatment outcomes that should be included are primary death and primary default. 
These occur if a child is diagnosed with DR-TB disease but dies, refuses treatment or is lost to 
follow up before DR-TB treatment is initiated. Finally, treatment failure is defined as at least six 
months of adherent therapy on an appropriate DR-TB regimen with evidence of 
microbiological, clinical or radiological deterioration in the absence of IRIS. 
Drug-resistant tuberculosis in children James Seddon P age 176 
Table 9 - Proposed terminology for drug-resistant tuberculosis in children and the assessment of drug-resistant tuberculosis exposure 
Recommended Term Definitions 
Epidemiological terms DR-TB index case The first identified, confirmed DR-TB case in a social group (e.g. a household) during an investigation or outbreak (wh ich 
may be the child) 
DR-TB source case An infectious (sputum-smear microscopy and/or culture positive) DR-TB case who could have infected the contact 
DR-TB exposure Ten points to be used for exposure score 401 
• Is the source case the child's mother? 
• Is the source case the child's primary caregiver? 
• Does the source case sleep in the same bed as the child? 
• Does the source case sleep in the same room as the child? 
• Dose the source case live in the same household as the child?· 
• Dose the source case see the ch ild every day?· 
• Is the source case coughing? 
• Does the source case have pulmonary TB? 
• Is the source case sputum-smear microscopy posit ive? 
• Is there more than one source case in the child's household? 
Infection and disease DR M . tuberculosis infection A posit ive immunological test of infection including TST or IGRA in combination with being a DR-TB contact 
DR-TB disease Clinical, radiological or microbiological pathology 
Type of treatment DR-TB treatment The treatment of DR-TB disease 
DR-TB preventive therapy Includes primary (pre-exposure) prophylaxis, post-exposure prophylaxis (including window prophylaxis), secondary 
prophylaxis, and treatment of TB infection 
Drug resistance categories Mono-resistant Resistance to one TB drug 
Poly-resista nt Resistance to two or more TB drugs other than both rifampicin and isoniazid 
Multidrug-resistant Resistant to at least both rifampicin and isoniazid 
Pre-extensively drug res istant MDR-TB with resistance to either a fluoroquinolone or an injectable second-line TB drug but not both 
Extensively drug resistant MDR-TB with resistance to both a fluoroquinolone and an injectable second-line TB drug 
---- ---_._-_. _-_ . _ . _- -------- - -
DR: drug-resistant; TB: tuberculosis; M. tb: Mycobacterium tuberculosis; IGRA: interferon-gamma release assay; TST: tuberculin skin test; MDR: multidrug-resistant 
·Either of these two components will classify the child as being a DR-TB contact if occurring in the preceding twelve months 
Drug-resistant tuberculosis in children James Seddon Page 177 
Table 10 - Classification of previous disease episodes, diagnostic certainty and description of drug-resistant tuberculosis disease in children 
Recommended Term Definitions 
Previous episodes and Previous TB disease Treatment taken for at least one month, after which there was a reported symptom-free period of ~ 6 months before the start of the current 
treatment episode DR-TB disease episode 
DR-TB disease episode If DR-TB disease is subsequently confirmed, the episode began when the child is first documented to have presented to the health care system, 
when the specimen was obta ined that eventually confirmed DR-TB disease, or when the child commenced any TB treatment, whichever is the 
first available documented event 
Previously treated with Treatment for one month or more with WHO group one drugs 
f irst-line TB drugs 
Previously treated with Treatment for one month or more with any WHO group two to five drugs 
second-line TB drugs 
Certa inty of diagnosis Confirmed TB disease At least one of the signs and symptoms suggestive of TB disease· and microbiological confirmation of M . tuberculosis 
ofTB disease40s Probable TB disease At least one of the signs and symptoms suggestive of TB disease· and the CR is consistent with intra-thoracic TB disease·· and presence of one 
of the following: a) a positive clinical response to TB treatment, b) documented exposure to a source case with TB disease or c) immunological 
evidence of TB infection 
Possible TB disease At least one of the signs and symptoms suggestive of TB disease· and either a) a clin ical response to TB treatment, documented exposure to a 
source case w ith TB disease or immunological evidence of TB infection or b) CR consistent with intra-thoracic TB disease·· 
Certainty of diagnosis Confirmed DR-TB disease At least one of the signs and symptoms suggestive of TB disease· and detection of M. tuberculosis from the child with demonstration of 
of DR-TB disease genotypic or phenotypic resistance 
Probable DR-TB disease DR-TB contact and diagnosis of probable TB disease 
Possible DR-TB disease Diagnosis of probable TB disease together with either failure of first-line TB treatment or contact of a source case with TB disease and risk 
factors for drug resistance (failed, irregular or chronic therapy, death, or default) 
Site of TB and disease ICD-lO code Code to be recorded 
severity Severe or non-severe Severity to be recorded411 
-_ ._---
WHO: World Health Organization; TB: tuberculosis; DR: drug-resistant; CR: chest radiograph; M. tuberculosis: Mycobocterium tuberculosis 
·Persistent cough, weight loss or failure to thrive, persistent unexplained fever, persistent unexplained lethargy or reduced playfulness or addit ional signs in the neonate (these signs and symptoms are defined in detail in 
referenced article) 
•• For extra-thoracic TB disease alternative appropriate rad iological imaging should be substituted 
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Table 11 - Classification of adverse events in children with drug-resistant tuberculosis 
Recommended Term Definitions 
Adverse drug events Clinical DMID grad ing scale 0_441> 
Laboratory DMID grading scale 0_441' 
Arthralgia/arthritis Not covered but parallels with DMID 
• Grade 0 - No pain 
• Grade 1- Pa in, but no interference with function or movement 
• Grade 2 - Moderate pa in affecting function, but able to carry out normal activities 
• Grade 3 - Severe pain limiting activities 
• Grade 4 - Disabling pain and unable to carry out normal activities 
Thyroid function Abnormal considered if TSH raised above and T4 below the threshold of normal, using the reference ranges that have been I 
specified by the laboratory with consideration of the analyzer used and the age of the child 
Hearing American Speech and Hearing Association (ASHA) criteria for hearing loss'''''·4<>-4'b using pure tone audiometry. Hearing loss 
defined as a change from baseline of: 
• 20dB decrease at anyone frequency or 
• 10dB decrease at any two adjacent frequencies or 
• Loss of response at three consecutive test frequencies where responses were previously obtained. 
-------- -- '--------- - - ------ -------
DMID: Division of M icrobiology and Infectious Diseases; TSH: thyroid st imulating hormone 
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Table 12 - Classification of treatment outcome in children with drug-resistant tuberculosis 
Recommended Term Definitions 
Treatment Outcome Cure Treatment completed, clinical and radiological improvement together with three or more negative sputum cultures in the 
last twelve months of treatment with no subsequent positive cu lture 
Probable cure Treatment completed with clinical and radiological improvement 
Treatment completed Completion of prescribed treatment 
Defau lt Treatment interruption for two months or more 
Primary default Never started on DR-TB treatment 
Death Death for any reason while on DR-TB treatment 
Primary death Death prior to starti ng DR-TB treatment 
Treatment failure Ongoing sputum culture positivity, or clinical or radiological deterioration after more than six months of the child receiving 
an appropriate DR-TB regimen (with adherence> 80%) 
- ---- - - - - - - --- -
~ ---- ---- ------ -- - - -- ----
- ---- -- --- -----
TB: tuberculosis; DR: drug-resistant 
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I Original research 
Study 1: the evolving epidemic of drug-resistant tuberculosis among children in Cape 
Town, South Africa 
The following study has been published as an article: 
• Seddon JA, Hesseling AC, Marais BJ, Jordaan A, Victor T, Schaaf HS. The evolving epidemic 
of drug-resistant tuberculosis among children in Cape Town, South Africa. Int J Tuberc Lung 
Dis 2012; 16: 928-33 
The first original research article in the thesis documents the burden ofTB drug resistance in 
the context that the research is to be carried out. A database of all children with culture-
confirmed TB at TCH is collected prospectively, including clinical characteristics as well as 
details of the DST of the strain isolated. This has been undertaken since 2003 and provides 
surveillance and detection of trends over time. For this study, I gathered the data for a two 
year period (previous reports have described two year periods), analysed it and compared it 
with previous surveillance periods. As this surveillance period included the point at which 
molecular LPAs were introduced into the Western Cape, we took the opportunity to compare 
the LPA results with conventional DST techniques in number of isolates. 
Introduction 
Children with DR-TB usually have transmitted resistance, whereby the child is infected by an 
organism with established resistance. 21• 36·37, 80 This contrasts to adults where drug resistance is 
a result of both transmission and acquisition, the latter due to a susceptible organism 
developing resistance because of inadequate treatment.427 Children rarely have acquired 
resistance as paediatric TB is usually paucibacillary; with small organism loads it is unlikely that 
resistant mutants will arise and be selected. This is supported by studies comparing the genetic 
DNA fingerprint (restriction fragment length polymorphism; RFLP), as well as the DST pattern 
of organisms from children with drug-resistant TB together with the likely source case. 64 
Usually both the RFLP and DST in such cases have been concordant, implying transmitted 
resistance from adults to children.68 Since paediatric MDR-TB cases represent recent infection 
Drug-resistant tuberculosis in children James Seddon Page 181 
with a DR strain, DST patterns in children, particularly those amongst young children, provide 
important information regarding current transmission patterns in a community or setting, 
facilitating individual case management, surveillance and public health planning. 
Traditionally DST has been determined by phenotypic methods whereby bacilli are grown in 
the presence of an antibiotic. If more than a certain percentage (usually 1% or more) of bacilli 
grow in comparison to a control without antibiotic, the bacilli are classified as being resistant. 
These tests are reliable but are expensive, time-consuming and operator-dependent. More 
recently, nucleic acid amplification tests (NAATs) have been developed to identify genetic 
mutations that are commonly associated with antibiotic resistance. The great majority (>95%) 
of rifampicin-resistant strains possess mutations in the rpoB gene. Most, but not all, strains 
that are resistant to isoniazid possess mutations in either the inhA promoter region or the katG 
gene. Since August 2008, the National Health Laboratory System in South Africa has used a 
NAAT, or LPA, to detect the presence of M. tuberculosis complex and mutations in rpoB, inhA 
and katG. Since not all isoniazid resistance mutations are detected, it is unclear what 
proportion of isoniazid-resistant strains has been missed since the introduction of LPA testing. 
This could potentially lead to either a sample being labelled as drug-susceptible when it is, in 
fact, HMR, or misclassification of RMR when it is, in fact, MDR. 
Previous surveillance studies from Cape Town described the proportion of children with DR-TB 
during different periods: 1994-1998,4282003-2005255 and 2005-2007, all using phenotypic 
DST.254 In the current study the prevalence of drug resistance amongst children with culture-
confirmed TB is determined from 2007 to 2009 and their clinical characteristics described 
including HIV co-infection. In addition, the results ofthis surveillance period are compared to 
previous studies to determine changes and trends over time. In order to document currently 
prevailing DST patterns, the children from this and previous study periods have been stratified 
into those less than and older than five years.429 Finally, the genotypic and phenotypic DST for 
isoniazid is compared on mycobacterial isolates since the introduction of the LPA. 
Methods 
All children less than 13 years old with culture-confirmed TB, routinely tested at TCH from 1 
March 2007 through 28 February 2009 were included. 
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Mycobacterial culture and drug susceptibility testing 
Samples were first decontaminated and then cultured using the MGIT 960 system (Becton 
Dickinson, Sparks, MD, USA). The presence of M. tuberculosis was confirmed by polymerase 
chain reaction (PCR) amplification.430 DST was performed on at least one isolate from each 
child with culture-confirmed TB. DSTs were performed for isoniazid and rifampicin, and if MDR, 
testing was completed for ethambutol and the second-line drugs amikacin, ethionamide and 
ofloxacin. For the first 18 months of the study, from March 2007 through July 2008, only 
conventional phenotypic DST was undertaken for isoniazid and rifampicin using the Bactec 
460TB system (Becton Dickinson, Sparks, MD, USA), according to international criteria.431 
Isoniazid was tested at a concentration of O.11lg/mI, rifampicin at 2.0 Ilg/ml and ethambutol at 
7.5Ilg/ml. The susceptibility of a strain was judged by comparing growth of organisms in drug 
containing versus non-drug containing media; resistance was defined as 1% or more bacterial 
growth in the drug containing media. 
During the latter six months of the study, routine genotypic testing was implemented by the 
local reference laboratory using LPA (GenoType- MTBDRplus; Hain Lifescience, Nehren, 
Germany), according to the manufacturer's instructions.432 All samples that underwent 
genotypic testing were then re-evaluated by conventional techniques for isoniazid DST to 
determine the concordance between the two testing strategies. If samples lost viability, gave 
inconclusive results or were contaminated, a second attempt was made to culture them. DST 
to second-line agents was performed individually by the indirect proportional method on 
Middlebrook 7H10 agar using critical concentrations of amikacin 40Ilg/ml, ofloxacin 21lg/ml 
and ethionamide 101lg/ml. 
Clinical data and patient management 
Once a specimen was found to be positive for M. tuberculosis, laboratory details were 
recorded regarding the date of sampling, specimen site and DST. Clinical case notes and 
laboratory data were reviewed and demographic and clinical data extracted. Chest radiographs 
were read by a single expert reader using a standardised approach.413 Children were treated 
according to national and international guidelines16, 102, 433 and if not already known, HIV testing 
was undertaken following informed consent from the parent or legal guardian with pre- and 
post-test counselling using ELISA or DNA PCR testing, according to national protocol. 
Different DST patterns are presented as percentages of the total number of samples (one per 
child) that had DST with 95% confidence intervals calculated. The significance of change over 
time for a DST pattern was calculated using a test of trend for the odds ratio of that DST 
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pattern. The significance of differences between the DST patterns for younger and older 
children in the most recent surveillance period was calculated using the X2 test or Fishers exact 
test. 
Results 
Two-hundred and ninety-four children were diagnosed with culture-confirmed TB in the period 
under review; demographic data are provided in Table 13. DST results were available in 292 
(99.3%): 45 (15.4%) had isoniazid and/or rifampicin resistance, 41 (14.0%) were isoniazid-
resistant including 26 (8.9%) that had MDR-TB. Table 14 compares findings from the current 
survey with those of previous surveillance periods. Any resistance to rifampicin increased 
between 1994 and 2009 (p<0.001) as did RMR- (p=0.009) and MDR-TB (p<0.001). Although 
resistance to either isoniazid and/or rifampicin (p=0.001) and any resistance to isoniazid 
(p=0.006) also increased (Table 14), these changes were not significant if comparison analysis 
was restricted to the period 2003-2009 (p=0.35 and p=0.65 respectively). However, trends in 
any resistance to rifampicin (p=0.03) and RMR-TB (p=0.04) remained significant in analysis 
restricted to this period, with a trend in MDR-TB of borderline significance (p=0.09). The DST 
patterns for children less than five years and those older were not significantly different 
(isoniazid and/or rifampicin resistance: p=0.86; any isoniazid resistance: p=0.85; HMR-TB: 
p=0.14; any rifampicin resistance: p=0.39; RMR-TB: p=1.0; MDR-TB: p=0.37) 
The prevalence of HIV infection remained stable amongst those tested over the last six years 
(see Table 14; p=0.80). Ethambutol resistance was present in 12/24 (50.0%) of MDR-TB cases 
tested in the present survey. Two isolates were resistant to ofloxacin, one to amikacin and one 
to ethionamide; none had XDR-TB. 
Of the 73 samples that initially underwent DST through lPA in the central reference laboratory, 
four could not be found, 14 lost viability on two attempts to culture them and one sample gave 
an inconclusive result. Fifty four isolates were located and successfully cultured to yield a 
conclusive conventional DST result; seven had initially demonstrated isoniazid resistance on 
genotypic DST; all ofthese were also resistant on phenotypic DST. Of the 47 classified as being 
isoniazid susceptible on genotypic DST, 46 were found to also be susceptible on phenotypic 
DST. If phenotypic testing was used as the reference standard, lPA testing yielded a sensitivity 
of 87.5% and specificity of 100%. 
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Discussion 
The overall proportion of drug resistance has remained relatively unchanged amongst children 
with culture-confirmed TB in the Western Cape Province of South Africa over the last few 
years; however, rifampicin resistance is increasing. From an epidemiological perspective, the 
greatest change is that less HMR-TB is compensated for by more MOR-TB, possibly signifying 
additional acquisition of rifampicin resistance among adult HMR-TB cases. Of great concern is 
that for those children with M. tuberculosis resistant to isoniazid and rifampicin, half were also 
resistant to ethambutol which has serious implications for the clinical management of MOR-TB 
in both children and adults in this setting. OST to pyrazinamide was not routinely undertaken 
as testing is complicated to perform and requires acidic conditions which inhibit mycobacterial 
growth. However, other studies from the Western Cape have demonstrated high levels of 
resistance to ethambutol and pyrazinamide in strains already MOR.161.434-435 The implication of 
these findings is that, in our context, both ethambutol and pyrazinamide should not be 
assumed to be effective drugs in the treatment of MOR-TB, further restricting the choice of 
suitable drugs. 
The use of LPA reduces the turnaround time from specimen production to result.432 For acid-
fast bacilli smear-positive samples LPAs can be performed directly on clinical specimens 
whereas smear-negative samples must be first cultured prior to genotypic analysis. The 
majority of paediatric samples are paucibacillary and are cultured routinely prior to LPA. 
However, time is still saved using LPA as even following culture, phenotypic OST requires 
further processing. A concern with using LPA, however, is that a significant proportion of 
isoniazid-resistant strains are missed resulting in misclassification of OST status and 
inappropriate management. We found that the sensitivity and specificity of LPA was high. Only 
one of 47 isolates was classified as susceptible on genotypic OST but found to be resistant on 
phenotypic OST. All cases identified as isoniazid-resistant on genotypic OST were also 
confirmed to be resistant on phenotypic testing. Of note is that four cases of BCG disease (one 
disseminated) were missed using genotypic testing as the LPA does not identify isolates as M. 
bovis BCG or detect the presence of isoniazid-resistance, since this is not associated with katG 
gene or inhA promoter region mutations.436-437 If phenotypic isoniazid resistance is detected in 
a sample from an infant, BCG disease should always be a consideration especially in an 
immune compromised child; this opportunity is lost with the use of genotypic testing only. 
A limitation of this study is that children included may not be representative of all children 
with TB in the setting. First, children with culture-confirmed TB tend to have more extensive 
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disease than those with a presumptive diagnosis without bacteriological confirmation. It is also 
possible that some children with OR-TS had been treated previously with inadequate first-line 
therapy, leading to more advanced disease, in turn leading to a higher probability of culture-
confirmation. Second, this is a hospital based study and the spectrum of disease seen and the 
drug resistance profile may be different compared to community cohorts. The latter 
phenomenon has not, however, been observed in a previous study from our group.2S5 Third, 
TCH is a regional referral hospital for children with OR-TB and so higher proportion ofTS cases 
may therefore have OR-TS compared to other hospital settings. Finally, child contacts of MOR-
TS source cases (referred to TCH) are likely to be investigated more rigorously through repeat 
mycobacterial sampling than contacts of drug-susceptible source cases, possibly leading to a 
higher likelihood of culture-confirmation in those with DR rather than drug-susceptible 
disease. Although these factors may have contributed to our findings, all have been consistent 
over the previous study periods and so comparisons and trends over time are therefore likely 
to be valid. 
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Table 13 - Patient characteristics and disease spectrum in children with drug- resistant and 
drug-susceptible tuberculosis 
Characteristic With any drug-
resistance (%) 
Number of cases 45 (100) 
Known contact with TB source case 32 (71.1) 
Tuberculin skin test positive 
(>10mm if HIV-uninfected and >5mm if HIV- 24/36 (66.7) 
infected) 
rd 
23 (51.1) Weight <3 percentile for age 
Severe malnutrition 5 (11.1) (marasmus/kwashiorkor) 
Pulmonary TB* * (All) 41 (91.1) 
Extrapulmonary TB (All) 20 (44.4) 
Both Pulmonary & Extrapulmonary TB 16 (35.6) 
Types of extrapulmonary TB (some had more 20 (100) than one type) 
TBM (miliary TB in 7) 5 (25.0) 
Miliary TB (TBM in 7) 4 (20.0) 
Abdominal TB 3 (15.0) 
Peripheral lymphadenopathy 7 (35 .0) 
Pleural effusion (large or loculated) 1 (5.0) 
Pericardia I effusion 2 (10.0) 
Osteoarticular TB 2 (10.0) 
Ear or mastoid TB 3 (15.0) 
Skin involvement 1 (5.0) 
Children with chest radiographs (some had 45 (100) 
more than one finding) 
Ghon focus 2 (4.4) 
Hilar/mediastinallymphadenopathy 21 (46.7) 
Large airway compression 13 (28.9) 
Collapse lobe/segment 4 (8.9) 
Hyperinflation lobe/segment 2 (4.4) 
Pleural effusion - all 6 (13 .3) 
Miliary opacification (not LIP) 4 (8.9) 
Alveolar opacification lobe/segment 29 (64.4) 
Cavities 13 (28.9) 
Bronchopneumonic opacification 5 (11.1) 
Calcification 1 (2.2) 
Normal CXR 7 (15.6) 
• Only two cases had unknown drug susceptibility test pattern 
•• Pulmonary T6 included hilar and mediastinal lymphadenopathy 
T6 - Tuberculosis 
T6M - Tuberculous Meningitis 
LIP - Lymphocytic Interstitial Pneumonit is 
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Fully drug- Total (%) 
susceptible or 
unknown· (%) 
249 (100) 294 (100) 
134 (53.8) 166 (56.5) 
118/171 (69.0) 142/207 (68.6) 
102 (41.0) 125 (42.5) 
44 (17.7) 49 (16.7) 
204 (81.9) 245 (83.3) 
142 (57.0) 162 (55.1) 
99 (39.8) 115 (39.1) 
142 (100) 162 (100) 
29 (20.4) 34 (21.0) 
22 (15.5) 26 (16.0) 
31 (21.8) 34 (21.0) 
70 (49.3) 77 (47.5) 
15 (10.6) 16 (9.9) 
3 (2.1) 5 (3.1) 
17 (12.0) 19 (11.7) 
9 (6.3) 12 (7.4) 
5 (3.5) 6 (3.7) 
234 (100) 279 (100) 
4 (1.7) 16 (5.8) 
113 (48.3) 34 (12.3) 
SO (21.4) 63 (22 .8) 
13 (5.6) 16 (5.8) 
10 (4.3) 12 (4.3) 
25 (10.7) 31 (11.2) 
22 (9.4) 26 (9.4) 
116 (49.6) 145 (52.5) 
34 (14.5) 47 (17.0) 
22 (9.4) 27 (9.8) 
4 (1.7) 5 (1.8) 
43 (18.4) SO (18.1) 
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Table 14 - Comparison of drug susceptibility test results for children with culture-confirmed tuberculosis over four surveillance periods (1994-2009) 
Number of cases 
Median Age (years) 
Boys 
Previous TB treatment 
HIV test done 
HIV-infected 
DST undertaken 
Any resistance to isoniazid or rifampicin! 
Any isoniazid resistance' 
Isoniazid mono-resistance' 
Any rifampicin resistance" 
Rifampicin mono-resistance' 
Multidrug-resistanceb 
Number of children 0-5 years 
DST undertaken 
Any resistance to isoniazid or rifampicin 
Any isoniazid resistance 
Isoniazid mono-resistance 
Any rifampicin resistance 
Rifampicin mono-resistance 
Multidrug-resistance 
Number of children 5-13 years 
DST undertaken 
Any resistance to isoniazid or rifampicin 
Any isoniazid resistance 
Isoniazid mono-resistance 
Any rifampicin resistance 
Rifampicin mono-resistance 
Multidrug-resistance 
-----
Human immunodeficiency virus - HIV; Drug susceptibility test - DST 
·Percentages and 95% confidence intervals in parentheses 
1994-1998* 
338 
2.6 
193 (57. I} 
32 (9.5) 
166 (49.1) 
13 (7.8) 
306 (90.5) 
21 (6.9; 4.5-10.3) 
21 (6.9; 4.5-10.3) 
14 (4.6; 2.8-7.5) 
7 (2.3; 1.1-4.7) 
0(0; 0-1.2) 
7 (2.3; 1.1-4.7) 
241 
218 (90.5) 
16 (7.3; 4.6-11.6) 
16 (7.3; 4.6-11.6) 
9 (4.1; 2.2-7.7) 
7 (3.2; 1.6-6.5) 
0 
7 (2.3; 1.6-6.5) 
97 
88 (90.7) 
5 (5.7; 2.5-12.6) 
5 (5.7; 2.5-12.6) 
5 (5 .7; 2.5-12.6) 
0 
0 
0 
Trend in odds ratios over successive surveillance periods: I p=O.OOl; 2p=O.OO6; 3p=O.73; ·p<O.OOOl; sp=O.OO9; · pO.OOO5 
" Isoniazid mono-resistance" may be poly-resistance in some cases 
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2003-2005* 2005-2007* 2007-2009* 
323 291 294 
2.5 2.75 2.13 
173 (53.6) 154 (52.9) 156 (53.1) 
59 (18.3) 65 (22.3) 50 (17.0) 
243 (75.2) 174 (59.8) 217 (73.8) 
64 (26.3) 49 (28.2) 63 (29.0) 
313 (96.9) 285 (97.9) 292 (99.3) 
41 (13.1; 9.8-17.3) 43 (15.1; 11A-19.7) 45 (15.4; 11.7-20.0) 
40 (12.8; 9.5-16.9) 41 (14.4; 10.8-18.9) 41 (14.0; 1O.5-18.5) 
23 (7.3; 5.0-10.8) 22 (7.7; 5.2-11.4) 15 (5.1; 3.1-8.3) 
17 (5.4; 3.4-8.5) 21 (7.3; 4.9-11.0) 30 (10.3; 7.3-14.3) 
0(0; 0-1.2) 2 (0.7; 0.2-2.5) 4 (104; 0 .5-3 .5) 
17 (SA; 3.4-8.5) 19 (6.7; 4.3-10.2) 26 (8.9; 6.2-12.7) 
230 187 212 
223 (97.0) 184 (98.4) 210 (99.1) 
27 (12.1; 8.5-17.1) 25 (13.6; 9.4-19.3) 32 (15.2; 11.0-20.7) 
27 (12.1; 8.5-17.1) 25 (13.6; 9.4-19.3) 29 (13.8; 9.8-19.1) 
16 (7.2; 4.5-11.3) 14 (7.6; 4.6-12.4) 8 (3.8; 2.0-7.3) 
11 (4.9; 2.8-8.6) 11 (6.0; 3.4-10A) 24 (11.4; 7.8-16.5) 
0 0 3 (1.4; 0.5-4.1) 
11 (4.9; 2.8-8.6) 11 (6.0; 3.4-10.4) 21 (10.0; 6.7-14.8) 
93 104 82 
90 (96.8) 101 (97.1) 82 (100) 
13 (14.4; 8.7-23.2) 18 (17.8; 11.6-2604) 13 (15.9; 9.5-25.3) 
13 (14.4; 8.7-23.2) 16 (15.8; 10.0-24.2) 12 (14.6; 8.6-23.9) 
7 (7 .8; 3.9-15.2) 7 (6.9; 3.4-13.6) 7 (8.5; 4.3-16.6) 
6 (6.7; 3.1-13.8) 11 (10.9; 6.2-18.5) 6 (7.3; 3.5-15.1) 
0 2 (2.0; 0.6-6.9) 1 (1.2; 0.3-6.5) 
6 (6.7; 3.1-13.8) 9 (8.9; 4.8-16.1) 
---
_ 5 (6.1; 2.7-13.5) 
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Figure 3 - Trends in drug resistance for children with culture-confirmed tuberculosis over four 
surveillance periods (1994-2009) 
18 
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H or R - resistance to either isoniazid or rifampicin; H - any resistance to isoniazid; HMR - isoniazid mono-resistance; R - any 
resi stance to rifampicin; RMR - rifampicin mono-resistance; MDR - multidrug-resistance 
P values are for test of trend in odds ratio for each type of drug susceptibili ty category 
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Study 2: risk factors for infection and disease in child contacts of drug-resistant 
tuberculosis 
The following study has been prepared as an article: 
• Seddon lA, Godfrey-Faussett P, Hesseling AC, Fielding K, Schaaf HS. Risk factors for 
infection and disease in child contacts of multidrug-resistant tuberculosis (submitted) 
Introduction 
Determining which of the children exposed to MDR-TB children are at the highest risk of 
becoming infected and of developing disease would allow informed health planning and 
targeted use of available healthcare resources. A cohort study design, where children are 
followed from the time of exposure, allows for the monitoring of transition from exposure to 
infection, and from infection to disease, over time. However, cross-sectional study designs, 
whereby children are identified who have exposure but no infection, exposure and infection 
and those who present with TB disease, also allow for an assessment of risk factors for each 
state. This study aims to determine risk factors for the transition from exposure to infection, 
and from infection to disease in child MDR-contacts, using a cross-sectional study design. 
Methods 
Patient population 
All children evaluated at TCH or community outreach specialist paediatric TB clinics during May 
2010 through April 2011, were eligible if they were less than five years old, had been in 
significant contact with an infectious (sputum smear or culture positive) pulmonary MDR-TB 
source case within the preceding six months and had an available TST result. Significant 
exposure was defined as living with or having regular daily interaction with the MDR-TB source 
case. Children were recruited following written, informed consent from the parent/caregiver. 
Data collection and classification 
This study employed a cross-sectional design. Following informed consent, families were 
interviewed and data collected regarding the demographic profile and clinical condition of the 
child. Information on the source case was collected both from the attending families and 
subsequently from the provincial TB register. The nature and intensity of the interaction 
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between the source case and child, as reported by the parent/caregiver was documented as 
well as the duration of exposure. Children were classified as uninfected or infected, and if 
infected, as having TB disease or not. While the study aimed to assess risk factors for prevalent 
TB disease, confirmation of diagnosis depended on radiological and bacteriological 
investigations, in some instances requiring a number of weeks for liquid culture results. 
Standard research definitions were applied to classify TB diseasej40S children with either 
confirmed and probable disease were included. Infection was classified as having a positive 
TST; infection was also assumed in the presence of TB disease. A transverse TST diameter of 
~10mm was considered positive in HIV-negative and ~5mm in HIV-positive children. 
Statistical analysis 
Data were double-entered into a database and checked for entry errors. Logistic regression 
was used to assess risk factors for (i) M. tuberculosis infection and (ii) TB disease (among those 
with infection). Results are reported as unadjusted and adjusted odds ratios (OR), 95% 
confidence intervals (Cis) and p-values, calculated using the likelihood ratio test (LRT). For 
ordinal variables a test for trend and departures from linearity using the LRT was conducted. 
For models assessing risk factors for infection, exposures were included if they demonstrated a 
relationship with infection in univariable analysis based on p<O.05. If two exposures were 
thought to be co-linear they were not included together in the same model. For models 
assessing risk factors for disease, variables were only adjusted for the age of the child, given 
the small number of children with disease. Ages for the child and source case were re-coded as 
ordinal variables, using age bands. Relationships between exposures were assessed using the 
X2 test. All statistical analyses were conducted using Stata software (version 11; Stata Corp, 
College Station, TX). 
Results 
Description of cohort 
Over the twelve-month study period 377 children were referred to the specialist clinic services 
as child contacts of MDR-TB source cases. A number of children did not meet the eligibility 
criteria for the study: the source case did not have MDR-TB (n=27), the child was older than 
five years (n=56), the intensity of contact was not judged to be significant by the clinical team 
(n=l1) or a TST result was not available in the presence of an asymptomatic child (n=2). Of 281 
children eligible for the study, 228 (81%) were recruited. The remaining 53 children were not 
brought to the clinic by a parent or legal guardian who could provide informed consent (n=31), 
the parents did not consent to the study (n=3) or the families left the clinic before the research 
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team could speak to them (n=19). These children all received routine standard of care. The 
median age of children recruited was 30 months (inter-quartile range [IQR]: 13-43 months); of 
217 children tested for HIV, 8 (3.7%) were positive. Of the 228 children, 102 (44.7%) were 
classified as M. tuberculosis-infected. Of the 102 infected, 15 (14.7%) also had TB disease. 
Risk factors for infection 
In adjusted analysis, increasing age of the child was associated with increasing odds of 
infection (adjusted odds ratio (AOR) for one year increase in age: 1.43; 95%CI: 1.13-1.91; 
p=0.002); children of coloured ethnicity (compared to children of Xhosa ethnicity) were also 
more likely to be infected (AOR: 2.51; 95%CI: 1.22-5.17; p=O.Ol). Children with a previous 
treatment history were more likely to be infected in univariable analysis, with the effect 
reduced after adjustment (Table 15). Increasing age of the source case was associated with a 
reduced odds of infection (AOR: 0.67 for an approximate 10 year increase in age; 95%CI: 0.45-
1.00; p=0.05; Table 16) and reported alcohol use by source case was associated with increased 
odds of infection (AOR: 2.59; 95%CI: 1.29-5.22; p=0.007). Before adjustment there was a 
strong relationship between HIV status in the source case and M. tuberculosis infection in the 
child, with HIV positivity in the source case associated with lower odds of infection. In 
multivariable analysis this association was reduced (AOR 0.48,95% CI 0.22-1.04; p=0.04). 
Risk factors for prevalent tuberculosis disease 
Younger age of the child was associated with increased odds of disease (p-value for test of 
trend; p=O.Ol) as was HIV-positive status in the child (AOR: 25.3; 95%CI: 1.63-393; p=O.Ol), HIV 
positivity of the source case (AOR: 4.07; 95%CI: 1.19-13.S; p=0.03), increasing number of 
rooms in the house (AOR: 1.39; 1.02-1.91; p=0.04; Table 17) and alcohol use by the source case 
(AOR 2.90; 95% CI 0.90-9.31; p=0.07; Table lS). Male gender (AOR: 0.29; 95%CI: 0.OS-1.00; 
p=O.04) was associated with reduced odds of disease. Characteristics of prevalent TB cases are 
presented in Table 19. 
Relationships between exposures 
HIV positivity in the source case was associated with HIV-positive status in the child (p=0.019), 
but also with ethnicity (p<O.OOl), and with the age of the source case (p-value for test of 
trend=0.003). Ethnicity of the child was associated with type of residence (p<O.OOl), type of 
water source (p<O.OOl) and type of toileting (p<O.OOl). The age of the source case was 
associated with sputum smear status (p=O.OOl), with older source cases less likely to have 
sputum smear-positive TB. 
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Discussion 
This is the first study to assess risk factors for M. tuberculosis infection and disease in children 
exposed to an adult with MDR-TB. Consistent with data from the natural history of drug-
susceptible TB in children, this study demonstrates that as children become older, they are 
more likely to be infected but once infected, that younger children are more likely to develop 
disease. HIV-positive children, while having no additional risk of infection, have a substantially 
increased risk for disease following infection. Alcohol use in the source case appears to be a 
risk factor for infection in the child and possibly for disease. The relationship between 
ethnicity, HIV positivity, age and sputum-smear status of the source case is complex. In the 
study, older source cases were more likely to be HIV-positive and ethnicity was strongly 
associated with HIV positivity. Other studies have demonstrated that HIV-positive adults with 
pulmonary TB are less frequently smear-positive than HIV-negative adults.438 The increased 
risk ofTB disease in child contacts of HIV-positive source cases may be due to biological (e.g. 
increased risk of HIV positivity) and epidemiological factors in HIV-affected households. 
Previous studies have demonstrated that as children get older they are more likely to become 
infected, likely due to increasing duration of exposure to more potential source cases and 
more interaction with the community in addition to household exposure.so The relationship 
between alcohol use in the source case and both infection and disease in the child requires 
further study. It may be that alcohol is a surrogate for other socioeconomic factors but alcohol 
was not associated with ethnicity or any of the other socioeconomic exposures recorded in our 
study. It may be that source cases that drink are in some way more infectious than those who 
do not drink or that their behavior is more likely to lead to infection (e.g. prolonged exposure 
due to diagnostic and treatment delay) in the child. Adherence to treatment may be affected 
as might health-seeking behavior. Alcohol is a demonstrated risk factor for TB disease in adults 
with drug-susceptible114 and MDR_TB.439 That HIV positivity 63 and younger age61 of the child is 
associated with increased risk of progression to disease following infection is well described in 
the drug-susceptible TB literature and it has also been demonstrated to be true for children 
exposed to MDR-TB. The proportion of children with disease is consistent with other 
household contact studies from this setting.440 The association between gender of the child 
and disease also requires further examination. It is possible that girls are more likely to 
progress to disease or this association may reflect some sociological or cultural attitude to 
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child-rearing or health-seeking behavior. Houses with more rooms may be a surrogate for 
socioeconomic status, TB transmission, lifestyle, behavior or nutrition. It may be that more 
families live in houses with more rooms, whereas buildings with fewer rooms only house one 
family. 
A limitation of the study is the relatively small number of children included, and the small 
number of children with disease. This may have concealed associations that may have been 
evident if larger numbers had been included. In previous drug-susceptible childhood contact 
studies, measures of intensity (e.g. proximity of sleeping) and duration of exposure 
demonstrated a graded relationship with risk of infection in the child, as did the infectiousness 
of the source case.so These relationships were not seen in this study. This study also did not 
compare children exposed to MDR-TB with children exposed to drug-susceptible TB to 
determine if systematic differences between the two populations exist (e.g. in child and source 
case demographics or risk factors for infection and disease). It is possible that MDR-TB in the 
source case, where typically long exposure durations are seen due to previous failed first-line 
treatments, may potentially obscure the relationship between risk factors and infection. It 
would also have been useful to compare MDR-TB-exposed children with community controls 
without a known source case to document the background (Le. community, presumably drug-
susceptible) infection rate. Finally, the definition of infection in this study was one TST 
measurement undertaken at the initial evaluation. Not only is TST an imperfect measure of 
infection, but TST retesting was not retested at follow-up visits in this cross-sectional study. 
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Table 15 - Risk factors for infection in child contacts of multidrug-resistant tuberculosis: child and household characteristics (n=228) 
Variable Total Infected Unadjusted OR p-value AOR p-value1 
(n=228) (row") (95%(1) (95%(1)1 
(n=102) 
Age of ch ild (n=224) <1 year 53 15 (28.3) 1 
1-2 years 36 15 (41.7) 1.81 (0.74-4.42) 
2-3 years 51 25 (49.0) 2.44 (1.08-5.48) 0.05 1.43 (1.13-1.91) 0.0022 0.0072 
3-4 years 48 27 (56.3) 3.26 (1.43-7.44) 
4-5 years 36 18 (50.0) 2.53 (1.05-6.14) 
Gender (n=227) Female 109 46 (42.2) 1 0.43 
Male 118 56 (47.5) 1.24 (0.73-2.09) 
Ethnicity Xhosa 101 30 (29.7) 1 1 
Colored 125 70 (56.0) 3.01 (1.69-5.36) <0.001 2.51 (1.22-5.17) 0.01 
Previous TB treatment No 207 86 (41.5) 1 1 
Yes 21 16 (76.2) 4.50 (1.59-12.8) 0.002 2.76 (0.84-9.12) 0 .08 
HIV status (n=217) Negative 209 96 (45.9) 1.0 
Posit ive 8 3 (37.5) 0.71 (0.16-3.03) 0.64 
Weight-for-age z-score (n=218) More than -1 138 60 (43.5) 1 
-1 to -2 47 26 (55.3) 1.61 (0.83-3.13) 0.14 
Less than-2 33 11 (33.3) 0.65 (0.29-1.44) 
BCG scar visible (n=222) No 40 14 (35.0) 1 
Yes 182 87 (47.8) 1.70 (0.83-3.47) 0.14 
Type of residence (n=217) Tin shack 33 8 (24.2) 1 
Brick House 168 79 (47.0) 2.77 (1.18-6.50) 0.007 
Wendy House 16 11 (68.8) 6.87 (1.83-25.8) 
Number of rooms in house 1-2 61 28 (45.9) 1 
3-4 102 42 (41.2) 0.83 (0.44-1.56) 0.58 
>4 65 32 (49.2) 1.14 (0.57-2.30) 
Number of people living in house :'>5 people 109 47 (43.1) 1 
>5 people 119 55 (46.2) 1.13 (0.67-1.91) 0.64 
Density of people living in house $2 people per room 153 72 (47.1) 1 
>2 people per room 75 30 (40.0) 0 .75 (0.43-1.31) 0.31 
Water source (n=225) Piped water in residence 176 84 (47.7) 1 
Piped water from public source 49 16 (32.7) 0.53 (0.27-1.03) 0.06 
Toilet Flush toilet in house 163 79 (48.5) 1 
0.07 Other 65 23 (35.4) 0.58 (0.32-1.05) 
-
IAdjusted for ethnicity, age of child, previous TB in the child, age of source case, alcohol use in source case and HIV status of source case, 'rest for trend, AOR: adjusted odds ratio; CI: confidence interva l 
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Table 16 - Risk factors for infection in child contacts of multidrug-resistant tuberculosis: source case and exposure characteristics (n=228) 
Variable Total Infected OR p-value AOR p-value1 
(n=228) (row ") (95" el) (95%0)1 
(n=102) 
Age of source case (n=219) 16-25 55 31 (56.4) 1 
26-35 86 40 (46.5) 0.67 (0.34-1.33) 0.06 0.67 (0.45-1.00) 0.052 
>35 78 28 (35.9) 0 .43 (0.21-0.88) 0.02
2 
Gender of source case (n=226) Female 138 62 (44.9) 1 
Male 88 39 (43.3) 0.98 (0.57-1.67) 0.93 
Smoking status of source case (n=225) Non-smoker 130 52 (40.0) 1 
Smoker 95 49 (51.6) 1.60 (0.94-2.73) 0.09 
Alcohol use by source case (n-225)' Never drinks 166 65 (39.2) 1 1 
Drinks alcohol 59 36 (61.0) 2.43 (1.32-4.47) 0.004 2.59 (1.29-5.22) 0.007 
Smear result of source case (n-224) Negative 28 9 (32.1) 1 
Positive 196 90 (45.9) 1.79 (0.77-4.16) 0.17 
Smear grade of source case (n=217) Negative 28 9 (32.1) 1 
Scanty 18 8 (44.4) 1.69 (0.50-5.73) 
1+ 28 15 (53.6) 2.44 (0.82-7.22) 0.13 
2+ 107 44 (41.1) 1.47 (0.61-3.56) 
3+ 36 22 (61.1) 3.31 (1.17-9.37) 
HIV status of source case (n=224) Negative 150 79 (52.7) 1 1 
Positive 74 20 (27.0) 0.33 (0.18-0.61) <0.001 0.48 (0.22-1.04) 0.06 
CD4 count of source case if HIV-positive (n-71) <200 33 7 (21.2) 1 
>200 38 11 (28.9) 1.51 (0.50-4.56) 0.46 
Relationship of source case to child Parents 100 38 (38.0) 1 
Grandparent 31 15 (48.4) 1.53 (0.68-3.45) 
Uncle or aunt 66 33 (50.0) 1.63 (0.87-3.06) 0.34 
Other 31 16 (51.6) 1.74 (0.77-3.92) 
Duration of exposure between source case and child less than a month 30 13 (43.3) 1 
One month to six months 92 38 (41.3) 0.92 (0.40-2.11) 0.62 
More than six months 106 51 (48.1) 1.21 (0.54-2.74) 
Primary caregiver to child Index case 55 21 (38.2) 1 
Not index case 173 81 (46.8) 1.43 (0.77-2.65) 0.26 
Frequency of contact between source case and child Daily 213 93 (43.7) 1 
less frequently 15 9 (60.0) 1.94 (0.67-5.63) 0.23 
Intensity of contact between child and source case Sleeps in the same bed 57 25 (43.9) 1 
Sleeps in the same room 34 13 (38.2) 0.79 (0.33-1.89) 
Sleeps in the same house 101 45 (44.6) 1.03 (0.53-1.98) 0.67 
- ----- ------ - - -------
_Slee!l~ir1 _a different house 36 19 (52.8) 1.43 (0.62-3.31) 
----- - --- -- - - ----- - --
lAdjusted for ethnicity, age of child, previous TB in the child, age of source case, alcohol use in source case and HIV status of source case, ~est of trend, 3Regular alcohol use in source case as reported by the parent or legal 
guardian of the child, AOR adjusted odds ratio; CI confidence interval 
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Table 17 - Risk factors for disease in child contacts of multidrug-resistant tuberculosis : child and household characteristics (n=102) 
Variable Total Disease OR p-value Age-adjusted OR p-value 
(n=102) (row%) (95%CI) (95%CI) 
(n=15) 
Age (n=lOO) <1 year 15 4 (26.7) 1 
1-2 years 15 3 (20.0) 0.69 (0.12-3.79 ) 
2-3 years 25 6 (24.0) 0.87 (0.20-3.77) 0.28 nfa nfa 
3-4 years 27 2 (7.4) 0.22 (0.03-1.38) 0.01
1 
4-5 years 18 0(0) -
Gender Female 46 11 (23.9) 1 1 
Male 56 4 (7.1) 0.24 (0.72-0.83) 0.02 0.29 (0.08-1.00) 0.04 
Ethnicity Xhosa 30 7 (23.3) 1 
0.13 Colored 70 8 (11.4) 0.42 (0.14-1.33) 
Previous TB treatment No 86 14 (16.3) 1 
0.32 Yes 16 1 (6.3) 0.34 (0.04-2.81) 
HIV status (n=99) Negative 96 13 (13.5) 1 0.04 1 0.01 
Positive 3 2 (66.7) 12.8 (1.07-151.1) 25.3 (1.63-393) 
Weight-for-age z-score (n-97) More than -1 60 10 (16.7) 1 
-1 to-2 26 1 (3.8) 0 .20 (0.02-1.65) 0.19 
Less than-2 11 1 (9.1) 0.50 (0.06-4.45) 
BCG scar visible (n=lOl) No 14 2 (14.3) 1 
0.95 Yes 87 13 (14.9) 1.05 (0.21-5.27) 
Type of residence (n=98) Tin shack B 1 (12.5) 1 
Brick House 79 12 (15.2) 1.25 (0.14-11.1) 0.84 
Wendy House 11 1 (9.1) 0.70 (0.04-13.2) 
Number of rooms in house 1-2 28 2 (7.1) 
3-4 42 4 (9.5) 1.37 (0.23-8.03) 0.04 1.39 (1.02-1.91) 0 .041 0.021 
>4 32 9 (28.1) , 5.09 (1.00-26.0) 
Number of people living in house ~5 people 47 5 (10.6) 1 
>S people 55 10 (18.2) 1.87 (0.59·5.91) 0.29 
Density of people living in house ~2 people per room 72 12 (16.7) 1 
>2 people per room 30 3 (10) 0.56 (0.14-2.16) 0.39 
Water source (n=loo) House tap 84 12 (14.3) 1 0.65 
No house tap 16 3 (18.8) 1.38 (0.34-5.60) 
Toilet Flush toilet in house 79 12 (15.2) 1 
Other 23 3 (13.0) 0.84 (0.21-3.26) 0.80 
-- ----- -
~---------
'Test of trend, OR: odds ratio; CI : confidence interval 
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Table 18 - Risk factors for disease in child contact s of multidrug-resistant tubercu losis: source case and exposure characteristics (n=102) 
Variable Total Disease OR p-value Age-adjusted OR p-value 
(n=102) (row") (95"a) (95"a) 
(n=15) 
Age of source case (n=99) 16-25 31 4 (12.9) 1 
26-35 40 5 (12.5) 0.96 (0.24-3.94) 0.81 
>35 28 5(17.9) 1.47 (0.35-6.12) 
Gender of source case (n=101) Female 62 11 (17.7) 1 
Male 39 4 (10.3) 0.53 (0.16-1.80) 0.31 
Smoking status of source case (n=101) Non-smoker 52 8 (15.4) 1 
Smoker 49 7 (14.3) 0.92 (0.31-2.75) 0.88 
Alcohol use by source case (n=101) Never drinks 65 6 (9.2) 1 1 
Drinks alcohol 36 9 (25.0) 3.28 (1.06-10.1) 0.04 2.90 (0.90-9.31) 0 .07 
Smear result of source case (n=99) Negative 9 0(0) - 0.35 Positive 90 15 (16.7) -
Smear grade of source case (n-98) Negative 9 0(0) -
Scanty 8 0(0) -
1+ 15 5 (33.3) - 0.05 
2+ 44 9 (20.5) -
3+ 22 1 (4.5) -
HIV status of source case (n=99) Negative 79 8 (10.1) 1 
0.009 1 Positive 20 7 (35.0) 4.78 (1.45-15.5) 4.07 (1.19-13.8) 0.03 
CD4 count of source case if HIV-positive (n=18) <200 7 3 (42.9) 1 
>200 4 (36.4) 0.76 (0.11-5.28) 0.78 11 
Relationship of source case to child Parents 38 5 (13.2) 1 
Grandparent 15 4 (26.7) 2.4 (0.55-10.6) 
Uncle or aunt 33 4 (12.1) 0.91 (0.22-3.71) 0.62 
Other 16 2 (12.5) 0.94 (0.16-5.45) 
Duration of exposure between source case and child less than a month 13 3 (23.1) 1 
One month to six months 38 7 (18.4) 0 .75 (0.16-3.47) 0.35 
More than six months 51 5 (9.8) 0 .36 (0.07-1.77) 
Primary caregiver to child Index case 21 2 (9.5) 1 
Not index case 81 13 (16.0) 1.82 (0.38-8.76) 0.46 
Frequency of contact between source case and child Daily 93 12 (12.9) 1 
less frequently 9 3 (33.3) 3.38 (0.74-15.3) 0.12 
Intensity of contact between child and source case Sleeps in the same bed 25 3 (12.0) 1 
Sleeps in the same room 13 1 (7.7) 0.61 (0.06-6.54) 
Sleeps in the same house 45 6 (13.3) 1.13 (0.26-4.96) 0.47 
- - -- - --------- - --- - --
Sleeps in adlfferent house 19 5 (26.3) 
---- -
2.§.2_ (0.54-g.]) .. _ 
l Regular alcohol use in source case as reported by the parent or legal guardian of the child, OR; odds rat io; CI : confidence interval 
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Table 19 - Characteristics of children presenting with prevalent TB disease following exposure to adult with multidrug-resistant tuberculosis (n=lS) 
Age in months Gender HIVstatus Source case(s) orr 
3 Girl Negative Father MDR 
6 Boy Negative Aunt MDR 
12 Girl Negative Grandmother Pre-XDR 
12 Girl Negative Great uncle MDR 
13 Boy Negative Sister XDR 
13 Girl Positive Mother MDR 
16 Girl Negative Father Pre-XDR 
27 Boy Negative Aunt MDR 
29 Girl Negative Uncle MDR 
31 Girl Negative Aunt MDR 
32 Girl Negative Aunt MDR 
35 Boy Negative Mother MDR 
36 Girl Negative Aunt XDR 
39 Girl Negative Mother and aunt XDR 
43 Girl Positive Mother MDR 
OST: drug susceptibility test; MOR: multidrug-resistant; XOR: extensively drug-resistant; pre-XOR: MOR with addit ional resistance to either a fluoroquinolone or an injectable medication 
'OST of the isolate from the child where the diagnosis was confirmed and from the source case when probable 
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Study 3: drug-resistant tuberculosis in children is caused by transmission and 
amplification of resistance within families 
The following study has been published as an article: 
• Seddon lA, Warren R, Enarson DA, Beyers N, Schaaf HS. Drug-Resistant tuberculosis 
transmission and resistance amplification within families. Emerg Infect Dis 2012; 18:1342-5 
The first study in the thesis documented the burden of drug resistance in the context of the 
research. The second explored the epidemiological risk factors for infection and disease in 
child contacts of DR-TB. This study and the next examine the transmission of DR M. 
tuberculosis strains from adults to children within families. The first of these two describes the 
clinical and molecular investigations of two families following the identification of children 
with drug-resistant TB. 
The study 
This investigation was carried out in a suburban community of Cape Town, South Africa where 
the TB incidence was 978/100,000 population in 2009.441 Since 1994, microbiological samples 
from all patients treated for TB in this area have been collected routinely. Between 2008 and 
2010 two children from these communities were diagnosed with MDR-TB. 
Information was obtained from several sources to document the sequence of events 
culminating in the child developing MDR-TB. A home visit was carried out and the family was 
interviewed following written informed consent. Family members were included if they either 
lived with or spent significant periods of time with the child.442 Information on TB diagnoses, 
treatment and outcome was obtained at interview. If a family member was identified as having 
had TB, significant family contacts of that person were then also included. Searches were 
made at the local clinic, the academic hospitals and the regional TB hospital responsible for 
drug-resistant TB management, for case notes of any of those included. Additionally, the local 
clinic TB register was consulted. 
Samples were identified from patients in the two social networks and isolates were genotyped 
by spoligotyping443 and IS6110 DNA fingerprinting.444 Strains were identified according to 
distinct IS6110 banding patterns using Gelcompar II (Applied Maths, Sint-Martens-Latem, 
Belgium) or by their characteristic spoligotype pattern.445 Mutations conferring resistance to 
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isoniazid, rifampicin, ethambutol, pyrazinamide, ofloxacin and amikacin were determined by 
DNA sequencing of the inhA promoter, katG, rpoB, embB, pncA, gyrA and rrs genes, 
respectively.2l1 
Case one 
A 19-month-old girl (A3) was diagnosed with TB in March 2008 following a six month course of 
isoniazid preventive therapy. She presented with two weeks of cough, respiratory distress and 
fever. She had significant contact with a pre-XDR-TB patient (MDR-TB resistant to either a 
fluoroquinolone or a second-line injectable drug) and so was treated with capreomycin, 
ethionamide, ethambutol, PAS, terizidone, clarithromycin and high-dose isoniazid. Gastric 
aspirate samples were sent, from which M. tuberculosis was cultured, resistant to rifampicin, 
isoniazid and ofloxacin, susceptible to amikacin and ethionamide. She was treated for 18 
months from the time of her first negative culture, the first six months including the injectable 
medication. She was cured. 
Family one 
Eighteen people were found in the family (Figure 4). The husband of an aunt (A2) had known 
DR-TB. He cared for the girl on a daily basis. He had been treated initially for drug-susceptible 
TB, changed to MDR-TB therapy when resistance to rifampicin and isoniazid was determined 
and then to XDR-TB treatment when resistance to second-line drugs was discovered. He 
subsequently died. His mother (Al) had repeatedly defaulted treatment and was finally 
diagnosed with DR-TB in 1998. She refused further treatment until her death in 2003. The 
clinical chronology is shown in Figure 5 with molecular details for the samples located shown 
in Table 20. 
Case two 
A 13-year-old girl (BS) was identified in April 2009 as a contact of multiple family members 
with XDR-TB. She was asymptomatic but had an abnormal chest radiograph. She was started 
on capreomycin, ethionamide, pyrazinamide, terizidone, PAS, co-amoxicillin/clavulanic acid, 
clarithromycin, linezolid and high-dose isoniazid. M. tuberculosis was cultured from a sputum 
sample, resistant to isoniazid, rifampicin, ethambutol, ofloxacin and amikacin. The 
capreomycin was given for six months and she was treated for a total of 18 months. She was 
cured. 
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Family two 
The family is demonstrated in Figure 4. The eldest brother (Bl) had been in prison and 
developed TB soon after release in 1998. He was started on first-line treatment and died soon 
afterwards. His sister (B2), mother (B3) and brother (B4) then developed TB. All were started 
initially on first-line therapy, converted onto MDR-TB and, for the brother, XDR-TB treatment 
regimens when resistance profiles became available. All three died. A chronology is shown in 
Figure 5 with molecular details for the samples demonstrated in Table 20. 
Discussion 
In family one, the uncle's mother (Al) had pre-XDR-TB and probably transmitted it to her son 
(A2). He likely transmitted it to his niece (A3). All three had identical strains. In family two, it is 
unknown whether the oldest brother (Bl) had DR-TB. His sister (B2) had pre-XDR-TB but then 
in sequence her mother (B3), brother (B4) and sister (B5) developed XDR-TB, of a strain 
identical to hers. This investigation, therefore, demonstrates the potential for resistance to be 
both transmitted and amplified within families. 
Other than the two child index cases (A3 & B5), all were initially started on first-line therapy 
and treated until OST results became available, often despite a known drug-resistant contact. 
Local policy is to diagnose TB solely from sputum smear in new patients who have no risk 
factors for drug resistance. Re-treatment patients and those at risk of resistance have DST 
done to rifampicin and isoniazid. If MDR-TB is diagnosed, DST to second-line drugs is then 
performed. Giving inadequate regimens not only leads to more advanced disease until 
effective treatment is initiated but also risks amplifying resistance.446-447 For a patient with TB 
symptoms, in contact with drug-resistant TB, it is important to obtain microbiological samples 
and then start treating according to the OST of the source case. If a less resistant organism is 
grown, treatment can be changed. In the context of mUltiple possible TB source cases, deciding 
on treatment is challenging. Consideration must be given to the infectiousness of potential 
source cases as well as the intensity, frequency and duration of exposures. Local policy is to 
carry out household contact tracing for drug-resistant TB patients. Whilst in reality this occurs 
infrequently, we demonstrate the importance of careful investigation of contacts to identify 
those who may have sub-clinical disease who could be treated early. Given the social 
interactions, chronology and mycobacterial results, it is highly likely that the transmission 
sequence occurred as described. However, in both clusters, the strain identified is one that is 
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predominant locally. We must, therefore, be aware that this is a potential confounder to the 
transmission lines suggested. 
Drug-resistant tuberculosis in children James Seddon P age 1103 
Table 20 - Gene sequencing, 156110 DNA fingerprinting and genotype for isolates from members of the two families 
156110 
Family One rpaB inhA katG embB gyrA pncA rrs 1401 Cluster 
number 
R H H E F Z A 
Uncle's mother 
A1 TCGs31TTG WT AGC31sACC ATG306ATA GCG90GTG 
ACA160GCA & 
WT 213 
ACC100ATC 
Uncle A2 TCGs31TTG WT AGC31sACC ATG306ATA GCG90GTG 
ACA160GCA & 
WT 213 
ACC100ATC 
Index child ACA160GCA & 
A3 TCGs31TTG WT AGC31sACC ATG306ATA GCG90GTG WT ** ACC100ATC 
Family Two 
Oldest brother* 
B1 
Sister 
B2 TCGs31TTG WT AGC31sACC ATG306ATA GCG90GTG 
ACA160GCA& 
WT 213 
ACC100ATC 
Mother 
B3 TCGs31TTG WT AGC31sACC ATG306ATA GCG90GTG 
ACA160GCA& ACG1401GCG 213 
ACC100ATC 
Other brother 
B4 TCGs31TTG WT AGC31sACC ATG306ATA GCG90GTG 
ACA160GCA& ACG1401GCG 213 
ACC100ATC 
Index child 
WT AGC31sACC ATG306ATA GCG90GTG 
ACA160GCA& 
ACG1401GCG ** 85 TCGs31TTG ACC100ATC 
R - rifampin; H - isoniazid; E - ethambutol; F - f1uoroquinolones; Z - pyrazinamide; A - aminoglycosides, WT - wild type 
The earliest sample available for each patient is shown; in all incidences where more than one sample was available for a patient, all samples demonstrated identical gene sequence and strain type results 
·Developed TB and died prior to systematic sample collection and storage. No culture or drug susceptibility testing requested on sample 
"Only spoligotype performed as isolates repeatedly lost viability on culture 
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Figure 4 - Families investigated following the diagnosis of two children with multidrug-resistant 
tuberculosis 
Family One 
Family Two 
D Person identified as having tuberculosis 
Identified child index case 
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Figure 5 - Chronology of tuberculosis treatment and outcomes for the two families 
Family one 
Uncle's mother Al 
A2 
A3 
Uncle 
Index ch ild 
Family two 
Oldest brother B1 
Sister B2 
Mother 
Other brother 
B3 
B4 
BS Index ch ild 
TB with no treatment 
Treatment for drug-susceptible TB 
Treatment for MDR-TB 
Treatment for XDR-TB 
Death 
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Study 4: discordant drug susceptibility for M. tuberculosis within families 
The following study has been published as an article: 
• Seddon JA, Jordaon AM, Victor Te, Schaaf HS. Discordant drug susceptibility for 
Mycobacterium tuberculosis within families. Pediatr Infect Dis J 2012; 31: 783-5 
As with the previous study, this investigation examines the transmission M. tuberculosis 
between adult source case and child contact. Children with presumed TB who are in contact 
with a MDR-TB source case should be treated according to the DST pattern of the source case's 
isolate.16.197 As it is assumed that children will have the same strain and DST as the identified 
source case,64 this general strategy is usually valid. However, it is important to strive to obtain 
a microbiological diagnosis as it is possible for the child to have a different DST to the source 
case. The implications for the management of the child are significant. Two children are 
described who developed TB following exposure to a parent with MDR-TB. 
Case one 
A 50-month-old girl presented with fever, weight loss, cough and contact with her father who 
had previously been diagnosed with MDR-TB, susceptible to ethambutol, ethionamide, 
ofloxacin and amikacin. She had received BCG immunisation at birth and she was HIV-
uninfected. She was on the 50th percentile for weight and height for age. There were no 
abnormal signs on clinical examination. She had a TST induration of 18mm and a CR that 
showed left upper lobe opacification and an apical cavity. 
Two early morning gastric aspirates were taken for culture and DST. While awaiting DST 
results, the child was started on an MDR-TB treatment regimen including high-dose isoniazid, 
pyrazinamide, ethambutol, amikacin, ofloxacin, ethionamide and terizidone. 
When the laboratory results were available one month later, the culture was positive for M. 
tuberculosis and DST showed resistance to isoniazid but susceptibility to rifampicin. On gene 
sequencing an inhA promoter region mutation was identified (confirming isoniazid resistance), 
while no mutations were detected in the rpoB region (confirming susceptibility to rifampicin). 
The amikacin, ethionamide and terizidone were stopped, isoniazid continued and rifampicin 
started. Gene sequencing of the father's strain demonstrated a TAC mutation at the 516 
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location of the 'poB gene, confirming that the father was infected with a rifampicin-resistant 
strain. The spoligotypes for the girl and her father are shown in Figure 6. The girl responded 
well clinically and radiologically. 
Case two 
A 26-month-old boy presented with a two month history of enlarged bilateral cervical lymph 
nodes. His mother had been diagnosed with MOR-TB three months earlier with a strain 
susceptible to ethambutol, ethionamide, ofloxacin and amikacin. She had been three-plus 
sputum smear-positive for acid-fast bacilli and had been started on an MOR-TB treatment 
regimen. 
The clinical examination of the child was unremarkable other than enlarged cervical lymph 
nodes bilaterally. He was on the 50th percentile weight for age, had a BeG scar, was HIV-
uninfected and had an ulcerating 25mm TST induration. His chest radiograph showed bilateral 
hilar lymphadenopathy. He had gastric aspirate and lymph node fine needle aspiration biopsy 
(FNAB) samples taken for culture and OST. Oue to the clinical presentation, radiology and the 
history of contact with an MOR-TB source case, he was started on a MOR-TB regimen of 
ethambutol, pyrazinamide, amikacin, ofloxacin, ethionamide, terizidone and high-dose 
isoniazid. As part of contact investigations, the child's asymptomatic father was screened with 
sputum culture and was shown to have MOR-TB, resistant to isoniazid and rifampicin but 
susceptible to the other medications tested. He was started on MOR-TB treatment. 
Six weeks later two independent OST results from the child's gastric aspirate and also the FNAB 
showed M. tuberculosis, resistant to isoniazid but susceptible to rifampicin. Genotypic results 
showed a katG gene mutation, confirming isoniazid resistance. The treatment was continued 
until full gene sequencing demonstrated that there was no 'poB gene mutation (confirming 
susceptibility to rifampicin). At this point the amikacin, terizidone and isoniazid were stopped 
and rifampicin was started. Gene sequencing for both parents' isolates showed a TIG mutation 
at the 531 location of the 'poB gene (rifampicin resistance). The spoligotypes for the child, his 
mother and his father are shown in Figure 6. The boy responded well clinically and 
radiologica IIy. 
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Discussion 
Although it is appropriate to treat children according to the DST pattern of the likely source 
case when a microbiological sample in the child is not obtained, these cases highlight the 
importance of striving for a microbiological diagnosis in all patients. The sequence of events 
and transmission circumstances for these children are not completely clear. A number of 
possible scenarios could have taken place. First, there may have been a laboratory error in 
either the DST of the parents or that of the children. Without the gene sequencing and 
spoligotyping this has to be considered but with these results it seems unlikely. Second, the 
children could have been infected from a source case other than their parents. In high burden 
settings it is possible for children to develop disease caused by a strain transmitted from 
someone other than the identified source case.66. 69 In the first case the discriminating power 
of the spoligotype is good and it is unlikely that the child contracted TB from source cases 
outside the social group. It is possible, however, that a third party transmitted TB first to the 
child, whilst isoniazid-resistant, and later to the father after developing MDR. In the second 
case, the strain type is from the Beijing family, which is common in the Western Cape Province 
of South Africa. This strain could have been transmitted from a number of different source 
cases but given the close proximity of the child to the parents and the lack of other source 
cases, it is less likely. Another possibility is that in the parent(s) both isoniazid-resistant and 
MDR strains co-existed (multiple strain infection) with the MDR strain isolated from the adult 
but the isoniazid-resistant strain transmitted to the child.71-72 Finally, and probably most likely, 
one of the parents may have had HMR-TB and transmitted the mycobacterium to the child 
prior to developing rifampicin resistance. 
Testing the infecting organism for the presence of the mutations that are usually associated 
with drug resistance (genotypic testing) has advantages over conventional (phenotypic) testing 
in which the organism is grown in the presence of antibiotic. It is more rapid, cheaper and is 
less labour intensive. For M. tuberculosis the rpoB gene is almost always (>95%) associated 
with rifampicin resistance. Isoniazid resistance, however, is associated with a number of 
mutations, the most common of which are in the inhA promoter region and kotG gene. If a 
katG mutation is present the strain usually has high-level resistance to isoniazid, whereas if an 
inhA promoter region mutation is present the strain usually has low-level resistance. In the 
case of inhA promoter region mutations, isoniazid, given at high dose, may be of use.90 As 
isoniazid and ethionamide share similar biochemical pathways, if an inhA promoter region 
mutation is present the strain is likely to be ethionamide-resistant.91.448 With the roll-out of 
genotypic testing (both the line probe assays449 and the GeneXpert MTB/RIF assay [Cepheid]407 
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have been endorsed by the WHO) it is important that treating clinicians are aware of the 
implications, strengths and weaknesses of these new tests. 
The main reason to strive to obtain a microbiological diagnosis in MDR-TB contacts is the 
difference in management of MDR, HMR, RMR and drug-susceptible strains. Drug-susceptible 
strains are treated with a highly effective six-month first-line regimen which is well tolerated 
and associated with good outcomes. The treatment for HMR disease involves treatment with 
rifampicin, ethambutol and pyrazinamide (adding a fluoroquinolone in extensive disease if 
identified early) taken for nine months.197 MDR-TB strains (and RMR cases iftested by 
genotypic-based DST only) are treated with a second-line injectable medication for six months 
and treatment is for eighteen months from the time of the first negative culture. Drugs used 
for the full duration of treatment include high-dose isoniazid (if an inhA promoter region 
mutation is present) ethionamide (if a katG gene mutation is present), pyrazinamide, 
ethambutol, a fluoroquinolone and terizidone (or cycloserine). The adverse effects of the 
additional medications, together with the extended treatment duration make treating for MDR 
or RMR-TB a serious proposition. 
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Figure 6 - The spoligotypes of the children and parents for the two cases with positive controls, 
negative controls and BeG shown alongside 
Drug-resistant tuberculosis in children James Seddon 
1 - Case One - Child 
2 - Case One - Father 
3 - Case Two - Child 
4 - Case Two - Father 
5 - Case Two - Mother 
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Study 5: decentralised care for the management of child contacts of multidrug-
resistant tuberculosis 
The following study has been accepted as an article: 
• Seddon lA, Hesseling AC, Dunbar R, Cox H, Hughes l, Fielding K, Godfrey-Faussett P Schaaf 
HS. Decentralised care for child contacts of multidrug-resistant tuberculosis. Pub Health 
Action 2012; 2: 66-70 
Introduction 
This study and the next explore the operational and programmatic identification and referral 
of child contacts of MOR-TS source cases. The first of these two examines the number of MOR-
TS child contacts that are identified and brought for specialist assessment, under routine, 
programmatic conditions. It then links these children with adults that are registered for MOR-
TS treatment in the City of Cape Town, to provide an indication of the proportion of children 
identified who might have been exposed. In addition it compares the identification and 
referral in Khayelitsha (a decentralised model of MOR-TS care) with the other seven sub-
districts (a centralised, hospital-based model) to determine if more children are identified and 
if there are any implications for delay to be seen. 
Methods 
Identification and treatment of child contacts 
According to provincial and national guidelines, following the diagnosis of OR-TS in an adult, a 
home visit should be conducted to educate the patient and their family, give advice about 
infection control and identify symptomatic contacts. A professional nurse oversees this process 
within each of the eight sub-districts. Children less than five years and HIV-infected children 
are referred to their local clinic for assessment prior to referral to TCH which serves as the 
main provincial paediatric OR-TS referral centre. In the Khayelitsha sub-district these children 
are referred to the specialist outreach clinic, conducted monthly in Khayelitsha. Children from 
outside the City of Cape Town health district are also sometimes referred to the OR-TS clinic at 
TCH. 
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Case identification, data collection and eligibility: source cases 
Adult "source cases" (>18 years) treated for MDR-TB in the City of Cape Town Health District 
from 1 April 2010 to 31 March 2011 were identified from routine TB register data. Source 
cases were included if they had been started on MDR-TB treatment during the stated time 
period for sputum smear and/or culture positive pulmonary TB, and had been registered at a 
TB clinic in one of the eight sub-districts. Adults were excluded if they did not have TB resistant 
to both isoniazid and rifampicin, or were registered in hospital or prison (i.e. unclear sub-
district of origin). 
Case identification, data collection and eligibility: child contacts 
From 1 May 2010 to 30 June 2011 all children evaluated at the TCH, or at the outreach DR-TB 
clinic, were prospectively recorded. Children were included in the study if they were either 
HIV-infected or were less than five years old and had significant contact with a source case 
with sputum smear and/or culture positive pulmonary MDR-TB. Significant contact was 
defined as living with or having regular daily interaction with the source case over the 
preceding six months. 
Data analysis 
After removing duplicates from the MDR-TB register, probabilistic linking was done using 
software Registry Plus™ Link Plus (Centers for Disease Control and Prevention, Atlanta, GA, 
USA) to match adult cases from the register to the names of source cases provided by the 
parents/caregivers of children attending DR-TB clinics.4s()"4s1 An inclusive algorithm was used 
allowing the software to use four demographic variables: name, surname, sex and age. Names 
and surnames were converted using the New York State Identification and Intelligence System, 
a phonetic coding system that allows for inconsistencies and variations in spelling. The total 
number of source cases, the number of children assessed and the number of linked source 
cases were determined. Time to assessment was defined as the time from sputum production 
in the source case, for the sample that diagnosed MDR-TB, to the child being evaluated at the 
DR-TB clinic. 
Statistical analYSis was performed using STATA version 11. Missing data were excluded from 
analysis. The association between categorical variables was assessed using the X2 test or 
Fisher's exact test, where appropriate. The Mann Whitney test was used to compare 
quantitative data which were not normally distributed, and data summarised using the median 
and IQR. The t-test was used to compare normally distributed quantitative data. 
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Results 
Of the 1265 adult MDR-TB source cases registered during the study period, 1221 were 
included. The sub-district could not be determined for the remaining 41 cases. Six hundred and 
seventy (55.0%) were male; the median age at diagnosis was 35 years (lOR: 27-44 years). 
(Table 21) One hundred and eighty nine (15.5% of total) patients were registered in 
Khayelitsha. Clinical characteristics of the source cases from Khayelitsha vs. other sub-districts 
were similar, except for the prevalence of HIV infection, which was higher in the Khayelitsha 
group (70.5% vs. 49.8%; p<O.OOl). 
Two hundred and sixty-five children were evaluated at TCH, or at the outreach DR-TB clinic, 
during the assessment period. Eleven were excluded as not meeting the criteria of significant 
contact. Of the 254 included, 146 (57.5%) were linked to 126 source cases; the median number 
of contacts per source case was 1 (range 1 to 4). Of the 108 unmatched children, 26 (24.1%) 
were linked to a source case resident outside the City of Cape Town. Of the linked children, a 
total of 35 children (linked to 31 source cases) were from Khayelitsha and 111 children (linked 
to 95 source cases) were from the remaining seven sub-districts. Eighty (54.8%) children were 
male; median age 32 months (lOR: 13-46 months). (Table 22). As expected, children from 
Khayelitsha were more likely to be Xhosa than from the other sub-districts (100% vs. 36%; 
p<0.001). Children from Khayelitsha were better nourished with mean weight-for-age z-score 
0.07 compared to -0.63 (p=0.012). Other characteristics were similar between the two groups. 
Of source cases in Khayelitsha, 16.4% (31/189) led to the assessment of at least one child 
contact, compared to 9.2% (95/1032) from source cases diagnosed in the other sub-districts 
(p=0.003). Children in Khayelitsha were seen at a median of 71 days (lOR: 37-121 days) from 
the date of source case MDR-TB sputum production compared to 90 days (lOR: 56-132 days) in 
the other sub-districts (p=0.15). 
Discussion 
In a previous MDR-TB contact study in Cape Town, a mean of 1.7 child contacts five years or 
less were identified for each source case with sputum-positive TB.21 Recent TB household 
studies from Cape Town also indicate a mean of 1.7 children younger than five years identified 
per drug-susceptible TB source case. (Personal communication: Anneke Hesseling). Based on 
our findings, it is therefore likely that only a small proportion of possible MDR-TB child 
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contacts were identified, referred and evaluated by a specialist as is recommended in national 
and international guidelines. There appears to be some advantage provided by decentralised 
care, in terms of number of children identified per source case and time for child to be seen, 
but the number of children evaluated remains low for both models. Furthermore, despite a 
trend towards children being seen earlier in Khayelitsha, the time to assessment is sub-optimal 
in the light of the high risk of disease progression in young children. 
The reason so few children are evaluated may be explained by a number of factors. First, the 
definition of child contact used by healthcare workers may not be sufficiently inclusive. If a 
definition is used where only children living in the same house as the source case are included, 
fewer contacts will be revealed than if a definition of any significant contact is used, as in our 
study.404 It is therefore possible that children are not identified by local healthcare teams. 
Furthermore, if children are locally identified, then personal, logistic or financial barriers to 
accessing clinic appointments may occur. In this operational study, we used the source case as 
the denominator and children evaluated in the specialist clinic as the numerator; we are 
therefore unable to determine where the attrition occurred. However, studies examining 
children exposed to drug-susceptible TB have demonstrated that this 'drop off' occurs at every 
step in the care pathway.452-453 
Delay in the assessment of child contacts has a number of components. These include the time 
to diagnosis in the source case, time to identification of child contacts, time for the child to be 
seen locally and the time for the child to be seen in the specialist clinic. Since we captured the 
date of sputum production in the source case and the date the child was seen in the specialist 
clinic we were unable to determine the respective duration of each of these components. 
However, the delay associated with starting TB treatment has been well explored and is 
associated with both patient and health system delays.454-456 The delay from sputum sampling 
to the initiation of DR-TB treatment initiation has fallen from 72 days in 2005 to 33 days in 
2010, in Khayelitsha.122 In a sample of ten health facilities in the City of Cape Town excluding 
Khayelitsha, the mean delay was 83 days in 2005-2008 and 53 days in 2008-2011. (Personal 
communication: Pren Naidoo). The impact of health system strengthening and availability of 
more rapid diagnostic tests has improved delay (lPA was introduced at the end of 2008) but 
there is a suggestion that some of the health system delay may be improved by decentralised 
care. 
A limitation to the study is the number of children seen in clinic for which we could not match 
to a source case from the DR-TB register. Nearly a quarter were from outside the region but 
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for the rest the reason is unclear. There may have been a matching problem despite our 
inclusive matching approach; this would likely apply equally to the two models of care 
compared in our study. It may have been that children were seen during the inclusion period 
but that the source case was registered outside the dates searched. It may also have been that 
some of the source cases were primary defaulters and were diagnosed but never started 
treatment. Finally, the registration of source cases could have been incomplete. Although this 
is a limitation, we set out to document the proportion of registered MDR-TB source cases in 
which child contacts were identified and assessed in clinic as per local guidelines. These 
limitations do not affect the conclusion that child contacts are seen in only a small proportion. 
Drug-resistant tuberculosis in children James Seddon P age 1116 
Table 21- Characteristics of adult multidrug-resistant tuberculosis source cases identified by health district in the period 1 May 2010 - 30 June 2011 (n=1221) 
Khayelitsha 
(n=189) 
Median age in years; n=1211 (IQR) 34 (27-40) 
Male gender; n=1219 (%) 93 (49.5) 
HIV positive; n=1070 (%)* 117 (70.5) 
Positive sputum smear; n=1011 (%) 73 (42.4) 
XDR (%) 16 (8.5) 
HIV: human immunodeficiency virus; XDR: extensively drug-resistant; IQR: inter-quartile range 
*Difference in HIV prevalence between Khayelitsha and the other seven sub-districts: p<O.OOl. 
Drug-resistant tuberculosis in chi ldren 
Other sub-districts Total 
(n=1032) (n=1221) 
36 (28-44) 35 (27-44) 
577 (56.0) 670 (55.0) 
450 (49.8) 567 (53.0) 
397 (47.3) 470 (46.5) 
86 (8.3) 102 (8.4) 
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Table 22 - Characteristics of child MDR-TB contacts identified by health district and linked to a source case in the period 1 May 2010 - 30 June 2011 (n=146) 
Gender Male (%) 
Age (months) Median (IQR) 
Ethnicity (n=145)· Xhosa (%) 
Coloured (%) 
White(%) 
HIV status (n=140) Positive (%) 
Previous T6 treatment reported by Yes (%) 
family 
Weight-for-age z-score (n=142)·· Mean (sD) 
Relationship of source case to child Mother (%) 
Father (%) 
Grandparent (%) 
Aunt/uncle (%) 
Other (%) 
Was the source case the primary Yes (%) 
caregiver? 
Most intense exposure between child Sleeps in different house (%) 
and source case Sleeps in same house (%) 
Sleeps in same room (%) 
Sleeps in same bed (%) 
- ------ - - -- -- - -- - --- -- -- ---
HIV: human immunodeficiency virus; IQR: inter-quartile range; SO standard deviation 
• Difference between Khayelitsha and the other seven sub-districts: p<O.OOl 
··Difference between Khayelitsha and the other seven sub-districts: p=O.012 
Drug-resistant tuberculosis in children 
Khayelitsha Other sub-districts (n=I11) Total 
(n=35) (n=146) 
16 (45.7) 64 (57.7) 80 (s4.8) 
31 (12-44) 32 (13-47) 32 (13-46) 
35 (100) 39 (35.5) 74 (5l.0) 
0 70 (63.6) 70 (48.3) 
0 1 (0.9) 1 (0.7) 
2/34 (5.9) 5/106 (4.7) 7 (5.0) 
1 (2.9) 11 (9.9) 12 (8.2) 
0.07 (1.49) -0.63 (1.36) -0.46 (1.42) 
14 (40.0) 36 (32.4) SO (34.3) 
2 (5.7) 18 (16.2) 20 (13.7) 
5 (14.3) 15 (13.5) 20 (13.7) 
7 (20.0) 30 (27.0) 37 (25.3) 
7 (20.0) 12 (10.8) 19 (13.0) 
10 (28.6) 30 (27.0) 40 (27.4) 
2 (S.7) 16 (14.4) 18 (12.3) 
19 (S4.2) 43 (38.7) 62 (42.s) 
7 (20.0) 19 (17.1) 26 (17.8) 
7 (20.0) 33 (29.7) 40 (27.4) 
--- - ------
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Study 6: non-attendance at clinic appointments in child contacts of multidrug-
resistant tuberculosis 
The following study has been accepted as an article: 
• Zimri K, Hesseling AC, Godfrey-Faussett, Schaaf HS, Seddon lA. Why do child contacts of 
multidrug-resistant tuberculosis not come to the assessment clinic? Pub Heath Action 2012; 
2: 71-75 
Introduction 
Following from the previous section which determined that only a small proportion of the 
eligible child contacts are identified and referred to specialist assessment, this study continues 
to explore reasons for this. In the paediatric TB literature few studies have quantified the 
proportion of eligible child contacts brought for assessment following exposure to a case of 
infectious drug-susceptible TB.452-453,457-459 Few studies have examined reasons for non-
attendance. Children may not be identified or they may be identified but then not brought to 
clinic appointments. In other healthcare contexts, the reasons for failure to attend paediatric 
clinic appointments are complex but include logistical and financial aspects, parental 
educational status and the attitudes of the parents towards the child, including perceptions 
regarding the importance of the disease.460-461 The attrition for child TB contacts appears to 
occur at every step in the identification and referral cascade.453 This study aimed to determine 
potential reasons for clinic non-attendance amongst child contacts of MDR-TB cases, using 
qualitative and quantitative methodology. 
Methods 
Study design 
The aim of the study was to determine whether there were differences between the children 
brought for assessment to DR-TB specialist clinics and those not brought. Whilst it was 
postulated that factors such as distance and cost may be important, it was felt that an initial 
focus group discussion would be useful to identify potential key variables which could then be 
examined in a quantitative case-control study. 
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Focus group discussion 
Parents/caregivers were purposively sampled to create a focus group of ten people,462 to 
include a mix of genders, ages, residential locations, ethnicity and whether they had brought 
their children to appointments. The discussion took place on 5th August 2011 and lasted 90 
minutes. The semi-structured session was facilitated by KZ to cover a series of broad topics but 
with open-ended discussion encouraged between participants. The session was recorded, 
transcribed and translated where needed. The transcript was analysed by KZ and JAS, using 
standard ethnographic techniques, to determine themes and concepts that led to the design of 
question na ires. 463-464 
Study population and inclusion 
From the 1st September 2011 a register was created of all children «5 years or <13 years if 
HIV-infected) referred to the DR-TB clinic at TCH or outreach clinic, who had been referred as a 
well child, in significant contact with an infectious case of pulmonary MDR-TB (sputum smear 
or culture positive) within the preceding six months. This register was compiled from the 
telephone referrals. The first SO children who had been referred and who subsequently 
attended their clinic appointments were recruited following written informed consent from 
their parent/caregiver (assent in children over seven years of age). Only the first child referred 
from a household was eligible for inclusion. The first SO children who had been referred but 
who failed to attend their clinic appointment were identified, traced and also recruited 
following consent/assent. Once recruited, a structured interview was conducted with the 
parents/caregivers. All interviews were conducted by a study nurse (KZ; English and Afrikaans 
speaking) and research counsellor (English and Xhosa speaking) who asked questions in a 
standardised manner following training. If the participant did not understand the question, it 
was repeated, where necessary with explanation from the interviewer. Questionnaire fields 
included demographics of the household and source case, the logistical and financial 
implications of attending clinic appointments, together with perceptions of MDR-TB. 
Living standards measure 
Parents/caregivers were asked a series of questions to determine their assets and disposable 
income. A well-established market segmentation tool, the Living Standards Measure, has been 
used widely in South Africa since 1989, devised and subsequently revised, by the South African 
Advertising Research Foundation.46s The results from 27 variables are used to create a 'score' 
from 1 to 14 which reflects the standard of living in a household. 
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Data classification and analysis 
Data were analysed using STATA version 11; missing data were excluded from analysis. 
Associations were assessed using the X2 (or Fishers exact) test with the effect estimated (OR) 
and 95% CI calculated. The Mann Whitney test was used to assess associations between non-
parametric data, with median and IQR calculated. 
Results 
Focus group discussion 
From the focus group discussion, a number of themes emerged. Some were associated with 
the physical challenges of getting a child to an appointment. 
'7he local clinic is easier to go to but to go to Tygerberg Hospital is sometimes difficult 
sometimes to get there because of money we don't have. N 
'7he weather plays a role if you must go to the MDR clinic because you must wait at the taxi 
rank or bus stop and sometimes take two to three rides to get there. N 
Other themes that emerged included the attitude of clinic staff. 
nrhe sisters at the clinic toke sometimes very long to give the letter. N 
''Just like yesterday we were sitting the whole day for the referral letter. N 
"1 just feel some of the staff at the clinic is inexperienced. N 
'7he sister gave us the wrong letter and when we went back to say it is the wrong letter they 
were more aggressive than we were supposed to be that had to come back for the right letter. N 
Other concerns were about the appointment itself. 
"1 feel uncomfortable because my child is very small and some adults -/ could hear how they 
say that some of them don't take their medication. This one man said today, '1 didn't take my 
medication for more than two weeks'. It would be much better if they could maybe thinking of 
putting up a mobile clinic for either the adults or the children to see them separately. N 
''Your first time, you wait very long because of the file. N 
"1 had sleepless nights when I first heard / must take my child to the clinic, I even thought my 
child is going to die; I didn't know what the doctor is going to sayN 
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Finally, some parents/caregivers felt that personal elements affected whether children were 
brought to appointments. 
"/ feel some parents just don't take their children to the clinic because they just don't care. They 
don't take their children's health seriously". 
"Some parents are just plain lazyl They don't want to get up from bed to go to the clinic". 
'7he other reason is also that some parents found it very difficult to get off from work. II 
"1 think a lot of business people or employers is not informed about the disease" 
Quantitative study 
Of the first 56 children referred who attended, 50 were included. Of the six not included, three 
were too old (over five but HIV-negative), one child presented with TB disease and two families 
left the clinic before the study team could approach them. Of the first 58 children who were 
referred but who did not attend, 50 were included. Of the eight not included, five were too 
old, one had moved to a different province and two could not be traced. 
Significant risk factors for non-attendance included ethnicity (Coloured vs. Xhosa; OR: 2.82; 
95%CI: 1.21-6.59; p=O.Ol) the mother being the TB source case (OR: 3.78; 95%CI: 1.29-11.1; 
p=0.02) and cigarettes smoked in the house (OR: 2.37; 95%CI: 1.01-5.57; p=0.04). (Table 23) 
There were significant logistical and financial differences, including time taken to get to the 
DR-TB clinic (45 vs. 60 minutes; p=0.002) and cost of transport (18.5 vs. 40 SA Rand; p=0.03). 
Ofthose not attending specialist clinic appointments, more had to use multiple minibuses (OR: 
3.08; 95%CI: 1.28-7.41; p=0.008). (Table 24) 
Families not bringing their children to appointments were more concerned about infection risk 
whilst waiting to be seen (OR: 2.45; 95%CI: 1.07-5.60; p=0.03). (Table 25) Families failing to 
attend DR-TB appointments were more likely to feel that they had to wait a long time to be 
seen at the local clinic (OR: 2.47; 95%CI: 1.07-5.69; p=0.03). 
Discussion 
As far as can be determined, this is the first study to examine reasons for non-attendance of 
child contacts of MDR-TB cases. A focus group discussion was conducted to determine 
appropriate questions to examine quantitatively in a systematic sample of children. Children 
not brought to appointments were more frequently of Coloured ethnicity and lived in families 
containing smokers. If the mother was the person with TB, the child was less likely to be 
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brought. For those attending DR-TB clinic appointments, travel times were shorter, cheaper 
and required fewer transport changes. Those attending were less concerned about infection 
risk while waiting to be seen at the DR-TB clinic and were made to wait less at their local clinic. 
The reasons for the association between ethnicity and attendance are complicated and may be 
a surrogate for other socio-economic and cultural characteristics. While details regarding 
employment, education and living standard were captured, the complex social and cultural 
implications of ethnicity and lifestyle were not fully investigated. The reason for children being 
brought less frequently if the mother was the source case may be more easily explained. 
Mothers were the main carer for the child in the majority of instances and if the mother was 
unwell or hospitalised, access to evaluation for the child was impaired. Smoking may also be a 
surrogate for other socio-economic or cultural factors, or it may be that smokers have less 
money available for transport or feel stigmatised interacting with healthcare services. 
Although it is not surprising that fewer children were brought to clinic appointments if the 
journey was long, expensive or complicated, it is interesting that the Living Standard Measure 
or education of the parent did not differ between the two groups. Also of note, attendance 
appeared to be more influenced by the attitudes of staff at local clinics than staff at the DR-TB 
clinic. This reinforces the significance of quality local care to inform and explain the importance 
of attending appointments as well as to educate children and their families about the disease. 
It is also important to note parental perceptions of MDR-TB. Concerns that either they or their 
child may be exposed to MDR-TB whilst waiting to be evaluated at either the local or DR-TB 
clinic may be appropriate; significant rates of hospital acquired infections have been suggested 
in previous high-profile outbreaks.466 Even if not justified, such perceptions are important 
determinants of non-attendance. Consideration should be given to infection control practices 
and in having children attend local clinic appointments at a separate time or space from adults. 
Parents/caregivers should also be screened for symptoms when they bring children to 
appointments to avoid the risk, or the perception of risk, of exposure. Perceptions regarding 
the danger of MDR-TB disease and its treatment also need to be explored and addressed, as 
do attitudes to MDR-TB and discrimination against those with MDR-TB. This would include 
education for both healthcare workers as well as the community. 
This observational study employs a combination of qualitative and quantitative research 
techniques to examine a complex social issue regarding determinants of human behaviour 
influencing access to health care. The study examines an important topic affecting a vulnerable 
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and marginalised group. Limitations to the study include the relatively small sample, which 
may have obscured true associations. The retrospective nature of the study may have allowed 
recall bias to influence responses from the non-attendees who may have wanted to justify 
their decisions not to attend. Also, families were only examined in which the child had been 
identified and referred to the DR-TB clinic. The previous study in the thesis demonstrated that 
only a small proportion of child contacts of MDR-TB accessed specialist assessment; reasons 
for non-identification of child contacts are not explored. Finally, children exposed to MDR-TB 
have not been compared with children exposed to drug-susceptible TB. Some of the issues 
identified in this study may be specific to MDR-TB but some may be common to all children 
exposed to TB. 
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Table 23 - Characteristics of children, households, main carers and source cases of children referred as contacts of multidrug-resistant tuberculosis 
Not Attending OR (95%CI) p-value : 
attending 
Median age of child in months (lOR) 35 (25-51) 36 (23-53) - 0.35 
Male gender of child (%) 26(52) 22 (44) 1.38 (0.62-3 .05) 0.43 
Coloured ethnicity (%) 30(60) 17 (34) 2.82 (1.21-6.59) 0.01 
Child HIV-infected (%; n=88) 3/40 (7.5) 1/48 (2.1) 3.81 (0.37-39.4) 0.33 
Mother main carer for child (%) 44 (88) 41 (82) 1.61 (0.52-4.97) 0.58 
Median number of years of education of main carer (lOR) 10 (8-11) 10 (8-11) - 0.35 
Main carer without ·any paid work (%) 34 (68) 35 (70) 0.91 (0.39-2.14) 0.83 
Main carer looks after other children (%) 20 (40) 29 (58) 0.48 (0 .n-1.09) 0.07 
Male gender of main carer (%) 2 (4) 6 (12) 0.31 (0.06-1.64) 0.27 
Male gender of source case (%) 19 (38) 25 (SO) 0.61 (0.27-1.37) 0.23 
Mother source case (%) 17 (34) 6 (12) 3.78 (1.29-11.1) 0.02 
Median LSM score of household (lOR) 6 (6-8) 7 (6-8) - 0.29 
Cigarettes smoked in house (%) 36 (72) 26 (52) 2.37 (1.01-5.57) 0.04 
Alcohol drunk in house (%) 27 (54) 27 (54) 1.00 (0.45-2.20) 0.80 
Illegal drug use in house (%) 10 (20) 9 (18) 1.14 (0.42-3.11) 1.00 
--- -- ----- ------- - -
IQR: Inter-quartile range; LSM: Uving standard measure; OR: Odds ratio; CO: Confidence interval 
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Table 24 - Financial and travel implications of accessing care for child contacts of multidrug-resistant tuberculosis 
Not Attending OR (95% el) p-value 
attending 
Median distance to DR-TB clinic in km (IQR; n=82) 5 (4-8) 6 (2-14) - 0.77 
Median number of minutes taken to travel to DR-TB clinic (IQR; n=93) 60 (45-90) 45 (25-60) - 0.002 
Median cost of travel to DR-TB clinic in SAR (IQR) 40 (20-60) 18.5 (4-50) - 0.03 
More than one minibus taxi required to get to DR-TB clinic (%) 26 (52) 13 (26) 3.08 (1.28-7.41) 0.008 
--_. _- -_ . -
DR-TB: drug-resistant tuberculosis; IQR: Interquartile range; SAR: South African Rand; OR: Odds ratio; CO: Confidence interval 
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Table 25 - Perceptions of disease amongst parents/caregivers of children referred as contacts of multidrug-resistant tuberculosis 
Positive responses to the following questions: Not Attending OR (95% el) p-value 
attending 
Do you have confidence in the medical staff at your local clinic? 33 (66) 41 (82) 0.43 (0.16-1.10) 0.07 
Do you have confidence in the medical staff at the MDR-TB clinic? 48 (96) 49 (98) 0.49 (0.04-5.67) 1.00 
Does the weather affect your decision on whether to attend appointments at the MDR-TB clinic? 16 (32) 13 (26) 1.34 (0.56-3.21) 0.51 
Do you consider MDR-TB a disease that can kill you? 43 (86) 38(76) 1.94 (0.68-5.50) 0.31 
Do you consider MDR-TB a disease that can be treated successfully? 46 (92) 50 (100) - 0.12 
Do you think that people in your community with MDR-TB are discriminated against? 24 (48) 25 (50) 0.92 (0.42-2.03) 0.84 
Do you feel that employers in your community discriminate against people with MDR-TB? 37 (74) 28 (56) 2.24 (0.94-5.30) 0.06 
Are you concerned about the risk of being infected with MDR-TB while waiting at the MDR-TB cl inic? 30(60) 19 (38) 2.45 (1.07-5.60) 0.03 
Do you think that your child would take anti-TB medicines every day without a problem? 27 (54) 34(68) 0.55 (0.24-1.26) 0.15 
Are you concerned about the side effects of the anti-TB medicines for the child? 30 (60) 24 (48) 1.63 (0.73-3.62) 0.23 
Do you feel that you have to wait a long t ime to be seen at your local clinic? 28 (56) 17 (34) 2.47 (1.07-5.69) 0.03 
Do you feel that you have to wait a long time at the MDR-TB clinic? 11 (22) 10 (20) 1.13 (0.43-2.97) 0.81 
Do you think that parents should be responsible for preventing children from getting MDR-TB? 46 (92) 45 (90) 1.28 (0.32-5.11) 1.00 
Out of ten, for you how important a priority is having your child assessed in the MDR-TB clinic? (Median [IQR)) 10 (10-10) 10 (10-10) - 0.37 
-------
MDR-T6: multidrug-resistant tuberculosis; IQR: Interquartile range; OR: Odds ratio; CO: Confidence interval 
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Study 7: tolerability and toxicity of preventive therapy for child contacts of 
multidrug-resistant tuberculosis 
The following study has been submitted as an article: 
• Seddon lA, Hesseling AC, Finlayson H, Schaaf HS. Toxicity and tolerability of multidrug-
resistant tuberculosis preventive treatment in children. (submitted) 
The next two studies in the thesis assess preventive therapy for child contacts of MDR-TB. As 
mentioned in the section describing context, the provincial policy in the Western Cape is that 
children who have had significant contact with an infectious case of MDR-TB (pulmonary 
sputum- or smear-positive microscopy) are provided with preventive therapy for six months 
irrespective of TST result. The first study describes the tolerability and toxicity of the drugs and 
the second describes the outcome of children given this regimen. 
Introduction 
One of the major concerns regarding the provision of preventive therapy in children using 
drugs other than isoniazid, is potential toxicity. In the treatment of MDR-TB disease, the risk-
benefit ratio of potentially toxic therapy is relatively clear. In contrast, this risk-benefit ratio is 
altered when using potentially toxic preventive therapy in children who are currently well, but 
are at risk of developing disease in the future. 
Suggested medications for MDR-TB preventive therapy in children include the 
fluoroquinolones, ethambutol, pyrazinamide and ethionamide/prothionamide.87 Isoniazid, 
given at a high dose (lS-20mg/kg daily), can also be used as some isolates have low-level 
isoniazid resistance.90, 92 There has been concern regarding the use of ethambutol in children 
due to the difficulties in testing for optic nerve toxicity. When given at the dosage now advised 
(lS-2Smg/kg daily) this is rare, occurring in less than 0.1% of cases.167 Caution has been 
exercised regarding the use ofthe fluoroquinolones in children, based on early animal model 
data showing damaging effects to the cartilage growth of young beagles. l64 With extensive 
paediatric use of fluoroquinolones, mainly in children with cystic fibrosis, few adverse events 
have however been reported to date.334-335 Pyrazinamide has been shown to be associated 
with significant hepatotoxicity in adults when given as preventive treatment 156,158 while 
ethionamide/prothionamide commonly cause nausea and vomiting467 and are associated with 
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hypothyroidism in children.262 There are limited published data regarding the tolerability and 
toxicity of preventive therapy regimens given to children exposed to MDR-TB. 
Methods 
Standard of care 
Following exclusion of TB disease through history, examination and plain film chest radiology, 
children who were less than five years of age or HIV-infected, with significant exposure to an 
infectious case of MDR-TB, were given a regimen of MDR-TB preventive therapy, as advised by 
provincial guidelines. Significant exposure was defined as living with or having regular daily 
interaction with the MDR-TB source case. If the source case had MDR-TB with susceptibility to 
the fluoroquinolones, the child was given ofloxacin (lS-20mg/kg daily; 200mg tablets: Tarivid, 
Sanofi-Aventis, Midrand, South Africa; 400mg tablets: Tafloc, Aspen Pharmacare, Durban, 
South Africa), ethambutol (20-2Smg/kg daily; 400mg tablets; Sandoz Ethambutol HCI 400, 
Sandoz SA [Pty] Ltd, Kempton Park, South Africa) and isoniazid (lS-20mg/kg daily; 100mg 
tablets; Be-Tabs Isoniazid; Be-Tabs Pharmaceuticals [Pty] Ltd, Roodepoort, South Africa) for 6 
months. Ofloxacin was the only fluoroquinolone available in the National TB Programme 
during the study period. Children exposed to MDR-TB resistant to ofloxacin were given only 
high-dose isoniazid (lS-20mg/kg daily) for 6 months. Children were routinely evaluated at two, 
four, six and twelve months, at the TCH or the community outreach sites, when clinical 
evaluation and chest radiography were completed. Drugs were dispensed at local community 
TB clinics where each week parents were provided with seven days of treatment for the child. 
The parents were then responsible for the daily delivery of medications as tablets or divisions 
of tablets. 
Study population and eligibility 
All children routinely evaluated at the TCH or community outreach clinic, were eligible if they 
had been in significant contact with an infectious case of pulmonary MDR-TB (sputum smear 
or culture positive) within the preceding six months, had started preventive therapy during 
May 2010 through April 2011, and had attended at least one follow up appointment. Children 
were recruited following written, informed consent from the parent/caregiver. 
Data collection 
Children were routinely seen at two, four and six months; details of any additional, 
unscheduled consultations were also recorded. Parents/caregivers were interviewed 
concerning potential drug-related adverse events using a structured questionnaire. Adverse 
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events were categorised using the OMIO system.415 (Table 26). As arthralgia is not categorised 
in this classification we allocated five grades consistent with the classification system. If old 
enough to co-operate, visual toxicity was evaluated with Ishihara charts. Parental impression 
of visual function was used for children who could not be evaluated in this way. 
Data analysis 
The most severe grade for each category of adverse event, cumulatively experienced during 
the six month preventive therapy regimen, was determined. Missing data were excluded from 
analysis. For analysis, children were categorised into those that experienced only Grade 0 and 
Grade 1 adverse events and those that experience any Grade 2 or higher adverse event. 
Patient and treatment characteristics were assessed to determine potential association with 
toxicity. Age was categorized into those less than two years and those older, based on the age 
distribution of the sample, and weight-for-age z-scores were divided into those less than -1 
standard deviations below the reference population and those greater than -1. Data were 
analysed using STATA version 11. Associations were assessed using the X2 (or Fisher's exact) 
test and effect estimates (OR) and 95% CI were calculated. 
Results 
Two hundred and forty-five children were initially eligible; 193 were included. In the 52 
children not included, the child was not brought to clinic by an adult who could legally provide 
consent (n=12), consent was not given (n=2), the child was not brought back for follow up 
(n=37) or the source case was subsequently found not to have MOR-TB (n=1). The median age 
was 31 months (IQR: 13-45). The mean weight-for-age z-score was -0.55 standard deviations 
(SO) from the reference population mean (SO: 1.44). One hundred and two (53.1%) were boys; 
9 (4.6%) were HIV-infected and 83 (43.2%) were of Xhosa ethnicity. One hundred and seventy 
three children (89.6%) were given three drugs for preventive therapy and 20 (10.4%) received 
isoniazid alone, based on the susceptibility pattern of the adult source case. ( 
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Table 27) 
Adverse events are demonstrated in Table 28, with all Grade 3 adverse events shown in Table 
29. Of the seven children (3.6%) who experienced a Grade 3 adverse event, three were 
associated with inadvertent overdosing of ofloxacin. No adverse events necessitated the 
discontinuation of preventive therapy and all resolved without intervention. The most 
common Grade 2 or higher adverse events were loss of appetite and nausea (12 children; 
6.2%), itchy skin (9 children; 4.7%), disturbance of sleep or mood (7 children; 3.6%) and skin 
rash (7 children; 3.6%). Risk factors for the development of Grade 2 or more severe adverse 
events are shown in Table 30. No clinical or treatment characteristics were associated with 
cumulative adverse events, including HIV infection and concomitant treatment with 
antiretroviral therapy. 
Discussion 
This study demonstrates that a regimen of ofloxacin, ethambutol and high-dose isoniazid, 
given as preventive therapy for children exposed to MOR-TB, is well tolerated and associated 
with few clinically significant adverse events. The three cases of Grade 3 toxicity associated 
with inadvertent overdosing of ofloxacin is concerning. In South Africa, at the time the study 
was conducted, ofloxacin was available in two formulations: 200mg and 400mg. Medications 
are frequently dispensed as loose tablets within a re-sealable packet with the number of 
tablets to be taken written on outside. If the packet is refilled with a different strength of 
tablet, confusion can occur, as was reported for the children in this study. Attention to correct 
dispensing is essential, both to achieve optimal efficacy and minimise toxicity. Only one Grade 
2 or higher episode of joint, muscle or bone pain was noted. Given the historical concerns 
regarding fluoroquinolone use in children, these findings are reassuring. No hepatotoxicity or 
visual problems were observed, which is encouraging. 
There is limited published evidence regarding clinically significant toxicity for preventive MOR-
TB therapy in adults or children. To our knowledge, there are no published studies reporting 
the systematic evaluation and grading of toxicity of MOR-TB preventive regimens in children. 
One study described a cohort in which some of the children were given preventive therapy for 
MOR-TB exposure (n=41) and some were given MOR-TB treatment (n=25).21 Ethionamide was 
associated with gastrointestinal adverse events in 49%, necessitating cessation of the drug in 
four cases. One child developed arthralgia thought to be likely due to ofloxacin, which led to 
drug discontinuation. In another study, 8 of 22 (24%) children experienced adverse events 
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thought to be attributable to MDR-TS preventive therapy.l44 Gastrointestinal toxicity was the 
most common, with two experiencing behavioural changes and one an itchy rash. Two patients 
had elevated liver function tests necessitating discontinuation of therapy. A systematic review 
and meta-analysis of children treated for MDR-TB disease showed that 39% of children 
experience adverse events,221 but there were limited data regarding the severity of adverse 
events. Fluoroquinolones, used for indications other than MDR-TB, appear to be well tolerated 
and have limited toxicity.334-335 However, treatment duration is usually much shorter for 
indications other than for MDR-TB preventive therapy. The toxicity of ethambutol (1S-2Smg/kg 
daily) and isoniazid (S-lOmg/kg daily) have been well studied at the recommended dosages for 
the treatment of drug-susceptible TS210 but no studies have evaluated the toxicity of isoniazid 
given at a high dose in children on treatment of MDR-TS. In children treated forTS meningitis, 
isoniazid given at high dose (lS-20mg/kg daily) was not found to be associated with 
hepatotoxicity, even when given with three other potentially hepatotoxic drugs (rifampicin, 
pyrazinamide and ethionamide).468 
This study has strengths and limitations. A prospectively recruited cohort of children exposed 
to MDR-TB have been characterised who have received routine preventive therapy. Adverse 
events were systematically documented and categorised and potential risk factors for toxicity 
were assessed. Nearly two hundred children were followed over six months, providing nearly 
one hundred years of patient follow-up time. Toxicity evaluation was elicited by discussion 
with parents/caregivers who reported perceived adverse events and by clinical evaluation of 
the children. As the children were mostly less than five years of age it was not possible to elicit 
symptoms directly from them. Furthermore, routine biochemical or radiological monitoring for 
potential toxicity was not completed, leading to a possible reduced detection of abnormal liver 
function or joint abnormality. As detailed ophthalmological examinations were not performed 
on all children it is also possible that subtle visual changes were missed. Determining the 
potential cause of toxicity in children on multiple concomitant medications can be challenging. 
To be certain that a specific drug is responsible, the child should be only receiving one drug, or, 
if being given a multidrug regimen, all drugs should be stopped and sequentially restarted. As 
preventive therapy was usually multidrug and was continued in spite of minor toxicity, 
determining the cause of specific adverse events was not possible. This is particularly 
important for children concomitantly treated for HIV with cART where multiple medications 
are given together. That only one child with HIV (out of nine) developed a Grade Two adverse 
event is reassuring. 
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Table 26 - Classification of adverse events used in children receiving multidrug-resistant tuberculosis preventive therapy 
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 
Joint, muscle or bone No adverse event Pa in but no interference with Moderate pain, affecting function but able Severe pain limiting activities Disabling pain - unable to carry 
pain function or movement to carry out normal activities out activities 
Skin Rashes No adverse event Small areas of redness trash Dry peeling or widespread rash Wet peeling, ulcers or urticaria Severe, widespread rash, necrosis 
needing hospitalization 
Itchy skin No adverse event Slight itching in localised areas Severe itching in localised areas Widespread itching over entire Uncontrollable scratching 
body needing hospitalization 
Headache No adverse event Mild - does not need treatment Transient/moderate - needs non-narcotic Severe -responds to narcotics Intractable pain 
treatment 
Sleeping/mood No adverse event Mild anxiety Moderate anxiety or problems getting to Severe anxiety, problems getting to Psychosis, unable to sleep for 
sleep sleep or repeated waking more than an hour 
Lethargy No adverse event Activity Reduced but for <48 hours Slightly irritable or slightly subdued Very irritable or lethargic Inconsolable or obtunded 
Visual problems No adverse event None Blurred vision or minor visual disturbance Repeated episodes of blurring or Permanent decrease in visual 
lasting less than 1 hour visual disturbances which resolve acuity or field defect 
Vomiting No adverse event 1 episode in 24 hours 2-3 episodes in 24 hours 4-6 episodes in 24 hours >6 episodes in 24 hours or 
needing hospitalization 
Diarrhoea No adverse event Sl ight change in consistency or Liquid stool Liquid stool >4x normal frequency Liquid stool >8x normal frequency 
frequency of stool for ch ild for child 
Jaundice No adverse event Jaundice detectable clinically - Obvious clinical jaundice - bi li rubin 1.6- Severe jaundice - bil irubin 2.6 - 5 x Hospital ization - bilirubin >5x 
bilirubin 1.1- 1.5 x ULN 2.5x ULN ULN ULN 
Loss of No adverse event Mild - still eating/drinking well Moderate - decreased appetite Severe -little food taken No solid or liquid food taken 
appetite/nausea 
ULN: Upper limit of normal (as determined by reference range for age of ch ild and assay used) 
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Table 27 - Characterist ics of children given preventive therapy as contacts of multidrug-resistant tuberculosis (n=193) 
Characteristic Number 
Median age (IQR; n=191) 31 (13-45) 
Male gender (%; n=192) 102 (53.1) 
HIV-infected (%) 9 (4.6) 
Mean weight-far-age z-score (SD; n=186) -0.55 (1.44) 
Regimen (%) Isoniazid, ethambutol, ofloxacin 173 (89.6) 
Isoniazid 20 (10.4) 
Ethnicity (%) Xhosa 83 (43.2) 
Coloured 108 (56.8) 
Other 2 (1.0) 
IQR: Inter-quartile range; SO: Standard deviation 
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Table 28 - Summary of cumulative most severe adverse event in children receiving six months of multidrug-resistant tuberculosis preventive therapy (n=193j 
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Total 
Joint, muscle or bone pain* 183 5 1 0 0 189 
Skin Rashes 144 42 6 1 0 193 
Itchy skin 151 33 8 1 0 193 
Headache* 155 3 2 0 0 160 
Sleeping/mood 177 9 4 3 0 193 
I 
lethargy 190 3 0 0 0 193 
Visual problems 193 0 0 0 0 193 
Vomiting 161 31 1 0 0 193 
Diarrhoea 174 18 1 0 0 193 
Jaundice 193 0 0 0 0 193 
loss of appetite/nausea 164 17 10 2 0 193 
°Total not 193 as some parents stated that they could not determine if the child had experienced the adverse event 
Drug-resistant tuberculosis in children James Seddon P age 1135 
Table 29 - Characteristics of children developing Grade 3 adverse events (n=7) on MDR-TB preventive therapy 
Age Gender HIV Regimen Adverse event(s) Details 
(months) status 
38 Girl Negative HEO Insomnia Mother reported severe insomnia at the two month appointment but stated that the problem had been evident prior to 
starting the preventive therapy 
Preventive therapy continued and sleeping improved 
21 Boy Negative H Skin rash and itch Child had eczema prior to starting preventive therapy 
Rash and itching started four days after preventive therapy 
Preventive therapy continued and rash resolved within two weeks 
25 Boy Negat ive HEO Insomnia and At the two month appointment child reported not sleeping due t o hallucinat ions 
hallucinations Child had been prescribed 300mg ofloxacin but inadvertently given 600mg by clinic staff 
Preventive therapy continued at correct dose and symptoms resolved 
45 Boy Negative HEO Insomnia At the two month appointment the mother reported that the child did not sleep at all 
Child had been prescribed 300mg ofloxacin but inadvertently given 600mg by clinic staff 
Symptoms resolved on correct dosage 
6 Girl Negative HEO Loss of appetite Appetite reported as normal at the two month appointment, Grade 2 at the four month appointment and Grade 3 at 
the six month appointment 
Mother reported that some of the loss of appetite might have been due to teething 
38 Girl Negative HEO Insomnia and At the two month appointment the mother reported the child to be having hallucinations and sleep problems 
hallucinations Child had been prescribed 300mg ofloxacin but inadvertently given 600mg by clinic staff 
Symptoms resolved on correct dosage 
14 Boy Negative HEO Loss of appetite Child reported to have Grade 3 appetite loss at two months, then none at 4 months but Grade 1 at six months 
Preventive therapy continued throughout 
------
H: isoniazid; E: ethambutol; 0 : ofloxacin 
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Table 30 - Risk factors for the development of Grade 2 or greater adverse events in children on 
MDR-TB preventive therapy (n=193) 
Total Grade 0 or Grade 2 or OR (95%CI) P-value 
1 3 
Age < 2 years 73/191 62 11 1.22 (0.52-2.83) 0.65 
Male gender 102/192 89 13 0.87 (0.38-1.98) 0.73 
H IV -i nfected 9/193 8 1 0.80 (0.09-6.67) 0.83 
Weight-for-age z-score <-1 72/186 62 10 0.99 (0.42-2.32) 0.98 
Xhosa ethnicity 83/191 72 11 1.03 (0.44-2.40) 0.95 
Three drug regimen 173/193 149 24 1.45 (0.31-6.69) 0.63 
OR: Odds rat io; CI : Confidence Interval 
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Study 8: preventive therapy for child contacts of multidrug-resistant tuberculosis 
The following study has been prepared as an article: 
• Seddon lA, Hesseling AC, Fielding K, Cox H, Hughes l, Godfrey-Faussett P, Schaaf HS. 
Preventive treatment for child contacts of MDR-TB (in preparation) 
Introduction 
This study describes a cohort of children who were given a multidrug preventive therapy 
regimen following exposure to an adult with MDR-TB. The study describes the children as well 
as exploring risk factors for poor outcome. 
Methods 
Standard of care 
As described earlier, following exclusion of TB disease through history, examination and plain 
film chest radiology, children who are less than five years of age or HIV-infected, with 
significant exposure to an infectious case of MDR-TB, are given a regimen of MDR-TB 
preventive therapy, irrespective of TST result, as advised by provincial guidelines. Significant 
exposure is defined as living with or having regular daily interaction with the MDR-TB source 
case. If the source case has MDR-TB with susceptibility to the fluoroquinolones, the child is 
given ofloxacin (lS-20mg/kg daily), ethambutol (20-2Smg/kg daily) and isoniazid (lS-20mg/kg 
daily) for 6 months. Children exposed to MDR-TB resistant to ofloxacin are given only high-
dose isoniazid (lS-20mg/kg daily) for 6 months. Children are routinely evaluated at two, four, 
six and twelve months, at the TCH or the community outreach sites, where clinical evaluation 
and chest radiography are performed. Drugs were dispensed at local community TB clinics, on 
either a daily, weekly or monthly basis, dependent on clinic and patient preference. HIV testing 
is offered to all TB contacts following informed consent from the parent or legal guardian, with 
assent from the child where appropriate, using ELISA in children older than 18 months or DNA 
PCR if younger or breast-fed. cART is routinely initiated in all HIV-positive children following 
appropriate evaluation. TST was completed by injecting two tuberculin units intradermally 
(purified protein derivative RT23, Statens Serum Institute) with results read at 48-72 hours. 
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Study population and eligibility 
All children evaluated at the TCH or community outreach clinic were eligible if they had been in 
significant contact with an infectious case of pulmonary MDR-TB (sputum smear or culture 
positive) within the preceding six months and had started preventive therapy from May 2010 
through April 2011. 
Data collection 
Children were seen in clinic at two, four, six month and 12 months, as well at any additional, 
unscheduled visits. In addition, during the first half of 2012, children were traced and either 
recalled to clinic or visited at their local clinic or home by the study team. Where this was not 
possible, local clinics and families were contacted to confirm that the child was clinically well 
and were putting on weight. The date of this final interaction was recorded. Follow-up time for 
the children, therefore, was a minimum of 12 months but up to 24 months. Adherence was 
measured in three ways with equal weighting given to each in determining overall adherence. 
The first was three day recall, the second a 30 day visual analogue score and the third 
confirmation from the local clinic to confirm medication uptake.469-472 Adherence was divided 
into those with good adherence (~80% of doses given) and those with poor adherence «80% 
doses given).473 Study outcomes were: well at the end of the observation period, death of any 
cause, incident TB disease and lost to follow up. Standardized research definitions were 
applied to classify incident TB disease.40s Children with confirmed and probable disease were 
included. Where patients were lost to follow up their censure date was recorded as the last 
interaction with the study team. 
Data analysis 
Data were dual-entered and checked for entry errors. Data were analyzed using STATA 
software (version 11; Stata Corp, College Station, TX). Cohort analysis was undertaken to 
examine the rate of cohort failure for different exposures. Incident TB disease and death were 
classified as outcome failures. Time into the cohort was the date of recruitment and time out 
of the cohort was the date of death, diagnosis of incident TB, date last seen when lost to 
follow up or date last seen when well. Due to the small number of cohort failures, exact 
Poisson analysis was undertaken for a small number of predetermined characteristics of the 
child and treatment, with rate ratios (RR), 95% CI and p-values calculated. 
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Results 
Of 245 children initially eligible, 215 were included, contacts of 173 MDR-TB source cases. Of 
the children not included, 12 were brought by an adult who could not provide legal consent, 
for two children consent was not given and in the remainder (n=16), although the source case 
was said to have MDR-TB at the initial assessment and the child given MDR-TB preventive 
therapy, on contacting the clinic, the adult was confirmed to have resistance to only either 
isoniazid or rifampicin. Forthe children included, median age was 31 months (lOR: 13-24), and 
116 (54%) were boys (Table 31). Mean weight-far-age z-score was 0.64 standard deviations 
below the reference population and of 207 children tested for HIV, 10 (4.8%) were positive. 
Children received either a regimen of isoniazid, ethambutol and ofloxacin (n=192; 89%) or 
isoniazid alone (n=23; 11%) and adherence was good in 165 (77%) children. 
The median age of source cases was 32.5 (lOR: 26-40) and 71 (42%) were male. Of 170 (98%) 
tested for HIV, 59 (35%) were positive. Of 167 with DST to ofloxacin, 11 (7%) were resistant. 
Ninety-nine (62%) out of 170 with recorded smear results, had 2+ or 3+ sputum smear 
microscopy results (Table 32). 
One child died (0.5%), seven developed incident TB (3%) and four (2%) were lost to follow-up 
(Table 33). In cohort analysis 248.6 patient years of observation time were included. The rate 
for poor outcome was 32.2 outcomes (95%CI16.1-64.3) per 1000 years of patient follow up. 
Risk factors for poor patient outcome (Table 34) were: HIV positivity (RR: 9.87; 95%CI: 0.97-
55.2; p=0.05) and poor adherence (RR: 9.66; 95%CI: 1.73-97.9; p=0.006). Children older than 
12 months were less likely to have poor outcomes (RR: 0.16; 95%CI: 0.002-0.81; p=O.02). 
Discussion 
This study demonstrates that following exposure to an MDR-TB source case and the provision 
of MDR-TB preventive therapy, in nearly 250 patient years of follow-up, one child died and 
seven developed incident TB. It is likely that the child that died did not develop TB but died of 
some other form of illness. Of the seven who developed incident TB, one was exposed to M. 
tuberculosis resistant to ofloxacin and five did not take the medications. Therefore, only two 
children who were exposed to ofloxacin-susceptible M. tuberculosis, who took a three-drug 
regimen with good adherence, developed TB. Significant risk factors for poor outcome 
included young age and HIV infection. These risk factors are well described in the drug-
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susceptible pediatric TB Iiterature61, 63 and should prompt enhanced vigilance in these 
vulnerable populations. 
The study was associated with some limitations. As this is an observational study, it is not 
possible to conclude with certainty that this regimen is effective. It is possible that only this 
number of children would have developed TB had they been given isoniazid or even no 
medications at all. However, the pre-chemotherapy data do not support this. In the absence of 
preventive therapy, 50% of M. tuberculosis-infected children less than twelve months 
developed TB disease.61 The figure is 20-30% for children between one and two years and 5% 
for children between two and five years. Although only 40% of our cohort was TST positive, a 
far higher numbers of children would be expected to develop TB if the regimen was not 
effective. In addition, the evidence that poor adherence to preventive therapy was strongly 
associated with poor outcome adds support to the argument that this regimen is effective in 
reducing the risk of progression from infection to disease. This leads onto the next limitation, 
in that children were included irrespective of TST status, in line with national and provincial 
guidelines. The rationale for this is that TST is not a highly sensitive test for M. tuberculosis 
infection and by only including TST positive children a number of infected children are 
excluded. This is especially true of young and HIV positive children. Also, if a TST is negative at 
the time of initial assessment, there is a chance that the child may have been infected but is 
yet to mount an immune response. Rather than use a two stage protocol with all children 
started on preventive therapy which is then stopped if a second TST at two months is negative, 
the local policy is for all exposed children to be treated. These entry criteria were employed in 
this study. It could, therefore, be argued that some of the children in the study did not need to 
be treated. A final limitation of the study is the limited duration of follow up for the children. 
All children were followed up for a minimum of twelve months with some followed up for 24 
months. Although the vast majority of children who are going to develop disease do so with 
this time period,21, 60, 83 it is accepted that some children might progress to disease after the 
period of observation. 
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Table 31 - Characteristic of children exposed to a multidrug-resistant tuberculosis source case 
and placed on preventive therapy (n=215) 
Characteristic 
Median age in months (IQR) 31 (13-45) 
Gender (%) Male 116 (54.0) 
Female 99 (46.1) 
Ethnicity (%) Coloured 120 (55.8) 
Xhosa 93 (43.3) 
White 1 (0.5) 
Other 1 (0.5) 
Weight in cm (SO) 12.4 (4.3) 
Height (SO; n=174) 90.6 (71.0) 
Weight-for-age z-score (SO; n=211) -0.64 (1.50) 
Height-for-age z-score (SD; n=162) -0.98 (1.38) 
Weight-for-height z-score (SO; n=l17) 0.15 (1.40) 
TST (%; n=212) Positive 85 (40.1) 
Negative 127 (59.9) 
TST size in mm for those positive (IQR; n=72) 15.5 (13 .5-20) 
Evidence of BCG scar (%; n=210) Yes 170 (81.0) 
No 40 (19.1) 
Previous TB disease treatment (%) Yes 17 (7.9) 
No 146 (92.1) 
Previous preventive therapy (%; n=213) Yes 67 (31.5) 
No 146 (68.5) 
HIV (%; n=207) Positive 10(4.8) 
Negative 197 (95.2) 
On ART at start of preventive therapy (%; Yes 8 (80.0) 
n=10) 
No 2 (20.0) 
Regimen given (%) HEO 192 (89.3) 
H 23 (10.7) 
Type of medication delivery (%) Oaily 28 (13.0) 
Weekly 157 (73.0) 
Monthly 21 (9.8) 
Other 9 (4.2) 
Adherence (%) Good 165 (76.7) 
Poor SO (23.3) 
Outcome (%) Oied 1 (0.5) 
Incident TB 7 (3.3) 
Well 203 (94.4) 
lTFU 4(1.9) 
so: standard deviation; TST: tuberculin skin test; BeG: Bacille Calmette-Guerin; TB: tuberculosis; HIV: human Immunodeficiency 
virus; HEO: isoniazid, ethambutol & ofloxacin, H: isoniazid; LTFU : lost to follow up 
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Table 32 - Characteristics of source case with multidrug-resistant tuberculosis (n=173) 
Characteristic 
Median age source case in years (IQR; n=168) 32.5 (26-40) 
Gender (%; n=l71) Male 71 (41.5) 
Female 100 (58.5) 
Source case DST Amikacin resistant (n=168) 15 (8.9) 
Ofloxacin resistant (n=167) 11 (6.6) 
Smear result (%; n=170) Negative 22 (12.9) 
Scanty 15 (8.8) 
1+ 23 (13.5) 
2+ 76 (44.7) 
3+ 29 (17.1) 
Positive without smear recorded 5 (2.9) 
HIV (%; n=170) Negative 111 (65.3) 
Positive 59 (34.7) 
Median CD4 count (IQR; n=56) 192 (103-350) 
On ART at start of MDR-TB treatment (%; No 38 (64.4) 
n=59) 
Yes 21 (35.6) 
Current smoker (%; n=l71) No 103 (60.2) 
Yes 68 (39.8) 
Regular alcohol use (%; n=l71) No 137 (80.1) 
Yes 34 (19.9) 
Previous hospital admission (%; n=161) No 114 (70.8) 
Yes 47 (29.2) 
Previously in prison (%; n=166) No 138 (83.1) 
Yes 28 (16.9) 
IQR: inter-quartile range; 05T: drug susceptibility test ; HIV: human immunodeficiency virus; MOR-TB: mul t idrug-resistan t 
tuberculosis 
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Table 33 - Mortality and incident tuberculosis in children given preventive therapy for multidrug-resistant tuberculosis (n=8) 
Age Gender HIVstatus Regimen Source DSTof Time to Adherence Details 
I case source case outcome 
3 months Girl Positive HEO Mother MDR 9 months Poor Child defaulted preventive therapy when mother was 
admitted to hospital 
12 days Boy Negative HEO Mother's MDR 3 weeks Poor Baby died after three weeks in what looked like 
cousin sudden infant death syndrome. Preventive therapy not 
given at all 
34 months Girl Negative HEO Mother MDR 2 months Poor No preventive therapy given by parents at all 
12 months Girl Negative H Aunt x2, XDR 1 month Poor No preventive therapy given by parents at all 
Mother 
51 months Boy Negative HEO Aunt MDR 10 months Good 
9 months Girl Positive HEO Mother MDR 6 months Poor Poor adherence following the death of the mother 
2 months Boy Negative HEO Mother MDR 10 months Poor 
10 months Girl Negative HEO Mother MDR 2 months Good 
-- --
HIV: human immunodeficiency virus; OST: drug susceptibil ity test; HEO: isoniazid, ethambutol & ofloxacin; H: isoniazid; MOR: multidrug-resistant; XOR: extensively drug-resistant 
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Table 34 - Assessment of risk factors for poor outcome (death or incident tuberculosis disease) in children exposed to multidrug-resistant tuberculosis and treated 
with a preventive therapy regimen (n=21S) 
Number of Years of Incidence rate with 95% CI (events per Rate Ratio (95% CI) p-value 
events observation 1000 person years) 
Age 0-12 months 5 51.6 97.0 (40.4-233.0) 1 -
>12 months 3 197.0 15.2 (4.91-47.2) 0.16 (0.02-0.81) 0.02 
Gender Female 4 108.1 37.0 (13.9-98.6) 1 -
Male 4 140.5 28.5 (10.7-75.9) 0 .77 (0.14-4.13) 0.98 
TST Negative 4 149.6 26.7 (10.0-71.2) 1 -
Posit ive 3 96.9 31.0 (10.0-96.0) 1.16 (0.17-6.84) 1.00 
HIV status Negative 6 229.5 26.1 (11. 7-58.2) 1.0 -
Positive 2 7.8 257.9 (64.5-1031.4) 9.87 (0.97-55.2) 0.05 
Regimen HEO 7 225.4 31.1 (14.8-65.2) 1 -
H 1 23.2 43.0 (6.1-305.5) 1.39 (0.03-10.8) 1.0 
Ofloxacin DST of source case Susceptible 7 225.5 31.0 (14.8-65.1) 1 -
Resistant 1 14.2 70.6 (9.9-500.9) 2.27 (0.05-17.7) 0.77 
Adherence Good 2 189.7 10.5 (2.6-42.2) 1 -
Poor 6 58.9 .101.8J4S.8-2}6.7) 9.66 (1.73-97.9) 0.006 
- - - ---- - ---- - -
-- -_ . . _---
CI: confidence interval; TST: tuberculin skin test; HEO: isoniazid, ethambutol & ofloxacin, H: isonizid; DST: drug susceptibility test 
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Study 9: culture-confirmed multidrug-resistant tuberculosis in children: clinical 
features, treatment, and outcome 
The following study has been published as an article: 
• Seddon lA, Hesseling A~ Willemse M, Donald PR, Schaaf HS. Culture-confirmed multidrug-
resistant tuberculosis in children: clinical features, treatment and outcome. Clin Infect Dis 
2012; 54: 157-66 
The final five studies of the thesis concern the treatment of children with DR-TB. The first two 
are cohorts of children treated for MDR-TB, the first a cohort of culture-confirmed MDR-TB 
and the second including confirmed as well as presumptively treated children. The subsequent 
two studies involve specific body systems, namely MDR-TB meningitis and MDR-TB of the 
spine. The final study assesses the hearing loss of children being treated for MDR-TB. 
Introduction 
Treatment outcomes are generally poor in adults with MDR-TB, with favourable outcomes 
reported in only 60% of those receiving treatment.l90 Even though childhood TB comprises 
approximately 15-20% ofthe global TB burden,17 MDR-TB is poorly studied in children, the 
literature including mainly case reports or small case series.58, 89,144,191.193-196,204-205,260.474-475 
The diagnosis ofTB in young children is challenging and often delayed.476 Symptoms and signs 
may be non-specific, especially in children younger than three years of age and in children 
infected with HIV. 477 Due to the paucibacillary nature of childhood TB, a microbiological 
diagnosis is typically made in only 20-40% of cases with radiological evidence of intrathoracic 
disease.99 Since DST assessment is only possible following bacteriological confirmation, 
confirmed MDR-TB in children is infrequent. In the absence of a known MDR-TB source case, 
children are often initially treated for drug-susceptible TB and MDR-TB treatment started only 
once treatment is failing, microbiology and DST results become available, or an MDR-TB source 
case is identified. 
Treating children with MDR-TB is complex. Few of the multiple drugs routinely used to treat 
MDR-TB have been studied in children and guidance on drug regimens, dosages, appropriate 
monitoring and duration of therapy is frequently extrapolated from adult data. As young 
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children metabolize drugs more rapidly than adults and generally have paucibacillary 
disease,lso this may not always be appropriate. This study describes the clinical presentation, 
treatment and outcome of a large cohort of children with confirmed MDR-TB and evaluates 
factors influencing treatment response. 
Methods 
Eligibility criteria 
Children less than 15 years of age were included if they were diagnosed with confirmed MOR-
TB between 1st January 2003 and 31st December 2008. DST on all children with culture-
confirmed TB was routine during the study period. Follow up was documented until 31st May 
2011. 
Mycobacterial culture and drug susceptibility testing 
Mycobacterial culture was completed at the accredited National Health Systems Reference 
Laboratory following a standard protocol to prevent mycobacterial cross-contamination. 
Primary mycobacterial cultures were established by inoculation of routine clinical samples into 
Middlebrook 7H9 broth-based Mycobacterial Growth Indicator Tubes (MGIT960; Becton 
Dickinson, Sparks, MD, USA) following a standard protocol for decontamination, while lymph 
node aspirates, pleural fluid, cerebrospinal fluid and other bodily fluids were directly 
inoculated. M. tuberculosis complex isolates were confirmed through PCR.430 Phenotypic OST 
was performed using two different assays which have been shown to yield highly concordant 
results as previously described.478 
Definition of tuberculosis episodes and treatment delay 
A previous TB episode was defined as standard T6 treatment (isoniazid, rifampin and 
pyrazinamide with or without ethambutol) for at least one month, followed by a symptom-free 
period of ~ 6 months (reported by parent/carer and the absence of presentations to any health 
care providers) before the start of the current MOR-TB episode; a commonly used 
programmatic definition of a separate episode.479 A MDR-TB episode was defined as beginning 
(if MDR-TB was subsequently confirmed) at the child's initial documented presentation to the 
health care system, when the specimen was obtained confirming MDR-TB, or when TB 
treatment was commenced. Treatment delay was defined as time from the start of MOR-TB 
episode to initiation of MOR-TB treatment. Treatment delay could not be determined in 
children who died or were lost to follow-up prior to start of MDR-TB treatment, and for those 
treated inadvertently with first-line drugs only. 
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Clinical data and standard of care 
MDR-TB treatment was based on local standard of care, informed by international 
recommendations and available Iiterature.16, 102, 197, 268, 433, 480·482 High-dose (15-20mg/kg) 
isoniazid was used in the majority of cases, as there is evidence that isolates with an inhA 
promoter region mutation usually have a low MIC.90 An injectable agent, most frequently 
amikacin (l5-30mg/kg), was typically used for six months; capreomycin (l5-30mg/kg) was 
substituted if resistance to amikacin was detected. Ofloxacin (lS-20mg/kg), the most effective 
fluoroquinolone available in the South African National TB Programme, was used. Further 
drugs were added to result in at least four effective drugs. These included: ethionamide (15-
20mg/kg), PAS (150mg/kg), terizidone (10-20mg/kg), co-amoxiclavulanic acid (lO-lSmg/kg 8 
hourly), clarithromycin (7.S-1Smg/kg 12 hourly) and linezolid (10mg/kg twice daily). All 
antituberculosis drugs were given under DOT for the full treatment duration. Most children 
remained hospitalized during the intensive phase when an injectable was given. Thereafter, 
children were treated at their local TB clinic with hospital out-patient follow-up every two 
months. Children with XDR-TB were treated for longer periods, typically for 24 months. If not 
yet on cART, cART was started in HIV-infected children after the Initiation of MDR-TB 
treatment, consistent with national guidelines. 
Clinical data collection 
Data were collected through chart review. HIV testing followed written informed consent from 
the parent or legal guardian with pre- and post-test counselling using ELISA in children >18 
months and DNA PCR test in younger and breast-fed children. Immunological staging in HIV-
infected children used the WHO classification.483 Weight was recorded and plotted on National 
Centre for Health Statistics weight-for-age percentile chart. Malnutrition was classified as 
weight <3rd percentile for age. Two tuberculin units were injected, intradermally (purified 
protein derivative RT23, Statens Serum Institute) for TST assessment. Results were read at 48-
72 hours with a transverse diameter of ~10mm considered positive in HIV-uninfected and 
~Smm in HIV-infected children. TB disease severity was defined using CR features following 
review by a single expert reader, read systematically with standardized recording.413 Disease 
was classified as pulmonary if there were any CR changes attributable to TB or if any thoracic 
samples were positive for M. tuberculosis. Extra-pulmonary disease (EPTB) was classified if any 
imaging (ultrasound, plain film radiology or computerized tomography) demonstrated extra-
thoracic TB or if a microbiological sample confirmed TB from a site other than the lungs. Intra-
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thoracic radiological features were classified as non-severe (normal, hilar lymphadenopathy, 
airway compression, lobar/segmental collapse/opacification or pleural effusions) and severe 
(cavities, miliary opacification or a widespread bronchopneumonic picture). 
Outcome 
Respiratory samples in children with pulmonary involvement were obtained monthly to 
monitor response to therapy. Cure for this study was defined as three consecutive negative 
respiratory cultures obtained at least one month apart with no positive cultures after the first 
negative result, in the presence of treatment completion. Treatment outcomes were further 
classified as favourable (cured and treatment completed) or unfavourable (died, lost to follow-
up, treatment failure, transferred out). For MDR-TB episodes with an initial sputum positive 
culture, culture-conversion was defined as the time from initiation of therapy until the first 
negative culture, provided there were no subsequent positive cultures and at least two further 
negatives. Two-month culture-conversion is described as it is a frequently-used surrogate 
marker for final treatment outcome in adult treatment trials.484 
Statistical analysis 
Data were analyzed using STATA version 11. All identifier details were dissociated from clinical 
data by unique study numbers. Missing data were excluded from analysis. Continuous 
variables were used for age and delay. Associations between clinical characteristics at 
presentation were assessed using the X2 test (or Fisher's exact test) when comparing 
categorical data; effect estimates (OR) and 95% CI were calculated. The Mann -Whitney test 
was used to assess the effect of age and delay given the non-normal distribution of the data. 
Risk factors for treatment outcomes (two-month culture-conversion, final treatment outcome 
and death) were assessed in univariate analysis. Multivariate logistic models were used to 
analyse the relationship between presenting characteristics and outcomes if either the 
univariate relationships showed significance (p<0.05) or where variables were thought to be 
clinically or epidemiologically relevant. Variables classified as collinear were not used in 
combination in the model. 
Results 
During the study period, 111 children with MDR-TB were identified with a median age of 50 
months ([IQR: 19-108); all were included. Forty-two samples underwent DST to second-line 
drugs which identified three MDR-TB cases resistant to amikacin, four resistant to ofloxacin 
and five to both ofloxacin and amikacin (XDR-TB). An overview of the cohort with treatment 
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outcomes is provided in Figure 7. Demographic and clinical characteristics at the start of MDR-
TB treatment are described in Table 35. The median time to MDR-TB treatment initiation 
(n=102) was shorter in the presence of a known adult MDR-TB index case (median 58 days [IQR 
25-120] vs. 123 days [IQR 67-231]; p<0.001). Fifty-three of 85 (62%) children with a sputum 
result were smear positive; a positive sputum smear was more common in older children 
(median 85 months [IQR 25-132] vs. 24 months [IQR 15-59]; p<0.001) and in children with 
more severe CR changes (OR 9.95 [CI 2.98-33.3]; p<0.001). Of children HIV-tested (n=100, 
90.1%),43 (43%) were positive; 27 (64%) had severe immune suppression. Nineteen children 
were on cART prior to initiation of MDR-TB treatment; 21 were started afterwards (median 
time to initiation: 75 days [IQR 18-123]). Fifty children (n=109; 46%) had severe CR changes at 
diagnosis; children with severe CR changes were older (median 84 months [IQR 27-121] vs. 28 
months [IQR 15-68]; p=0.002) [Table 35] 
Of the 111 cases, 91 (82%) had a favourable treatment outcome. Of these, three were treated 
successfully with only first-line drugs: two had cervical lymph node disease and the other only 
hilar lymphadenopathy. Four patients were transferred to another hospital and three were lost 
to follow -up. One adolescent, diagnosed with pulmonary XDR-TB, was a repeat defaulter and 
her sputum never converted. She was declared a treatment failure after two years of 
intermittent treatment and eventually transferred into adult care. One patient was still on 
treatment at the end of the study period, having been initially treated for MDR-TB with 
additional resistance to amikacin according to his bacteriology, and then as XDR-TB based on 
his mother's bacteriology. The overall mortality was 12% (13 deaths; Table 36) regardless of 
treatment initiation. Eleven children died during their MDR-TB episode, one was cured ofTB 
but died in the year following the end of treatment and one died following treatment failure. 
Of the 88 cases successfully treated with MDR-TB drugs, 79 (89.8%) were alive and well at 
twelve months after completion of treatment. Of the remaining nine, three had been 
transferred to another institution, five had been lost to follow-up and one had died. Those 
successfully treated were treated for a median of 18 months, including median six months on 
an injectable, and were treated with a median of seven drugs over the total course of 
treatment. (Table 37; Figure 8-11) 
Univariate analysis of clinical features and their association with outcome are shown in Table 
38. Malnutrition and severe CR changes were associated with a failure to culture-convert by 
month two, unsuccessful treatment outcome and death. HIV infection and EPTB were 
associated with death. Children with positive smears at diagnosis were less likely to have 
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culture-converted by month two. Multivariable analysis is shown in Table 39. After adjustment 
for age and smear status (or CR severity), malnutrition at diagnosis predicted failure to culture-
convert by two months (OR: 4.49 [CI: 1.32-15.2]; p=0.02). Malnutrition (OR: 15.0 [CI: 1.17-
192.5]; p=0.04), HIV infection (OR: 24.7 [CI: 1.79-341.1]; p=0.02) and EPTB (OR: 37.8 [CI: 2.78-
513.4]; p=0.006) all independently predicted mortality in a model adjusting for age. 
Discussion 
This study describes the clinical presentation, treatment and outcomes of children with 
culture-confirmed MDR-TB under routine clinical conditions in a high TB-burden setting. The 
data indicate that children with cUlture-proven MDR-TB tend to be young, malnourished, are 
frequently HIV-infected and often present with radiological features of advanced disease. 
Furthermore, the absence of a known MDR-TB source case led to considerable delay in 
initiation of appropriate therapy. Treatment regimens were long (median 18 months) of which 
six months included an injectable. 
Of key importance is that, despite advanced disease and the presence of EPTB in more than 
30%, the majority were treated successfully, with more than 80% favourable outcomes. 
Important risk factors for clinically and programmatically relevant treatment outcomes are 
identified, including mortality. HIV infection, malnutrition and extrapulmonary involvement 
were independent risk factors for death in adjusted analyses. Five of the 13 deaths occurred 
before MDR-TB was confirmed and appropriate treatment started indicating the importance of 
early diagnosis. Although severe disease on CR was associated with all outcome measures in 
univariate analyses, this association was less pronounced in adjusted analyses. These findings 
suggest that, once identified and treated appropriately with individualized therapy based on 
available DST, children with MDR-TB have a good prognosis, even with high prevalence of HIV 
co-infection. 
Other reports of MDR-TB in children include a previous study from Cape Town of 39 children 
with culture-confirmed disease; similar to the present study, treatment delay was common if 
an MDR index case was not identified.58 A study from Peru described 38 children treated for 
MDR-TB, 28 with confirmed disease, and also found considerable delay in the initiation of 
appropriate therapy.204 A study from New York of 20 children treated for MDR-TB (six culture-
confirmed), demonstrated good outcomes and minimal toxicity.144 A recent case series of 13 
children with culture-confirmed MDR-TB from Johannesburg (54% HIV-infected) indicated high 
mortality of 30%.191 Other case reports and small series are reported from other settings. 89,193-
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196,205,260,474-475 Despite the delay in diagnosis, severe disease at presentation and the need for 
second-line medications, these studies all describe good outcomes, in dramatic contrast to 
adult MDR-TB data.190 Reasons for this contrast are unclear. Children may have less severe and 
paucibacillary disease, may tolerate and adhere to medications better, may be less frequently 
HIV-infected or may have less concomitant pathology. 
The absence of an identified adult MDR-TB source case was strongly associated with delay in 
initiation of appropriate treatment in children. Of note, there were 16 (14.4%) children who 
had a source case documented to have died, failed treatment or who was a re-treatment case, 
indicating a high MDR risk exposure. These factors highlight the importance of careful history 
taking from both the child's caregiver and health services regarding adults with known MDR-TB 
or with known risk factors for MDR-TB. 
Since only children with culture-confirmed disease are described, these data are not 
representative of all children with MDR-TB, many of whom are treated on the basis of MDR-TB 
contact history or poor clinical response to therapy. As bacteriologic yield is associated with 
radiological extent of disease,99 this study likely reports children with more advanced disease. 
The study reports on children diagnosed with MDR-TB using combined sources of surveillance 
(laboratory and TB register sources), rather than only those who started therapy (the 
traditional TB treatment cohort approach). Given this conservative approach, treatment 
success is likely underestimated in this cohort. The long duration of treatment (median of six 
months with a second-line injectable medication and 18 months overall) could possibly be 
reduced in children with less severe disease in future, if adequate evidence from clinical 
studies becomes available. 
In this study, many children had severe disease at initiation of treatment. There was a high 
proportion with a positive smear and nearly half had cavities, severe bronchopneumonic 
changes or a miliary opacification on CR. Young children are traditionally considered to have 
paucibacillary TB and as they generally have a poor tussive force, are considered to pose low 
infection risk. However, these data indicate that children with culture-confirmed MDR-TB 
frequently have severe disease, are somewhat older than those with drug-susceptible TB,lS4-2SS 
and coupled with high rates of smear-positivity may prove a greater infection risk than 
previously thought. Infection control should be an important consideration in the management 
of children with MDR-TB. 
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This retrospective study has limitations including reliance on routine data. Adverse effects and 
the tolerability of multiple medications, frequently unpalatable, was not systematically 
assessed. Although all samples were confirmed MOR, DST to second-line drugs was not 
routinely completed during the study period. The second-line OST results that were available 
were reported, but due to inconsistent testing and significant bias in completion of OST 
meaningful conclusions are difficult to draw. Finally, although treatment outcomes were good, 
morbidity as a result of MOR-TB disease and treatment is not explored. 
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Figure 7 - Overview of treatment outcomes in children with MDR-TB (percentages of the total 
number of children; n=111) 
I Culture-confirmed MDR-TB cases (n=111) I 
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Table 35 - Clinical characteristics at initial presentation in children with bacteriologically 
confirmed MDR-TB (n=111) 
Characteristic Description Number 
(percentagel1 
Age Median months (IQR) SO (19-108) 
M ale gender 46 (41.4) 
Treatment delay (n=105) Median days (lQR) 91 (51-166) 
Index case None identified 33 (29.71 
Index case identified with no evidence of MDR- 17 (15.31 
TB 
MDR-TB index case indentified 45 (40.5) 
Index case defaulter, treatment failure or died 16 (14.4) 
Previous treatment episode 28 (25.2) 
Positive Mantoux test (n=89) 63 (70.8) 
Weight <3'0 percentile for age 41 (36.9) 
3'0 - 10tn percentile for age 28 (25.2) 
>10tn percentile for age 42 (37.8) 
Type ofTB PTB only 73 (65.8) 
EPTB only 12 (10.8) 
Both PTB and EPTB 26 (23 .4) 
Site of EPTB (n=38) (>1 site possible) Miliary 7 (18.4) 
Tuberculous meningitis 6 (15 .8) 
Pericardia I effusion 2 (5 .3) 
Pleural effusion 7 (18.4) 
Abdominal 8 (21.1) 
Peripheral lymph node 16 (42.1) 
Bone/joint/spine 9 (23.7) 
Ear 5 (13 .2) 
Sputum smear positive (n=85) 53 (62.3) 
Drug susceptibility test pattern (n=42) MDR 30 (71.41 
MDR with resistance to amikacin 3 (7.1) 
MDR w ith resistance to ofloxacin 4 (9.5) 
XDR 5 (11.9) 
CR features (n=109) (> 1 feature present Normal CXR (all had EPTB) 11 (10.1) 
in the majority) Hilar lymphadenopathy or airways compression 52 (47.7) 
Lobar/segmental collapse/opacification 76 (69.7) 
Large pleural effusion 7 (6.4) 
Cavities 38 (34.9) 
Miliary opacification 7 (6.4) 
Widespread bronchopneumon lc changes 21 (19.21 
CR severity (n=109) Non-severe 59 (54.1) 
Severe SO (45.9) 
Time to sputum conversion (n=74) Median months (IQR) 2 (1-3 ) 
HIV-infected (tested n=100) 43 (43.0) 
HIV immunological stage (n=42) Not significant' 7 (16.7) 
Mild' 5 (11.9) 
Moderate" 3 (7 .1) 
Severe) 27 (64.3) 
When started on cART (n=43) Never (all died) 3 (7 .0) 
Already on cART at start of MDR TB episode 9 (20.9) 
Started on cART between start of episode and 10 (23 .3) 
start of MDR-TB treatment 
After start of MDR-TB treatment 21 (48.8) 
Time from start of MDR-TB treatment to Median days (IQR) 75 (18-123) 
cART initiation (n=21) 
unless otherwise stated 
2 CD4 value: <11 months: >35%; 12-35 months: >30%; 36-59 months: >25% & >5 years: >500 ceils/mm1 
l CD4 value: <11 months: 30-35%; 12-35 months: 25-30%; 36-59 months: 20-25% & >5 years: 350-499 ceils/mm1 
' CD4 value: <11 months: 25-29%; 12-35 months: 20-24%; 36-59 months: 15-19% & >5 years: 200-349 ceils/mm1 
sCD4 value: <11 months: <25%; 12-35 months: <20%; 36-59 months: <15% & >5 years: <200 ceils/mm1 or <15% 
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Table 36 - Description of deaths (N=13) in children with cu lture-confi rmed MDR-TB (n=111) 
Age at Gender HIVstat us CD4 Site of disease History Attribut ed cause of death 
death count 
('" 
11 years Male Unknown Spinal Presented with severe disease, underwent surgery and biopsy sample MDR-TB of the spine 
taken, started on first-l ine treatment but died one month later prior to 
diagnosis being made 
6 months Male Positive 1652 Pulmonary TB Died after one month on first-line therapy, MDR-TB diagnosed Hepatotoxicity, HIV, MDR-TB, Down's synd rome, severe 
36% posthumously only card iac defect, marasmic, bacterial pneumonia 
10 years Female Positive 37 Disseminated (miliary) Died after 12 months of MDR-TB treatment Developed disseminated TB including TB meningitis wh ilst 
8% on fu ll MDR-TB treatment in hospital. Possible XDR-TB 
6 years Male Posit ive 33 Pulmonary and abdominal Treated for 10 months w ith first-line drugs before sample sent for Disseminated MDR-TB 
2% TB culture. MDR-TB diagnosed posthumously only 
9 months Male Posit ive 825 Pulmonary, miliary and Died after three months of MDR-TB treatment Mult i-system failure, HIV, extensive d isseminated TB 
19% lymph node TB disease at presentation, sepsis, heart fa ilure, 
thrombocytopenia 
4 years Female Posit ive Not TB meningit is Died after three months of MDR-TB treatment Severe TB meningit is (stage 3) 
tested 
12 months Female Posit ive 117 Pulmonary TB Died after five months of MDR-TB treatment Severe HIV, systemic candida infection, osteomyelit is, 
6% respiratory fa ilure, pneumonia, S. aureus sepsis 
2 years Female Negative TB meningit is, pulmonary, Died after one month first -line treatment, MDR-TB diagnosed after death Disseminated MDR-TB meningit is 
abdominal and lymph 
nodeTB 
15 years Female Unknown Pulmonary TB Died after one month MDR-TB treatment, pre-XDR result returned after Congenita l myopathy, aplastic anaemia, requ iring mult iple 
death transfusions, extensive pre-XDR-TB 
2 years Male Posit ive 1065 TB meningit is Given 24 days first- line treatment for stage t hree, TB meningit is prior to MDR-TB meningit is, HIV 
26% MDR-TB diagnosis. Died after one mont h MDR-TB treatment 
8 years Female Unknown Pulmonary TB SpastiC quadriplegia from previous illness, died 6 days after starting first- Severe MDR-TB, pre-existing neurological cond it ion making 
line t reatment, MDR-TB diagnosed after death diagnosis cha llenging 
12 years Female Negative Pulmonary TB Adolescent repeated defaulter w ith pre-XDR TB. Never sputum culture- Died of pre-XDR TB under the care of adult phYSician 
converted and declared a treatment fa ilure after 12 months of MDR-TB 
t reatment. Transferred to adult care 
8 years Female Negative Pulmonary TB Registered as cured of MDR-TB with 20 months of therapy. Significant Developed bronchiectasis and chronic lung abscess. Died 
lung damage as a result of TB with in a year of finishing MDR-TB treatment w ith a 
bacterial infection. 
- --- -- - - -
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Table 37 - Treatment characteristics in children successfully treated with an MDR-TB regimen 
(n=88·) 
Median number of drugs used at any point during treatment (range) 
Median duration of intensive phase therapy (range) 
Median total duration of therapy (range) 
Number of patients using anti-TS drugs 
(percentage) 
• With percentage unless stated otherwise 
•• No injectable used in six cases 
••• Available only from 2007 
Drug-resistant tuberculosis in children 
Isoniazid (high-dose) 
Rifampicin 
Pyrazinamide 
Ethambutol 
Streptomycin 
Amikacin 
Capreomycin 
Ofloxacin 
Ethionamide 
Terizidone or cycloserine 
PAS 
Clarithromycin 
Augmentin 
linezolid 
James Seddon 
7 (4-13) 
6 (0-18) 
18 (8-26) 
83 (94.3) 
14 (15.9) 
81 (92.0) 
82 (93.2) 
1 (1.1) 
80 (90.9) 
6(6.8) 
86 (97.7) 
86 (97.7) 
57 (64.8) 
7 (8.0) 
7 (8.0) 
6(6.8) 
2 (2.3) 
P age 1157 
Figure 8 - Number of drugs used in the treatment of children with culture-confirmed 
multidrug-resistant tuberculosis 
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Figure 9 - Drugs used in the treatment of children with multidrug-resistant tuberculosis 
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Figure 10 - Length of intensive phase in children treated for multidrug-resistant tuberculosis 
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Figure 11- Total length of treatment in children treated for multidrug-resistant tuberculosis 
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Median - 18 months 
Range - 8 - 26 months 
Mean -17.7 months 
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Table 38 - Univariate analysis of clinical features, two month culture-conversion, treatment outcome and death in children with MDR-TB 
Chilracterlstlc F.ilu~ to culture-convert by month two Unfavourable treatment outcome Deaths 
Number Number fallilll Odds ratio P-value Number Number Odds ratio P-value Number Number Odds ratio (95" CI) P-
aNlyzed to convert (95" 0) analyzed unfavourable (95"0) analyzed dying value 
outcome 
Age 74 26 0.06 111 20 0.80 111 11 0.97 
Gender Female 46/74 13 65/111 10 65/111 6 
Male 28/74 13 2.20 (0.80-6.01) 0.11 46/111 10 1.53 (0.57-4.07) 0.39 46/111 5 1.20 (0.34-4.22) 0.78 
Nutrit ion <!3" percentile 53/74 14 70/111 8 70/111 2 
<3" percentile 21/74 12 3.71 (1.22-11.3) 0.01 41/111 12 3.21(1.15-8.96) 0.02 41/111 9 9.56 (1.79-51.2) 0.001 
HIV Negative 42/71 14 57/100 7 57/100 1 
Positive 29/71 11 1.22 (0.45-3.31) 0.69 43/100 10 2.16 (0.74-6.36) 0.15 43/100 7 10.9 (1.17-101.0) 0.008 
TIming of cART Before MDR-TB 14/29 4 22/43 5 22/43 4 
initiation treatment 
After MDR-TB 15/29 7 2.19 (0.44-10.8) 0.32 21/43 5 1.06 (0.25-4.45) 0.93 21/43 3 0.75 (0.14-3.92) 0.73 
treatment 
Mantoux skin Negative 16/62 2 26/89 7 26/89 3 
test 
Positive 46/62 28 4.SO (0.85-23.7) 0.05 63/89 8 0.39 (0.12-1.27) 0.10 63/89 5 0.66 (0.14-3.03) 0.59 
MDR-TB contact No contact 35/74 13 66/111 15 66/111 8 
Contact 39/74 13 0.85 (0.32-2.21) 0.73 45/111 5 0.43 (0.14-1.29) 0.12 45/111 3 0.52 (0.13-2.09) 0.35 
Treatment delay 74 26 0.25 103 15 0.36 103 8 0.18 
Site ofT8 No EPT8 60/74 20 73/111 10 73/111 3 
EPTS 14/74 6 1.SO (0.45-4.97) O.SO 38/111 10 2.25 (0.83-6.11) 0.10 38/111 8 6.22 (1.45-26.6) 0.005 
Smear status Negative 27/68 4 32/85 4 32/85 2 
Positive 41/68 20 5.48 (1.47-20.4) 0.004 53/85 10 1.63 (0.46-5.77) 0.443 53/85 5 1.56 (0.28-8.68) 0.61 
CR severity Non-Severe 39/74 9 59/109 5 59/109 2 
Severe 35/74 17 3.15 (1.11-8.92 0.022 SO/109 13 3.79 (1.20-12.0) 0.014 SO/109 8 5.43 (1.05-28.2) 0.02 
---- - - - - - ------ - - - - - - -- - ---- -- -- - --- -----
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Table 39 - Multivariate analysis of clinical and bacteriological features at diagnosis, two month 
culture-conversion, treatment outcome and death in children with MDR-TB 
Characteristic Number in OR (95% CI) P value 
analysis 
Failure to culture-convert by two 
months' 
Smear positivity 68 3.24 (0.82 - 12.8) 0.10 
Malnutrition 68 4.49 (1.32 - 15.2) 0.02 
Age 68 0.15 
Poor treatment outcome 
Severe CR changes 99 2.50 (0.68 - 9.19) 0.17 
Malnutrition 99 1.87 (0.58 - 6.07) 0.30 
HIV positivity 99 1.46 (0.46 - 4.63) 0 .52 
Age 99 0.51 
Death 
EPTB 99 37.8 (2.78 - 0.006 
513.4) 
Malnutrition 99 15.0 (1.17 - 0.04 
192.5) 
HIV positivity 99 24.7 (1.79 - 0.02 
341.1) 
Age 99 0.18 
In an alternative model, holding all variables constant but replacing smear posit ivity with CR severity, findings 
were similar (n=74; severe CR changes: OR: 1.88 [CI : 0.61-5.781; p=0.270, malnutrition : OR: 3.51 [el: 1.12-11.01; 
p=0.031, age: p=0.148) 
In an alternative model, holding all variables constant but replacing severe CR changes with EPTB, f indings were 
similar (n=100; EPTB: OR: 2.59 [CI : 0.86-7.75); p=0.90, malnutrition : OR: 2.43 [CI : 0.80-7.40); p=0.115, HIV posit ivity: 
OR: 2.43 [CI : 0.65-5.981; p=0.232, age: p=0.679) 
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Study 10: the spectrum of presentation, treatment and outcome in children with 
multidrug-resistant tuberculosis 
The following study has been prepared as an article: 
• Seddon lA, Hesseling AC, Godfrey-Foussett, Schaaf HS. The spectrum of presentation, 
treatment and outcome in children with MDR-TB (in preparation) 
Introduction 
This study describes all children treated for MDR-TB over a two year period. It includes 
children with a confirmed diagnosis as well as children treated presumptively for MDR-TB. The 
study describes the presentation of the children as well as their treatment, adverse events and 
the outcome. The study also compares children with severe disease and those with limited 
disease. 
Methods 
Eligibility criteria 
A register of all children (defined as <15 years in the setting), routinely treated for MDR-TB, 
was reviewed for children starting treatment from 1 January 2009 until 31 December 2010. As 
children with RMR-TB (resistant to rifampicin, but susceptible to isoniazid, with or without 
resistance to other drugs) are treated as MDR-TB due to concerns regarding 'missed' isoniazid 
resistance on molecular diagnostic tests,226 children diagnosed with RMR-TB were included. 
Children with both confirmed MDR-TB as well as presumed MDR-TB were included. A 
presumed diagnosis was typically made by the attending clinical team if the child was failing a 
first-line TB regimen with documented good adherence, or if the child had clinical symptoms, 
signs and radiology ofTB with documented close MDR-TB exposure. Children initially started 
on MDR-TB treatment due to MDR-TB exposure who were subsequently confirmed to have 
drug-susceptible TB were excluded. 
Mycobacterial culture and drug susceptibility testing 
Mycobacterial culture (paediatric and adult samples), was completed at the accredited 
regional National Health Systems Reference Laboratory. Samples were first decontaminated 
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and then cultured using the Mycobacterial Growth Indicator Tube (MGIT) 960 system (Becton 
Dickinson, Sparks, MD, USA). The presence of M. tuberculosis was confirmed by PCR 
amplification.43o Genotypic DST to isoniazid and rifampicin was carried out using LPA 
(GenoType llD MTBDRplus; Hain Lifescience, Nehren, Germany), according to the manufacturer's 
instructions.432 DST to ethambutol was carried out using the Bactec 460TB system (Becton 
Dickinson, Sparks, MD, USA), according to international criteria431 using a concentration of 
7.Sllg/ml. DST to second-line agents was performed by the indirect proportional method on 
Middlebrook 7H10 agar using critical concentrations of amikacin 401lg/ml, ofloxacin 21lg/ml 
and ethionamide lOllg/ml. 
Standard of care 
MDR-TB treatment was based on local standard of care, based on international guidelines.16.197 
High-dose isoniazid (lS-20mg/kg) was used in almost all children, due to the demonstrated 
activity against low-level isoniazid resistance.90-91 An injectable agent, usually amikacin, was 
added in cases with more severe disease (cavitating lesions, disseminated disease or 
widespread pulmonary changes on CR); capreomycin was substituted if resistance to amikacin 
was present. Ofloxacin was used unless resistance had been demonstrated; further drugs were 
added, to result in the use of at least four effective drugs. These included: ethionamide, PAS, 
terizidone (equivalent to cycloserine, which was not locally available) and, if necessary, co-
amoxiclavulanic acid, clarithromycin and linezolid. All TB drugs were routinely available, free of 
charge to the patient, through the local TB control programme. cART was started in HIV-
infected children, if not already on cART, as soon as possible after the start of MDR-TB 
treatment. 
Data collection 
From 1 January 2010, data were collected from patients and their families, following written 
informed consent, at each outpatient clinic appointment. Data were, therefore, collected both 
retrospectively and prospectively, as some children had already begun treatment at the start 
ofthe data collection period. To document clinical data during 2009, folder reviews were 
completed at both TCH and BCH. Follow-up continued until 30 June 2012 and included 
telephone calls and home visits to determine clinical progress and outcome. 
Study measures 
HIV testing was completed by routine health services following informed consent from the 
parent or legal guardian, with pre- and post-test counselling using ELISA in children >18 
months and DNA PCR test in younger or breast-fed children. The WHO classification was used 
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for immunological staging in HIV-infected children.483 Weight and height were recorded at 
baseline, with weight-for-age, height-for-age and weight-for-height z-scores calculated. Where 
possible, weight was determined at three, six and twelve months from the start of treatment. 
As children were not necessarily seen at those time-points, weights taken within window 
periods around those time points were accepted: one month for the three month weight, six 
weeks for the six month weight and two months of the twelve month weight. TST (Mantoux, 2 
tuberculin units injected intradermally; purified protein derivative RT23, Statens Serum 
Institute) was used. Results were read at 48-72 hours with a transverse diameter of ~10mm 
considered positive in HIV-uninfected and ~Smm in HIV-infected children. 
Case definitions and treatment outcomes 
For this study the consensus definitions previously described in the thesis were used regarding 
exposure to source cases, episode initiation and delay, certainty of diagnosis, site and severity 
of disease, adverse events and disease outcome. Specifically, an MDR-TB episode was defined 
as beginning (if MDR-TB was subsequently confirmed or treatment subsequently started) at 
the child's first presentation to a health care provider, when a specimen was obtained that 
eventually confirmed MDR-TB or when the child was started on treatment for MDR-TB. 
Treatment delay was defined as the time from the start ofthe MDR-TB episode to initiation of 
MDR-TB treatment. Certainty of MDR-TB diagnosiS was divided into confirmed, probable and 
possible MDR-TB disease using the consensus definitions and based on previous definitions of 
TB disease certainty.40s Probable MDR-TB disease was therefore defined as probable TB 
disease and contact with an MDR-TB source case, while possible MDR-TB was defined as 
probable TB disease in combination with failure of first-line treatment with confirmed 
adherence. Severity of disease was classified as severe and non-severe based on criteria by 
Wiseman et a1.411 Disease was classified as pulmonary if there were any CR changes (including 
hilar lymphadenopathy attributable to TB) or if any respiratory samples were positive for M. 
tuberculosis. Extrapulmonary TB disease was classified if any imaging (ultrasound, plain film 
radiology or computerised tomography [CT]) demonstrated evidence ofTB outside the thorax 
or if a microbiological sample confirmed TB from an extrathoracic site. Radiological features of 
pulmonary TB were classified as non-severe (normal, hilar lymphadenopathy, airway 
compression, lobar/segmental collapse/opacification or pleural effusions) and severe (cavities, 
miliary opacification or a widespread bronchopneumonic picture) using radiographic features 
reviewed by a single expert reader, read in a systematic manner using a standardised reporting 
and recording form.413 The family and, where appropriate, the child were asked about adverse 
events at each clinic appointment; results were recorded using standardised DMID toxicity 
tables.415 Hearing was measured at baseline and at monthly intervals using PTA or OAE, 
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dependent on the age of the child. ASHA guidelines were used to define hearing loss248 (see 
later chapter on hearing loss in children treated for MDR-TB for more details of the hearing 
assessments). The most severe grade of adverse event experienced over the course of 
treatment, for each category, was determined. MDR-TB treatment outcome was classified as 
cure, probable cure, treatment completed, failure, death, lost to follow up and transferred out, 
as defined by the specified definitions. 
Statistical analysis 
Data were analysed using STATA version 11. Missing data were excluded from analysis. 
Associations between clinical characteristics at presentation were assessed using the X2 test (or 
Fisher's exact test) when comparing categorical data; effect estimated (OR) and 95% CI were 
calculated. The Mann Whitney test was used to assess the relationship between categorical 
data and non-parametric continuous data with median and IQR calculated. The relationship 
between disease severity and patient and treatment characteristics was determined in 
univariate analysis. 
Results 
One hundred and forty nine children were started on treatment for MDR-TB over the two year 
study period; the median age was 36 months (IQR: 16-66), 69 (46.3%) were male and 32 
(21.9%; out of 146 tested) were HIV-infected (Table 40). A culture-confirmed diagnosis was 
made in 59 children (39.6%); 82 (55.0%) had probable and 8 (5.4%) possible MDR-TB disease. 
Forty-five (30.2%) children had severe (intra-or extra-thoracic) disease and 23 (50%; of 46 
children with sputum CUlture-positive TB) were also smear-positive. 
One hundred and three (69.1%) children were admitted to hospital for a median of 5 months 
(IQR: 3-7). Of 94 (66.2%) children treated initially with injectable drugs, the median treatment 
duration was 4 months (IQR: 4-6). The total treatment duration was a median of 13 months 
(IQR: 11-18). Thirty-six children (24.2%) were cured, 101 (67.8%) were probably cured, one 
(0.7%) was transferred out, eight (5.4%) were lost to follow-up and three (2.0%) died (Table 
41). Of the children with HIV infection (n=32), 14 (43.8%) were cured, 14 (43.8%) were 
probably cured, 2 (6.3%) died and 2 (6.3%) were lost to follow up. The TB drugs used are 
documented in Table 42 and documented adverse events reflected in Table 43. One girl 
developed DRESS syndrome (drug reaction with eosinophilia and systemic symptoms) after 
one month on MDR-TB treatment. She experienced mUltiple grade 4 adverse events. Other 
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than this teenager, there were two grade three reactions (nausea and joint pain) both of which 
resolved without cessation of treatment. 
Children with severe disease were older (54 months [lOR: 18-142] vs. 31.5 months [lOR: 17.5-
53.5]; p=O.Ol) and less frequently had an MOR-TB source case identified (OR: 0.19; 95%CI: 
0.08-0.44; p<O.OOl) compared to children with less severe disease (Table 44). Children with 
severe disease were more commonly HIV-infected (OR: 6.25; 95%CI: 2.50-15.6; p<O.OOl), more 
commonly had extrapulmonary involvement (OR: 5.64; 95%CI: 2.24-14.2; p<O.OOl) and had 
poorer nutritional status (mean weight-for-age z-score: -2.11 [SO: 1.61] vs. -0.76 [SD: 1.32]; 
P<O.OOl). Children with severe disease were also more likely to have a bacteriologically 
confirmed TB diagnosis (OR: 8.25; 95%CI: 3.37-20.2; p<O.OOl), to be admitted to hospital (OR: 
9.87; 95%CI: 2.64-36.9; p<O.OOl), be treated with injectable drugs (OR: 16.3; 95%CI: 3.27-81.3; 
P<O.OOl) and to die (p=0.008). 
Discussion 
In this cohort, with bacteriologically confirmed and clinically diagnosed disease, treatment was 
overall well tolerated with few significant adverse events. Treatment outcomes were excellent, 
with over 90% of children cured or probably cured. Many ofthe children were identified and 
started on treatment early, following the diagnosis of an MOR-TB source case, illustrating the 
importance of contact tracing in paediatric case ascertainment. The three children who died 
either presented late with severe TB disease and concomitant HIV infection or had extensive 
disease and had defaulted care. 
Standardised definitions were used to document the presentation, treatment and outcome 
and demonstrate that these definitions were found to be robust and easy to use. In 
comparison to previously described cohortS,sS.144.191-192. 204 this study included younger 
children, included children with a clinical diagnosis in the absence of bacteriological 
confirmation, described fewer adverse events and documented a higher proportion of children 
with less severe disease. Treatment outcomes in the present cohort are also better than the 
outcomes described in a systematic review and meta-analysis of all previous paediatric 
studies.221 The prevalence of HIV (21.9%) is lower than that found in the previous study in the 
thesis (43%) in the same context, which documented only bacteriologically confirmed MOR-TB 
from 2003-2008. This may be the result of more effective prevention of mother to child 
transmission programmes or may indicate that HIV disproportionately predisposes to severe 
(culture-confirmed) TB disease. Systematic reviews of adults with MOR-TB report successful 
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treatment outcomes in 54-64% of cases, 116,190 with poor nutrition, alcohol, extensive 
resistance, standardised (as opposed to individualized) treatment, shorter duration of therapy 
and male gender found to be associated with poor outcome. 
Although it is appreciated that severity of disease is a spectrum, children were categorised as 
having severe and non-severe disease, based on a classification which considers the 
anatomical location, extent and local complications of disease.411 Using this comprehensive 
research definition of disease severity, successful treatment outcomes are possible in children 
treated for non-severe disease with a median of 12 months of therapy, with injectable drugs in 
only 50% of children and many (41%) children treated entirely as outpatients. 
For principles of good clinical practice, as well as the need for improved paediatric surveillance 
data, clinicians should strive to obtain a microbiological diagnosis in children where possible. 
However, this will, in reality, not always be achieved given the paucibacillary nature of 
paediatric TB. A subset of children will therefore need to be presumptively treated for MDR-TB 
disease (as contacts of MDR-TB cases or failing adherent first-line TB treatment) based on 
symptoms, signs and radiology. In any MDR-TB treatment cohort, as with drug-susceptible TB, 
there will be a balance between those with confirmed and those with presumed disease. If too 
many children are treated for presumed disease, it is likely that either not enough 
commitment is being made to confirming the diagnosis or children are being over-treated for 
non-TB diseases. If the majority is bacteriologically confirmed, it is likely that clinicians are not 
treating enough children presumptively. The exact proportion of confirmed and presumed 
diagnoses will vary dependent on resources, clinical experience, intensity of clinical sampling, 
the observed spectrum of disease, HIV prevalence, age demographics of society and other 
factors including patient and health system delays. However, based on this and previous 
studies, it is likely that the figure confirmed 'should' be between 25_50%.5,99,485-486 
It was challenging to define children who defaulted treatment before the time advised by their 
attending clinician, but who were found on follow-up, in most over two years later, to be well, 
free of TB symptoms or signs and growing successfully. They were categorised as "probably 
cured". These results imply that perhaps not all of the treated children required the advised 
duration or therapy. Older studies from the drug-susceptible literature suggested that a 
significant proportion of children with what would be now described as limited disease were 
cured with either isoniazid given alone or with no drug therapy at all.61 However, it is not clear 
which children with non-severe disease would progress to develop more extensive disease 
with limited or no treatment. Most clinicians today would not feel it was ethical, especially in 
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the presence of HIV co-infection, young age and poor nutritional status, to withhold treatment 
from a child with respiratory symptoms and hilar lymphadenopathy on CR, even though it is 
possible that a proportion could improve without treatment. If health systems carry out more 
comprehensive and more rapid contact tracing following the diagnosis of MDR-TB source 
cases, more children will be identified at an earlier stage in the natural history of their disease. 
A limitation of this study is that the diagnosis was not confirmed in all children, even though 
clear research definitions were used. This is, however, the reality of treating children for TB, 
also for MDR-TB, where a presumptive diagnosis is frequently necessary and appropriate. As 
this study used data collected as part of routine care, another limitation is missing data. Also, 
due to the partial retrospective data collection, possible recall bias may have occurred in the 
description of adverse drug events. In addition, apart from thyroid and renal function, other 
laboratory investigations were not carried out unless clinically indicated. A further limitation is 
that comprehensive second-line DSTfor all children and their source cases were not available. 
This study described children treated for MDR-TB rather than children with MDR-TB and 
therefore included children with RMR-TB. Whilst children with RMR-TB may be systematically 
different from those with MDR-TB, their treatment is not. Finally, the study reports on a 
relatively short follow-up time. Whilst the first children recruited (at the beginning of 2009) 
were followed for over three years from the start of treatment, those starting at the end of the 
study period were followed for eighteen months, some only to the end of treatment. Longer 
follow-up would be required to assess long-term treatment outcomes including recurrent TB. 
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Table 40 - Patient demographics in children treated for multidrug-resistant tuberculosis (n=149 unless otherwise stated) 
Characteristic 
Median age in months (IQR) 36 (18-66) 
Gender Male 69 (46.3) 
Female 80 (53.7) 
Ethnicity Xhosa 90 (60.4) 
Coloured (mixed ethnicity) 59 (39.6) 
Source case None 20 (13.4) 
MOR-TB 111 (74.5) 
Defaulter 2 (1.3) 
Died 10 (6.7) 
OSl 6(4.0) 
Multiple source cases Yes 36 (24.2) 
No 113 (75.8) 
Median delay from start of MDR-TB episode to MOR-TB treatment (IQR) 14 (0-53) 
Tubercul in skin test (n=111) Positive 90 (81.1) 
Negative 21 (18.9) 
Previous TB Yes 13 (8.7) 
No 136 (91.3) 
Median weight (IQR; n=142)' 12.8 (10.3-19.1) 
Median height (IQR; n=124)' 87.3 (76.3-107.8) 
Mean weight-for-age z-score (SO; n=136) -0.98 (1.54) 
Mean height-for-age z-score (SO; n=118) -1.05 (1.79) 
Mean weight-for-height z-score (SO; n=64) -0.29 (1.4) 
Type ofTB Pulmonary 120 (80.5) 
Extrapulmonary 12 (8.1) 
Both 17 (11.4) 
Extrapulmonary involvement (more than one possible; n=39) M iliaryTB 4 (10.3) 
TB meningitis 7 (17.9) 
Abdominal TB 6 (15.4) 
Peripheral lymph node TB 6 (15.4) 
Bone, joint or spinal TB 8 (20.5) 
Other 1 (2.6) 
Certa inty of diagnosis of OR-TB Confirmed 59 (39.6) 
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Probable 82 (55.0) 
Possible' 8 (5.4) 
Severity of disease Non-severe 104 (69.8) 
Severe 45 (30.2) 
Sputum smear microscopy result (n=46) Positive 23 (50.0) 
Negative 23 (50.0) 
HIV status (n=146) Positive 32 (21.9) 
Negative 114 (78.1) 
WHO immunological stage (n=32) Not significant 5(15.6) 
Mild 3 (9.4) 
Advanced 11 (34.4) 
Severe 13 (40.6) 
Timing of ART initiation (n=32) ART started prior to MDR-TB episode 11 (34.4) 
ART started after start of MDR-TB episode but before MDR-TB treatment 10 (31.3) 
ART started after MDR-TB treatment 11 (34.4) 
Median time to start ART after MDR-TB treatment in days (IQR; n=l1) 17 (12-35) 
Drug resistance of isolate from child or from identified source case 4 Rifampicin (n=141) 141 (100) 
Isoniazid (n=141) 125 (88.7) 
Ethambutol (n=92) 23 (25.0) 
Ethionamide (n=102) 5(4.9) 
Amikacin (n=104)5 16 (15.4) 
Ofloxacin (n=103)5 14 (13.6) 
Chest radiograph features at start of MDR-TB treatment (more than one Normal 16 (10.8) 
possible; n=148) Perihilar infiltrates 32 (21.6) 
Hilar lymphadenopathy or airways compression 81 (54.7) 
lobar/segmental collapse or opacification 69 (46.6) 
Pleural effusion 10 (6.8) 
Cavities 22 (14.9) 
Miliary picture 4 (2.7) 
Widespread bronchopneumonic changes 15 (10.1) 
Chest radiograph severity (n=148) Non-severe 72 (48.6) 
Severe 76 (51.4) 
2At start of MDR-TB treatment 
3AII cases of possible DR-TB diagnosed on basis probable TB and failing first-line therapy 
·No DST to guide therapy in 8 patients treated for failing first-line regimen with no identified source case 
5Six children were treated for XDR-TB due to samples from them or their source case demonstrating resistant to both amikacin and ofloKacin 
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Table 41- Treatment and outcome in children treated for multidrug-resistant tuberculosis (n=149 unless otherwise stated) 
Characteristic 
Admitted to hospital Yes 
No 
Median duration of admission in months (n=103) 
Treated with injectable drugs (n=142)1 Yes 
No 
Median duration of injectable drug use (n=94;IQR) 
Median duration of total treatment (n=137 ;IQR)~ 
Median weight gain (IQR; kg) 3 months (n=115) 
6 months (n=102) 
12 months (n=84) 
Median number of months to culture conversion (n=40)' 
Outcome Cure 
Probable cure 4 
Transferred out 
lost to follow up 
Died~ 
~ -
--- --
lExciudes patients who died or absconded from hospital prior to the end of the prescribed period of injectable use 
'Excludes patients who died, were transferred out or were lost to follow up 
- -
~-
--
3For children with an initial culture-positive sputum sample with at least one follow up culture (excludes culture·positive extrapulmonary cases) 
103 (69.1) 
46 (30.9) 
5 (3-7) 
94 (66.2) 
48 (33.8) 
4 (4-6) 
13 (11-18) 
0.6 (0.2-1.5) 
1.4 (0.7-2.2) 
2.9 (1.0-4.0) 
1 (0.5-2) 
36 (24.2) 
101 (67.8) 
1 (0.7) 
8(5.4) 
3 (2.0) 
~ -
-
(Includes 8 patients who stopped their therapy before indicated but were clinically well at follow up and one patient who all drugs were stopped due to severe DRESS syndrome but found to be well after two years of follow 
up and discharged 
srhree children died: 14 year girl. confirmed pre-XDR-PTB and extensive adult-type disease, absconded from hospital after 3 weeks and was lost to follow up, found to have died 12 months later; 6 month boy, presented with 
abdominal and pulmonary confirmed MDR-TB, measles and HIV with severe immunosuppression, died after three weeks in hospital; 9 year old bOy, presented with extensive, confirmed adult-type pulmonary pre-XDR-TB and 
HIV, CD4 count 7, died after 3 months from sepsis and hypokalaemia 
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Table 42 - Drug therapy for children treated for multidrug-resistant tuberculosis who completed therapy (n=137) 
Drug Number of patients with drug included in regimen (%) Median duration of treatment in months (IQR) 
Isoniazid 136 (99.3) 13 (11-18) 
Rifampicin 16 (11.7) 7.5 (4.5-12) 
Pyrazinamide 136 (99.3) 13.5 (11-18) 
Ethambutol 121 (88.3) 12 (1O-18) 
Streptomycin 2 (1.5) 5.5 (4-7) 
Amikacin 82 (59.9) 4 (3-6) 
Capreomycin 11 (8.0) 4 (4-6) 
Ofloxacin 132 (96.4) 13 (1O.5-18) 
Moxifloxacin 2 (1.5) 18 (17-19) 
Ethionamide 135 (98.5) 13 (10-18) 
Terizidone 80 (58.4) 17 (12-18.5) 
PAS 27 (19.7) 17 (12-18) 
Clarithromycin 3 (2.2) 12 (4-18) 
Augmentin 3 (2.2) 18 (4-19) 
Linezolid 3 (2.2) 16 (4-21) 
-- ----- --
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Table 43 - Adverse events in children treated for multidrug-resistant tuberculosis 
Grade 0 Grade 1 Grade 2 Grade 3 Grade4~ Total 
Joint, muscle or bone pain 122 11 2 1 1 137 
Skin rashes 104 30 2 0 1 137 
Itchy skin 110 24 2 0 1 137 
Headache 119 16 1 0 0 136' 
Sleep/mood problem 124 9 3 0 1 137 
Lethargy 118 17 1 0 1 137 
Visual problem 132 5 0 0 0 137 
Vomiting 113 20 3 0 1 137 
Diarrhoea 125 10 1 0 1 137 
Jaundice 133 1 2 0 1 137 
Appetite/nausea 118 14 3 1 1 137 
Hearing loss3 117 25 142 
Thyroxine supplementation provided 4 _ 110 32 142 
------
'One child developed DRESS syndrome after a month on therapy with severe symptoms and signs. Al l drugs were stopped and it was unclear which drug was responsible. All grade four reactions are from th is one chi ld 
zOne mother felt unable to tell if her child had experienced headache 
l Hearing loss was not graded but categorised as present or not using ASHA criteria 
'The decision to start thyroxine supplementation was based on elevated thyroid stimulating hormone (TSH) and low free T41evels 
Drug-resistant tuberculosis in children James Seddon P age 1173 
Table 44 - Comparison of characteristics for children with severe and non-severe multidrug-resistant tuberculosis disease (n=149 unless otherwise stated) 
Children with severe disease 
(n=45) 
Median age (IQR; months) 54 (18-142) 
Male gender 22 (48.9) 
Coloured ethnicity 18 (40.0) 
Median delay (IQR; days) 39 (9-89) 
MDR-TB source case identified 23 (51.1) 
Multiple source cases 12 (26.7) 
Previous TB 6 (13.3) 
TST positivity (n=111) 16/24 (66.7) 
Mean weight-for-age z-score (SD; n=136) -2.11 (1.61) 
Extrapulmonary involvement 18 (40.0) 
Bacteriologically confirmed TB diagnosis 33 (73.3) 
Smear positive (n=46)1 19/29 (65.5) 
Severe chest radiographic changes (n=148) 35/45 (77.8) 
HIV infection (n=146) 20/44 (45.5) 
Hospital admission 42 (93.3) 
Injectable TB drug use (n=142)' 39/41 (95.1) 
Median duration of injectable drug in those treated with injectables (n=94)' 6 (4-6) 
Median total duration of therapy (lQR; n=137)~ 18 (18-20) 
Mortality 3 (6.7) 
IOf children who were sputum culture posit ive 
2Excludes children who died or absconded from hospita l prior to the end of the prescribed period of injectable use 
l Excludes children who died, were transferred out or were lost to follow up 
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Children with non- OR (95% el) p-value 
severe disease (n=l04) 
31.5 (17.5-53.5) 0.01 
47 (45.2) 1.16 (0.57-2.34) 0.68 
41 (39.4) 1.02 (0.50-2.10) 0.95 
2 (0-41.5) <0.001 
88 (84.6) 0.19 (0.08-0.44) <0.001 
24 (23.1) 1.21 (0.54-2.71) 0.64 
7 (6.7) 2.13 (0.67-6.82) 0.19 
74/87 (71.2) 0.35 (0.12-1.01) 0.04 
-0.76 (1.32) <0.001 
93 (10.6) 5.64 (2.24-14.2) <0.001 
26 (25.0) 8.25 (3.37-20.2) <0.001 
4/17 (23.5) 6.18 (1.38-27.7) 0.007 
41/103 (39.8) 5.29 (2.23-12.5) <0.001 
12/102 (11.8) 6.25 (2.50-15.6) <0.001 
61 (58.7) 9.87 (2.64-36.9) <0.001 
55/101 (54.5) 16.3 (3.27-81.3) <0.001 
4 (3-5) <0.001 
12 (10-16) <0.001 
0(0) 0.008 
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Study 11: the impact of drug resistance on clinical outcome in children with 
tuberculous meningitis 
The following study has been published as an article: 
• Seddon JA, Visser D, Bartens M, Jordaan A, Victor T, van Furth AM, Schoeman JF, Schaaf HS. 
Impact of drug resistance on clinical outcome in children with tuberculous meningitis. 
Pediatr Infect Dis J 2012; 31: 711-6 
Introduction 
TBM is a severe form of TB and frequently occurs in early childhood.487 Haematogenous spread 
of bacilli from a primary pulmonary focus leads to the development of a Rich focus in the 
brain. Rupture of this caseous granuloma into the subarachnoid space causes the clinical 
features of TBM.488-489 This usually starts insidiously with a prodromal period of non-specific 
symptoms but as the disease progresses, neck stiffness, loss of consciousness, motor paresis 
and convulsions invariably follow. The diagnosis is often delayed and only considered once 
irreversible neurological damage has already occurred.487, 490 Untreated, the condition is 
almost universally fatal with a median time to death of 19.5 days.491 Even for those treated, 
TBM is associated with high rates of mortality and morbidity; about 80% of children with 
advanced disease at diagnosis (TBM stage II and TBM stage III) will suffer severe neurological 
sequelae.487,49o TBM is the commonest cause of bacterial meningitis In the Western Cape.492 
MDR-TBM has very poor outcome493-496 but there are little data regarding children. The 
relationship between the M. tuberculosis strain and clinical phenotype has been explored in 
both adults and children with TBM41, 76, 497 with conflicting results. The relationship between 
strain type and drug resistance pattern is complex but a strong association exists between drug 
resistance and the Beijing genotype.39. 75, 79 The aim of this study is to analyse whether a 
relationship exists between the drug susceptibility pattern of the infecting M. tuberculosis 
organism and the clinical outcome of TBM in children and to determine if this relationship is 
influenced by the genotype of the strain, 
Drug-reSistant tuberculosis in children James Seddon P age 1175 
Methods 
Study population and tuberculous meningitis definition 
All children admitted to TCH from January 2003 until April 2009, aged 0-13 years, were 
included if they had either a diagnosis of confirmed TBM (M. tuberculosis isolated from the 
CSF), or of probable TBM with a positive culture of M. tuberculosis from a source other than 
the CSF. Probable TBM was defined as a clinical diagnosis of meningitis, supported by the 
presence of characteristic CSF findings (pleiocytosis, elevated protein level and reduced 
glucose level). In addition, two or more of the following criteria were required: recent weight 
loss, a positive TST, a CR compatible with TB, a cranial CT scan compatible with TBM or finally, 
household contact with sputum smear-positive pulmonary TB.49O 
Clinical care 
In the Western Cape, HIV-uninfected children with TBM are treated with isoniazid (20mg/kg, 
maximum 400mg daily), rifampicin (20mg/kg, maximum 600mg daily), pyrazinamide (40mg/kg, 
maximum 2g daily) and ethionamide (20mg/kg, maximum 19 daily) for six months with HIV-
infected children treated for nine months. If the child's isolate of M. tuberculosis, or that of the 
source case, is resistant to any of the drugs used in the local TBM treatment regimen, or if the 
child deteriorates clinically on this regimen, alternative TB treatment is considered. Treatment 
is tailored to the DST of the child or source case's isolate. If diagnosed in the context of a failing 
regimen, treatment is directed at the DST of locally prevailing strains. Treatment for HMR-TB 
involves the addition of a fluoroquinolone and terizidone with treatment for nine months 
irrespective of HIV status. Treatment of MDR- and RMR-TB includes any first-line drugs to 
which the organisms are susceptible, a second-line injectable medication, a fluoroquinolone, 
and further drugs (from WHO classes four and five) to make up at least four effective drugs 
with good CSF penetration.l02.197. 433 Treatment for MDR (and RMR)-TB, for both HIV-infected 
and -uninfected children, typically consists of six months of intensive phase therapy including 
an injectable medication followed by a further twelve months of oral therapy. 
Children are treated as inpatients at TCH or BCH unless social circumstances are assessed and 
deemed satisfactory for a home-based care programme. MDR-TBM patients are treated in 
hospital for at least the intensive phase. All children are treated with steroids. An air 
encephalogram is performed if there is evidence of hydrocephalus on CT scan; if non-
communicating, a ventriculoperitoneal shunt is inserted. HIV testing is performed following 
informed consent from the parent or legal guardian using ELISA if older than 18 months or 
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DNA PCR if younger or breast-fed. cART is initiated as soon after HIV diagnosis as is 
possible.TST is performed by injecting two tuberculin units intradermally (purified protein 
derivative RT23, Statens Serum Institute) with results read at 48-72 hours. A transverse 
diameter of ~10mm is considered positive in HIV-uninfected and ~Smm in HIV-infected 
children. 
Data collection 
Every child with culture-confirmed TB at TCH is recorded prospectively in a clinical database 
with DST to rifampicin and isoniazid routinely performed on a single sample from all children. 
A list of children with a diagnosis of TBM was extracted from the database. Case notes were 
retrieved for these children from TCH and BCH to confirm inclusion criteria and extract clinical 
details. Patients were included if there was complete documentation of presentation, clinical 
course and outcome. Development Quotient (DQ) was measured at the end of TB treatment 
using the Bayley test, Griffiths test or Junior South African Individual Scale, dependant on age. 
Visual testing was performed clinically. In the majority, formal assessments had been 
performed by a developmental paediatrician but for some children, an outcome was assigned 
by the study team based on clinical examinations that had been undertaken by paediatric 
neurologists, general paediatricians, paediatric registrars or medical officers. For those with 
complete clinical details, isolates underwent spoligotype analysiS. 
Mycobacterial culture and drug susceptibility testing 
Respiratory samples were inoculated into Middlebrook 7H9 broth-based Mycobacterial 
Growth Indicator Tubes (MGIT; Becton Dickinson, Sparks, MD, USA) following a standard 
protocol for decontamination, while samples from sterile sites, including CSF, were inoculated 
directly. M. tuberculosis complex isolates were confirmed as M. tuberculosis through PCR.430 
From January 2003 until August 2008 conventional, phenotypic DST was by the indirect 
proportion method.2s4 From August 2008 genotypic DST was performed using the GenoType-
MTBDRplus (Hain Life Science, Nehren, Germany) LPA, carried out according to the 
manufacturer's instructions.432 
Spoligotyping 
Genotype determination was performed using standardized spoligotyping methodology.498 
Isolates were assigned to specific genotype families according to their spoligotype signature 
which included the internationally recognized families of Beijing, LAM (Latin American and 
Mediterranean family), Haarlem, CAS (Central Asian lineage), a group of ill-defined strains of 
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the T family, LCC (Low Copy Number Clade) and S family.445, 499 It was not possible to classify 
some of the remaining strains. 
Data classification 
The time from first reported symptoms to initiation of TB therapy was recorded. In cases of 
DR-TBM, the time from the first reported symptoms to appropriate second-line therapy was 
also determined. TBM stage was classified as TBM stage I (Glasgow Coma Scale [GCS] lS with 
no focal neurological signs), TBM stage II (GCS 11-14 or GCS 15 with focal neurology) or TBM 
stage III (GCS <11).490 GCS (or modified paediatric GCS) was assessed and recorded at the time 
of presentation by the attending doctor. HIV immunological staging was based on WHO 
criteria.483 Although the identified strains were recorded, strains were classified as simply 
Beijing or non-Beijing for analysis. DST was recorded as drug-susceptible, HMR, RMR and MDR. 
Motor function at the end of therapy was classified as normal, hemiparesis or quadriparesis, 
cognitive function as normal (DQ >80), mild handicap (DQ: 50-80) or severe handicap (DQ<50) 
and vision as normal, impaired vision or blind. For analysis, we looked at two dichotomous 
outcome measures: mortality (alive or dead) and clinical outcome (favourable or 
unfavourable). A child was classed as having an unfavourable outcome if they died or were left 
with quadriparesis, severe cognitive handicap or blindness. 
Statistical analysis 
Data were analysed using STATA version 11 with missing data excluded from analysis. 
Continuous variables were used for age, time to initiation of appropriate therapy and CSF 
parameters; all other data were categorical. Associations were assessed using the Fisher's 
exact test when comparing categorical data with the effect estimated (OR) and 95% CI 
calculated. The Mann Whitney test was used to assess the effect of age, treatment delay and 
CSF measurements, given the non-normal distribution of the data with median and IQR. 
Risk factors for the two outcomes (unfavourable clinical outcome and death) were assessed in 
univariate analysis. Multivariable models were used to analyse the relationship between risk 
factors and outcome if either the univariate relationships showed significance (p<0.05) or 
where variables were thought to be clinically relevant. Standard tests for co-linearity were 
used. 
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Results 
Patient characteristics 
One hundred and forty-two children were identified from the database of children with 
culture-confirmed TB. On review of the clinical records five did not meet the inclusion criteria. 
Of the remaining 137 cases, comprehensive clinical details could be found on 123 (Figure 12). 
The baseline clinical characteristics of these patients are demonstrated in Table 45 with the 
initial investigations, clinical course and outcome in Table 46. For 104 of these patients 
samples were located and spoligotyping successfully performed. Ninety-eight (79.7%) of the 
123 children included in the analysis were tested for HIV, and of these 20 (20.4%) were HIV-
infected. Six (30.0%) of the HIV-infected children had severe immunosuppression at the time 
of TBM diagnosis, and only three (15.0%) were on cART. 
Drug resistance, strain type and outcome 
Sixteen children (13.0%) had isolates with drug resistance, five MDR (4.1%), ten HMR (8.1%) 
and one RMR (0.8%). No XDR-TB cases were identified. Univariate analysis showed an 
association between MDR-TB and both poor clinical outcome (OR 8.97; 95%CI 0.83-4447.5; 
p=0.04) and death (OR 67.3, 95%CI 5.0-3343; p<O.OOl) as shown in Table 47. There was no 
association between Beijing strain and unfavourable outcome (p=0.29) or mortality (p=l.O). In 
addition, there was no relationship between Beijing strain and any drug resistance (p=0.21) or 
MDR (p=I.00). A trend towards an association existed between MDR-TB and HIV (OR 6.71, 
95%CI 0.69-83.7; p=0.056), but not with TBM stage (p=0.22). Beijing strain was not associated 
with HIV status (p=0.78) or TBM stage (p=0.14). 
Clinical factors and outcome 
Children with unfavourable outcome were younger than those with favourable outcome 
(median age: 21 months [IQR: 7-35] vs. 30 months [IQR: 15-72]; p=0.008). They also had lower 
CSF lymphocyte counts (median: 35 celiS/ill [IQR: 17-61] vs. 75 celiS/ill [IQR: 27-159]; p=0.002). 
CSF lymphocyte counts were not associated with HIV infection (p=0.24) or strain type (p=0.07). 
TBM stage III (p<O.OOl), shunt insertion (p=0.002) and intensive care admission (p=0.02) were 
associated with unfavourable outcome and reflect disease severity (Table 47 & Table 48). HIV 
infection was associated with death (OR 6.17, 95%CI1.15-34.1; p=0.02) and for those dying the 
time from first symptoms to appropriate treatment was longer (median: 22 days [IQR: 6-61] vs. 
10 days [IQR: 5-21]; p=0.049). Time from start of symptoms to initiation of appropriate TS 
treatment was longer for those with any drug-resistance than those with drug-susceptible TBM 
(median: 31 days [IQR: 13-66] vs. 9 days [IQR: 5-21]; p=O.OOI). Time to start appropriate 
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therapy was not influenced by the presence of a known TB source case (p=0.82), the HIV status 
of the child (p=0.10) or the age of the child (p=0.82). 
Multivariable analysis 
Following adjustment for HIV status in multivariate analysis (Table 49) the relationship 
between MDR-TB and death persisted (AOR 63.9, 95%CI 4.84-843.2; p=0.002). Young age 
(p=O.013) and MDR-TB (AOR 12.4, 95%CI1.17-132.3; p=0.037) remained independent risk 
factors for unfavourable outcome. Those with HMR-TB did not have an increased risk of 
unfavourable outcome after adjustment for age (AOR 0.22, 95%CI 0.03-1.87; p=0.17). The 
relationship between HIV and death was less significant following adjustment for drug 
resistance (AOR 6.17, 95%CI 0.92-41.3; p=0.061). 
Discussion 
Children with TBM in the Western Cape are young, generally present with advanced disease 
and, if they survive, are usually left with some form of disability. Rates of drug resistance are 
relatively low but this study has demonstrated that the time from first symptoms of TBM to 
the child being given appropriate, effective treatment is longer when the child's isolate is 
resistant to rifampicin and/or isoniazid. Young age is associated with a poor outcome. In this 
study, Beijing strain was not associated with drug resistance and there was no association 
between Beijing strain and either poor outcome or death. MDR-TB, however, was strongly 
associated with both unfavourable outcome and death, even after adjusted analysis. 
A study by Thwaites and colleagues demonstrated that adults with TBM were much more likely 
to die if infected with an organism resistant to both isoniazid and rifampicin but had no 
increased risk if resistant to isoniazid alone and/or streptomycin.494 Other work by the same 
group demonstrated that HIV infection in adults does not change the clinical presentation of 
TBM but does influence outcome.5OO A case series of adults from KwaZulu-Natal demonstrated 
that MDR-TBM was often associated with poor outcome493 and a series from Durban described 
eight children with MDR-TBM, of whom seven died.193 Caws and colleagues demonstrated a 
relationship between Beijing strain and both HIV infection and drug resistance in adults with 
TBM.75 However, Maree and colleagues found, as with our study, no association between 
strain type and either presentation or outcome in an investigation of children with TBM. 76 
Other studies have demonstrated a relationship between strain type and disease phenotype in 
children77 and in adults41, 78 and a number of investigations have demonstrated that strain 
type, and the Beijing strain specifically, is associated with drug resistance.39, 79-81 
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The association between low CSF lymphocyte count and poor outcome in TBM has been 
demonstrated in other studies.41. SOl Previous investigations have shown a relationship 
between different strains and CSF lymphocyte count which we did not demonstrate. The 
inflammatory response to TBM is the cause of some of the pathology but it is clear from these 
and previous data that a failure to mount a lymphocyte response is associated with poor 
outcome. 
In the Western Cape, children with TBM are treated with rifampicin, isoniazid, pyrazinamide 
and ethionamide.4G8 This is in contrast to the WHO guidelines which previously recommended 
rifampicin, isoniazid, pyrazinamide and streptomycin for two months followed by isoniazid and 
rifampicin for four months16 but now recommends rifampicin, isoniazid, pyrazinamide and 
ethambutol for two months followed by rifampicin and isoniazid for ten months.ll3 Isoniazid, 
pyrazinamide and ethionamide penetrate into the CSF well, rifampicin adequately and 
ethambutol and streptomycin poorly.s02 In addition, a high proportion of MOR-TB cases have 
evidence of resistance to ethambutol and pyrazinamide,161 implying that if a strain is MOR, 
ethambutol and pyrazinamide should not be assumed to be effective. One final factor that 
needs to be considered is the genotypic basis of drug resistance which is complicated by cross-
resistance and co-resistance.91 Resistance to isoniazid is usually caused by mutations in either 
the katG gene or the inhA promoter region. KatG mutations are usually associated with total 
resistance to isoniazid but if the mycobacteria posess an inhA promoter region mutation, this 
usually results in low-level isoniazid resistance which can be overcome by giving isoniazid at a 
higher dose (15-20mg/kg).90. 92 InhA promoter region mutations, however, usually result in 
ethionamide resistance. One explanation for the good outcomes in our study for children with 
HMR-TB might be that until the diagnosis was made and appropriate treatment started, they 
received a number of effective drugs with good CSF penetration. Using either the old or the 
new WHO guidelines this would not have been the case. 
The majority (63%) of children presenting with TBM had an identified TB source case but few 
(15%) had been given preventive treatment. In addition to identifying a source case it is vital to 
determine the OST pattern of that source case to start appropriate preventive treatment or, if 
disease develops, disease treatment for the child. Although four of the five children with MOR-
TB had been given some kind of prior treatment, none had been treated appropriately. As 
children in contact with MOR-TB have been previously demonstrated to develop TB on 
isoniazid preventive treatment,88 the correct preventive treatment for child contacts of MOR-
TB remains unclear.87 Although it is important to strive to obtain a microbiological diagnosis 
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from the child, in reality only a small proportion of children with TBM have microbiological 
confirmation with DST. Most children are treated presumptively and unless a source case is 
identified, M. tuberculosis cultured and DST performed, cases of drug-resistant TBM in children 
will be missed. Where this is HMR-TBM, it is possible that the current local regimen will 
adequately treat the disease; however in the context of MDR-TBM outcome is poor unless 
appropriate second-line treatment is initiated rapidly. Of note, although over 85% of children 
had evidence of BCG vaccination, TBM still occurred. The protective efficacy of BCG remains 
debated and the need for effective vaccines is a pressing priority. Only 80% of children were 
tested for HIV, despite prolonged hospitalisation for a condition known to be associated with 
HIV infection. All children suspected of TBM should be tested for HIV, especially in a region 
with high HIV prevalence. 
This study is retrospective and the data analysed is reliant on collection from routine sources 
such as case notes and laboratory records. As there were relatively few cases that had drug 
resistance, statistical analysis may not have revealed associations that may have been evident 
if a larger proportion of the cases had been DR. The children in this study may not be 
representative of all children with TBM. First, the study was carried out in a hospital which may 
have a more severe disease phenotype than those managed in the community. Second, as a 
positive mycobacterial result was required for Inclusion in the study it is possible that the 
children had more advanced disease than is typical. A further limitation may have been that 
survival bias occurred with those presenting to TCH having a greater chance of both survival 
and drug resistance being diagnosed. Finally, the outcome was only recorded at the end of 
therapy. longer follow up would have been desirable. 
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Table 4S - Presenting clinical characteristics (n=123 unless otherwise stated) 
05(107) HMR (10) RMR(l) MOR(S) Total (123) 
Age (median & lOR in months) 28 (12-56) 25 (21-38) 14 26 (26-50) 27 (13-55) 
Male gender (%) 53 (49.5) 5 (50) 0 1 (20) 59 (48.0) 
HIV-infected (n=98; %) 16 (19.3) 1 (11.1) 0 3 (60) 20 (20.4) 
Evidence of BCG (n=111; %) 83 (85.6) 7 (87.5) 1 4 (80) 95 (85.6) 
TB contact history (n=116; %) 61 (60.4) 7(77.8) 1 4(80) 73 (62.9) 
Preventive/previous treatment (n=122; %) 11 (10.4) 2 (20) 1"" 4 (80)" 18 (14.8) 
T5T positive (n=108; %) 64 (68.8) 7 (77.8) 0 3 (60) 74 (68.5) 
Time from start of symptoms to treatment initiation (median & lOR in 9 (5-21) 16 (14-30) 3 6 (2-19) 9 (5-21) 
days) 
Time from start of symptoms to appropriate treatment initiation 9 (5-21) 31 (14-53) 82 19 (6-51) 11 (5-22) 
(median & lOR in days) 
Presenting symptoms (more than one in most cases; %) Decreased consciousness 57 (53.3) 5 (50) 0 5 (100) 67 (54.5) 
Headache 26 (24.3) 4 (40) 0 0 30 (24.4) 
GI disturbance 16 (15.0) 2 (20) 0 1 (20) 19 (15.5) 
Poor feeding 17 (15.9) 1 (10) 0 0 18 (14.6) 
Seizures 47 (43.9) 5 (50) 0 2 (40) 54 (43.9) 
Vomiting 50 (46.7) 3(30) 0 2 (40) 55 (44.7) 
Cough 40(37.7) 4(40) 1 3 (60) 48(39.3) 
Weight loss 93 (86.9) 8(80) 1 5(100) 107 (87.0) 
Fever 72 (67.3) 8(80) 1 4 (80) 85 (69.1) 
Irritability 9 (8.4) 0 0 0 9 (7.3) 
Lethargy 30 (28.0) 1 (10) 1 1 (20) 32 (26.0) 
Neck stiffness 23 (21.5) 1 (10) 1 1 (20) 25 (20.3) 
TBM stage (%) I 22 (20.1) 3 (30) 1 26 (21.1) 
II 44 (41.1) 5 (50) 0 1 (20) 50(40.7) 
III 41 (38.3) 2 (20) 0 4(80) 47 (38.2) 
GCS (median & lOR) 12 (9-15) 14 (11-15) 15 6(5-11) 12 (9-15) 
Cranial nerve abnormalit ies noted at presentation (%) 52 (48.6) 8(80) 1 3(60) 57 (46.3) 
Motor abnormalities noted at presentation (%) 
-- - ---- - - ----
72 (67.3) 2 (20) 1 0 85(69.1) 
TB = tuberculosis; TBM = TB meningitis TST = tuberculin skin test; os = drug-susceptible; HMR = isoniazid monoresistant; RMR = rifampin monoresistant; MDR = multidrug resistant; lOR = inter-quartile range; GCS = Glasgow 
coma scale 
"One child developed TBM whilst on first-line treatment for pulmonary TB. One child was given isoniazid prophylaxis, one child developed TBM whilst on treatment for confirmed MDR-TB (suspicion of XDR-TB). One child had 
MDR-TB prophylaxis (isoniazid, ethambutol and ofloxacin) from birth but was then re-exposed over a year later and developed MDR-TBM. The final child received no preventive treatment. 
--This child was prescribed isoniazid and rifampin prophylaxis at birth, but it was not given. The child presented almost a year later with Stage I TBM. Nearly three months later resistance testing showed RMR, and although 
clinically well, treatment was changed to MDR-TB treatment. However, she died two months later after sudden deterioration. 
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Table 46 - Investigations at diagnosis, clinical course and outcome (n=123 unless otherwise stated) 
os (107) HMR(lO) RMR (l) MOR(S) Total (123) 
Diagnosis (%) Confirmed TBM 23 (21.5) 2 (20) 1 4(80) 30 (24.4) 
Probable TBM 84 (78.5) 8 (80) 0 1 (20) 93 (75.6) 
Strain (n=104; %) Beijing 30 (33.0) 6(60) 0 1 (33.3) 37 (35.6) 
LAM 18 (19.8) 2 (20) 0 0 20 (19.2) 
Haarlem 5 (5.5) 1 (1) 1 0 7 (6.7) 
CAS 3 (3.3) 0 0 0 3 (2.9) 
III-defined T family 16 (17.6) 0 0 0 16 (15.4) 
LCC 5 (5.5) 0 0 0 5 (4.8) 
5 family 7 (7.7) 0 0 2 (66.7) 9 (8.7) 
Undefined 7 (7.7) 0 0 0 7 (6.7) 
CSF Lymphocytes (n=116; median & IQR) 57 (24-138) 28 (5-130) 73 75 (35-105) 57 (22-132) 
CSF Protein (n=108; median & IQR) 1.3 (0.9-2.1) 1.3 (0.4-2.2) 1.2 8.4 (1.3-15.5) 1.4 (0.9-2.1) 
Air encephalogram (n-61; %) Non-communicating hydrocephalus 19 (34.6) 1 (25) - 1 (SO) 23 (37.7) 
Communicating hydrocephalus 36 (65.5) 3 (75) - 1 (50) 38 (62.3) 
Ventriculoperitoneal shunt inserted (%) 25 (23.4) 2(20) 0 2 (40) 29 (23.6) 
Admitted to intensive care (%) 13 (12.2) 0(0) 0 4(80) 17 (13.8) 
Duration of admission (median & IQR in days) 27 (16-38) 32 (18-53) 35 36 (29-40) 28 (17-39) 
Motor function amongst survivors at end of therapy (n=112; %) Normal 54 (53.5) 8 (80) 0 1 63 (56.3) 
Hemiparesis 34 (33.7) 2 (20) 0 0 36 (32.1) 
Quadriparesis 13 (12.9) O{O) 0 0 13 (11.6) 
Cognit ive function amongst survivors at end of therapy (n=112; Normal 37 (36.6) 5 (50) 0 0 42 (37.5) 
%) Mild handicap 37 (36.6) 4(40) 0 1 42 (37.5) 
Severe handicap 27 (26.7) 1 (10) 0 0 28 (25.0) 
Vision at amongst survivors at end of therapy (n=108; %) Normal 77 (79.4) 9(90) 0 1 87 (80.6) 
Impaired vision 15 (15.5) 1 (10) 0 0 16 (14.8) 
Blind 5 (5.2) 0 (0) 0 0 5 (4.6) 
Mortality (%) Survived 101 (94.4) 10(100) 0 1 (20) 112 (91.1) 
Died 6 (5.6) 0(0) 1 4(80) 11 (8.9) 
Clinical outcome (%) Favourable 74 (69.2) 9 (90) 0 1 (20) 84 (68.3) 
Unfavourable 33 (30.8) 1 (10) 1 4(80) 39 (31.7) 
- --
• Duration of admission at Tygerberg Children's Hospita l 
TB = tuberculosis; TBM = TB meningit is TST = tubercu lin skin test; os = drug-susceptible; HMR = isoniazid monoresistant; RMR = rifampin monoresistant; MDR = mult idrug resistant; IQR = inter-quartile range; GCS = Glasgow 
coma scale; CSF = cerebra-spinal fluid; CAS - Centra l Asian Strain; LAM - Latin American Mediterranean; lCC - Low-copy-number Clade 
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Table 47 - Univariate relationship between microbiological factors, clinical characteristics and clinical outcome 
Total number 
DST Drug susceptible 107 
Ison iazid mono-resistant 10 
Rifampicin mono-resistant 1 
Multid rug resistant 5 
Stra in Beijing 37 
Non-Beijing 67 
H IV status of ch ild Negative 78 
Positive 20 
Age of child* 
Gender of child Female 64 
Male 59 
BeG status of child None 16 
Given 95 
TBM stage of child I 26 
" 
50 
'" 
47 
TIme to appropriate therapy·· 
CSF Lymphocyte count-·· 
CSF Protein···· 
Ventriculoperitoneal shunt inserted No 94 
Yes 29 
Admission to intensive care No 106 
Yes 17 
OR = odds ratio, CI = confidence interval, TBM = tuberculous meningitis, CSF = cerebrospinal fluid; DST = drug susceptibility test 
Unfavourable outcome - death, quadriparesis, severe cognit ive handicap or blindness 
# Fisher's Exact test used 
## Mann Whitney test used 
• Median age in months: Favourable outcome: 30; Unfavourable outcome: 21 
** Median t ime in days: Favourable outcome: 9; Unfavourable outcome: 14 
*** Median count: Favourable outcome: 75; Unfavourable outcome: 35 
•••• Median value: Favourable outcome: 1.32; Unfavourable outcome: 1.41 
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Favourable 
Outcome 
74 
9 
0 
1 
22 
47 
54 
11 
41 
43 
12 
61 
22 
47 
15 
71 
13 
77 
7 
Unfavourable OR (95%CI) p-value 
Outcome 
33 1.00 
1 0.25 (0.01-1.95) 0.28" 
1 - 0.32" 
4 8.97 (0.83-447.5) 0.04" 
15 1.00 
20 0.62 (0.25-1.58) 0.29" 
24 1.00 
9 1.84 (0.59-5.61) 0.29' 
0.008" 
23 1.00 
16 0.66 (0.28-1.53) 0.34' 
4 1.00 
34 1.67 (0.46-7.64) 0.57' 
4 1.00 
3 0.35 (0.05-2.30) 0.22' 
32 11.7 (3 .10-53.2) <0.001' 
0.98" 
0.002" 
0.8S" 
23 1.00 
16 3.80 (1.45-9.94) 0.002' 
29 1.00 
10 3.79 (1.16-12.8) 0.02' 
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Table 48 - Univariate relationship between microbiological factors, clinical characteristics and death 
Total number 
DST Drug susceptible 107 
Isoniazid mono-resistant 10 
Rifampicin mono-resistant 1 
Multidrug resistant 5 
Stra in 
-
Beijing 37 
Non-Beijing 67 
HIV status of child Negative 78 
Positive 20 
Age of child· 
Gender of child Female 64 
Male 59 
BeG status of child None 16 
Given 95 
TBM stage of child I 26 
II 50 
III 47 
Time to appropriate therapy·-
CSF Lymphocyte count--· 
CSF Protein···· 
Ventriculoperitoneal shunt inserted No 94 
Yes 29 
Admission to intensive care No 106 
Yes 17 
OR = odds ratio, C\ = confidence interval, TBM = tuberculous meningit is, CSF = cerebrospinal fluid; DST = drug susceptibili ty test 
# Fisher's Exact test used 
## 
• 
.. 
••• 
•••• 
Mann Whitney test used 
Median age in months: Survival: 28; Death: 26 
Median t ime in days: Surviva l: 10; Death: 22 
Median count: Survival : S7; Death: 39 
Median value: Survival: 1.32; Death: 2.0 
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Survivors Deaths OR (95%CI) p-value 
101 6 1.00 
10 0 - L OR 
0 1 - 0.06" 
1 4 67.3 (5.0-3343) <O.OOlR 
34 3 1.00 
61 6 1.11 {0.22-7.32} 1.0" 
74 4 1.00 
15 5 6.17 {1.15-34.1} 0.02R 
0.34" 
56 8 1.00 
56 3 0.38 (0.061-1.68) 0.21" 
14 2 1.00 
86 9 0.73 (0.13-7.69) 0.66' 
23 3 1.00 
49 1 0.15 (0.003-2.12) 0.11" 
40 7 1.34 (0.27-8.78) 1.0' 
0.049" 
0.54" 
0.16"" 
85 9 1.00 
27 2 0.70 (0.07-3.70) 1.0" 
100 6 1.00 
12 5 6.94 {1.41-31.6} O.OOS" 
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Table 49 - Multivariable relationship between drug resistance and outcome 
Outcome Characteristics in model Variable 
Unfavourable outcome Age 
DST Isoniazid mono-resistant 
Rifampin mono-resistant 
Multidrug-resistant 
Mortality HIV status 
DST Isoniazid mono-resistant 
Rifampin mono-resistant 
Multidrug-resistant 
DST = drug susceptibility test 
Unfavourable outcome - death, quadriparesis, severe cognit ive handicap or blindness 
·Perfectly predicts fa ilure in th is model so dropped from analysis 
··Perfectly predicts success in th is model so dropped from analysis 
Number in analysis 
122 
122 
122 
122 
88 
88 
88 
88 
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Odds Ratio 95% Confidence Interval P-value 
0.013 
0.22 0.03-1.87 0.17 
- - -
12.4 1.17-132.3 0.037 
6.17 0.92-41.3 0.061 
- - -
- - -
63.9 4.84-843.2 0.002 
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Figure 12 - Patient identification, inclusion, mycobacterial characteristics and outcome 
Beijing 
Cases identified from 
,----7 (n=37; 35.6%) 
database 
Drug susceptible (n=142) (n=107; 87.0%) ~ 
I 
J, CAS f--7 (n=3; 2.9%) Inclusion criteria met 
(n=137; 96.S%) 
Isoniazid mono- Haarlem 
resistant ~ ~ ~ (n=7; 6.7%) (n=10; 8.1%) 
DST available Complete clinical Strain type available 
I- (n=123) ~ data available ~ (n=104; 84.6%) r-- Tfamily (n=123; 89.8%) 
~ (n=16; 15.4%) Rifampin mono-
resistant k- t (n=1; 0 .8%) 
Outcome LAM 
(n=123) ~ (n=20; 19.2%) 
Multidrug-resistant 
I (n=5; 4 .1%) ~ J, -!,. LCC 
f--7 (n=5; 4 .8%) Mortality , Clinical outcome 
(n=123) (n=123) 
S family I I f---? (n=9; 8 .7%) ~ -.it ,J, -.it 
Died Survived Unfavorable Favorable outcome 
(n=l1; 8.9%) (n=112; 91.1%) outcome (n=84; 68.3%) 
(n=39; 31.7%) Unclassified 
~ (n=7; 6 .7%) 
DST - drug susceptibility test; CAS - Central Asian Strain; LAM - Latin American Mediterranean; LCe - Low-copy-number Clade 
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Study 12: multidrug-resistant tuberculosis of the spine in children 
The following study has been published as an article: 
• Seddon lA, Donald PR, Vlok GJ, Schaaf HS. Multidrug-resistant tuberculsois of the spine in 
children - characteristics from a high burden setting. J Trop Pediatr 2012; 58: 341-7 
Introduction 
Spinal TB in children can be a debilitating disease with potential long-term neurological 
sequelae. Treatment involves a combination of surgical and medical care with long courses of 
drug therapy. Few paediatric spinal MDR-TB studies have been published. This study describes 
the clinical characteristics, management and outcome for children with MDR-TB of the spine. 
Methods 
Identification of cases 
A prospectively maintained register of admissions to BCH was analysed searching for any 
patient started on treatment for MDR- TB of the spine between January 2004 and December 
2010. In addition, laboratory records were consulted to identify any MDR-TB samples from 
spinal tissue at TCH. Cases were included if the child had a sample taken from the spine that 
confirmed MDR-TB either phenotypically or genotypically. 
Laboratory methods 
From January 2004 until August 2008 conventional, phenotypic DST to isoniazid and rifampicin 
was performed on all paediatric samples CUlture-positive for M. tuberculosis. The indirect 
proportion technique was used. From August 2008 onwards line probe assay (GenoType-
MTBDRplus, Hain Lifescience, Nehren, Germany) was undertaken to test for the presence of 
M. tuberculosis and also for mutations responsible for rifampicin (rpoB gene) and isoniazid 
(inhA promoter region and katG gene) resistance. The laboratory techniques employed are 
discussed elsewhere.432 
Standard of care 
Surgery was conducted at the discretion of the attending surgeon. Surgery was indicated to 
obtain a microbiological diagnosis, to decompress the spinal cord and to correct kyphotic 
deformity. Children were treated medically according to WHO guidelines, using the DST of the 
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child to guide treatment when culture-confirmed or that of the source case when diagnosed 
presumptively. At least four drugs to which the organism was susceptible were used which 
included pyrazinamide (30-40mg/kg), ethambutol (20-25mg/kg), ofloxacin (15-20mg/kg), 
amikacin (15-2Smg/kg), capreomycin (15-25mg/kg), terizidone (15-20mg!kg), PAS (150-
200mg/kg) and isoniazid given at high dose (15-20mg/kg). The injectable drug (amikacin or 
capreomycin) was typically given for the first six months and the total treatment duration was 
for a minimum of eighteen months. Regular monitoring of response included radiology with CT 
or magnetic resonance imaging (MRI), growth and clinical assessment. The monitoring of 
adverse effects included clinical examination, audiology and blood tests. Follow-up continued 
to twelve months following the end of therapy. 
Results 
Eleven children were identified of which four were excluded. Clinical details and presentation 
are summarised in Table 50. One of the excluded children was diagnosed as having MDR-TB 
from a gastric aspirate and whilst an inpatient noted to have reduced tone, power and reflexes 
in lower limbs. An MRI scan of the spine showed changes consistent with TB but as the 
diagnostic sample was not from the spinal tissue this girl did not meet our inclusion criteria. 
Two children were excluded as they were only treated presumptively for MDR-TB. In one of 
these, acid-fast bacilli were seen on a biopsy sample, the child was failing first-line therapy and 
he had been in contact with an MDR-TB source case. However, the biopsy sample did not grow 
on culture. The other presumptively-treated child developed spinal TB whilst on first-line 
therapy. The final child excluded had radiological TB ofthe spine and was a contact of an MDR-
TB source case. He was started on MDR-TB treatment but when the biopsy result from the 
spine demonstrated drug-susceptible TB he was converted onto first-line therapy. 
Of the seven children with culture-confirmed MDR-TB, five were boys and the median age was 
eight years (range 1.5 to 14). The median delay from start of MDR-TB episode to initiation of 
appropriate therapy was 36 weeks (range 7 to 76 weeks). One child (child 4) was infected HIV 
and had a CD4 count of 545 (19%). MDR-TB source cases were not identified for any of the 
children. 
Details of treatment and outcome are shown in Table 51. Injectable treatment was given for a 
median of 6 months with total treatment duration a median of 18 months. One child died, five 
completed treatment and one was near the end of therapy at the time of the study. The 
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medications were well tolerated and although two of the surviving children had marked spinal 
deformity, none had any significant neurological deficit. 
Discussion 
All seven cases were associated with Significant delay in initiation of appropriate therapy with 
the diagnosis usually only made after a first-line regimen had failed. Failure to take 
microbiological samples early on and request appropriate tests was frequently to blame. This 
is not only important for making the diagnosis of MDR-TB but also for confirming drug-
susceptible TB in those suspected of MDR-TB; consequently one child was spared long and 
unnecessary treatment. All samples taken from children suspected of TB should be sent for 
culture and DST to at least isoniazid and rifampicin. Although a contact history is important in 
the diagnosis of TB and particularly MDR-TB, its absence, particularly in older children who 
may spend more time in the community, does not exclude the diagnosis. A number of the 
children initially had pUlmonary TB which then seems to have spread to the spine in the face of 
inadequate treatment. All the children, even those with relatively minor involvement, were 
treated for at least eighteen months and all were operated on, even if only to drain collections 
of pus or cold abscesses. Where vertebral damage had occurred and deformity was present, 
posterior fusion was indicated following decompression. The children tolerated both surgical 
and medical therapy well without the severe adverse effects frequently described in adult. so3 
Additionally, the short-term outcome seems to have been reasonable, again contrary to the 
poor results seen in older patients.19o The reason for this is not clear but in this series only one 
child was HIV-infected, a factor commonly associated with poor outcome. Long-term results, 
however, have not been assessed and for some of the severe cases, morbidity may occur in 
time. 
In the paediatric literature, little has been written concerning MDR-TB and almost nothing with 
regards to MDR-TB of the spine. Case histories of paediatric MDR-TB of the ankle504, 
mastoidsSos, femoral heads06 and hipso7 have been described. Case series of sternal TBs08 and 
non-contiguous spinal TBS09 included some MDR-TB cases and some children. In a further 
series of 39 paediatric MDR-TB cases, two had osteoarticular TB.S8 Several papers describe 
case series or surveys of TB in which a proportion are described as paediatric, some spinal and 
a percentage drug-resistant.s10-511Undquist et al. describe a child with MDR-TB of the first 
cervical vertebraS12 and Hussey et al. describe a case of disseminated MDR-TB with mUltiple 
bony foci including the spine.S13 Agashe et al.514 report 93 osteoarticular TB cases of which five 
are MDR in children under ten. Pawar et al.238 describe 2S cases of MDR spinal TB, of which 
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seven were in children. In all these reports, diagnoses were associated with significant delay. 
However, most of the studies describe children tolerating therapy well with a good response 
to medical treatment. Long term follow up was not undertaken. 
It is known that following initial infection, seeding to the spine shows preference for the 
vertebral bodies. There is bony destruction with both caseous and avascular necrosis. The 
disease, if untreated, is likely to spread directly into adjacent vertebrae, the spinal cord or into 
the paraspinal muscles causing a cold abscess.515-S16 Mycobacteria can also disseminate into 
other, more distant, vertebral bodies via the valveless venous plexus system to produce skip or 
non-contiguous lesions.sOg The neurological consequences of spinal TB are the most concerning 
and the evolution of a Pott's paraplegia the most severe, occurring in up to 10% of untreated 
cases.S17-S18 Indirect damage can result from either compression on the spinal cord from an 
abscess or the collapse of a vertebra. Direct damage can result from invasion of the cord by 
mycobacteria.Sl9 ln addition, even if successfully treated, the patient can suffer major 
neurological consequences, often many years later, due to spinal cord damage secondary to 
vertebral collapse, fibrosis or calcification.Sl6 
Little is known regarding the treatment and outcomes for paediatriC spinal MDR-TB. It is, 
therefore, worth looking at the treatment of drug-susceptible spinal TB in children and 
drawing comparisons. A series of studies was carried out in the 1960s and 1970s by the 
Medical Research Council Working Party on Tuberculosis of the Spine.516 Although medical 
management alone seems to result in similar outcomes in terms of mycobacterial clearance, 
there is evidence that benefit is seen with additional surgical drainage, debridement and 
fixation. Attention has been drawn to the consequences of late onset paraplegia developing in 
those with extensive bone destruction treated conservatively in childhood.Sl6 
Controversy exists regarding the length of treatment for drug-susceptible spinal infections. 
Whilst most evidence suggests that treating for the same duration as pulmonary TB has 
excellent outcomes in well adhered-to regimens, S20 a couple of studies have shown cases of 
treatment failure with six month treatment courses.S21 Monitoring therapy with radiology, 
inflammatory markers (C-reactive protein, erythrocyte sedimentation rate) and immune 
markers (interferon-v release assays) are often emploved by clinicians in deciding when to stop 
treatment; only stopping when markers return to normal. It is unclear whether these 
strategies are beneficial. Both the Joint Tuberculosis Committee of the British Thoracic 
Societl22 and NICE137 have stated that a six month regimen is appropriate for drug-susceptible 
spinal TB. This is similar to the ATS, CDC, I DSAs23 and the AAP.524 WHO had previously advised 
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that six months was sufficient/6 but now recommend twelve months. They concede that this is 
based on poor quality evidence.ll3 lt is probably safe to use the same indications for surgery in 
spinal lesions infected with MDR and drug-susceptible TB and until further evidence emerges, 
the duration of therapy for MDR spinal disease should be the same as for MDR pulmonary TB. 
It appears that both first- and second-line drugs are able to penetrate bone, cartilage, pus, 
cavity and granuloma, achieving levels well above the MIC for each drug. lOS, 525-527 Penetration 
into cortical and sclerotic bone, although adequate, is much poorer than into other tissues.S28 
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Table 50 - Patient characteristics and presentation in children with culture-confirmed multidrug-resistant tuberculosis of the spine 
Gender and age in years TIme from start of MDR- Known contact Initial presentation Rx prior to MDR TB treatment 
at start of MDR TB TB episode to start of 
treatment MDR-TB treatment 
1 M(8) Died prior to MDR-TB None Progressive paraplegia and Six months of first-l ine therapy four years earlier and then a further course of first-l ine therapy 
treatment marked gibbus formation over from surgery until death 
preceding two years 
2 M(4) 7 weeks Father retreatment TB Three weeks of cough, loss of Given f irst -line therapy from presentation until the results of DST from operative specimen 
case, no DST weight, fever, vomiting and returned 
undertaken inability to walk 
3 F (8) 10 months None Pa in and deformity in lumbar Six months of f irst-line therapy then three months no treatment. Recurrence of spinal TB and 
spine bilateral psoas abscesses. Drained and MDR-TB grown. 18 months MDR-TB treatment but with 
uncertain adherence. No treatment for 2S months prior to representation with recurrence of 
spinal disease_ Further nine months of MDR-TB treatment with uncertain adherence prior to 
development of draining sternal sinus and new spinal lesions. Admitted for full MDR-TB 
treatment as inpat ient 
4 M(l.S) 8 months None Cough, loss of weight, sweating Started on first-l ine therapy but developed worsening respiratory distress 5 months into 
treatment 
5 F (9) 19 months None Cough, loss of weight and Completed six months of first-l ine therapy. Well for 5 months before developing back pain, night 
sweating sweats, weight loss and mass in flank. Restarted on first-line therapy but after one month, 
without improvement, referred for surgical drainage 
6 M(14) S months None Neck pain Init ially given analgesia for sporting injury. The neck pain worsened and he lost weight and 
developed fever. Three sputum samples were sent for smear (all negative) but no cu lture. 
Started presumptively on first-line therapy. Continued deterioration before chest radiograph 
demonstrated pulmonary TB with likely paravertebral abscess and collapse of T2/T3 
7 M(2) 18 months MotherTB Spinal deformity At presentation biopsy sample taken and child started on first-line therapy for spinal TB. Culture 
result showed MDR-TB but the child could not be traced. Child represented 18 months later with 
marked deterioration and significant gibbus 
--- -- - -- --- ---- --- --
----_ .. _---
- - - ---------- -- ----
(MDR = mult idrug-resistant, DST = drug susceptibility testing) 
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Table 51 - Treatment and outcome in children with culture-confirmed multidrug-res istant tuberculosis of the spine 
Basis of spinal MDR-TB Spinal involvement Surgery DST length of Total length Drugs used Outcome Deficit 
diagnosis intensive of t reatment 
phase 
1 Culture confirmation from T4 to Tl1 breakdown, Posterior decompression and Resistant nla nla nla Died Died 
spinal tissue sample large abscess and 90 abscess drainage toRH 
degree angulat ion 
2 Culture confirmat ion f rom C5 to Tl with possible Anterior decompression and Resistant 6 months 18 months H;Z;E;Eto;O;T;A Treatment completed Some residual clawing of 
spinal tissue sample myelopathy at C8 external fixation with HALO to RH little and ring fingers of 
jacket left hand 
3 Culture-confirmation on Breakdown at C7/C8 and Repeated drainage of psoas Resistant 6 months 18 months H;Z;E;Eto;O;T;A Treatment completed Bilateral high frequency 
multiple occasions from LS/Sl with repeated abscesses but no spinal surgery to RH hearing loss. No 
pus samples collections neurological deficit 
4 Culture-confirmation C4/CS with post and pre- Drainage of abscesses w ithout Resistant 6 months 18 months H;Z;Eto;O;A Treatment completed Free from any 
from surgery biopsy paraspinal abscesses spinal surgery to RHE neurological symptoms 
specimen 
5 Culture confirmation from lytiC lesions Tl2-12 Drainage of abscesses Resistant 6 months 18 months H;Z;Eto;O;T;C Treatment completed Slight scoliosis but with 
pus samples bilateral psoas abscesses to RHEA full range of movement 
6 Culture confirmation from Collapse T2/T3 with Anterior decompression C7-T4 Resistant 6 months Plan for 18 H;Z;Eto;A;T;PAS 15 months of treatment Free from any 
pus sample paraspinal collection Tl- followed two weeks later by to RHEO months completed with a further neurological symptoms 
T4 posterior fusion 3 months planned 
7 Culture confirmation from Collapse ofT10/ Anterior decompression and Resistant 7 months 24 months H;Z;E;Eto;O;A;T Treatment completed Marked deformity but 
biopsy sample Tl1 with 90 degree posterior fusion to RH intact neurology 
angulation of spine 
_ .. _ -- ----
(R-rifampicin, H-isoniazid, E-ethambutol, Z-pyrazinamide, Eto-ethionamide, O-ofloxacin, A-amikacin, T-terizidone, C-capreomycin, PAS-para-aminosalicylic acid) 
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Study 13: hearing loss in children treated for drug-resistant tuberculosis 
The following study has been submitted as an article: 
• Seddon JA, Thee 5, Jacobs K, Ebrohim A, Hesseling AC, Schaaf HS. Hearing loss in children 
treated for mulitdrug-resistant tuberculosis. J Infect (in press) 
Introduction 
The aminoglycosides (amikacin and kanamycin), together with capreomycin (a polypeptide), 
are classified as group two drugs by WHO. These injectable second-line agents are vital for the 
management of MDR-TB.197 Although strains resistant to rifampicin but susceptible to isoniazid 
can be treated with slightly less intense regimens, these RMR cases are usually treated as 
MDR-TB in most National TB Programmes. This is due to the limitations of modern molecular 
diagnostic tests which either do not test for isoniazid resistanceS29 or miss a significant 
proportion of cases which have phenotypic resistance.226 In most circumstances rifampicin 
resistance is seen as a surrogate for multidrug resistance. 
Both the aminoglycosides and polypeptides are known to have adverse effects that include 
renal and eighth cranial nerve impairment.214, 241, 530 The effects on the kidneys are thought to 
be temporary but those on the vestibulo-cochlear system are permanent.m -m Hearing loss 
related to injectable TB drug use usually starts in the high frequencies and if treatment 
continues, there is progression to the lower frequencies required for communication; 
however, in some cases severe hearing loss can develop acutely. Hearing is vital not only for 
effective communication but also for neurological development. Children with hearing deficits 
have delayed developmental and communication milestones compared to children with 
normal hearing.243, 531-532 
Hearing testing for children is performed for two reasons. The first is to identify and quantify 
hearing loss to enable the provision of support, education, training and hearing aids. The 
second is to identify hearing loss early, when it is mild and only at high frequencies, so that 
treatment, where pOSSible, can be changed to prevent further damage. The testing of hearing 
is challenging in children. PTA is the method of choice for testing adults and allows the testing 
of different frequencies and amplitudes in both ears independently.425 PTA is only possible in 
children on therapy who are able to understand commands and co-operate with testing, which 
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effectively precludes its use in children younger than five years. As young children are at high 
risk of developing TB following infection and as young children bear the brunt of the epidemic 
in many settings,254 this means that many children are excluded from this form of testing. 
Auditory brainstem response (ABR) testing is the optimal testing methodology for young 
children533 but is only available in South Africa in specialist centres. OAE testing can assess 
cochlear patency in younger children and is widely available. OAEs are not fully validated for 
quantifying hearing loss and do not provide as comprehensive an assessment as PTA or ABR. 
The frequency and severity of hearing loss is unknown in children treated for MDR-TB with 
injectable medications. Some data are available for children given these injectable drugs as 
short antibiotic courses for the treatment of other bacterial infections.241. 534 Some data 
regarding ototoxicity are available for adults treated for MDR-TB,244 but few studies have 
examined the adverse effects of injectable drugs in children treated for MDR-TB. The aim of 
this study was to determine the frequency and extent of hearing loss in children treated with 
an aminoglycoside or polypeptide as part of an MDR-TB regimen. 
Methods 
Setting 
Children with MDR- and RMR-TB present to various regional health centres but once 
diagnosed and stabilized all children requiring injectable TB medications are transferred to 
BCH. Routine hearing testing for children treated with injectable TB medications was 
introduced in 2008. Children are assessed prior to starting injectable drugs and then monthly. 
If there are challenges to testing or if abnormalities are found, testing is carried out every two 
weeks. Children are treated for MDR- and RMR-TB with amikacin (20mg/kg once daily 1M 
injection) for between four and six months. Children treated for isolates resistant to amikacin 
are treated with capreomycin (20mg/kg once daily 1M) or streptomycin (20mg/kg once daily 
1M) dependent on drug susceptibility test results. 
Study population 
This retrospective study included all children routinely admitted to BCH from January 2009 
until December 2010, aged 0-lS years, ifthey had been a) diagnosed with confirmed MDR- or 
RMR-TB (M. tuberculosis isolated using liquid culture with demonstrated resistance)535 or 
presumed MDR- or RMR-TB (a clinical diagnosis of TB in the presence of a drug-resistant 
source case or the child failing first-line TB therapy), b) were treated with an injectable TB drug 
for at least a month, and c) had received at least one audiological assessment. 
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Audiological assessments 
Children were assessed using a combination of otoscopy, tympanometry, PTA (including 
conditioned play audiometry) and/or distortion product otoacoustic emissions (DPOAEs). 
Otoscopy was used to ensure that there were no anatomical abnormalities and that the 
external ear canal was clear of occluding wax, foreign bodies or obstruction. A Welch Allyn 262 
tympanometer (MFI Medical Equipment Inc. San Diego, USA) was used to assess middle ear 
function using a 226Hz probe tone. The probe was placed into the child's ear canal ensuring a 
tight seal with no leakage. Static compliance between 0.2-1.Bcm3, middle ear pressure 
between +100 and -150 dekapascals, and ear canal volume of 0.2-2.0cm3 were used. If a type B 
tympanogram (indicating possible middle ear infection) was noted, the audiologist would 
notify the attending physician. A five day course of oral antibiotics was usually prescribed 
before reassessment. If the problem persisted, the child was referred to the ear, nose and 
throat team. 
PTA was performed in a sound-proof booth with calibrated equipment. The AC40 dual channel 
audiometer (Interacoustics, Assens, Denmark) and the MA51 audiometer (MAICO Diagnostics 
GmbH, Berlin, Germany) were used. Pure tone air conduction hearing thresholds were 
obtained for children between six and fifteen years of age, for each ear by testing the octave 
bands from 250Hz to BkHz. Audiologists followed the modified Hughson-Westlake 
procedure536 (i.e. 10dB down, 5dB up, repeated twice to reliably determine hearing threshold). 
Stimuli were presented in the following order: 1kHz, 2kHz, 4kHz, BkHz, repeated at 1kHz, then 
500Hz and 250Hz. If there was a difference of 20dB between consecutive frequencies the 
audiologist would test half octave frequencies, i.e. 750Hz, 1.5kHz, 3kHz and 6kHz. For 
participants younger than six years, either conditioned play audiometry or DPOAE were 
performed. For descriptive purposes we considered thresholds of <25dB as normal, 26-40dB as 
mild, 41-55dB as moderate, 56-70dB as moderately severe, 71-90dB as severe and >90dB as 
profound hearing impairment.537-538 
DPOAEs were obtained using an OtoRead™ machine (Interacoustics, Assens, Denmark). A 
rubber-tipped probe was placed in the external ear canal to create a tight seal. Two 
simultaneous pure tone signals were then presented to each ear at two different primary 
frequencies (fl and f2, where f2 > fl) with f1:f2 ratio of 1.22 and an intensity of 65dB Sound 
Pressure level (SPl) and 55dB SPL respectively. Frequencies 2kHz, 4kHz, 6kHz, BkHz, 10kHz and 
12kHz were tested. In order for a child to pass the DPOAE, the emission amplitude needed to 
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be 6dB or greater above the noise floor. If a child was unable to be tested for any reason, or if 
the test was abnormal, they were re-tested two weeks later. If the child passed the DPOAE, 
then they were assessed monthly. DPOAE results were classified as pass, fail or unable to test. 
Data collection 
BCH admission records were reviewed to identify all patients treated for MDR- and RMR-TB 
over the study period. Records were compared with data from the audiology department to 
determine which of the patients had received audiological testing. Clinical records were 
reviewed to determine the dosage and duration of injectable treatment, demographic and 
clinical details, as well as audiological and laboratory data. 
Data classification and analysis 
A distinction was drawn between hearing deficit and hearing loss. Hearing deficit describes the 
absolute impairment in hearing experienced by a child at treatment completion whereas 
hearing loss is a measured deterioration in hearing function between two assessments. 
Children could therefore have hearing deficit at the end of treatment but if previous 
assessments were not carried out, hearing loss could not be determined. Conversely, it was 
possible for children to have hearing deficit at the beginning and at the end of treatment, but 
to experience no hearing loss between assessments. 
Hearing deficit assessed by PTA was classified as, at the last hearing assessment, a threshold of 
greater than or equal to 25dB at any tested frequency, in the presence of normal 
tympanograms. When testing using OAEs, a classification of hearing deficit was made if the 
child failed the assessment in the presence of normal tympanograms. When assessed using 
PTA, hearing loss was classified according to the ASHA guidelines: a) an increase in pure tone 
thresholds of greater than or equal to 20dB at anyone test frequency, b) an increase of 
greater than or equal to lOdB at any two adjacent test frequencies, or c) a loss of three 
consecutive frequencies.248, 425-426 A diagnosis of hearing loss using OAE was made if the child 
failed the assessment in the presence of normal tympanograms having passed a previous 
assessment. The classification of hearing loss used is shown in Table 52. 
Risk factors for hearing loss were determined by comparing the frequency or mean/median 
value for children with hearing loss (determined by both PTA and OAE) vs. children without. 
Chi square (or Fishers Exact) tests, student t-tests or Mann Whitney tests were used; ORs and 
95% Cis calculated. 
Drug-resistant tuberculosis in children James Seddon P age 1199 
Results 
Patient characteristics 
Ninety-four children were included in the study from 113 who were started on injectable 
treatment for MDR-TB (Figure 13). Median age was 43 months (inter-quartile range [IQR]: 20-
110). Forty-five (48%) were boys and 30 (32%) had evidence of extrapulmonary TB. Children 
were generally malnourished with weight-for-age z-scores a mean of 1.48 standard deviations 
below the reference mean and median body mass index of 15.5kg/m2 (IQR: 14.5-17.3). Fifty-
two (55%) had a culture-confirmed diagnosis and the majority (62 children; 66%) were treated 
for MDR-TB. The other children either had disease with more extensive resistance or were 
started on treatment for MDR-TB but were later confirmed to have less resistant organisms. 
Twenty-eight children (out of 93 tested; 30%) were HIV-infected of which 20 (71%) were 
already on cART at the start of TB treatment. Most children (n=82; 87%) were treated with 
amikacin (Table 53). 
Audiological testing 
Thirty-six children were assessed using PTA and 58 assessed using OAEs. Hearing deficit is 
demonstrated in Figure 13, and hearing loss in Figure 14. When combining results of both PTA 
and OAE testing, 23 (24%) children had hearing loss and 27 (29%) had normal hearing. Forty-
four (47%) children could not be classified using this approach. In 7 of the 11 children who had 
hearing loss determined by PTA (Table 54), hearing loss progressed even after the injectable 
medication was discontinued. 
Assessment of risk factors far hearing loss 
A culture-confirmed diagnosis of TB (OR: 4.12; 95%CI: 1.13-15.0; p=0.02) was a significantly 
associated with hearing loss (Table 55). There was a trend towards the median duration of 
injectable antibiotic use being longer in children with hearing loss: (164 days; IQR: 119-184 vs. 
123; IQR: 70-183; p=0.07). 
Discussion 
This study demonstrates that both hearing deficit and hearing loss are common in children 
treated for MDR-TB. The association between hearing loss and culture-confirmed TB disease 
appears to reflect the extent or severity of disease and might suggest that treating clinicians 
are more likely to continue injectable drug use in children with extensive pathology. Since the 
aim was to describe children with definitive hearing loss or normal hearing, a classification 
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system was developed which precluded the accurate classification of a relatively large number 
of children. However, despite this conservative estimate, over half of the children had hearing 
deficit at the end of therapy and a quarter of children experienced hearing loss. 
In addition to documenting the risk and degree of hearing loss in children treated for MDR-TB, 
this study highlights some of the challenges in the assessment of hearing in children, including 
the classification of hearing deficit and hearing loss. Hearing testing is partially subjective, 
requires relatively sophisticated equipment, trained staff and co-operative patients. Elements 
of the frequency (pitch), amplitude (volume), laterality (unilateral or bilateral) and aetiology 
(sensorineural, conductive or both) need to be considered; all of these factors need to be 
monitored longitudinally and change classified. The established ASHA criteria were followed to 
classify whether hearing loss occurred between two PTA assessments. However, a 
classification system was developed to determine whether children in this study should be 
classified as having hearing loss or not. This lack of established existing criteria limits 
meaningful comparisons between different studies. 
Several studies have documented the treatment of MDR-TB, mainly in adults; only a handful 
have systematically assessed hearing loss and analyzed risk factors for ototoxicity. De Jager et 
al. found no association between clinical or treatment factors and the incidence of hearing 
loss.539 Peloquin et al. assessed whether the size and frequency of dosage affected hearing loss 
and found no association, but demonstrated that older age and cumulative dose were 
associated with an increased risk.273 Sturdy et al. found that impaired renal function, older age 
and the use of amikacin were associated with hearing loss in adults treated for MDR-TB.S40 A 
number of studies describe cohorts including small numbers of children but few have included 
those less than ten years of age. The only previous paediatric study examining the adverse 
effects of children on treatment for MDR-TB describes 38 children treated in Peru; 30 
underwent hearing assessments.204 The testing methodology and classification was not 
specified; audiology testing was undertaken in children receiving an injectable for more than 
six months. Two children were found to have mild, high-frequency, conductive hearing loss. 
Studies of short courses of aminoglycoside use in neonates319 and children with cystic 
fibrosis32o demonstrate limited toxicity but assessment of hearing loss in children receiving 
longer courses of aminoglycosides following liver transplantation found hearing loss in 15 of 66 
children evaluated, using a 35dB loss at one frequency to define hearing loss. 321 
Hearing has particular relevance in children since they need hearing to develop skills and 
acquire language. The primary means of education is through oral teaching. Hearing loss 
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during childhood can therefore have profound implications for development.242-243, 531-532, 541-543 
If ototoxicity is identified early, rapid intervention can be implemented.544-545 
The study has a number of strengths and limitations. It reports the largest study to date 
documenting hearing loss in children treated for MDR-TB and assess risk factors for hearing 
loss using a robust classification system. It reports on hearing loss resulting from care provided 
under routine, programmatic conditions. The retrospective nature of the study limited 
systematic data collection; therefore some audiological assessments were missing, irregular or 
incomplete. Clinical parameters were determined from routine data and were incomplete in 
some instances. The findings may not be representative of all children treated for MDR-TB 
since only children admitted to hospital are described. Finally, it was not possible to classify 
and analyse a considerable number of children due to the rigorous classifications used and 
there was no pharmacokinetic data available for children on the injectable drugs to correlate 
with toxicity. 
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Table 52 - Classification of hearing loss using otoacoustic emissions and pure tone audiometry 
Otoacoustic emissions Pure tone audiometry 
No hearing loss • A normal OAE in the last month of therapy or after • A normal PTA (all frequencies better than 25dB) in the last month of or after 
completing injectable medication completing injectable medication with no subsequent abnormal tests 
or 
• No significant deterioration (as determined by ASHA criteria)248 between an 
audiogram performed before or within the first month of therapy and one 
performed after within the last month of therapy with no subsequent 
deterioration 
Hearing loss • A normal OAE documented before or during therapy • A significant deterioration (as determined by the ASHA criteria) 248 between an 
followed by an abnormal OAE in the presence of normal audiogram performed before or during therapy and one performed later 
tympanograms during therapy or after completing therapy in the presence of normal 
tympanograms 
Unable to classify • Normal final OAE but performed before the last month of • An abnormal audiogram without an earlier audiogram for comparison 
therapy • A normal final audiogram (all frequencies better than 25dB) before the last 
• Abnormal tympanograms month of therapy 
• Abnormal OAE throughout therapy • Abnormal tympanograms 
• Unable to test child due to noise or child unable to co- • Unable to test child due to noise or child unable to co-operate 
operate 
--_. _--
OAE: otoacoustic emission; PTA: pure tone audiometry; ASHA: American Speech and Hearing Association 
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Figure 13 - Hearing deficit in children treated for multidrug-resistant tuberculosis with second-line injectable drugs 
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Table 53 - Demographic and treatment data in children treated for multidrug-resistant 
tuberculosis (n=94) 
Characteristic Number (% unless 
Indicated otherwise) 
Median age in months (IQR) 43 (20-110) 
Male gender 45 (47.9) 
Type ofTB Pulmonary 64 (68.1) 
Extrapulmonary 17 (18 .1) 
Both extra pulmonary and pulmonary 13 (13.8) 
Site of extrapulmonary TB (n=30) Miliary 1 (3.3) 
Pleural effusion 2 (6.7) 
TB meningitis 8 (26.7) 
Abdominal TB 4 (13 .3) 
Lymph node TB 6 (20.0) 
Musculoskeletal TB 9 (30.0) 
Median weight in kg (IQR) 13.5 (10.1-21.2) 
Median weight/length in cm (lQR) (n=90) 93 (78-121) 
Median MUAC in cm (IQR; n=83) 15.3 (14-17) 
Mean weight for age z-score (SD) -1.48 (1 .55) 
Median BMI (lQR) 15.5 (14.5-17.3) 
Certainty of TB diagnosis Culture-confirmed 52 (55 .3) 
Presumed 42 (44.7) 
DST of child or source case if diagnosed OS 1 (1.1) 
presumptively HMR 2 (2.1) 
RMR 11 (11.7) 
MDR 62 (66.0) 
Pre-XDR 16 (17.0) 
XOR 2 (2.1) 
HIV-infected (n=93) 28 (30.1) 
On ART prior to TB diagnosis (n=28) 20 (71.4) 
Type of injectable drug given Amikacin 82 (87.2) 
Capreomycin 9 (9.6) 
Streptomycin 1 (1.1) 
Two or more injectables 2 (2.1) 
Mean dose of injectable drug (mg; SD) 320 (189) 
Mean dose of injectable drug (mg/kg; SO) 19.4 (2 .04) 
Mean duration of injectable drug uses (days; SD) 136.2 (51.6) 
IQR: inter-quartile range; TB: tuberculosis; MUAC: mid upper arm circumference; BMI : body mass Index; DST: drug susceptibility 
testing; HIV: human immunodefiCiency virus; ART: antiretro\liral therapy; DS: drug-susceptible; HMR: Isoniazid-monoreslstant; 
RMR: rifampicin-monoresistant; MDR: multidrug-resistant; XDR: extensi\lely drug-resistant; 
Confirmed diagnosis : M. tuberculosis isolated from child with resistance demonstrated 
Presumed diagnosis: child treated for MDR-TB due to a clinical diagnosis ofTB and either contact with an MDR-TB source case or 
following failure of first-line therapy 
·These three children were started on treatment for MDR-TB due to contact with a MDR-TB source case but were subsequently 
found to ha\le DS- or HMR-TB 
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Figure 14 - Hearing loss in children treated for drug-resistant tuberculosis with second-line injectable drugs (n=94) 
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Table 54 - Characteristics of children treated for multidrug-resist ant t uberculosis with hearing loss determined using pure tone audiometry (n=l1) 
Age Gender HIV DST Diagnosis Treatment Hearing loss 
status 
I 
15 yr Girl Neg RMR Confirmed 2 months Unilateral severe high frequency hearing loss at the first assessment carried out one month after the start of treatment. One month later 
abdominal TS amikacin bilateral severe high frequency hearing loss so injectable stopped. No further hearing loss 
10 yr Girl Pos MDR Confirmed PTS 5 X months Normal hearing at baseline and at monthly intervals whilst on therapy. Moderately severe high frequency hearing loss detected two 
amikacin months after competing injectable treatment 
5 yr Girl Neg MDR Confirmed PTS 6 months Normal hearing at basel ine and throughout therapy. At the end of therapy found to have unilateral moderate high frequency hearing loss , 
amikacin 
10yr Soy Neg MDR Confirmed IN TS 6 months Normal hearing at baseline and throughout therapy. At the end of therapy found to have moderately severe unilateral high frequency 
amikacin hearing loss. A further month later found to have bilateral moderately severe high frequency loss 
10 yr Girl Neg MDR Confirmed PTS 6 months Normal hearing at baseline and throughout therapy. Two months after complet ing therapy found to have unilateral high frequency 
amikacin moderate loss 
12 yr Boy Pos MDR Confirmed PTS 8 months Normal hearing at baseline. After four months found to have unilateral moderate high frequency loss, progressing to severe unilateral 
amikacin high frequency loss by the end of therapy and to bilateral high frequency loss, severe in one ear and moderate in the other by 4 months 
after finishing 
13 yr Soy Pos MDR Confirmed PTS 6 months Normal hearing at baseline and monthly throughout treatment. At end of therapy found to have bilateral moderately severe high 
amikacin frequency loss 
8yr Girl Pos MDR Confirmed PTB 2 X months Normal hearing at first assessment one month after starting therapy. After two months found to have bilateral moderately severe high 
amikacin frequency loss. After stopping the injectable, hearing loss progressed to severe bilateral hearing loss affecting all frequencies. Hearing aid 
required 
3 yr Boy Neg MDR Confirmed LN TS 4 months Normal hearing at baseline. Found to have moderate unilateral high frequency loss after four months so injectable stopped. No further 
amikacin tests carried out. 
12 yr Girl Neg MDR Presumed PTB S months Normal hearing at baseline and at the end of therapy. One month after completing injectable medications found to have moderate 
amikacin unilateral high frequency loss, progressing to bilateral high frequency loss (mild in one ear and moderately severe in the other) after a 
further month 
10yr Girl Pos MDR Confirmed PTS 4 months Found at first assessment (2 months after starting therapy) to have bilateral moderate high frequency loss. By 2 months after completing 
amikacin therapy high frequency loss progressed in one ear to severe 
--- ---- ---- --
HIV: human immunodeficiency virus; TS: tuberculosis; RMR: rifampicin-monoresistant; MDR: multidrug-resistant; prs: pulmonary TS; LN: lymph node 
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Table 55 - Univariate assessment of risk factors of hearing loss in children treated for multidrug-resistant tuberculosis 
Hearing loss (n=23) No hearing loss (n=27) OR (95%CI) P-value 
Age in months (IQR) 52 (28-132) 53 (25-120) 0.90 
Male gender 9 11 0.94 (0.30-2.95) 0.91 
EP involvement 9 6 2.25 (0.63-8.00) 0.20 
WFA z-score -1.07 (-2.29--0.32) -0.82 (-2.34--0.33) 0.78 
BMI in kg/mz (IQR) 15.9 (13.9-17.6) 16.1 (14.9-17.3) 0.48 
MUAC in cm (IQR) 15.0 (14.0-17.0) 16.4 (14.5-18.1) 0.28 
Culture-confirmed diagnosis of TB 17 11 4 .12 (1.13-15.0) 0.02 I 
HIV-infected 9 6 2.14 (0.60-7.63) 0.23 
I 
Amikacin use 21 24 0.76 (0.11-5.11) 0.78 
Mg/kg dose injectable (IQR) 19.6 (18.3-20.4) 19.4 (17.4-20.1) 0.30 
Duration of injectable (IQR) 164 (119-184) 123 (70-183) 0.07 
Pre-XDR or XDR-TB 4 5 0.93 (0.21-4.01) 0.92 
EP: extrapulmonary; WFA: weight-for-age; 8MI: body mass index; MUAC: mid upper arm circumference; HIV: human immunodeficiency virus; XDR: extensively drug-resistant; OR: odds ratio; CI : confidence interval 
Drug-resistant tuberculosis in children James Seddon Page 1208 
I Discussion 
The first literature review demonstrated that our understanding of how to manage children 
exposed to MDR-TB is limited, as few studies have been conducted to guide practice and 
international policy documents provide little guidance to help the clinician confronted by such 
a child . The second literature review assessed studies that have described children treated for 
MDR-TB disease. All are observational and the total numbers are small. High quality, grade one 
evidence, derived from randomised controlled trials, are lacking and clinicians are forced to 
draw lessons from these small observational studies, the adult DR-TB literature, the paediatric 
drug-susceptible literature and combine it with their own clinical experience and judgement. 
The final literature review discussed the drugs used to treat DR-TB in children. Again, our 
understanding is incomplete, regarding the properties of the drugs themselves, their toxicity 
and their interactions with other medications. These reviews led to a series of connected 
original research studies that explored the cascade from exposure to infection, from infection 
to disease and from disease to outcome. Below I go through each of these stages and discuss 
the findings of the research studies in the thesis and how our understanding of DR-TB 
epidemiology and treatment is affected. 
The burden of drug-resistant tuberculosis in children 
Study 1 ofthe thesis documented the burden of drug-resistance amongst children with TB in 
Cape Town. This study provides two insights. First, a description of the population of children 
who develop TB and second, a measure of changing trends in paediatric drug-resistance over 
time. As there are so few studies documenting childhood TB in a systematic mannerS46-S48 and 
as recording and reporting can be poor in developing countries/ studies such as this, provide 
an important insight into the epidemic. 
This study only described children with culture-confirmed disease and still the median age for 
this, and previous surveillance periods, was between two and three years. As younger children 
are less likely to have extensive disease, and thereby less likely to have a confirmed diagnosis, 
it may be that the age spectrum of all children with TB might be younger. Children were 
frequently malnourished but it is encouraging that the proportion HIV-infected seems to be 
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levelling off, possibly as an effective prevention of mother to child transmission programme 
begins to take effect. 
Although the overall proportion of cases that had any drug resistance has remained relatively 
unchanged over the last few years, rifampicin resistance has increased and with it multidrug 
resistance. These results are not directly transferable to contexts outside Cape Town but these 
results provide details not only of the epidemic of drug-resistance in children but also of drug-
resistant TB in its entirety due to the sentinel nature of childhood TB. 
The final, additional finding of this study that is that although previous studies have raised 
concerns regarding the use of molecular lPAs for the diagnosis of drug resistance, we found 
the lPA that is widely used in the Western Cape to be both sensitive and specific when 
compared to conventional DST. 
Risk of infection and disease for child contacts of drug-resistant tuberculosis 
Study 2 was a cross-sectional study looking at children presenting to the DR-TB clinic following 
exposure to an infectious case of MDR-TB. High rates of both infection and disease were seen 
in these children. A significant risk factor for infection was increasing age, an unsurprising 
finding which is seen in the drug-susceptible paediatric TB literature and makes biological 
sense. That Coloured ethnicity was also associated with infection, even in adjusted analysis, is 
more complex and confirms that TB is, to a great degree, a sociological disease. Alcohol use in 
the source case was a significant risk for infection in the child but older and HIV-positive source 
cases seemed to be less infectious. Alcohol abuse in South Africa, and in the Western Cape in 
particular, is widespread and long-standing. It has complex interactions on both a biomedical 
and a behavioural level. It is likely that if the DR-TB epidemic is to be brought under control, 
alcohol use will need to be addressed. High levels of alcohol abuse are also seen in other areas 
of the world with significant DR-TB control problems, such as Eastern Europe and the former 
Soviet States; the two problems will need to be managed together. The impact of the age and 
HIV status of the source case is complex and potentially has implications for infection control 
and case management. However, due to the complex inter-relationship between multiple 
exposures, these risk factors need further investigation with larger patient numbers. 
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Again, consistent with the drug-susceptible literature, younger children and HIV-positive 
children are at increased risk of developing TB disease, following infection. Alcohol in the 
household, again seems to influence this progression. 
This study highlights the importance of screening children exposed to MDR-TB as a significant 
proportion will have TB disease that needs to be treated. The study also confirms that young 
and HIV-infected children are at the highest risk of disease progression following infection and 
are the most likely to benefit from preventive therapy. 
Transmission of drug-resistant M. tuberculosis 
Studies 3 and 4 describe investigations into a number of families to try to determine the 
sequence of events that resulted in a number of children developing DR-TB disease. In both 
studies the children were very likely infected by adults within their families. The transmission 
dynamics demonstrate the potential for people to transmit strains at different time points in 
the evolution of molecular resistance. However, when combined with a review of the 
literature surrounding transmission, these studies, reinforce two lessons. The first is that 
extensive efforts should be made to isolate the organism in children with clinical/radiological 
evidence of TB as there is the possibility that the strain is either different or has a different DST 
to the putative source case. The second, however, is that in spite ofthis, transmission is usually 
from the person known to have TB in the family and when confronted with a child with 
clinical/radiological TB, following sampling, it is appropriate to treat them according to the DST 
of the strain from that source case. 
Models of care for children exposed to drug-resistant tuberculosis 
Study 5 assessed what proportion of child contacts of MDR-TB are identified, referred and 
seen in a specialist clinic as directed by provincial guidelines. This study achieved this by 
looking at how many source cases led to a child contact being seen rather than what 
proportion of child contacts are actually seen. However, the magnitude of the discrepancy 
renders this distinction relatively unimportant and it is fair to draw the conclusion that few of 
the eligible children were seen. A decentralised model of care demonstrated some advantage 
over a traditional, hospital-based system but it is clearly not the sole solution. 
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Study 6 explored reasons why only some of the children identified by health systems access 
specialist care and found that ethnicity and identity of the source case were important. 
Unsurprisingly it also discovered that the long, expensive and complex journeys put people off 
coming to appointments. Families concerned about infection risk were also less likely to 
attend. 
It is clear from these studies that the current provincial guidelines are not being successfully 
carried out. Some of the reason is likely that resources are limited and the job is large. The 
identification and referral of well children may not be the greatest priority in a health service 
that has many other pressing health needs. However, in combination with the results from 
Study 2 (i.e. the high risk of infection and disease in these contacts) it is concerning. These 
results suggest that more children should be identified and also that it should be made as easy 
as possible for children who are identified to access care. Services should be sympathetic, 
professional and delivered close to the family. Infection control must be addressed and 
education of health providers and the public at large must improve. Particular assistance 
should be provided when mothers are diagnosed with MDR-TB as their children are not only 
very vulnerable to becoming infected and of developing disease but they are also at high risk 
of not accessing care. 
Preventive therapy for child contacts of drug-resistant tuberculosis 
Studies 7 and 8 described the provision of a three-drug preventive therapy regimen to child 
contacts of MDR-TB. Children less than five years or those HIV-infected were given the drugs 
daily for six months irrespective of TST. This study was not a trial and so efficacy cannot be 
conclusively determined. The study was observational and carefully documented the standard 
of care as it was being given in the Western Cape. Study 7 found that adverse events were rare 
in children given this course of preventive therapy and three out of seven children developing 
severe adverse events were inadvertently overdosed. The majority of adverse events were skin 
rashes and itch, sleep/mood disturbances and loss of appetite. All resolved without stopping 
the medications. Co-administration with cART did not seem to increase the risk of adverse 
events, even though the number of children with HIV was relatively small. 
Study 8 found that most of the children who were prescribed the medications were given 
them with good adherence. Few of the children provided with preventive therapy developed 
TB and the only death was in a young child who was thought unlikely to have died of TB. HIV 
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infection, age less than twelve months and poor adherence to medications were found to be 
associated with poor outcome. 
Taken together these two studies suggest that when confronted with a child who has been 
exposed to a source case with MDR-TB, a safe option is to give multidrug preventive therapy. 
Few children given this regimen develop TB. When this is considered alongside Study 2, the 
provision of preventive therapy to young and HIV-infected children should be strongly 
considered. 
The treatment of drug-resistant tuberculosis 
Studies 9 to 12 document children treated for MDR-TB. The first two are large cohorts of 
children, the first with culture-confirmed MDR-TB and the second with a combination of 
confirmed and presumed MDR-TB (as well as RMR-TB). The cohort of culture-confirmed MDR-
TB frequently had advanced disease with a high proportion smear positive and with severe CR 
changes. HIV infection was common and in many cases there was a significant delay in the 
diagnosis and initiation of treatment. In spite of this, successful outcomes were seen in the 
majority of children. The second cohort, in contrast, included younger children with less severe 
disease and lower rates of HIV infection. Successful outcomes were even more common than 
in the previous study and only three children were known to have died - all had severe disease 
in combination with either HIV infection or treatment default. For children with limited 
disease, the diagnosis was more often presumed, delay was less (often non-existent), 
treatment durations were shorter and both hospital admission and injectable drug use was not 
universal. 
These results suggest that even with severe disease, the majority of children can be 
successfully treated. However, they also advocate for early identification and rapid initiation of 
treatment in child contacts of MDR-TB who have symptoms, signs and radiology ofTB. For this 
to take place, contact tracing must occur following the identification of adults with MDR-TB. 
For those children who are identified early and who have non-severe disease, shorter 
treatments can be given, they can be treated in an ambulatory way and the injectable 
medication can frequently be withheld. 
Study 11 examines children with culture-confirmed TB and a diagnosis of TBM. This study finds 
that delay was longer in children infected with DR strains and that MDR-TB was associated 
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with poor outcome and death. Children with HMR-TB had similar outcomes to children with 
fully susceptible strains. That children with MDR-TBM have poor outcomes is perhaps not 
surprising as TBM is a severe disease process and if no drugs are provided that have efficacy 
against the strain, ongoing damage will occur. The results of the HMR-TB are, however, more 
interesting. It may be that the numbers in the study were not large enough to detect 
differences and certainly absence of evidence for an effect is not evidence for absence of an 
effect. However, children in the Western Cape with TBM are treated with four drugs with good 
CSF penetration for six months and where isoniazid resistance is present, it is likely that the 
child will still receive at least two effective drugs with good CSF penetration for the whole 
treatment course. This is unlikely to be the case if the WHO-recommended regimen is given. 
The absence of an association between strain type and either outcome or drug resistance is 
also interesting given previously described relationships. 
Study 12 describes the presentation, management and outcome for children with culture-
confirmed MDR-TB of the spine. The diagnosis was frequently delayed, leading to advanced 
disease and severe vertebral damage. However, once the diagnosis was made and appropriate 
treatment instigated, good outcomes were seen. An implication of this study is that when 
spinal TB does not respond to first-line therapy it is essential that clinical samples are taken 
and tested for DR-TB. 
The adverse effects of drug-resistant treatment 
Studies 10 and 13 both assess the adverse effects of second-line TB drugs when given to 
children with DR-TB disease. Study 10 describes the adverse events experienced in a cohort of 
treated children. Apart from one girl who developed DRESS syndrome few significant adverse 
effects were seen. An exception was that an important proportion of children developed 
hypothyroidism and were given supplementation. Study 13 investigated the effects of the 
injectable drugs on hearing. It determined that both hearing deficit and hearing loss were 
common in children treated with injectables. Having culture-confirmed disease was found to 
be a risk factor for hearing loss. Of note, a number of children developed hearing loss after 
cessation of their injectable medications. 
The implications of these two studies should both reassure and alarm. On the one hand, the 
majority of the drugs used to treat DR-TB in children are well tolerated and have limited 
toxicity. This should reassure a clinician when managing such a child. However, the incidence 
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of hearing loss, a fundamental component of communication, education and the ability to 
interact with the world, is very high. Regular hearing testing must playa part in the 
management of any child treated for DR-TB, drugs to mitigate the damaging effects of 
injectables must be explored and alternative treatments need to be developed. 
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Conclusions and implications for policy and practice 
Many children each year are exposed to DR bacilli and the children most likely to become 
infected and then develop disease are the most vulnerable. This includes young children, 
children with HIV infection, children with malnutrition, children from poor backgrounds, and 
children exposed to alcohol and smoking in their homes. Such children frequently have worse 
treatment outcomes if they do develop TB disease. Few of these children are identified by 
routine health services in Cape Town and few started on appropriate preventive therapy. A 
multidrug preventive therapy regimen is safe and likely effective for well children exposed to 
MDR-TB. Although confirmation is achieved in fewer than 50% of children with MDR-TB 
disease, the remaining children can be treated with a presumptive diagnosis. Extensive disease 
is effectively managed in the same way as adults, but children with limited disease respond 
well when given fewer drugs and for shorter durations. Although treatments are generally safe 
and effective particular care should be taken with the injectable medications due to their 
adverse effects on hearing. 
Based on the findings from these studies, from my reading of the literature and from the 
practical experience that I have accrued over the last three years, I make a number of 
pragmatic recommendations that could be implemented now into the majority of health 
programmes in the world. 
Recommendation 1 
Following the diagnosis of MDR-TB in an adult, a home visit should be undertaken. All children 
in contact with the source case should be screened with symptom questionnaires. Dedicated 
staff at a clinic or local healthcare level should provide this service. Particular focus should be 
placed on child contacts of mothers with MDR-TB as they are at high risk of exposure as well as 
of failure to access care. 
Recommendation 2 
Health workers at primary healthcare level should be given gradual and incremental 
responsibility for the management of MDR-TB exposure and disease in childhood. This will 
require training courses, followed by outreach services by a specialist, then joint care between 
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primary care and a specialist and finally care provided by primary care with clear referral and 
advice pathways to specialists. 
Recommendation 3 
Children under five years ,or any child with HIV-infection, following significant contact with an 
MDR-TB source case, irrespective of TST/IGRA result, should be prescribed a six month course 
of preventive therapy, to be given daily. The composition of this should be a fluoroquinolone 
and high-dose isoniazid. Treatment support and supervision should be provided by trained 
local lay workers. 
Recommendation 4 
Children with symptoms, signs and/or radiology ofTB, with significant exposure to a DR-TB 
source case, should have extensive microbiological sampling but then should be started on a 
regimen tailored to the DST of the source case, as a significant proportion of children with DR-
TB will never have a confirmed diagnosis. 
Recommendation 5 
Children with TB of the spine, not responding to first-line treatment should have clinical 
samples taken from the spine or surrounding tissue to be tested for DR-TB. 
Recommendation 6 
Children with extensive disease (miliary disease, TBM, disseminated disease, cavitating 
disease, widespread bronchopneumonic changes on CR) should be managed as adults, 
irrespective of age. Children with limited disease (hilar or cervical lymphadenopathy) can be 
managed with fewer drugs, for shorter durations and with either no injectable medication or 
an injectable given for a shorter period. Ambulatory treatment should be the norm in the 
majority of cases. 
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Recommendation 7 
All children treated with ethionamide/prothionamide or PAS should have their thyroid 
function tested regularly whilst on treatment 
Recommendation 8 
Children treated with an injectable medication should have their hearing tested at baseline 
using audiological tests (PTA or OAE) with regular testing carried out monthly whilst on 
treatment. A further test should be carried out six months after completing treatment. 
Consideration should be given to stopping injectable drugs as soon as is clinically possible. 
Recommendation 9 
All children treated for TB, with confirmed or presumed resistance to isoniazid, rifampicin or 
both drugs, should be recorded in a drug-resistant TB register and reported through to a 
national level. 
Recommendation 10 
Older children (older than ten years) should be included in all prevalence surveys; currently 
these focus only in adults. In a sample of sentinel sites, the full age range of children should be 
included using standardised clinical criteria. 
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I Further research 
In the course of this thesis I have reviewed the literature surrounding DR-TB in children and 
have carried out a number of studies to try to better understand the epidemic. However, there 
are still many areas that remain unclear. Whilst better vaccines, better diagnostics and an 
improved knowledge ofTB immunology and immunotherapy in children would be beneficial, I 
have restricted research suggestions to those specific to DR-TB. A number of further areas of 
research would include the following: 
1. An expert group should produce a consensus statement describing a prioritized research 
agenda 
2. Widespread surveillance, using techniques similar to those carried out in Study 1 and with 
standardised definitions, in a number of different contexts, to better quantify the burden 
of childhood DR-TB in different setting 
3. Operational research to improve the identification and referral of child contacts of DR-TB, 
by assessing different forms of health system intervention 
4. A randomised, controlled trial to compare a preventive therapy regimen, including a 
fluoroquinolone against isoniazid to prove efficacy 
S. An improved understanding of the pharmacokinetics of the second-line TB drugs in 
children especially when used in combination with cART 
6. An improved understanding of the penetration of second-line TB drugs into different body 
compartments in children, especially CSF, bone, lymph nodes and lung tissue 
7. The development of paediatric formulations of novel TB drugs with pharmacokinetic 
investigations carried out 
8. Descriptive cohorts of children treated for MDR-TB in different sites and contexts using 
standardised definitions for diagnosis, adverse events and outcome 
9. Larger, randomised controlled trials of shortened treatment durations for children with 
limited disease compared to standard of care 
10. A randomised controlled trial of WHO recommended therapy vs. Western Cape 
recommended therapy for the management of children with TBM 
11. A trial of aspirin as prevention on aminoglycoside-induced hearing loss in children 
12. Assessment of novel and innovative techniques for promoting adherence for children 
being treated at home for DR-TB 
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I Appendices 
Ethical approval and consent forms 
All studies in the thesis were approved first by Stellenbosch University Ethics Committees and 
then by the Ethics Committee of the London School and Hygiene and Tropical Medicine. For 
studies funding by TREAT TB (through USAID), they were also submitted to, and approved by, 
the Ethics Committee of the International Union Against Tuberculosis and Lung Disease. Any 
research carried out on City of Cape Town Health District property was approved by City 
Health and any research carried out on Western Cape provincial property was approved by the 
Western Cape Department of Health. A number of the studies requested waiver of consent 
where it was impossible to trace patients and where data were collected from routine, 
anonymised patient notes or registers (Study 1, the source cases in Study 5, Study 9, Study 11 
and Study 13). These were approved. In all other studies, written informed consent was 
obtained from the parent/legal guardian with assent from children older than 7 years. Consent 
forms were generally produced in English, Afrikaans and Xhosa. 
In 2003, Professor Schaaf submitted a proposal to the Stellenbosch University Ethical 
Committee to describe children with tuberculosis at Tygerberg Children's Hospital. This study 
was approved (2003/005) and renewed each year until I arrived in Cape Town. Following 
discussion with the Ethics Committee Chair at Stellenbosch University, a number of studies 
were either conducted under that approval or minor amendments were submitted to cover 
those studies. These included Studies 1, 4, 9, 10, 12, 13. Existing patient information leaflets 
and consent forms were used. The original approval from the Ethical Committee of 
Stellenbosch University is shown on the following pages as well as a form approving ongoing 
approval for the time when I was carrying out the studies which make up the thesis. 
For the studies examining children exposed to DR-TB (Studies 2, 5, 6, 7, 8) a new proposal was 
submitted to the Ethical Committee. Approval was given (N09/10/280) and is shown in the 
following pages. An amendment to this study was required as many of the children were 
brought to clinic appointments by someone who was not the parent or legal guardian. In many 
families the parent/legal guardian had died and legal transfer of responsibility had not been 
made. After discussion with the Ethical Committee Chair we submitted an amendment to the 
effect that we would obtain contact details from the person who had brought the child and 
then would chase up the parent/legal guardian. If they were not alive, we would obtain 
consent from the responsible caregiver. Consent forms were produced in English, Afrikaans 
and Xhosa. The English forms are shown in the following pages. 
Study 3 was a sub-study of a larger study (PI : Nulda Beyers) examining the evolution of drug 
resistance in two communities in Cape Town. Approval is shown in the following pages 
(N09/05/144). An amendment was submitted to the parent study (which was approved) and 
consent forms produced in English and Afrikaans (the communities were not Xhosa-speaking). 
The English version is shown. 
Study 11 was a separate study for which a separate proposal was written. Approval is 
demonstrated below (Nl0/07/223). A waiver of consent was requested and approved for this 
retrospective study, examining case notes and previously collected samples. 
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30 lanuarie 2003 
Dr HS Schaaf 
[)~partt'mt'nt P~diatric en Kindcrgcsondheid 
Geagte dr Schaaf 
NAVORSINGSPROJEK : "A PROSPECTIVE EVALUATION OF THE PREVALENCE 
OF ANTITUBERCULOSIS DRUG RESISTANCE IN CHILDREN 
IN THE WESTERN CAPE" 
rROJEKNOMMER 2003/005 
U aansoek om rcgistrasie en goedk~uring van bogenoemde projek het op 30 September 2002 voor 
Subkomitee C van die Navoraingsicomitcc gedien. Die Komitec het in bcginscl die projck 
goedgekeur. maar versock dat verdcre inligting voorsien word. 
lIicrdie in ligting is verskaf en die projek is finaal goedge\ceur Qp 27 Januarie 20Q) . Die projek IS nou 
geregistreer en u Ic.an voortgaan met die werk. U moet flsseblie f in vcrderc kom:spondcnsic nl 
bogcno~~elotommer verwys. 
Ek vcslig grug u aandag daarop dllt pasii!nte wat deelneem aan 'n navoningsprojek In Tygerberg· 
hospitaal nie gratis behandeling sal ontvang nie ungesien die PAWl< nie navamng finansi e~1 
ond~rsteun nie. 
Ole verpleegkorps van die Tygcrbcrg-hospitaal lean ook nie omvattende vcrplecghulp met 
navorsingsprojckte lewer nie weens die swaar wcrkslading wauonder bulle reeds gebuk IIlI n. Oil 
kan dus van 'n navorser verwag word am in sulkc gevalle privaat vcrpleeg1cundiges te vcrlcry. 
Met vriendelike groetc 
~ 
CJ V A.l'i TONDER 
NA VORSINGSONTWIKKELING ES -STEIDl (TYGERBERG) 
CJVT/ev 
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07 July 2010 
Prof HS Schaaf 
Department of Paediatrics and Child Health 
Stellenbosch University 
PO Box 19063 
Tygerberg 
7505 
Dear Pro f Schaaf 
"A pro.pecllve .""tuallon 01 tn. pntvalence of antilubereutolia dNg r .. letanc. In children In 11M W .. tem Cepe." 
ETHICS REFERENCE NO: 2003/005 
RE ; PROGRESS REPORT 
At a review panel of lhe Health Research Ethics Committee that __ held on e Juty 2010. lhe progrels r8pon for the 
abovementioned project lias been approved and the study lias been granted an extension for • period of one year from this 
date. 
Please remember to submit progress reporta In good time for annuat renewal," the standard HREC format. 
Approval Date: 6 July 2010 El(piry Date: 6 July 2011 
Yours faithfully 
M 
Tel: 021 9389207 / E-mail: mertrude@sun.ac.za 
Fax: 021 931 3352 
07 July 201010:22 
VIKbInd tot Optlml. Gesondheid • Commlfted t. 0pIIm1l Hel"h 
Afdliflng NaltOMftg50l1rwIU:Mlng In .. btUn . DI_ll lon 0' " .... rch De~lopm.n. Md auppo" 
PosbuslPO Box 111063 . Tygerblrg 7505 . SUlcl-AlrtkllSoUlh ArrIC.I 
Tet.: _2721 93811075 · FltaIFax. +2721 931 m2 
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UN IVEH'>llClr·S I HlENBOSCII·UNIVER I1Y 
1"\1 ~ 'I1Jl' \rnl1o.."l · IIU' IIH 'I'''' t 1(" ft.rlnr, 
11 February 20 10 MAILED 
Prof HS Schaaf 
Department of Paedlatrtcs and Child Health 
StellenllosCh university 
I-' 0 Box 19063 
Tygerberg 
7505 
Dear Prof Schaaf 
"Mu~ldrug.r •• lstant TB In children." 
HICS REFERENCE NO: N09/10l100 
RE : APPROVEP 
At a meeting of the Health Research Ethics Commlt1ee that was h$1d on 11 November 2009. the above projea was approved 
on condition that further Information is submitted. 
This Information was l upplled and the project was nnaly approve<! on to February 201 0 for H perIOd of one year from thIS 
d8te. This project is therefore now registered end you can prooeed with the wor1<. 
Please Quote Ihe allove-mentJoned project number In ALL futur a>"" pond"""" 
Please note that a progress report (Obtainable on the w bslte of our 0 1 slon: www.aun.ac.zai.d should be sUDmlted the 
Committee before the year has exp~ed. The Comm ttee will then consider the continuation of the ptOject tor a fuM r year (It 
necessary). Annually a number Of projects may be selected randomly and lubjectOd 10 an external audlL 
Translation of the con ... nt document in the languages applicable to the s tudy particlpa ts should be lubmAted 
Federal Wide Assurance Number: 00001372 
Institutional ReView Board (IRB) Number: IRBOOOS239 
The Heelth Rasaanch Ethics Commktee complies with tha SA National Health Act No.61 2003 5 It pertains to h Ith r rch 
and the United States Code of Federal Regulations TIUe 45 Part 46. his a>mmltt •• lIbldas by the thlCal nonms and 
pmclples for researCh. established by the Declaration of H I Inkl. the South African Medical R March Council Guldellnel I 
W II as the Guidelines for Ethical ResearCh: PrinCiples Strucwres and Processes 2004 (Oap runent 01 He r.h) 
Please noto that for researCh at • primary or socond ry hoolthc:are facility permlsalon must aUI be obte nod from lIle re 0 ant 
authOrities (Westem Cape Department of Health andlor City Health) 10 conduct tha re.oarch aa Ill>tod In the prolDCOl. Conll>Cl 
persons are Ms Claude"" Abrahamg at Westem Cape Departmtlnl of H 81th (healthreaCpgwe gov.za Tal ' ·2721 483 gg(7) 
and Dr Helene Visser at City Health (Helene.Vlsserccapetown.goV.23 T I: +2721 400 3981) Reaaarch that will be 
conducted at any tertiary academic Institution 'equlres approval from the, levant hOspital manager. Ethics approval Is 
required BEFORE approval can be obtained from these health authorities. 
11 February 201010'34 Poge 1012 
Fakulteit Gesondheldswetensltapp' ". 
Vetblnd 101 Oplmale Gosondhsld . Comml~ed to Op~mal HeIIth 
Nd,lIno Nlvoralnglontwlklc.llng an .. t.un • Dlvlalon of R •••• cII Devllopment Ind Support 
PoebuaiPQ Box I I1OB3 . Tygerba<g 7505 S"Id..AhfkalScuth AfrlQl 
Til.: +2721 Q38 g()75 ' Flkllfa +2721 Q31 33S2 
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PARTICIPANT INFORMATION LEAFLET 
AND CONSENT FORM FOR USE BY PARENTS/LEGAL GUARDIANS 
TITLE OF THE RESEARCH PROJECT: Multidrug-resistant tuberculosis in children 
REFERENCE NUMBER: N09/10/280 
PRINCIPAL INVESTIGATOR: Professor H Simon Schaaf 
ADDRESS: Desmond Tutu TB Centre, Francie Van Zyl Road, Tygerberg 7507 
CONTACT NUMBER: 021-9389112/021-9389177 
Your child (or foster child if applicable) is being invited to take part in a research project. 
Please take time to read the information presented here, which will explain the details of this 
project. Please ask the study staff or doctor any questions about any part of this project that 
you do not fully understand. It is very important that you are fully satisfied that you clearly 
understand what this research entails and how your child could be involved. Also, your child's 
participation is entirely voluntary and you are free to decline to participate. If you say no, this 
will not affect you or your child negatively in any way whatsoever. You are also free to 
withdraw him/her from the study at any point, even if you do initially agree to let him/her take 
part. 
This study has been approved by the Committee for Human Research at Ste"enbosch 
University and will be conducted according to the ethical guidelines and principles of the 
international Declaration of Helsinki, South African Guidelines for Good Clinical Practice and 
the Medical Research Council (MRC) Ethical Guidelines for Research. 
What is this research study all about? 
This research is studying children who have been exposed to multidrug-resistant tuberculosis. 
Tuberculosis (TB) is very common in Cape Town and if a child is unwell with TB (sweating, 
weight loss, coughing) they need to be treated with four drugs for a number of months. 
However, it is possible to detect TB infection at an early stage before the child has any 
problems and feels completely well. To do this it is necessary to find all the children who live in 
the same house as an adult who is ill with TB. These children are called contacts. Contacts 
should be examined by a doctor and also have a small injection just under the skin in the arm 
which is then looked at after two days to see if there is any reaction. If there is any reaction the 
child may have early TB infection. Children under 5 years of age as well as older children who 
are HIV-infected are the children at highest risk to develop TB after being in contact with an 
adult TB case. All child contacts under 5 years of age or HIV-infected contacts of any age 
should however receive treatment (prophylaxis) if they are otherwise well. The drug that we 
normally give is called isoniazid. 
Because this prevents TB disease from developing it is called preventive treatment. It has been 
shown that giving this preventive treatment reduces the chance of developing TB disease. 
Sometimes people have TB which does not respond to the normal drugs that we give to treat 
it. When tested in the laboratory the TB bacteria are resistant to these normal drugs. As 
multidrug-resistant (MDR) TB is resistant to isoniazid it is difficult to know how to treat 
children Who are contacts of an adult with MDR TB. This is why these children (children under 
5 years of age and HIV-infected children <14years of age who are in contact with adults who 
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have MDR TB) are included in this study. In this study we are looking at how to look after these 
child contacts. 
We are going to carry out a study in two parts: 
The comparison part. We shall be comparing how effective the hospital system is at finding 
children needing preventive treatment compared to the community system in Khayelitsha. 
This will involve the research team coming to your house or meeting you in the local clinic and 
asking some questions. 
The cohort part. This will include all the children who have been in contact with adults with 
MDR TB. Detailed information will be collected from the carer at the initial clinic visit and the 
child will be examined. He/she will then be seen every two months for a year. At these reviews 
the child will be examined, measured and questions will be asked about the child and their 
health. 
As we are going to be carefully recording what is already happening, this study will not involve 
any tests in addition to those being currently done by the health teams looking after your child 
(this is the normal treatment of child contacts of MDR TB cases). 
What the study will involve is your time, as we shall be asking questions and recording 
information at each clinic appointment. We also may arrange appointments in addition to 
those needed if your child were not in the study. These may be at the hospital, local clinic or at 
your home - whichever is the most convenient and will involve asking questions and 
examining your child. 
Taking part in these studies is entirely optional and if you do not want to take part, your child 
will be cared for in the usual way. If you do decide to take part you will be given this 
information sheet to keep and be asked to sign a consent form. You can remove your child 
from the study at any time. 
Why has your child been invited to participate? 
Your child has been asked to participate as they have been in close contact with an adult who 
has MDR TB. They may be at risk of developing MDR TB disease themselves and so need to be 
followed up regularly. 
What will your responsibilities be? 
If you choose to take part in the study, we would ask that you answer our questions truthfully 
(all information that you tell us will remain strictly confidential) and bring your child to any 
arranged appointments to discuss progress and to be examined. 
Will your child benefit from taking part In this research? 
Taking part in the study will not be of any special benefit to your child. However we hope that 
the information gathered will help us to plan how best to look after all children exposed to 
multidrug-resistant TB in the future. 
Are there any risks involved in your child taking part In this research? 
We shall not be conducting any tests in addition to the ones required by the national 
programme to look after your child. The decision to prescribe treatment is not part of the 
study and so any risks associated with these drugs will not be affected by the study. The study 
team will ask questions at clinic appointments, after clinic appointments or at your home. This 
may mean that appointments take longer than usual. We do not feel that there will be any 
risks involved in your child taking part in this research. 
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If you do not agree to allow your child to take part, what alternatives does your child have? 
If you would rather not be in the study, your child will continue to be looked after in the 
exactly the same way. 
Who will have access to your child's medical records? 
All the information about your child will be recorded in a way so that they cannot be identified. 
The information will be kept safe in a locked drawer in a locked office. Only the investigators 
will see or use the information. If it is used in a publication or thesis the identity of the parents 
and children will remain anonymous. The study team alone will have access to the information 
and will keep it in the strictest of confidence. 
What will happen In the unlikely event of your child getting Injured In any way, as a direct 
result of taking part in this research study? 
As we are observing what is currently happening within the national programme, we do not 
anticipate that any children will become injured as a result of the study. 
Will you or your child be paid to take part in this study and are there any costs involved? 
You or your child will not be paid to take part in the study, but your/your child's transport 
and meal costs will be covered for each study visit. There will be no costs Involved for you if 
your child does not take part. 
Is there anything else that you should know or do? 
• You can contact Dr Seddon or Prof Schaaf at tel 021-9389177 (Seddon) or 021-9389112 
(Schaaf) if you have any further queries or encounter any problems. 
• You can contact the Committee for Human Research at 021-938 9207 if you have any 
concerns or complaints that have not been adequately addressed by your child's study 
doctor. 
• You will receive a copy of this information and consent form for your own records. 
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Consent to participate in research studies 
Declaration by parent/legal guardian 
By signing below, I (name of parent/legal guardian) ................................................. agree to allow 
my child (name of child) ........................................... who is .......... years old, to take part in a 
research study entitled "Multidrug-resistant tuberculosis in children" 
I declare that: 
• I have read or had read to me this information and consent form and that it is written in a 
language with which I am fluent and comfortable. 
• If my child is older than 7 years, he/she must agree to take part in the study and his/her 
ASSENT must be recorded on this form. 
• I have had a chance to ask questions and all my questions have been adequately 
answered. 
• I understand that taking part in this study is voluntary and I have not been pressurised to 
let my child take part. 
• I may choose to withdraw my child from the study at any time and my child will not be 
penalised or prejudiced in any way. 
• My child may be asked to leave the study before it has finished if the study doctor or 
researcher feels it is in my child's best interests, or if my child does not follow the study 
plan as agreed to. 
Signed at (place) .................................................. on (date) ........................... 20 .... . 
Signature of parent/legal guardian Signature of witness 
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Declaration by investigator 
I (name) .............................................................. declare that: 
I explained the information in this document to ........................................ . 
I encouraged him/her to ask questions and took adequate time to answer them. 
I am satisfied that he/she adequately understand all aspects of the research, as discussed 
above 
I did/did not use an interpreter (if an interpreter is used, then the interpreter must sign the 
declaration below). 
Signed at (place) .................................................. on (date) ........................... 20 .... . 
Signature of investigator Signature of witness 
Declaration by interpreter 
I (name) .............................................................. declare that: 
I assisted the investigator (name) ............................................ to explain the information in this 
document to (name of parent/legal guardian) ....................................... using the language 
medium of Afrikaans/Xhosa. 
We encouraged him/her to ask questions and took adequate time to answer them. 
I conveyed a factually correct version of what was related to me. 
I am satisfied that the parent/legal guardian fully understands the content of this informed 
consent document and has had all his/her questions satisfactorily answered. 
Signed at (place) .................................................. on (date) ........................... 20 .. .. 
Signature of interpreter Signature of witness 
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PARTICIPANT INFORMATION LEAFLET 
AND ASSENT FORM FOR USE BY CHILDREN 
TITLE OF THE RESEARCH PROJECT: Multidrug-resistant tuberculosis in children 
REFERENCE NUMBER: N09/10/280 
PRINCIPAL INVESTIGATOR: Professor H Simon Schaaf 
ADDRESS: Desmond Tutu TB Centre, Francie Van Zyl Road, Tygerberg 7507 
CONTACT NUMBER: 021-9389112/021-9389177 
You are invited to take part in a study. Please read the information presented here, which will 
explain what the study is about. Please ask the study staff or doctor any questions about any 
part of the study that you do not understand. It is important that you understand what this 
study is about and what it will mean if you take part in the study. Also, your participation is 
entirely voluntary and you are free to say no. If you say no, this will not affect you negatively 
in any way whatsoever. You are also free to withdraw from the study at any point, even if you 
do initially agree to take part. 
This study has been approved by the Committee for Human Research at Stellenbosch 
University and will be done in the correct ethical way. 
What Is this research study all about? 
This study is going to look at aspects of children who have been exposed to multidrug-resistant 
tuberculosis (that is TB that does not get better with the normal TB drugs). 
Tuberculosis (TB) is very common in Cape Town. Children can live in the same house as adults 
who have TB - these children are called contacts. Contacts should be examined by a doctor 
and also have a small injection just under the skin in the arm which is then looked at after two 
days to see if there is any reaction. If there is any reaction the child may have early TB infection 
(that means the TB bug is in the body, but you are not yet sick). Children under 5 years of age 
as well as older children who are HIV-infected are the children at highest risk to develop TB 
after being in contact with an adult TB case. All child contacts under 5 years of age or HIV-
infected contacts of any age should receive treatment (prophylaxis) if they are otherwise well. 
The drug that we normally use is called isoniazid. This normally protects children from getting 
sick from TB. 
Sometimes people have TB which does not respond to the normal drugs that we give to treat 
it. This is called multidrug-resistant (MDR) TB. We are not sure how children who have the 
MDR TB bug in the body, but are not sick, should be treated and this is what this study is 
about. 
We are only going to be looking at what is already happening to children that are in contact 
with adults with M DR TB. This study will not involve any tests other than those already done by 
the doctors/nurses looking after children (this is the normal treatment of child contacts of 
MDR TB cases). 
We are only asking for some of your time because we want to ask you and your mother/ 
caregiver some questions. We will also write all of this down. 
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Taking part in this study is entirely optional and if you do not want to take part, you will be 
cared for in the usual way. If you do decide to take part you will be given this information 
sheet to keep and be asked to sign an assent form. You can ask not to be part of the study at 
any time. 
Why have you been asked to be part of this study? 
You have been asked to be part of this study because you have been in close contact with an 
adult who has MDR TB. You may be at risk of getting MDR TB disease and so you need to be 
followed up regularly. 
What will your responsibilities be? 
If you choose to take part in the study, we would ask that you answer our questions truthfully 
(all information that you tell us will remain strictly confidential). 
Will you benefit from taking part in this study? 
Taking part in the study will not be of any special benefit to you, but we hope that it will help 
us to look after all children exposed to multidrug-resistant TB in the future. 
Are there any risks involved in taking part in this research? 
We are not going to do any tests in addition to the ones that are required by the national 
programme. The treatment is what you would normally get (no extra drugs). The study team 
will ask questions at clinic appointments, after clinic appointments or at your home. This may 
mean that appointments take longer than usual. We do not feel that there will be any risks 
involved in you taking part in this study. 
If you do not agree to take part, what alternatives you have 1 
If you choose not be in the study, you will be looked after in the exactly the same way. 
Who will have access to your medical notes? 
The information that we collect about you will be written down in such a way that it cannot be 
identified as information about you. The information will be kept safe. Only the investigators 
will see or use the information and will keep it in the strictest of confidence. 
Will you be paid to take part in this study? 
You will not be paid to take part in the study, but your transport and meal costs will be 
covered for each study visit. 
Is there anything else that you should know? 
You can contact Dr Seddon or Prof Schaaf at tel 021-9389177 (Seddon) or 021-9389112 
(Schaaf) if you have any further queries or encounter any problems. 
You will receive a copy of this information and consent form for your own records. 
Drug-resistant tuberculosis in children James Seddon Page 1234 
Assent to participate In research studies 
I agree to participate in the study called: IiMultidrug-resistant tuberculosis in children" as 
described in the Information Leaflet 
Assent of minor 
I (Name of Child/Minor) ....................................................... have been invited to take part in the 
above research project. 
• The study doctor/nurse and my parents have explained the details of the study to me and I 
understand what they have said to me. 
• They have also explained that this study will involve some of the appointments taking 
longer than if I was not in the study. 
• I also know that I am free to withdraw from the study at any time if I am unhappy. 
• By writing my name below, I voluntary agree to take part in this research project. I 
confirm that I have not been forced either by my parents or doctor to take part. 
Name of child Independent witness 
(To be written by the child if possible) 
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PARTICIPANT INFORMATION LEAFLET 
AND CONSENT FORM FOR USE BY PARENTS/LEGAL GUARDIANS 
TITLE OF THE RESEARCH PROJECT: The evolution of drug-resistant tuberculosis in a community 
REFERENCE NUMBER: N09/0S/144 
PRINCIPAL INVESTIGATOR: Professor Nulda Beyers 
ADDRESS: Desmond Tutu TB Centre, Francie Van Zyl Road, Tygerberg 7507 
CONTACT NUMBER: 021-9389114 
Your child (or foster child if applicable) is being invited to take part in a research project. 
Please take time to read the information presented here, which will explain the details of this 
project. Please ask the study staff any questions about any part of this project that you do not 
fully understand. It is very important that you are fully satisfied that you clearly understand 
what this research entails and how your child could be involved. Also, your child's 
participation is entirely voluntary and you are free to decline to participate. If you say no, this 
will not affect you or your child negatively in any way whatsoever. You are also free to 
withdraw him/her from the study at any point, even if you do initially agree to let him/her take 
part. 
This study has been approved by the Committee for Human Research at Stellenbosch 
University and will be conducted according to the ethical guidelines and principles of the 
international Declaration of Helsinki, South African Guidelines for Good Clinical Practice and 
the Medical Research Council (MRC) Ethical Guidelines for Research. 
What is this research study all about? 
This research is studying how drug resistance develops in tuberculosis. 
Tuberculosis (TB) is very common in Cape Town and is caused by a bug which can be spread 
from person to person. It can lead to illness such as cough, fever, sweating, weight loss and 
sometimes death. Normally TB can be treated with four drugs and if these are taken all the 
time it is usually cured. 
Sometimes people have TB which does not respond to the normal drugs that we give to treat 
it. When tested in the laboratory the TB bacteria are resistant to these normal drugs and is 
called drug-resistant (DR) TB. At the moment we are not completely sure how DR TB develops. 
This research is going to look at how the TB bugs go from being able to be treated by the 
normal drugs to being resistant. We are planning on looking at how TS spreads in families and 
then looking at the samples of the bugs in the laboratory to see when the resistance 
developed. This should help us to tell how resistance occurs. 
Why has your child been invited to participate? 
Your child has been asked to participate as they have had XDR TB. This form of TB is resistant 
to lots of the drugs used to treat TB. It is important to discover how they developed XDR TB 
and who else in the family, household and community had TB beforehand. 
What will your responsibilities be? 
If you choose to take part in the study, we would ask that you answer our questions truthfully 
(all information that you tell us will remain strictly confidential). We will ask you and your child 
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questions about your family, who had TB, what treatment they received and what happened 
to them. We will also ask some details about their health and about their life such as where 
they lived and what job they did. If anyone in the household has any symptoms of TB such as 
sweating, weight loss or cough we will ask them for a sputum sample so that we can test it for 
TB. We will tell them of the result of these tests and help them get treatment if needed. We 
also will look in the hospital and clinic records of your child and any household members who 
have had TB to give us some more information. Finally, we will look at the samples in the 
laboratory of any household members who have had TB. 
Will your child benefit from taking part in this research? 
Taking part in the study will not be of any special benefit to you or your child. However we 
hope that the information gathered will help us to understand how drug resistance develops 
and might allow us to treat drug-resistant tuberculosis better in the future. 
Are there any risks involved in your child taking part in this research? 
We shall not be conducting any tests other than asking for sputum samples if people have 
symptoms. The study team will ask questions which will take up your time and some of the 
questions may be difficult to answer as they are about family members who may have been 
unwell or who have even died. We do not feel, however, that there will be any risks involved in 
you or your child taking part in this research. 
If you do not agree to allow your child to take part, what alternatives does your child have? 
If you would rather not be in the study, your child will continue to be looked after in the 
exactly the same way. 
Who will have access to your child's medical records? 
All the information about your child will be recorded in a way so that they cannot be identified. 
The information will be kept safe in a locked drawer in a locked office. Only the investigators 
will see or use the information. If it is used in a publication or thesis the identity of the parents 
and children will remain anonymous. The study team alone will have access to the information 
and will keep it in the strictest of confidence. 
What will happen In the unlikely event of your child getting injured in any way, as a direct 
result of taking part in this research study? 
As we are asking questions and if necessary asking for sputum samples, we do not anticipate 
that anyone will become injured as a result of the study. However, the study team have 
medical training and will help in case of any problem. 
Will you or your child be paid to take part In this study and are there any costs Involved? 
You or your child will not be paid to take part in the study, but your/your child's transport and 
meal costs will be covered if you need to go anywhere as part of the study. There will be no 
costs involved for you. 
Is there anything else that you should know or do? 
• You can contact Dr Seddon at tel 021-9389177 if you have any further queries or 
encounter any problems. 
• You can contact the Committee for Human Research at 021-938 9207 if you have any 
concerns or complaints that have not been adequately addressed by your child's study 
team. 
• You will receive a copy of this information and consent form for your own records. 
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Consent to participate in research studies 
Declaration by parent/legal guardian 
By signing below, I (name oj parent/legal guardian) ................................................. agree to allow 
my child (name of child) ........................................... who is .......... years old, to take part in a 
research study entitled "The evolution of drug-resistant tuberculosis in a communityN 
I declare that: 
• I have read or had read to me this information and consent form and that it is written in a 
language with which I am fluent and comfortable. 
• If my child is older than 7 years, he/she must agree to take part in the study and his/her 
ASSENT must be recorded on this form. 
• I have had a chance to ask questions and all my questions have been adequately 
answered. 
• I understand that taking part in this study is voluntary and I have not been pressurised to 
let my child take part. 
• I may choose to withdraw my child from the study at any time and my child will not be 
penalised or prejudiced in any way. 
Signed at (place) .................................................. on (date) ........................... 20 .... . 
Signature of parent/legal guardian Signature of witness 
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Declaration by investigator 
I (name) .............................................................. declare that: 
I explained the information in this document to ....................................... .. 
I encouraged him/her to ask questions and took adequate time to answer them. 
I am satisfied that he/she adequately understand all aspects of the research, as discussed 
above 
I did/did not use an interpreter (if an interpreter is used, then the interpreter must sign the 
declaration below). 
Signed at (place) .................................................. on (date) ........................... 20 .... . 
Signature of investigator Signature of witness 
Declaration by interpreter 
I (name) .............................................................. declare that: 
I assisted the investigator (name) ............................................ to explain the information in this 
document to (name of parent/legal guardian) ....................................... using the language 
medium of Afrikaans/Xhosa. 
We encouraged him/her to ask questions and took adequate time to answer them. 
I conveyed a factually correct version of what was related to me. 
I am satisfied that the parent/legal guardian fully understands the content of this informed 
consent document and has had all his/her questions satisfactorily answered. 
Signed at (place) .................................................. on (date) ........................... 20 .. .. 
Signature of interpreter Signature of witness 
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PARTICIPANT INFORMATION LEAFLET 
AND ASSENT FORM FOR USE BY CHILDREN 
TITLE OF THE RESEARCH PROJECT: The evolution of drug-resistant tuberculosis in a community 
REFERENCE NUMBER: N09/0S/144 
PRINCIPAL INVESTIGATOR: Professor Nulda Beyers 
ADDRESS: Desmond Tutu TB Centre, Francie Van Zyl Road, Tygerberg 7507 
CONTACT NUMBER: 021-9389114 
You are invited to take part in a study. Please read the information presented here, which will 
explain what the study is about. Please ask the study staff any questions about any part of the 
study that you do not understand. It is important that you understand what this study is about 
and what it will mean if you take part in the study. Also, your participation is entirely 
voluntary and you are free to say no. If you say no, this will not affect you negatively in any 
way whatsoever. You are also free to withdraw from the study at any point, even if you do 
initially agree to take part. 
This study has been approved by the Committee for Human Research at Stellenbosch 
University and will be done in the correct ethical way. 
What is this research study all about? 
This research is studying how drug resistance develops in tuberculosis. 
Tuberculosis (TB) is very common in Cape Town and is caused by a bug which can be spread 
from person to person. It can lead to illness such as cough, fever, sweating, weight loss and 
sometimes death. Normally TB can be treated with four drugs and if these are taken all the 
time it is usually cured. 
Sometimes people have TB which does not respond to the normal drugs that we give to treat 
it. When tested in the laboratory the TB bacteria are resistant to these normal drugs and is 
called drug-resistant (DR) TB. At the moment we are not completely sure how DR TB develops. 
This research is going to look at how the TB bugs go from being able to be treated by the 
normal drugs to being resistant. We are planning on looking at how TB spreads in families and 
then looking at the samples of the bugs in the laboratory to see when the resistance 
developed. This should help us to tell how resistance occurs. 
Why have you been asked to be part of this study? 
You have been asked to participate as you have had XDR TB. This form of TB is resistant to lots 
of the drugs used to treat TB. It is important to discover how you developed XDR TB and who 
else in the family, household and community had TB beforehand. 
What will your responsibilities be? 
If you choose to take part in the study, we would ask that you answer our questions truthfully 
(all information that you tell us will remain strictly confidential). 
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Will you benefit from taking part in this study? 
Taking part in the study will not be of any special benefit to you, but we hope that it will help 
us to understand how drug resistance develops. It may help us to look after children in the 
future who have drug-resistant TB. 
Are there any risks involved In taking part in this research? 
We are not going to do any tests and so we do not expect there to be any risks. The study 
team will ask questions which may be difficult to answer as they are personal and may be 
about your family. However, we do not feel that there will be any risks involved in you taking 
part in this study. 
If you do not agree to take part, what alternatives you have? 
If you choose not be in the study, you will be looked after in the exactly the same way. 
Who will have access to your medical notes? 
The information that we collect about you will be written down in such a way that it cannot be 
identified as information about you. The information will be kept safe. Only the investigators 
will see or use the information and will keep it in the strictest of confidence. 
Will you be paid to take part in this study? 
You will not be paid to take part in the study, but your transport and meal costs will be 
covered if you need to go anywhere as part of the study. 
Is there anything else that you should know? 
• You can contact Dr Seddon at tel 021-9389177 if you have any further queries or 
encounter any problems. 
• You will receive a copy of this information and consent form for your own records. 
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Assent to participate In research studies 
I agree to participate in the study called: liThe evolution of drug-resistant tuberculosis In a 
community" as described in the Information leaflet 
Assent of minor 
I (Name of Child/Minor) ....................................................... have been invited to take part in the 
above research project. 
• The study doctor/nurse and my parents have explained the details of the study to me and I 
understand what they have said to me. 
• They have also explained that this study will take up some of my time. 
• I also know that I am free to withdraw from the study at any time if I am unhappy. 
• By writing my name below, I voluntary agree to take part in this research project. I 
confirm that I have not been forced either by my parents or doctor to take part. 
Name of child Independent witness 
(To be written by the child if possible) 
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30 Augu.t 2010 
Prof HS Schaaf 
Department of PaediatllC:s and Child Health 
Stetlenbosch Urll.erslty 
POBox 19063 
Tygerberg 
7505 
Dear Prof Schaaf 
The relationshIp between clinical outcome and Mycobacterium Tuberculo.1e dru9 euaceptiblllty In children with 
tubercu'o,'. manlngltla. 
ETHICS REFERENCE NO' N10/OZ/223 
RE ; APpROVAL 
At a meeting of the Health Research Ethics Committee that was held on ~ Augul t 2010, the abo ... project was approved on 
condition that further Information is submitted. 
This information was suppf",d and the proleet was finally approved on 24 Augult 2010 for. period of one year f,om thil dale 
This project i. thelefore now registered and you can proceed with the worle 
Please quote the 8.Dove~en1Ioned project number In ALL tutu,,, COfI~"wnd.I1c.e . 
Please note lhat a progress report (obtainable on the w.bI~. of our CiVil ion. www.wruc zairdl lhould be submitted to lhe 
Committee before the year hal expired. The Committee will then consider the continuation of the Pl'Oject tor. furthM Yllir Clf 
necessary) Annually a number of projects may be seladed rendornly and subjected to an external audit. 
Translations of th. consent documenl In the languages applicable 10 tho study partlcip nlo ohould be aubrrOtted. 
Feder.' Wide Assurance Number: 0OOO13n 
Institulional Review Board (IRB) Number IRBOOO5239 
The Heelth Reseerch Ethics CommIttee compiles wtth the SA National Hea"h Ad No.61 2003 as ~ pertalna to health research 
and the United Stales Coda of Federel Regulations Title ~5 Part ~6. This convrrUtee abides by thelllhical norma and 
princ'ples for research, established by the Dedaratlon of HelSinki , Ihe South African Medlcal R" .. rch Counci l Guidtlln .. al 
well as the Guidelines for Ethical Reaaarch: Principles Structures end Processes 2CXH (Department of HMlth) 
Please note that for research at a primary or aecondary healthcare facl~ty permiSSion must ati" be oblelned from the relevant 
authonliet (Weslem Cape Department of Hee"h and/or City Health) to conduct the resaarch as at ted in the protocol. Contact 
persons are Ms Claude"e Abrahams at WeSiem Cape Department of Health ChealtllreaCPQWC.goy .. Tel: '27 21 48~ 9907) 
and Dr Het6ne Visser at City Hea~h CHelane.VllIllr@cap8town gov za Tel. +2721400 3981) Research Ihat wMI be 
conducted at any tertiary academic institution requires approvallrom the relevant helpltal mar\llgllr. Ethic. approval I. 
required BEFORE approval can be obtained from thele heatth authorities. 
20 January 2011 14·31 Pao- 1 0' 2 
Verblnd tot Optima" GMOndheid Convnitted 10 Optlmol HOIMh 
Aldollng NlvorwlnaoonlwlkkeNng an .. ~n . OM.,on of _ .... h Dewlopmenl Ind Supj)O<t 
PosbuAIPO Box 19083 Tygerllerg 7505 SulcI-AlnkalSoulh Africa 
Tel: .2721 93a 11075 · FtIkaIF ... -272t 931 3352 
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Approval Date: 24 August 20tO 
MR FRANKLIN WEBER 
RESEARCH DEVELOPMENT AND SUPPORT 
Tel: +27 (0)21 938-9657 I E-mail : fweb@sun.acza 
Fax: +27 (0)21 931·3352 
2OJanuary201114·31 
expiry Datc: 24 August 2011 
Vcrblnd lot Olllirnal. G •• ondtMIld . Commltt.d to 0Il11",.1 ~.~h 
Aldoll"g N.vorwlnD.ontwlkkollnll on -.,..," . Dlv'.'on of RH_ch Dew'_nt and Support 
PosbuaIPO Ba. '_3 · Tyge,berg 7505 Su~rikliSouIh AInca 
Tel.: +2721 8389075 · FlUlFox +27 21 831 3352 
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Data capture tools 
Children exposed to MDR-TB (Studies 2, 7 and 8) 
The studies assessing children exposed to MDR-TS and subsequent preventive therapy (Studies 
2, 7 and 8) were captured in a systematic way using data capture forms that I designed. These 
were based on other forms that are in use in the Desmond Tutu TS Centre for household 
studies looking at child contacts of drug-susceptible TB. This allows synthesis and comparison 
between studies. These forms are provided in the following pages and correspond to the 
diagram on the next page which outlines at which point in the study different forms were 
completed. The following forms are: 
1. DCF1.0 
2. DCF1.2 
3. DCFl.4 
4. DCF1.6 
5. DCFl.12 
6. DCF1.U 
7. DCF2 
8. DCF3 
9. DCF4 
10. DCF5 
11. DCF6.2 
12. DCF6.4 
13. DCF6.6 
Demographic details at recruitment 
Demographic details at 2 months (only one DCF 1 shown) 
Demographic details at 4 months 
Demographic details at 6 months 
Demographic details at 12 months 
Demographic details at an unscheduled visit 
Child details 
Index case details 
Household details 
Index case details from register 
Follow up form for 2 month appointment 
Follow up form for 4 month appointment (only one DCF6 shown) 
Follow up form for 6 month appointment 
14. DCF6.12 Follow up form for 12 month appointment 
15. DCF6.U Unscheduled visit form 
16. DCF7.2 Adherence form after 2 month appointment (only one DCF7 shown) 
17. DCF7.4 Adherence form after 4 month appointment 
18. DCF7.6 Adherence form after 6 month appointment 
19. DCF7.U Adherence form after unscheduled appointment 
20. DCF8 Patient tracking form 
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Patient Flow for children exposed to multidrug-resistant tuberculosis 
Adult gives sputum 
sample 
Contact tracing conducted by local clinic staff, child contacts 
identified and referred to the DR TB clinic 
Result MDR TB on 
culture 
Result sent to clinic 
Child seen in 
Khayelitsha 
Child seen in 
Tygerberg 
Child seen in 
Brooklyn 
Clinical assessment to rule out active 
disease, CXR with standardised reporting, 
HIV test, Mantoux test 
If eligible child invited to join study 
I ~ (consent forms completed) 
~~-------l~------~ 
"t:J 
~ 
... 
~ 
0.. 
E 
o 
u 
co 
I.L. 
U 
o 
Child does not join 
study 
DCF 5 completed 
DCF 7.2 completed 
DCF 7.4 completed 
DCF 7.6 completed 
Recruited child brought for 
unscheduled visit - DCFs 1.U and 
6.U completed with DCF 7.U 
completed after the 
appointment, CXR 
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Consent obtained and initial 
questionnaires conducted (DCFs 1.1, 2, 3 
and 4 + adherence diary + CXR) 
Child brought back at 2 months and DCFs 
1.2 and 6.2 completed, CXR 
1 
Child brought back at 4 months and DCFs 
1.4 and 6.4 completed, CXR 
Child brought back at 6 months and DCFs 
1.6 and 6.6 completed, CXR 
Child brought back at 12 months and DCF 
6/12 completed, CXR 
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Demographic form at recruitment (DCF1.0) 
Initial consultation following recruitment 
1.0.1. First Name of child 1.0.2. Surname of child 
1.0.3. Alternative First name of child 1.0.4. Alternative Surname of ch ild 
1.0.5. Date of Birth of child (dd/mm/yyyy) 1.0.6. Hospital number of child 
1.0.7. First Name of Main Carer 1.0.8. Surname of Main Carer 
1.0.9. Alternative first name of Main Carer 1.0.10. Alternative Surname of Main Carer 
1.0.11. Contact telephone number of Main Carer 1.0.12. Alternative telephone number of Main Carer 
1.0.13. First Name of Other Carer 1.0.14. Surname of Other Carer 
1.0.15. Alternative first name of Other carer 1.0.16. Alternative Surname of Other Carer 
1.0.17. Contact telephone number of Other Carer 1.0.18. Alternative telephone number of Other Carer 
1.0.19. Address of child 1.0.20. Alternative address of ch ild 
1.0.21. Date Today (dd/mm/yyyy) 1.0.22. Health Clinic 
1.0.23. First name of Index Case 1.0.24. Surname of Index Case 
1.0.25. Alternative first name of Index case 1.0.26. Alternative Surname of Index case 
1.0.27. Registration number on T6 register of index case 1.0.28. Contact telephone number of Index case 
Drug-resistant tuberculosis in children James Seddon P J ge l 248 
Child Medical Form (DCF2) 
Initial consultation following recruitment 
2.1. Consent 
2.1.1. Consent for study o No 1 Yes 
participation (if no or unknown 
-5 Unknown then do not proceed) 
2.1.2. Consent to use HIV test o No 1 Yes 
result 
-5 Unknown 
2.1.3. Entry Point 4 Tygerberg 5 Khayelitsha 
6 Brooklyn -8 Other 
2.1.4. Date today (dd/mmNyyy) 
2.2 Personal Information 
2.2.1. DOB (dd/mm/yyyy) 
2.2.2. Gender 1 Male 2 Female 
2.2.3. Ethnicity 4 White 5 Coloured 
8 Xhosa 9 Zu lu 
10 Indian 11 Sotho 
-8 Other 
2.2.4. Home language 1 English 2 Afrikaans 
3 Xhosa 4 Sotho 
5 Zulu -8 Other 
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2.3. Medical information - Past tuberculosis history 
2.3 .1. Has the child had a TB skin 1 Yes o No 
test? (if no or not known go to 
2.3.4) 
-5 Not known 
2.3.2. If a Mantoux test, what 1 Positive o Negative 
was the result? (Positive >/=10 if 
HIV-uninfected, >/=5 if HIV-
-5 Unknown -4 Not applicable 
infected) 
2.3.3. If a Mantoux resu lt was 
recorded what is t he size (mm) 
(if not recorded go to 2.3.4.) 
2.3.4. Has the child ever been 1 Yes o No 
treated for TB disease before? (if 
no or not known go to 2.3.7) 
-5 Unknown 
2.3.5. If yes, when was t he most 
recent TB t reatment started 
(dd/mm/yyyy) ? 
2.3.6. Was TB treatment 1 Yes o No 
completed? 
-5 Unknown 
2.3.7. Has the chi ld been given 1 Yes o No 
TB preventive treatment before? 
(if no or unknown go to 2.4.1) 2 Currently on treatment -5 Unknown 
2.3.8. If yes, or on treatment, 
when was the most recent 
preventive treatment started 
(dd/ mm/yyyy)? 
2.3.9. Was TB preventive 1 Yes o No 
treatment completed? 
2 Currently on treatment -5 Unknown 
2.3.10. Which regimen was 1 INH 2 High dose INH 
prescribed? 
3HEO 4 HEthO 
-5 Unknown 
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2.4. Medical Information - HIV details 
2.4.1. Is the child HIV-infected? 1 Yes o No 
(if no or unknown go to 2.5 .1) 
-5 Not known 
2.4.2. If yes, when was the 
diagnosis made (dd/mm/yyyy)? 
2.4.3. Is the child currently on 1 Yes o No 
ART? (if no go to 2.4.7) 
-5 Unknown 
2.4.4. If yes, which ART? (ring 1 AZT 2 3TC 
any that apply) 
3 NVP 4 D4T 
5 LPV 6 LPV/Ritonavir 
7 EFV 8 ABC 
9 PI -8 Other (write in which) 
2.4.5. When was ART started 
(dd/mm/yyyy)? 
2.4.6. What was the CD4 count 
at ART initiation? (xxxx) 
2.4.7. What was the CD4 
percentage at ART initiation? 
(xx.x%) 
2.4.8. Most recent CD4 count? 
(xxxx) 
2.4.9. Most recent CD4 
percentage? (xx.x%) 
2.4.10. Date of most recent CD4 
test (dd/mm/yyyy)? 
2.4.11. Site of HIV care? 1 Government ARV clinic 2 Hospital ARV clinic 
3 Private doctor -8 Other 
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2.5. Medical Information - Other Medical Issues 
2.5.1 Child Weight (xx.x kg) 
2.5.2. Child Length/Height (xxx 
em) 
2.5.3 . BCG scar visible? 1 Yes o No 
-5 Unknown 
2.5.4. Is the child currently 1 Yes o No 
known to be asthmatic? 
-5 Unknown 
2.5.5. Does the child currently 1 Yes o No 
have any chronic bone or joint 
problems? 
-5 Unknown 
2.5.6. Does the child currently 1 Yes o No 
have a palpable liver? 
-5 Unknown 
2.5.7. Does the chi ld currently 1 Yes o No 
have a palpable spleen? 
-5 Unknown 
2.5.8. Does the child currently 1 Yes o No 
have any clinica l signs of chronic 
lung disease? 
-5 Unknown 
2.5.9. Is the chi ld's colour vision 1 Yes o No 
currently normal? 
-4 Not possible to test -5 Unknown 
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2.6. Details of Exposure 
2.6.1. What is t he relationship of 1 Mother 2 Father 
the index case to the chi ld? 
(biological relationships) 3 Grandmother 4 Grandfather 
5 Aunt 6 Uncle 
7 Cousin 8 Sibling 
9 Caregiver other than -8 Other 
family 
2.6.2. When did exposure to t he 1 More than six months ago 2 More than three months 
index case end? ago but less than six months 
3 Less than three months 4 Ongoing 
ago 
2.6.3. How long was t he child 1 less than a week 2 One week to one month 
exposed to the index case? 
3 More than one month to 4 More than three to six 
three months months 
5 More than six months to a 6 More than a year 
year 
2.6.4. Is the index case the 1 Yes o No 
child's primary care giver? 
-5 Unknown 
2.6.5. If not the primary 1 Yes o No 
caregiver, is t he index case the 
chi ld's secondary caregiver? 
-4 Not applicable -5 Unknown 
2.6.6. During t he exposure 1 Yes o No 
was/ is there da ily contact 
between t he index case and the 
-5 Unknown 
child? 
2.6.7. Does the index case live in 1 Yes o No 
the same house as the child? 
-5 Unknown 
2.6.8. Does t he index case sleep 1 Yes o No 
in t he same room as the child? 
-5 Unknown 
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2.6. Details of Exposure 
2.6.9. Does the index case sleep 1 Yes o No 
in the same bed as the child? 
-5 Unknown 
2.6.10. How many hours on 1 0-4 2 5-8 
average does the index case 
spend with the child each day? 3 9-12 4 >12 
2.6.11. Has the child been in 1 Yes o No 
contact with more than one 
index case? (If no, go to 3.1.) 
-5 Unknown 
2.7. Second Index case (If no third Index case, go to DCF 3) 
2.7.1. What is the D5T pattern of 1 Drug susceptible 2 INH/RIF monresistant 
the second index case? 
3 MDR -5 Unknown 
2.7.2. What is the relationship of 1 Mother 2 Father 
the secondary index case to the 
child? (biological relationships) 3 Grandmother 4 Grandfather 
5 Aunt 6 Uncle 
7 Cousin 8 Sibling 
9 Caregiver other than -8 Other 
family 
2.8. Third Index case 
2.8.1. What is the DST pattern of 1 Drug susceptible 2 INH/RIF monresistant 
the third index case? 
3 MDR -5 Unknown 
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Index Case Form (DCF3) 
Initial consultation following recruitment 
3.1. Index Case Information 
3.1.1. DOB (dd/mm/yyyy) 
3.1.2. Gender 1 Male 2 Female 
3.1.3. Is the index case HIV- 1 Yes o No 
infected? 
-5 Unknown 
3.1.4. Does the index case smoke 1 Yes o No 
currently? (if no go to 3.1.7) 
-5 Unknown 
3.1.5. How much do they smoke? 1 Does not smoke 2 Less than 5 cigarettes a 
day 
3 5 - 10 cigarettes a day 4 11 - 20 cigarettes a day 
5 More than 20 cigarettes a -5 Unknown 
day 
3.1.6. How many years has the 1 Does not smoke 2 Less than six months 
index case smoked? 
3 Six months to one year 4 More than one year to 
five years 
5 More than five years -5 Unknown 
3.1.7. Does the index case drink 1 Yes o No 
alcohol? (if no go to 3.1.9) 
-5 Unknown 
3.1.8. How much alcohol does 1 Never drinks 2 Drinks less than once a 
the Index case drink week 
3 Drinks more than once a 4 Drinks most nights 
week 
5 Drinks every night -5 Unknown 
3.1.9. Has the index case been 1 Yes o No 
admitted to a hospital for TB 
before this episode? 
-5 Unknown 
3.1.10. Has the index case been 1 Yes o No 
in prison 
-5 Unknown 
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Household form (DCF4) 
Initial consultation following recruitment 
4.1. Household details 
4.1.1. Type of residence 1 Main House 2 Yard House 
3 Flat -8 Other 
4.1.2 . Type of housing structure 1 Tin Shack 2 Prefab House 
3 Brick House 4 Container 
5 Wendy House -8 Other 
4.1.3. Number of rooms in house 
(xx) 
4.1.4. Are there the following 1 Electricity 2 A radio 
assets in the house? (circle any 
that apply) 3 DVD player 4 A television 
5 A refrigerator 6 A bicycle 
7 A motorcycle 8 A car 
9 A cell phone 10 Alandline 
4.1.5. What is the main source of 1 Piped water in the 2 Piped water from a public 
drinking water? residence tap 
-8 Other (specify in next 
box) 
4.1.6. What is the main type of 1 Flush toilet in the house 2 Shared Flush toilet 
toilet in the household? 
3 Pit latrine 4 VIP latrine 
5 Bush/field toilet 6 Bucket system 
-8 Other (specify in next 
box) 
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4.1. Household details 
4.1.7. Number of persons older 
than 15 living in the house? (xx) 
4.1.8. Number of persons 
younger than 15 living in the 
house? (xx) 
4.1.9. Number of persons 
younger than 5 living in the 
house? (xx) 
4.1.10. Number of smokers in 
the house? (xx) 
4.1.11. Alcohol usage by any 1 No one in the house 2 Adults in the house drink 
adult in the house? drinks less than once a week 
3 Adults in the house drink 4 Adults in the house drink 
more than once a week most nights 
5 Adults in the house drink -5 Unknown 
every night 
4.1.12. Is there a separate room 1 Yes o No 
for cooking in the house? 
-5 Unknown 
4.1.13. What fuel source is 1 Paraffin stove 2 Wood fire 
mainly used for cooking in the 
summer? 3 Coal fire 4 Open flame of other kind 
5 Electric oven 6 Electric heater 
-8 Other (specify in next 
box) 
4.1.14. What fuel source is 1 Paraffin stove 2 Wood fire 
mainly used for cooking in the 
winter? 3 Coal fire 4 Open flame of other kind 
5 Electric oven 6 Electric heater 
-8 Other (specify in next 
box) 
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Index Case Register Form (DCFS) 
To be obtained later from TB register or from 
5.1. Register information for the MDR IB episode in the index case 
5.1.1. Register number 
5.1.2. Registration Date 
(dd/mm/yyyy) 
5.1.3. Gender 1 Male 2 Female 
5.1.4. Patient Category 1 N - New patient 2 RC - Relapse (Pulmonary) 
4 RF - Retreatment after 6 RD - Retreatment after 
Failure (Pulmonary) default (Pulmonary) 
-8 OR - Other previously -5 Unknown 
treated 
5.1.5. Date of production of 
sputum sample that diagnosed 
MDR TB (dd/mm/yyyy) 
5.1.6. Method of diagnosis of 1 LPA on sputum sample 2 LPA on culture sample 
MDRTB 
3 Conventional DST on -5 Unknown 
culture sample 
5.1. 7. Date of initiation of 
treatment (dd/mm/yyyy) 
5.1.8. Smear result of sample o Negative 1 Scanty 
that diagnosed MDR TB 
10 1 + 20 2+ 
30 3 + 150 Positive without 
specifying smear pattern 
-5 Unknown 
5.1.9. Date of most recent 
sputum sample (dd/mm/yyyy) 
5.1.10. Smear result of most o Negative 1 Scanty 
recent sample 
10 1 + 20 2 + 
30 3 + 150 Positive without 
specifying smear pattern 
-5 Unknown 
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5.2. Resistance pattern of sample at which MDR T8 diagnosed (tick one box for each drug) 
Susceptible Resistant Not t ested Unknown 
5.2.1 R - rifampicin 
5.2.2 H - isoniazid 
5.2.3 E - ethambutol 
5.2.4 Z - pyrazinamide 
5.2.5 S - streptomycin 
5.2.6 Eth -
ethionamide 
5.2.7 A- amikacin 
5.2.8 0- ofloxacin 
5.3. HIV details of index case 
5.3.1. HIV status (if Negative 1 Positive o Negative 
omit next three questions) 
-5 Unknown 
5.3.2. On ART at initiation of 1 Yes o No 
MDR TS treatment? 
-5 Unknown 
5.3.3. last CD4 count (xxxx) 
5.3.4. Currently on ART? 1 Yes o No 
-5 Unknown 
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Follow up form (DCF6) 
To be completed at the 2 month appointment 
6.2.1. Follow up data 
6.2.1.1. Site of consultation 4 Tygerberg 5 Khayelitsha 
6 Brooklyn -8 Other 
6.2.1.2. Date Today 
(dd/mm/yyyy) 
6.2.1.3. Resu lt of consultation 1 Continue HEO/HEthO/H 2 Complete HEO/HEthO/H 
3 Stop HEO/HEthO/H 4 Diagnosed TB 
-8 Other (specify in next 
box) 
6.2.1.4. Weight (xx.x kg) 
6.2.1.5. Length/Height (xxx cm) 
6.2.1.6. Mantoux resu lt (Positive 1 Positive o Negative 
>/ =10 if HIV-uninfected, >/=5 if 
HIV-infected) 2 Not repeated -5 Unknown 
6.2.1.7. If a Mantoux resu lt was 
recorded what is t he size (xx 
mm) (if not recorded go to 
6.2.1.8) 
6.2.1.8. Has the RTH card been 1 Yes o No 
brought to the appointment? 
-5 Unknown 
6.2.1.9. Has the treatment diary 1 Yes o No 
been brought to the 
appointment? 3 No treatment diary -5 Unknown 
6.2.1.10. Has the child missed 1 Yes o No 
any appointments since last 
seen? (if no or unknown t hen go 
-5 Unknown 
to 6.2.2.) 
6.2.1.11. If yes, what were the 1 Forgot 2 Too far 
reasons? 
3 Not enough money for 4 Busy 
travel 
5 Child ill 6 Carer ill 
-5 Other (specify in next 
box) 
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6.2.2. Medical information - HIV details 
6.2.2.1. Is the child HIV-infected? 1 Yes o No 
(if no or unknown go to 6.2.3) 
-5 Not known 
6.2.2.2. If yes, when was the 
diagnosis made (dd/mm/yyyy)? 
6.2.2.3. Is t he chi ld currently on 1 Yes o No 
ART? (if no or unknown go to 
6.2.2.6.) 
-5 Unknown 
6.2.2.4. If yes, which ART? (ring 1 AZT 2 3TC 
any that apply) 
3 NVP 4 D4T 
5 LPV 6 LPV /Ritonavir 
7 EFV 8 ABC 
9 PI -8 Other (write in which) 
6.2.2.5. When was ART started 
(dd/mm/yyyy)? 
6.2.2.6. What was the CD4 count 
at ART initiation? (xxxx) 
6.2.2.7. What was the CD4 
percentage at ART initiation? 
(xx.x%) 
6.2.2.8. Most recent CD4 count? 
(xxxx) 
6.2.2.9. Most recent CD4 
percentage? (xx.x%) 
6.2.2.10. Date of most recent 
CD4 test (dd/mm/yyyy)? 
6.2.2.11. Site of HIV care? 1 Government ARV clinic 2 Hospital ARV clinic 
3 Private doctor -8 Other 
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6.2.3. Adherence 
6.2.3.1. How is the child 1 DOT from clinic 2 DOT from treatment 
receiving their medications support worker 
3 Parent receives pills 4 Parent receives pills 
weekly from clinic and weekly from treatment 
supervises treatment to support worker and 
child supervises treatment to 
child 
5 Parent receives pills -8 Other 
monthly from clinic and 
supervises treatment to 
child 
6.2.3.2. Did the child miss or 1 Yes o No 
vomit their medications 
yesterday? 
-5 Unknown 
6.2.3.3. Did the child miss or 1 Yes o No 
vomit their medications the day 
before yesterday (name day)? 
-5 Unknown 
6.2.3.4. Did the child miss or 1 Yes o No 
vomit their medications the day 
before that (name day)? 
-5 Unknown 
6.2.3.5. How many times in the 1 None 2 1 - 2 
last week have doses been 
missed? 3 3-4 4 5-6 
5 All of them -5 Unknown 
6.2.3.6. When was the last time 1 Never 2 During the last week 
that medications were missed? 
3 During the last two weeks 4 During the last month 
5 Over a month ago 6 Don't remember 
6.2.3.7. In the last 30 days how 
many doses has the child 
received? (score from visual 
scale) (0 - 30) (xx) 
6.2.3.8. From the treatment 
diary, how many doses have 
been missed in the last 2 
months? (xx) 
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6.2.4. Side effects of medications - since the last time the child was seen, have they had any of 
the following? (Refer to side effect grading sheet) 
None Grade 1 Grade 2 Grade 3 Grade 4 Not 
known 
Joint, muscle or bone pain 
(other than injuries) 
Skin Rashes 
Itchy skin 
Headache 
Sleeping/mood 
Lethargy 
Visual problems 
Vomiting 
Diarrhoea 
Jaundice 
Appetite/nausea 
6.2.5. Clinical examination 
6.2.5.1. Does the child have any 1 Yes o No 
bone or joint pain? 
-5 Unknown 
6.2.5.2. Does the child have a 1 Yes o No 
palpable or tender liver? 
-5 Unknown 
6.2.5.3. Does the child have a skin 1 Yes o No 
rash possibly attributable to the 
medications? 
-5 Unknown 
6.2.5.4. Is the child's colour vision 1 Yes o No 
normal? 
2 Not possible to test -5 Unknown 
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Adherence form (DCF7) 
To be completed after 2 month follow-up having telephoned local clinic 
7.2.1. Follow up data 
7.2.1.1. How is the child 1 DOT from clinic 2 DOT from treatment 
receiving their medications support worker 
3 Parent receives pills weekly 4 Parent receives pills 
from clinic and supervises weekly from treatment 
treatment to child support worker and 
supervises treatment to 
child 
5 Parent receives pills -8 Other 
monthly from clinic and 
supervises treatment to child 
7.2.1.2. Over the last month, 1 None 2 1 - 2 
how many medication pick-ups 
have been missed? 3 3-4 4 5 - 10 
5 More than 10 -5 Unknown 
7.2.1.3. How would the local 1 Completely reliable 2 Fairly reliable 
clinic staff rate the caregiver in 
respect to giving the medication 3 Fairly unreliable 4 Totally unreliable 
to the child? 
-5 Unknown 
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Child Tracking Form (DCF8) 
To complete at each consultation 
8.1. Recruitment 
8.1.1. Date of recruitment 
(dd/mm/yyyy) 
8.1.2. Planned date for 2/12 
appointment? (dd/mm/yyyy) 
8.1.3. Date TB regist er consulted 
to complete DCF 5? 
(dd/mm/yyyy) 
8.2. Two month visit 
8.2.1. Date of appointment? 
(dd/mm/yyyy) 
8.2.2. Planned date for 4/12 
appointment? (dd/mm/yyyy) 
8.2.4. Date DCF7.2 completed 
(dd/mm/yyyy) 
8.3. Four month visit 
8.3.1. Date of appointment? 
(dd/mm/yyyy) 
8.3.2. Planned date for 6/12 
appointment? (dd/mm/yyyy) 
8.3.4. Date DCF7.4 completed 
(dd/mm/yyyy) 
8.4. Six month visit 
8.4.1. Date of appointment? 
(dd/mm/yyyy) 
8.4.2. Planned date for 12/12 
appointment? (dd/mm/yyyy) 
8.4.4. Date DCF7.6 completed 
(dd/mm/yyyy) 
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8.5. Twelve month visit 
8.5.1. Date of appointment I 
(dd/mm/yyyy) 
8.6. Unscheduled visit 1 
8.6.1. Date of appointment 
(dd/mm/yyyy) 
8.6.2. Planned date for next 
appointment (dd/mm/yyyy) 
8.6.3. Date DCF7.U completed 
(dd/mm/yyyy) 
8.7. Unscheduled visit 2 
8.7.1. Date of appointment 
(dd/mm/yyyy) 
8.7.2. Planned date for next 
appointment (dd/mm/yyyy) 
8.7.3 . Date DCF7.U completed 
(dd/mm/yyyy) 
8.8. Study outcome 
8.8.1. Date lost to follow up 
(dd/mm/yyyy) 
8.8.2. Date defaulted 
(dd/mm/yyyy) 
8.8.3. Date withdrawn from study 
(dd/mm/yyyy) 
8.8.4. Date completed study 
(dd/mm/yyyy) 
8.8.5. Date TB diagnosed 
(dd/mm/yyyy) 
8.8.6. Date of death 
(dd/mm/yyyy) 
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Reasons for non-attendance at clinic (Study 6) 
For Study 6 three data capture forms were created following the focus group discussion to 
explore characteristics of children and their families, the logistical complications of getting to 
clinic and their perception of DR-TB. These are shown on the following pages 
1. DCFl 
2. DCF2 
3. DCF3 
4. DCF4 
Demographics 
Travel to clinics 
Perceptions 
Living standards measures 
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DCF 1 - Demographics 
1.1. Date today (dd/mm/yyyy) 
1.2. Date of birth of child (dd/mm/yyyy) 
1.3. Was the child brought for the appointment? 1. Yes D. No 
1.4. Gender of child 1. Male 2. Female 
1.5. Ethnicity 4. White 2. Black 
5. Coloured -8. Other 
1.6. HIV status of chi ld 1. Infected D. Uninfected 
-5. Unknown 
1.7. Relationship of main carer to child 1. Mother 2. Father 
3. Grandmother 4. Grandfather 
-8. Other 
1.8. Years formal education main carer 
1.9. Paid work of main carer 1. Does not work 2. Occasional work 
for pay for pay 
3. Regular part- 4. Regular full -
time work for pay time work for pay 
1.10. Does main carer look after other children? 1. Yes D. No 
1.11. Gender of main carer 1. Male 2. Female 
1.12. Gender of index case 1. Male 2. Female 
1.13. Relationship of index case to child 1. Mother 2. Father 
3. Grandmother 4. Grandfather 
-8. Other 
1.14 LSM score of household 
1.15. Does anyone in the house smoke 1. Yes O. No 
1.16. Does anyone in the house drink alcohol 1. Yes D. No 
1.17. Does anyone in the house use illegal drugs 1. Yes D. No 
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DCF 2 - Travel to clinics 
2.1. Distance to loca l clinic 
2.2. Time taken to local clinic 
2.3. Cost to local clinic 
2.4. Transport to local clinic 1. Walk 2. Train 
3. Minibus taxi 4. Private Car 
S. More than one -8. Other 
ride 
2.5. Distance to MDR-TB clinic 
2.6. Time taken to MDR-TB clinic 
2.7. Cost to MDR-TB clinic 
2.8. Transport to MDR-TB clinic 1. Walk 2. Train 
3. M inibus taxi 4. Private Car 
S. More than one -8. Other 
ride 
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DCF 3 - Perceptions 
3.1. Do you have confidence in the medical staff at 1. Yes D. No 
your local clinic? 
3.2. Do you have confidence in the medical staff at 1. Yes D.No 
the MDR-TB clinic? 
3.3. Does the weather affect your decision on 1. Yes D. No 
whether to attend appointments at the MDR-TB 
clinic? 
3.4. Do you consider MDR-TB a disease that can kill 1. Yes D. No 
you? 
3.5. Do you consider MDR-TB a disease that can be 1. Yes D. No 
treated successfully? 
3.6. Do you think that people in your community 1. Yes D.No 
with MDR-TB are discriminated against? 
3.7. Do you feel that employers in your community 1. Yes D. No 
discriminate against people with MDR-TB? 
3.8. Are you concerned about the risk of being 1. Yes D. No 
infected with MDR-TB while waiting at the MDR-TB 
clinic? 
3.9. Do you think that your child would take anti -TB 1. Yes D. No 
medicines every day without a problem? 
3.1D. Are you concerned about the side effects of 1. Yes D. No 
the anti-TB medicines for the child? 
3.11. Out of ten, for you how important a priority is 
having your child assessed in the MDR-TB clinic? 
3.12. Do you feel that you have to wait a long time 1. Yes D.No 
to be seen at your local clinic? 
3.13. Do you feel that you have to wait a long time 1. Yes D. No 
at the MDR-TB clinic? 
3.14. Do you think that the parents of children or 1. The parents 2. The health 
the health services should be responsible for services 
preventing children from getting MDR-TB? 
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DCF 4 - Living Standards Measures 
Metropolitan dweller DVD Player 
Living in a non-urban area Refrigerator or combined 
fridge/freezer 
House / Cluster House / Town House Electric Stove 
Tap water in house / on plot Microwave oven 
Flush Toilet inside house Deep Freezer - Free Standing 
Hot running water Have a washing machine 
Built in Kitchen Sink Have a tumble dryer 
No Domestic Workers Dishwashing Machine 
Home security service M-net / DSTV Subscription 
Cellphones in Household Home Theatre System 
3 or more Cellphones in Household Vacuum Cleaner 
Zero or One Radio set in Household Motor Vehicle in Household 
Hi-Fi / Music centre Computer - Desktop / Laptop 
Have TV set(s) Land line (exc!. Cell phone) 
VCR 
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The spectrum of presentation, treatment and outcome in children with multidrug-
resistant tuberculosis (Study 10) 
For Study 10 two forms were created. The first was used to capture the presentation and 
management up until that point in time when the family was consented and interviewed. The 
second was then completed every time the patient was subsequently seen. This allowed both 
retrospective and prospective data collection. The first form was CDF 2 and the second DCF 5. 
For the children on the this treatment study, DCFs 1, 3 and 4 from the studies assessing 
exposed children were also completed, so that five forms were completed for each child (DCF 
5 completed at each follow up appointment) 
1. DCF1 Demographic details (completed each time the child was seen) 
2. DCF2 Child details at the point when the child was recruited 
3. DCF3 Index case details 
4. DCF4 Household details 
s. DCFS Follow up forms (completed at each follow up appointment) 
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Child Medical Form (DCF2) -Initial consultation following recruitment 
2.1. Consent 
2.1.1. Consent for study o No 1 Yes 
participation (if no or unknown 
-5 Unknown then do not proceed) 
2.1.2. Consent to use HIV test o No 1 Yes 
result 
-5 Unknown 
2.1.3. Entry Point 4 Tygerberg 5 Khayelitsha 
6 Brooklyn -8 Other 
2.1.4. Date today (dd/mm/yyyy) 
2.2. Personal Information 
2.2.1. DOB (dd/mm/yyyy) 
2.2.2. Gender 1 Male 2 Female 
2.2.3. Ethnicity 4 White 5 Coloured 
8 Xhosa 9 Zu lu 
10 Indian 11 Sotho 
-8 Other 
2.2.4. Home language 1 English 2 Afrikaans 
3 Xhosa 4 Sotho 
5 Zulu -8 Other 
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2.3. DR 18 Episode 
2.3.1. Date of start of DR TB 
Episode (see definitions) 
(dd/mm/yyyy) 
2.3.2. Was the child admitted 1 Yes o No 
to hospita l? (if no then go to 
2.3.6.) 
-5 Unknown 
2.3.3. Date of admission to 
hospital (dd/mm/yyyy) 
2.3.4. Date of admission to 
Brooklyn Hospita l 
(dd/ mm/yyyy) 
2.3 .5. Date discharged from 
Brooklyn (dd/mm/yyyy) 
2.3.6. If sent to another 
hospita l, date of discharge 
from hospital (dd/mm/yyyy) 
2.3.6. Date TB treatment 
started in DR 1B episode 
(dd/mm/yyyy) 
2.3.7. Date DR TB treatment 
started (dd/mm/yyyy) 
2.3.8. If fin ished t reatment, 
date of treatment completion 
(dd/ mm/ yyyy) 
2.3.8. If cu lture-confirmed DR 
TB, date sample taken that 
diagnosed DR TB (dd/mm/yyyy) 
2.3.9. What was the child's 1 <60% expected 2 < 3,d percent ile 
weight at the beginning of the 
DR TB episode? 3 3ra - 10th percentile 4 > 10th percentile 
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2.4. Contacts 
2.4.1. Does the chi ld have any o None known 1 One 
TB contacts (if none go to 2.5.) 
2 Two or more -5 Not known 
2.4.2. What is the relationship 1 Mother 2 Father 
of the first contact to the child? 
3 Sibling 4 Grandparent 
5 Other relative 6 Non-relative 
2.4.3. What is the DST of the -5 DST not done/unknown 1 DSTB 
first contact? (if DST not 
done/unknown go to 2.4.4. if 2 RIF mono-resistant TB 3 INH mono-resistant TB known go to 2.4.5.) 
4 MDRTS 5 MDR + OFL resistant TB 
6 MDR + AMI resistant TB 7 XDR TS 
2.4.4. If the first contact has 1 Died 2 On first line treatment 
not had a DST or the result is 
unknown, what has happened 
3 Defaulted/ not on -5 Unknown to them? 
treatment 
2.4.5. What is the relationship 1 Mother 2 Father 
of the second contact to the 
child? 
3 Sibling 4 Grandparent 
5 Other relative 6 Non-relative 
2.4.6. What is the DST of the -5 DST not done/unknown 1 DSTB 
second contact? (if OST not 
done/unknown go to 2.4.7. if 
2 RIF mono-resistant TS 3 INH mono-resistant T8 known go to 2.5.) 
4 MORTS 5 MDR + OFL resistant TB 
6 MOR + AMI resistant TB 7 XOR TB 
2.4.7. If the second contact has 1 Died 2 On first line treatment 
not had a DST or the result is 
unknown, what has happened 3 Defaulted/ not on -5 Unknown 
to them? treatment 
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2.S. Previous Treatment 
2.5.1. Has the child had o Never 1 Once before 
previous episodes of TB 
before? 2 Twice or more before -5 Unknown 
2.5.2. For the most recent 1 Treatment for DS TB 2 Treatment for DR TB 
episode what type of 
treatment was it? 3 Prophylaxis for DS TB 4 Prophylaxis for DR T8 
2.5.3. For the most recent 
episode what date did t he 
treatment start? (dd/mm/yyyy) 
2.5.4. For the most recent 
episode what date did the 
treatment end? (dd/mm/yyyy) 
2.5.6. For the most recent 1 Treatment completed 2 Defaulted 
episode what was the result? 
3 Treatment failure -5 Unknown 
2.5.7. For the previous episode 1 Treatment for DS TB 2 Treatment for DR TB 
what type of treatment was it? 
3 Prophylaxis for DS TB 4 Prophylaxis for DR TB 
2.5.8. For the previous episode 
what date did t he treatment 
start? (dd/mm/yyyy) 
2.5.9. For t he previous episode 
what date did the treatment 
end? (dd/mm/yyyy) 
2.5.10. For the previous 1 Treatment completed 2 Defaulted 
episode what was the result? 
3 Treatment failure -5 Unknown 
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2.6. Child immunology details 
2.6.1. Largest Mantoux/Tine 1 Positive 2 Negat ive 
result during DR TB episode? 
3 Not done/unread -5 Unknown 
2.6.2. If the size of the 
Mantoux is recorded, what is 
the size? (xx mm) 
2.6.3. Was a BCG scar noted or 1 Yes o No 
recorded as being given in the 
RTHC? 
-5 Unknown 
2.7. HIV details 
2.7.1. Is the child HIV-infected? 1 Yes o No 
(if no or unknown go to 2.8.) 
-5 Not known 
2.7.2. If yes, when was the 
diagnosis made (dd/mmJyyyy)? 
2.7.3. Is the child currently on 1 Yes o No 
ART? (if no or unknown go to 
2.7.6.) 
-5 Unknown 
2.7.4. When was ART started 
(dd/mm/yyyy)? 
2.7.5. What was the CD4 count 
and percentage at ART 
initiation? (xxxx, xx.x%) 
2.7.6. What was the CD4 count 
and percentage at start of DR 
TB episode? (xxxx, xx.x%) 
2.7.7. Most recent CD4 count 
and percentage? (xxxx, xx%) 
2.7.8. Date of most recent CD4 
test (dd/mm/yyyy)? 
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2.B.DRTB 
2.8.1. What type of TB does 1 PTB 2 EPTB 
the child have? 
3 Both PTB and EPTB -5 Unknown 
2.8.2. If EPTB or both, what 1 Miliary 2 Pleural effusion 
type (circle all that apply) 
3 Pericardial effusion 4 TBM 
5 Abdominal 6 Lymph node 
7 Bone/joint/spine 8 Disseminated 
9 Other 
2.8.3. Was the child sputum 1 Yes o No 
smear-positive at any point in 
the DR TB episode? 
-5 Unknown 
2.9. Resistance pattern of sample at which DR TB diagnosed or of the likely Index case If 
diagnosed presumptively (tick one box for each drug) 
Susceptible Resistant Not tested Unknown 
2.9.1 R - rifampicin 
2.9.2 H - isoniazid 
2.9.3 E - ethambutol 
2.9.4 Z - pyrazinamide 
2.9.5 S - streptomycin 
2.9.6 Eth - ethionamide 
2.9.7 A- amikacin 
2.9.8 0- ofloxacin 
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2.10. Drugs used 
Date started Date stopped Date Date stopped 
restarted 
2.10.1 R - rifampicin 
2.10.2 H - isoniazid 
2.10.3 E - ethambutol 
2.10.4 Z - pyrazinamide 
2.10.5 5 - streptomycin 
2.10.6 Eto - ethionamide 
2.10.7 Amk - amikacin 
2.10.8 Ofx - ofloxacin 
2.10.9 Cm - capreomycin 
2.10.10 CS/ Trd -
cycloserine or terizidone 
2.10.11 Cip -
ciprofloxacin 
2.10.12 PAS 
2.10.13 KI -
clarithromycin 
2.10.14 Aug - augmentin 
2.10.15 Lzd - Iinezo lid 
2.10.16 Mfx -
moxifloxacin 
2.11. Diagnosis 
2.11.1. On what basis was the 1 Culture-confi rmation 2 TB In contact of DR TB 
DR TB diagnosed? 
3 Failing f irst line therapy -5 Unknown 
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2.12. Side effects of medications - since starting treatment In the DR T8 episode has the 
child had any of the following? (Refer to side effect grading sheet) 
None Grade 1 Grade 2 Grade 3 Grade4 Not 
known 
2.12.1. Joint, muscle or bone 
pain (other than injuries) 
2.12.2. Skin Rashes 
2.12.3. Itchy skin 
2.12.4. Headache 
2.12.5. Sleeping/mood 
2.12.6. Lethargy 
2.12.7. Visual problems 
2.12.8. Vomiting 
2.12.9. Diarrhoea 
2.12.10. Jaundice 
2.12.11. Appetite/nausea 
2.12.12. Anaemia 
2.12.13. Anaphylaxis 
2.12.14. Hepatotoxicity 
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2.13. Hearing and TFTs 
2.13.1. Has there been any 1 None 2 High frequency unilateral 
hearing impairment (loss of loss 
>15db) since starting 3 High frequency bilateral 4 Mid-range unilateral 
treatment? 
5 Mid-range bilateral -5 Unknown 
2.13.2. Has the injectible had to 1 Yes 2 No 
be stopped early due to 
hearing loss? 
3 Unknown 
2.13.3. Has there been any 1 Always normal 2 TSH alone raised once or 
derangement of TFTs? more 
3 T4 alone low once or 4 Both TSH raised and T4 
more low once or more 
2.13.4. Has a thyroxine 1 Yes 2 No 
substitute been instituted? 
2.14. Treatment outcome 
2.14.1. What was the 1 Cured 2 Treatment completed 
treatment outcome? 
3 Treatment failure 4 Defaulted 
5 Died 6 lost to follow up 
7 Transferred/moved out 8 Stili on tr atment 
9 Other 
2.14.2. Impairment at the end 1 None obvious 2 Chronic lung impairment 
of treatment? 
3 Neurological Impairment 4 Stili on tre tment 
5 Died 6 Other 
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2.15. Culture conversion 
2.15.1. Months to culture 
conversion if appropriate (time 
from start of DR TB treatment 
to date of sampling of first 
negative culture) 
2.16. Death 
2.16.1. If the patient died, what 
was the date of death? 
(dd/mm/yyyy) 
2.16.2. If the patient died, what 1 TB while on treatment 2 The consequences of T8 
was the cause of death? following treatment 
3 HIV-related illness 4 Other while on treatment 
5 Other following -5 Unknown 
treatment 
2.17. Radiology (use formal CXR reporting form) 
2.17.1. CXR at diagnosis 1 Normal 2 Hllar nodes/airway 
compression (mild) 
3 Lobar/segmental 4 Pleural effusion - I rge of 
collapse/opacification (mod) loculated (mod) 
5 Small cavities (mod) 6 Brochopneumonlc 
changes (I rg of s v re) 
(severe) 
7 Miliary (severe) 8 Large cavities (s ver ) 
2.17.2. CXR at end of 1 Normal 2 Improved but not normal 
treatment 
3 Radiologica l chronic lung 4 Destroyed lobe/lung 
disease 
5 Still on treatment 6 Other 
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DCF 5 (Follow-up form) To be completed at outpatient follow ups or inpatient reviews 
5.1. Follow up data 
5.1.1. Site of review 4 Tygerberg 5 Khayelitsha 
6 Brooklyn -8 Other 
5.1.2. Date Today 
(dd/mm/yyyy) 
5.1.3. If discharged from 
hospital since last review, date 
of discharge? (dd/mm/yyyy) 
S.2. Child Immunology details 
5.2.1. If a Mantoux/Tine test 1 Positive 2 Negative 
has been repeated what is the 
result? 3 Not done/unread -5 Unknown 
5.2.2. If the size of the 
Mantoux is recorded, what is 
the size? (xx mm) 
5.3. Culture conversion 
5.3.1. If cu lture conversion has 
occurred since last follow up, 
months to cu lture conversion 
(time from start of DR TS 
treatment to date of sampling 
of first negative culture) 
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5.4. HIV details 
5.4.1. Is the child HIV-infected? 1 Yes o No 
(if no or unknown go to 5.5.) 
-5 Not known 
5.4.2. If yes, when was the 
diagnosis made (dd/mm/yyyy)? 
5.4.3. Is the child currently on 1 Yes o No 
ART? (if no or unknown go to 
2.7.6.) 
-5 Unknown 
5.4.4. When was ART started 
(dd/mm/yyyy)? 
5.4.5. What was the CD4 count 
and percentage at ART 
initiation? (xxxx, xx.x%) 
5.4.6. What was the CD4 count 
and percentage at start of DR 
TB episode? (xxxx, xx.x%) 
5.4.7. Most recent CD4 count 
and percentage? (xxxx, xx%) 
5.4.8. Date of most recent CD4 
test (dd/mm/yyyy)? 
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5.5. Drugs used 
Current drugs Date stopped if stopped since last 
(tick) follow up 
5.5.1 R - rifampicin 
5.5.2 H - isoniazid 
5.5 .3 E - ethambutol 
5.5.4 Z - pyrazinamide 
5.5.s 5 - streptomycin 
5.5.6 Eto - ethionamide 
5.5.7 Amk - amikacin 
5.5.8 Ofx - ofloxacin 
5.5.9 Cm - capreomycin 
5.5.10 Cs/Trd - cycloserine or 
terizidone 
5.5.11 Cip - ciprofloxacin 
5.5.12 PAS 
5.5.13 KI - clarithromycin 
5.5.14 Aug - augmentin 
5.5.15 Lzd - linezolid 
5.5 .16 Mfx - moxifloxacin 
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5.6. Side effects of medications - since the last follow up has the child had any of the 
following (Refer to side effect grading sheet) 
None Grade 1 Grade 2 Grade 3 Grade 4 Not 
known 
5.6.1. Joint, muscle or bone 
pain (other than injuries) 
5.6.2. Skin Rashes 
5.6.3. Itchy skin 
5.6.4. Headache 
5.6.5. Sleeping/mood 
5.6.6. Lethargy 
5.6.7. Visual problems 
5.6.8. Vomiting 
5.6.9. Diarrhoea 
5.6.10. Jaundice 
5.6.11. Appetite/nausea 
5.6.12. Anaemia 
5.6.13. Anaphylaxis 
5.6.14. Hepatotoxicity 
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5.7. Hearing and TFTs 
5.7.1. Has there been any 1 None 2 High frequency unilateral 
hearing impairment (loss of loss 
>15db) since the last 3 High frequency bilateral 4 Mid-range unilateral 
appointment? 
5 Mid-range bilateral -5 Unknown 
5.7.2. Has the injectible had to 1 Yes 2 No 
be stopped early due to 
hearing loss? 
3 Unknown 
5.7.3. Has there been any 1 Always normal 2 TSH alone raised once or 
derangement of TFTs since the more 
last appointment? 
3 T4 alone low once or 4 Both TSH ra ised and T4 
more low once or more 
5.7.4. Has a thyroxine 1 Yes 2 No 
substitute been instituted? 
5.8. Treatment outcome and morbidity 
5.8.1. If the child has finished 1 Cured 2 Tre tment completed 
treatment, what was the 
outcome? 3 Treatment failure 4 Def ulted 
5 Died 6 Lost to follow up 
7 Transferred/moved out 8 Other 
9 Still on treatment 
5.8.2. What is the current level 1 None obvious 2 Chronic lung Imp Irment 
of impairment? 
3 Neurological impairment 4 Other 
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The impact of drug resistance on clinical outcome in children with tuberculous 
meningitis (Study 11) 
Personal Details 
Hospital number Study Number 
Date admission to TBH Date of discharge from TBH 
Date of birth Gender 
M F 
HIV details 
HIV status Unknown Positive Negative E posed but 
negative 
CD4 count at On ART at diagnosis ofTBM diagnosis of TBM? 
Yes No 
(if HIV-infected) 
Past medical history 
BCG scar 
visible/documented on Yes No Un nown 
RTHC? 
Mantoux result Unknown Positiv N gativ 
Time course 
Date symptoms reported to start Date of admission to hosplt I 
Date of initiation of treatment For DR TB, date of inlt! l ion of pproprlat 
treatment 
Any known TB 
Yes No Un nown 
contacts? 
Child given/currently 
Yes No Unknown 
on preventive therapy? 
Presentln, Symptoms (rin, those that apply) 
Decreased 
Headache GI Poorf d ng 
consciousness disturbance/diarrhea 
Seizures Vomit ing Cough Weight loss 
Fever Change in behavior Developmental Neck Stiffness 
regression 
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Neurological status at presentation 
TBM stage Stage one Stage two Stage three Not recorded 
GCS (3-15) Not recorded 
Central nervous system Normal Abnormal Unknown 
Peripheral nervous 
Normal Abnormal Unknown 
system 
Hemiplegia Yes No Unknown 
Raised ICP? 
Yes No Unknown 
Microbiology 
Source of positive Gastric washings Sputum CSF 
result 
Biopsy BAl Other 
DS RMP mono-resistant INH mono-resistant 
Resista nee pattern 
MDR XDR Unknown 
Smear result 
Positive Negative Unknown 
Beijing LAM Haarlem 
Strain type 
X Other Unknown 
CSF result 
Macro appearance I Clear Bloody I Turbid 
RBC PMN lymphocytes Glucose Protein 
(celiS/ill) (celiS/ill) (celiS/ill) (mmol/l) (giL) 
Other Investigations 
CXR Normal Signs ofTB Not done 
CT brain Normal Signs ofTBM Not done 
Air Encephalogram Communicating Non-communicating Not done 
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Inpatient progress 
Neurosurgery Not done Shunt 
ICU admission Admitted ICU Not admitted ICU 
Drugs used 
Steroids used Yes No Unknown 
INH PZA RMP ETH EMB AMI/KAN 
All TB drugs 
used 
OFL TER/CYC PAS CAP LNZ AUG 
I Outcome 
Motor Normal Hemiparesis Quadriparesis Died Unknown function 
Cognitive Normal Mild handicap Moderate/sev Died Unknown 
outcome ere handicap 
Vision Norma l Impaired Blindness Died Unknown 
vision 
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Hearing loss in children treated for drug-resistant tuberculosis (Study 13) 
Clinical Details 
1.1.Study Number 
1.2.Hospital Number 
1.4. Date of Birth (dd/mmfyyyy) 
1.5. Date of Admission to BCH (dd/mm/yyyy) 
1.6. Gender 
1. Male 2. Female 
1.7. Type ofTB 1. PTB 2. EPTB 
3. Both PTB and 
EPTB 
1.8. Ethnicity 4. White 5. Coloured 
8. Xhosa -8. Other 
1.9. Site of EPTB 1. Miliary 2. Pleural Effusion 
3. Pericardial 
4. TBM Effusion 
5. Abdominal TB 6. LN TS 
7. Bone/Joint TB -8. Other 
1.10. Weight at admission to BCH (xx.x kg) 
1.11. Length at admission to BCH (xxx em) 
1.12. MUAC at admission to BCH (xx.x em) 
1.13. Diagnosis of TB 1. Confirmed 2. Presumed 
1.14. DST 1. Not done 2. D5 
3. IMR 4. RMR 
5. MDR 6. Pre-XDR 
7. XDR -8. Other 
1.15. HIV status 1. Positive 2. Negative 
-5. Unknown 
1.16. Date Started HAART (dd/mmfyyyy) 
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2. Treatment Details 
2.1. Injectable given 1. Amikacin 2. Capreomycin 
3. Streptomycin 4. Kanamycin 
2.2. Dosage of injectable given (xxx mg) 
2.3. Date injectable started (d d/mm/yyyy) 
2.4. Date injectable completed (dd/mm/yyyy) 
2.5. Number of doses given (xx) 
2.6. TB drugs used during injectable phase 1. Isoniazid 2. Rifampicin 
3. Pyrazinamide 4. Ethambutol 
5. Ofloxacin 6. Ethionamide 
7. Terizidone 8. PAS 
9. Clarithromycin 10. Augmentin 
11. Unezolid -8. Other 
3. Renal Function 
Potassium Creatinine 
Date Result Date Result 
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Published work 
Management of children exposed to multidrug-resistant 
Mycobacterium tuberculosis 
Jam .. A s.ddO<1. Ptt .. Godfrry-F"JSS<t~ An".'" C Hes •• ',~ Rob«t P Gr. Nuldo Beym. H 5<mO<1 Schoof 
Children exposed 10 mullidn'll'resistanl (MDR) M} o/:tad",;,,,,, tub"' .... lo' ;' are" ri k of developing MDR lubereulosi . 
Where 'rea'm",,' is available. it is lengthy. expensive. and assocL,ted wilh poor adherence and nOlable morbldl!) and 
mortality. l' rev""Ii"e Irealment e/fooively lowers Ihe rl k of disea e progression for contacts of lndhidual wilh dnrC-
suS(eplible luberculosis. bUl llus s lralegy is poorly ludied forconbcls of peoplewilh MDR Ili herculosis. In Ihls Re\<if'W 
we discuss the nl.'tnagement of child onbcts of sourU' ca~ with MDR IlIi>ernaJo§is. w~ pa parti uJar attention to 
assessmenl . exisling international guidelines. possible preventive Ireatm""ts. rationales for different management 
strategies. and Ihe interaction with and implications ofHIV infection. 
Introduction 
Nearly half a milUon new cases of IUu llidrug·reslslant 
(MDR) tuberculosis are eslimaled 10 cur ea h )·ear.' 
including extens ively dnrg.resis tanl (XDR) tu berculos is. 
These forms of the disease are associated wilh high 
morlality. particularly in people livIng with H IV 
Infecllon.' MDR tuberculosis Is defined as disease 
ca used by M}t-QiJaderiutlI tuhCTtlllo~i\ resistant to 
rifampicin and I n i.zid . and XDR as tu berClllosls 
ca used by , lulx'rLulosi resis tant to both these drugs as 
well as a Auoroquln lone and an injeclable second·line 
anti tub€>rculosis med i aHon.) 
Thberculosis control programmes have traditi f1ally 
focused on case.finding a nd treatmenl of Infi tious 
patienls . m sl of whom are adl~ ts . From a public health 
persp'Ctive. Ihis . pproad, must remain Ihe priority 
because il wliliessen disease transmlssi n and . therefore. 
the number of new mfections. To decrease future disease 
burden and im prove lin ical care al an individual level. 
hCMt'Ver. these "rat gies need to be ompieme nled with 
the Ielentifi ation and treatment f prople who are al a 
high risk of fi rst becoming Infected and then of 
progress ing to disease afler contact \vilh infeclious 
Individuals.' Young children and immunosuppressed 
prople are .t Ihe highest risk of progressing 10 disease 
afier Infecti n. Few studies have Investlgaled Ihe 
managemenl of chUdren exposed 10 MDR tu berculosis. 
and Il,ere is no c nsensus about the use 0( pr..,entive 
Ireahne nt. In this Re\<lew we discllsseclsting international 
gUidelines for Il,e manageme nt of child contacts of 
individuals with MDR tuber ulosis. whether preventive 
Irea bnent could have a role. and what the pas Ible 
trea tme nts and rationales might be for dIfferent manage· 
menl tralegies. 
Tuberculos is pathophysiology and im muno logy 
AAe r exposure to :terosoli sed "tube,,'ulo is, some 
children will bec me infecled. aAer whi h Ihe 
adaptive Immune s)·stem mighl clea r Ihe Infection. fail 10 
contain it. or reach 3n equ ilibrium in which the immune 
system is unable to eradicate the Infect ion but prevents 
progressi n 10 disease. The definitions and pathophysl<>-
logi al bases of lu berClllosls infection are subl Is of 
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mu h debate. The lerms late nt tu bercul -Is Infectl n. 
lalenl tuberculosis . and luberculos ls latency are all u ed. 
In line WiUl ur a ad~1ll1 w ,.k and paedlatrl practice. 
In Ihis Review we use Ihe term tuberCllI Is I n~ i nto 
c",'er Ihe spectrum from r enl Infecti n with 
M tubcrllilom, befi re an immune response 1s n'lollntro . 
10 an establ i hed tat of equil ibrium. A proportion f 
individuals wi th tuber ulosIS i ll~ Ii II will al some po,nl 
devel p tuber ul Is d lsea .' n,e eraU risk f pr<>-
gresslon Is grealesl ln Ihe first 2 years ./ler Infecti n . and 
fi r young cll ildren progress n oc UI S wilhln I ycar in 
90% of cases." Data co li ted ber. r the e ra or he mo-
Ihe rapy show that change. seen n chest rad logmphy 
sponlaneously res Il'e with ut treatment In a pr pocti n 
of child ren ".1Il tuberculosis Inf< Ii n . In this Revl 
however, as in ur .linie-dl pract e. we Ust" tlK' rill 
tu bereu 10 Is d !sease 10 reft r 10 rm pt rn:11i ill nt'S or 
any radiograph k changes on eI, .... t radJogr:ophy Ihal are 
con istent with tu ber li s. 
Traditi naUy. Ihe only mean r detecting lu ber u • 
Infection was Iflhe patient had a hlst ry f ""posllre and 
a positi"e tuberculin skin lest (TST) result. Tht crude 
antigen mixture used In TSTs. however. d n I 
completely differentia te between BCG. J lllhmll/om. 
and envlronmenlal. r n·luberculous my oba tecla.' An 
Immune response might lake up t 1 months 10 d • lop. 
and II,. size f Induration can be aff. led by H IV 
infecti n.' malnutlitl n. nd olher cau '" f 
Immuno uppr .. I n (eg. viral Infecti ns. neopla tic 
disorders. or . ' er id u ).' Senslliv lty and spedfi ity ar 
d ifficul l to measure In Ihe absen . f a g Id standard. bul 
wh n n ItMty I m a ured againsl nfirmed 
tu berculosis disease. resull are arlabl . me I ... 
such as the Interfer n.y-release . ssays (IGRAs) . me .. ure 
U,e amounl of Interferon y re leased by T ceils r Ihe 
number of T cell tl1.11 release Interfer n y a/ler 
stimulation by M "'h<,,"/o<i .... pedfic a nlig ns ( g. 
ESAT-6. CFP· IO. or TB7.7). Large numbers f sludll'S h ve 
a essed Ihese In·vltro test . and in me onlexts Ull'')' 
seem I show in reased sens itIVity in onfirm .. '<1 tuber· 
eulosls case r against an e posure gradient.· JX'Clfi Ity 
does 'lot seem 10 be subslantiaUy affected by previ 
BCG vac Ina lion or exposure non·tuber ul 
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Concise Clinical Review 
Caring for Children with Drug-Resistant Tuberculosis 
Practice-based Recommendations 
James A. Seddon''>, Jennirer J. Furin], Marianne Gale", Herna n Del Castillo Barrientos''', 
Rocio M. Hurtado"I,t, Farhana Amanullah'·, Nathan Ford" , Jefl rey R. Starke", and 
H. Simon Schaal'· n ; on behall or the Sentinel Project on Pediatric Drug.Reslstant Tuberculosis 
' Desmond Tutu TB C.ntr., Departm.nt of Paedialrics and Child Health, Facu~y of Medicine and Health Sc"""es, Stellenbosch Unilltnlty, Cape 
Town, South Atria; ' Department of Oinlcal Research, Facu~y of Inf.ctious and Tropical Diseases, London School of Hygiene and Tropocal Medid~, 
London, United Kingdom; ' Division or Infectiow Diseases, TB Res.arch Unit. Ca .. West ... n Reserv. Univenity School 01 Medtd~, Oewlilnd. OhM); 
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Tuberculosis, Uma, Peru; ' Massachusetts ~al Hospital, Boston, Massachusetts; 'Global H.alth Comm~tee, Boston, MassachusetU; "Harvard 
Medical School, Boston, Massachus.tts; '"The Indus Hospital, /(ariKhi, Pakistan; " MOdecins Sans Fronti~ ... Geneva, Switzerland; " Deportment 01 
Pediatrics, Baylor Col lege of Medicine, Houslon, Texas; and " Tygerberg Childr.n's Hospital. Cape Town, South Africa 
The management of child ren with drug· reslstan t tuberculo.1s 
(DR .TB) Is chaUenging, and It Is likely that In many places, t he roll · 
ou t o f molecular d iagnostic testing will lead to more children 
being diagoosed. There I •• limited evidence ba.e to guide optimal 
treatment and follow.up in the pediatric population; In exlstlng 
DR·TB guideline., the CNe 01 chadron I. ohen r.le!gat ed to .mal 
"'peclal population." .eet lon •. This article! .eeks to add .. ss t his gap 
by providing clinician. with practical advice and guidance. Thi. Is 
ach ieved t hrough review o f t he av.ilable i terature on pediatric 
DR .TB, lncludlng re.earchstud les and In lernatlonalguldeines, com· 
bined with consensus opinion from ,1 t eam of experts who h~e 
exte nsive experience in the c,ue of ch ildren w;th DR·TB in a wide 
varie ty of contexts and with varying resources. The review covers 
treotment I n~iatlo n, regimen design and trea tment duration. man· 
age ment of comorbid condition,. tr atnlent monitoring. advers 
events, adherence promotion, and Infection control, al w ithin a 
mullidlsclp lnary environment . 
Keyword s: pediaIJic.; chid; drug resistaru 
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AT A GLANCE COMMENTARY 
Sclentllk Knowledge on the Subje<\ 
With increa!iingly avaiLlble rapid di.la".".tlc ",chnique • 
more childrcnlrc lil.el tobcdugnat>ed "llhdru~r. nt 
lube ulosis. Guidanc" i lading 10 i I the liNcian in 
caring ror children .. ,Ih drutl·r i IlInt tuber til. 
What Thl' Study Met. to the Field 
Th. article dra" i on the pu~ish d lil~ratur and avaaLlbk 
guidcli nes. mbining th IS .. IIh Ihe C Men u pinlUn of 
autho .. ho h vC clIcn-h.: c(pcncn In th man ' nlent 
of children with drug.rc io tunl I uber('Uk~ " P"""ci.! 
guidan on regiml'll icClion.lhe mana l'me nt tlC comon..d 
colld,lionsiirld ad,enee, nl>,lnd he 10mONI t~."m""l 
r pon '. It dio ~ the prom,IlK,n nr <.lhcrcllI;c, how to 
involle othe r dl<;ciplin ..... and the rnlo;) r inr",linn control. 
The \ rid Heallh 
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Management of 
Multidrug-Resistant 
Tuberculosis in Children: 
A Field Guide 
TBCARE II 
First Edition: November, 2012 
Sentinel 
Project 
This handbook is made possible by the support of the American people through the United States Agency for International 
Development (USAID). The contents of this report are the sole responsibility ofTB CARE" and The Sentinel Project on Pediatric Drug-
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Treatment outcomes for children with multidrug-resistant 
tuberculosis: a systematic review and meta-analysis 
Dena Ett.had. H S.mon Xhaaf lamesA Seddon Graham S Cook,' Nathan ford' 
Summary 
Background Paediatric mullid r" g.resista nt (M DR) t"he rwlos i. is a publ ic heallh challe nge of growing concern. 
accoun ling for an eslim ated 15% of aU global cases of MDR tuberculosis. Clinical management is especiolUy 
chall~nging , and recommendation s: a re based on restricted evidence. We aimt"d to assess exi ting e\'idt" u e for the 
Irea tment of MDR luberculosis in chi ldren. 
Methods We did a systematic re-iew and meta·,malysis of published and unpublis hed studies reporting Irealment 
outcomes for children with MOR tu berculo is. We .eardled PubMed. Ovid. Emlxl -e . Coch r.ne librdry. P hINFO. 
a nd BioMedCentral databases up to Oct 31. 20 11 . Eligible stud ies induded fh'e or more dtildren (aged :s 16 ear ) "ith 
MOR h.l",reulo,is wi thin a defined tr.:ttment roho rt. The primary outcome was tr.atment sucee,,,. defined. a 
composi te of cure a nd tr.atment completion. 
Results We ide nlified eight studies. which reported trea lmelll oulcomes for a total of3 15 pa ti.n . W. r",or<led much 
varialion in the characlerislics of palients and programmes. Tome 10 appr"""'I. tre:olm. nt varied front 2 da) 10 
46 month . A"erage dura';o" of Ireatnlenl ranged from 6 months to J4 months . • lId duration of follow.up ranged 
from 12 months 10 37 months. The pooled eslimate forlrealnw nt success w.ts 81· 67% (95% CI 72 · 54-90 · 80) . Aero. 
. U slud ies. 5 · 9% (95% CI 1· 3-10 · S) died . 6.2% (2 ·3-10 · 2) defa ulted .• nd 39 · 1% (28 ·7-49 · 4) had n ad"e e ",·e nt. 
The noost common dnog-reiated advpfSe ",·en" were nallsea and "o.ru ling. Olher seriolls .dver<e ",'e nts were he.ring 
loss. psychk.lric e/f",ls . a nd hypothyroidism. 
IntCfpreta tion TIlt" Ir ... lment of paed~.tric MOR luberculosis has been neglected. bUI when r hildrelt ar. Irealed 
outcomes ca" be achi"'ed th. 1 are alleast as good as lhose reported for adults. Progra ntn,... should be en oU"'I!l'<110 
repo rt oulcomes in child ren 10 improve Ihe knowledge b;L'W! for care. espec~ IIy . s new drug. llt'Come available. 
Fund'ng Non e. 
Introduction 
An estimated 12 mill ion people worldwide have tuber· 
eul sis. of whom about 650000 have multidrug·resis tanl 
(MDR) disease.' Childhood tuberCl.dosi is es timated to 
accou nt for 1~15% of the global tubereulosis burd n .' 
and probably accounts for a sim dar proportion whon 
onsideri ng only dfilg-resi tant disease. TIle highest 
rates of paediatric M DR t"berwlesis are reported in I 
income countries.' and in some regions the incidence of 
MDR tuberculosis has risen sharply in the past two 
decades-eg. in the Western c.'pe. South Afri a. the 
proportion of cultu re<onfirmed cases of tube r ulosis 
wi th multidrug.resistance has tripled in the pasl 15 years 
from 2· 3% to 7 · 3%.' 
MOR tuberculos is i underdetected in hildren . 
Diagn sis of drug resistan e needs mycobacterial 
cul ture and drug susceptibility testing (0 51).' but the 
difficulty in obtaining re piratory secretions. such as 
' pulum or ga tric aspira tes. or specimens of 
extra pU lmon ary tuberculosis from young children.' 
along with the fact that up to half of all children wi lh a 
clinical diagnosis of tuberculosis di ease are sllIear· 
negative and ulture.negative. makes mi robiologi . 1 
confirmation challenging.' Strict programmatic 
requirements for microbiologi al onfi rmati n of drug 
www th~MI(etconl/iofection Volll June lOU 
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resisrnnce combined with insuffi t nt ro! ogn .Ioon of Ih. 
importalt e f taking into a count 0 T iX.tt". n Irom 
adult sour e cases can lea d t sub tanlo.1 del"rs in 
diagnosis and ini tiati n of.ppropri.te Ireatm nt.' 11I;,>" 
delays ould Icad to pr gre. i n of di • incr a<;«l 
ris k of infectious ness of cllIld ren, greater n "l L. f dlse.1.!)f! 
complica ti ns u h as tubercul u S meningili and 
high., rales 1 morb.dity. nd m rt.lity." 
Poediatri dfilg-r .. istant tuber ulo i i • • 
con ern . , ith rew hildren being treated rela tove to the 
estimated dise:! e burdelt." W HO guid line for the 
trea tmen t f drug.resista nt tuherCl..losis III .dull art' 
based on e-ide. e from meta.anal)s s of indIVIdual 
patients' data .· H vever. recommenwti n. r. r children 
are based on expert opinion. drawing on data from case 
series and coh rt . tudles ... • often with mall mpl iz 
Conseque ntly. wria ti n ",ists in progr.lInll1.ti hoices of 
treatment regimens. with the choice of dnl informed b 
previous dfilg "'posu re and OST results ." Bee.u>e of 
un ertainti .. about diagn is and the best tre tmen! 
regimens. and concerns about the 10xi effoos as i.ted 
wid! MDR tu bercul is treatment. health-car provid"" 
are autious about treating paediatric MOR tuber ,I is. 
We did a sy tematic review and meta.analystS of the 
available ""iden e for treatment out mes In chddr n 
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REVIEW 
Hearing loss in patients on treatment for 
drug-resistant tuberculosis 
James A. Seddon"", Peter Godfrey.Faussell", Kayleen Jacobs', Adam Ebrahim, 
Anneke C. Hessellng" and H. Simon Schaaf" + 
ABSTRACT: Tho treatmont of dru~roilitant (DR)-tuborculolll (TB) nocolllta_ tho UIO 0/ 
locon6-lIno Injoctabl ntl-TB drugs which aro alloclated with h ring lou. Hearing lOll afloctl 
communication and tho devolopmont of languag and loci I Ikllli In children, Thll review 
doscribOl tho pathophyllology of hearing lOll and tho 1I11tlng methodologies that can bo 
mployod. It la tho firat papor to ay. matleally review tho IIteraturo reg rd ng hear ing lOll In 
tholO tr ted lor DR-TB. In tho studlol Identilled, tho mothodology uled 10' t lor and to clast/ly 
h ring lOll I. Inconalatent and children nd tholO with HIV ar. poorly represented, Thll rOYlew 
doscribOi oxlltlng guldolnOi nd luggesla managornont ItrateglOi when hearing lOll II found , It 
descrlbOitho chaliengOl 0/ testing hoarlng In the dowloplng world contedl whore tho maJority 0/ 
patlontl with OR-TB ar troated, Finally It makOl tho recommendation that a .andardlled tOlting 
mothodology nd clalll cation IYltont ahould be uaod. 
KEYWORDS: Drug-roallt nt , hearing lOll, ototoxJclty, Iyatomatlc review, tuberculo.1 
T e World Health rganizat' (WHO) estimates tha t there are 650, ell gltha lly of mulHd rug-resist t (MDR) 
t ~rcuI ' (TO) (NIl>" 'mllm 'ubm:u]ooi!< 
resistan t to ri !ampi ' and iazld) (1(. A ma ll 
pmpo rti o<\ o f these ca are diagn d and 
a ppmpriarely t ruled bu t ... ~th the imminen t 
roll~lu t of newer molecular diagn ~ ' tool 12, 
L a much 1a'b"eT pr rt l is likely to be 
truled 1be t reatment o( drug-re.' tant (DR)-11l 
requi1't5 the U'le o( do li e anb-TB media-
t ' many of .... hich are A'I ' ated .... ith g-
16 t ad"en", e" 15 (-l ~ 1llP injectable d ruS"> 
a minoglycos ideund polypep tide are a l;aled 
.... 1 a r is k to rena l fun ion. hearin and the 
ve ibular system. N."arotOldcity is gmera lly 
re\'erSlble but damage to the aud it y 
vc.1ibular terns is u.ua lly perm ent. e 
monitoring o( he.tring los. ~ Imp tant (or two 
r .... om. Firs ~ if del ted early it may be ble 
to al lier the regimen op or reduce the dose 
the respomible d rug. p"'" nting progressi O<\ 
hearing loss the poin t where it would impact 
on communi alion. Second, if igniCKa t I aring 
lot! ha de vel ed £I is dele led, inller"entiom 
ca n be implemented k> a • t Ul mmun ation. 
11lese include hearing aids, rochIear irnplann or 
o ther he.tring impaired toob, teaching and trai 
ing. pile the increA'ling Ii le rature on DR-1ll 
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Second-Line Antituberculosis Drugs: Current 
Knowledge, Recent Research Findings and 
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Abstract 
The trea tment of drug-reSistant tuberculosis (TB) necessitates the 
use of drugs that are poorly understood. less efficacious and often 
associated with more adverse effects than those used to treat drug-
susceptible TB. Many of these second-line compounds were discov-
ered over 50 years ago and were soon superseded by more effective 
and better tolerated drugs. However. in treating drug-resistant TB. 
we must re-eva luate these drugs as the available armamentarium 
of drugs is so limi ted . New medications, as well as established medi-
cations not previously used against TB. need to also be considered. 
As diagnostic techniques improve and more cases of drug-resistant 
TB are diagnosed, clinicians must be familiar with these second -line 
drugs to enable them to successfully manage patients. This article 
reviews the literature. often limited and sometimes elderly. regard-
ing the second -line drugs. It also examines recent research find ings 
and Identifies areas of controversy and discussion. It comments on 
the laboratory, pharmacokinetlC and pharmacodynamic properties 
of the drugs as well as discusses adverse effects. 
Copynght 0 2011 S. IYrger AG, 80 .. 1 
Mult idrug-resistant (MDR) and. more recently. extensively 
drug- resistant (XDR) tuberculosis (TB) has nece.sitated the 
use of second-line anti-TB agents, Worldwide • .t40,OOO new 
cases of MDR-TB were estimated to have occurred in 2008, 
5.4% of which were XDR-TB cases ( 11 . The majority of these 
patients are not diagnosed. and only a small proportion is 
Ireated with appropriate second-line anti-TB regimens, 
There is currently a strong move to roll out diagn stic facil -
ities to identify MDR-TB cases in high TB burden countries 
with limited resources. However. if the diagnosis f MDR-
TB is improved. treatment must be uVlIiJable. and for tre:lt-
ment to be available. it is imperative that there should be a 
good knowledge of the agents u ed, There~ re this overview 
does not di cu s treatment options for MDRlXDR-TB but 
rather prese nt the individual age nls ordruggroups that are 
used as se nd-line drugs wilh the empha is n re ent IIld-
ings and controversies. 
The World Health rgan itation (WHO) divide the 
age nts for MDRIXDR-TB lreatment into 5 maj r groups 
(t ble I), Alth ugh the urrent WHO guidelines las ify 
the injec table agents as group 2 and the flu roquinol ne 
as group 3. there are good rea n t argue that. due t the 
effi cyof thcagent the vcrityofadverseetr. t- andalso 
cost. the flu roquinolone h uld rather be group 2 and the 
injectable group 3 (3 I, In this verview we will di~ u only 
second-line agents excluding the flu roquil101 l1e • a these 
are discussed in a sep"f(lte paper (i.e, we will discus gr up 
2.4 and 5). A su mmary is p rovided In rable 2. 
The Injectable Antituberculosis Agents: 
Aminoglycosides and CyclIc Polypept ides 
The current WHO group 2 agent include sirept III cin. 
kanamy in, amikacin and capreomydn (¥iomy in. another 
cydi polypeptide. is n t urrently incl uded) (2J , I n many 
regions with M DR-TB, r ist nee urveillan e h w high 
rate (>50%) of streptomy in resi rance. pre luding its u in 
routine ."IDR-TB management. F r thi rea n kannlllycin 
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Tubcrt ulosis 
Chlldrrn 
Drug-reslsl"' l 
$(-cond-Unc 
Pholmklcokinetia 
Childhood multidrug-resi' t.lnt tuberculo,ls (MOR-T8) Is an emerclng global epidemic. W,th the Immi-
nent roll..,u t of rapid molecular diJgnosric trst~ more chlldrrn arr likely [0 br Identified ."d require 
"earment lis MOR-T8 Is rrslsldnt to thr most effective fl rst-lint drugs. cllniclaM will h.Jvr to rely on 
second-line medications which .. e less effective ."d often .ssoclated with more pronounced odvrrsr 
effects rh.m first-line thera.py. Despite the (,let that most ortht~ ~gents wtft disc~rt'd m.lny ytolrs olgo. 
robuS! Information Is lacking regard ing thdr pharmacoklnetic .nd pharm.codyrwnlc proprmes. 
adverse eifects and drug Int eroction~ especi.tlly in children. Childrrn diITer from .dults In thr w.y that 
drugs are administered. the manner In which they arr metabolised and In the .dvrrsr eITecrs experi-
enced The Interaction of these drugs with hum." Immunodeftclency virus Infretion ."d ."tlmrOYiro/ 
therapy Is .llso poorly documented. This ankle rrviews thr ... i"'blr second · lin. drugs currently usrd in 
the treannent of MDR-TB In children and discusses medication properties ."d advrrsr eifrets while 
potenti.ll interactions with .ntirttroviral therapy dirt expk>rtd. 
I. Introduction 
It is rarely emphasized that multld rug-resistant (MDR) and 
extensively drug-resistant (XDR) tuberculosis (TB) also arfect chil-
dren and [hat paediatric drug-resistant TB ca n be viewed .s an 
emerging globa l epldemic.1 MDR-T8 is defined as Mycobacrerlum 
tuberculosis (M. tuberculosis) resistant to the nlost potent fi rst-line 
antl-TB medications. Isoniazid and rifa mpicin. while XDR-TB hdS 
additional resistance to [he most active second-line agents. 
Injectable d rugs (d minog lycosldes and/or cydic polypeptides) and 
fl uoroquinolones. There were an estimated 440,000 CdSes globa lly 
of MDR-TB dur ing 2009.2 Given the fact that childhood TS repre-
sents at leas t 10- 20% of the total CdSes in areaS with poor epidemic 
co ntro l,l-s this translates into a minimum globa l estimate of 
• Corresponding .1uthor. ~mond Tutu TB Crntrr. Dtp.anmrnt of Pt1Cdi.ltrics oII'Id 
Child 11('.alth. Olnlcal BUild ing. Room ()(JJS . Fo1culry o(llrolith $drnct'S. S~II('nbosch 
UnlVcrslly. PO Box 19063. TnrlWfJ 7505. South Arricil. Ttl.: +27 7'1247ff19SI 
213789177: fax: 1-21219389792. 
E~maiJ addresses: jseddon@Sun..Jc.za. j.une:s.seddon8ldoclOl'S.ol'J.uk U. 
A. Seddon). a"nekrhOsun...1c.za (A.C. He1!irling). be-nmillchw,edu..au (OJ. Mara lsl 
hclcn.mdlll'l'oniJuctac.z. (fl. Mct llrron~ peloquinilcop.ufl.edu (e ...... PCloqUUl ~ 
prdi>sun.Ku (P.R Do""ld ~ hssOsun.ac.z. (115. Schaar} 
1472-9792/1 - set front m.vttr C 2011 Elsrvicr ltd. All rchls rHCrvtd. 
dol:tO. l016lj.tu~20111l001 
e 20 11 Elsevier IJd. All rights reserved. 
arou nd 40.000 paediatric cases of MDR-T8 per year. Accurate 
reporti ng ,lnd optltllJ l tllJnagemcnt of these Cases are challenging. 
d"" to the difficulty in confirming the diagnosl . limited awareness 
and experience in dealing with these patients. the complexity and 
duratio n of treatment. and the limited availability of adequate 
drugs and chi ld-friendly formulation . In .xIdltlon. In settings with 
a high burden of MDR-TO and human immunodeficiency virus 
(HtV), up to 4O't of children with MDR-TB are also IIIV-infectect.6 
These children arc at risk of multiple opponunl tic Infections. 
have specific n utri tional dnd Illttabolic requlrClllt'tlts and absorb 
medications in a d llTerent manner to those HIV-unlnfected. The 
combination of MDR-TB and HIV Cdn have seriou psychological 
effects. Both condi tions are stlgmatl d and dfe perceived to (drry 
poor prognosis. li lV-infected childrrn are also treated with Jntl-
retrovir.1 the rapy (ART) medicat ions which have the potential to 
Interact with the second-line anll-TB drugs. Few studies havr 
eXdmined the t1l.lIlagement of childrt'tl with MDR-TB. TII()$' that 
have are stllJ lI and focus lllJiniy on outcomes with little auentlon 
10 the c.lreful dOCUllltntdtion of the challenges of treatmrnt.' - 19 
With the imminent roll-out of more rapid. I1lOlecuLtr diagno tic 
tests to Identify MDR_TB.20JI <.Ise detection. Induding that of 
children. is likely to risco In order to n)Jnagechlldren with MDR-TO 
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Retooling Existing 
Tuberculosis Drugs for 
Children 
To THE EorroR-The art icle by Dooley 
and coUeagues [1 I. on behalf of the effi -
cacy subgroup of Research Excd lenee 10 
Stop TB Resistance (RESIST -TB). is 
timdy and much needed. New tuberculo-
sis drugs are indeed Ii kely lobe several 
years away from widespread use, necessi-
tating our continued rdian e on existing 
drugs. Because combinations of 3 or more 
new d rugs are even further away. the first 
new agents licensed will need to be pro-
tected by multidrug regimens of exi>ting 
medications. Regimens of existing drugs 
require optinlization of dose. treatmen t 
duration. and treatment combinations. 
Th L~ paper serves as a caU to ac tion to 
address these research priorities. 
Desp ite the much-needed perspecti\1! 
provided. we note wi th concern the 
absence of any discussion regarding the 
e.xisting. albeit limited . evidence base fo r 
pediatric use of existing tuberculosis 
drugs and the retooling of dosages and 
regimens necessary to optimize treat -
ment in ch ild ren. Fu rthermore. no re-
sea rch priorities are identified for the 
investigat ion of existing pediatr ic drugs. 
Children with tuberculosis differ from 
adult s in many respects: the spectrum of 
disease man ifested. the way medication 
are administered. the manner in wh ich 
drugs are absorbed. and also the adverse 
effects experienced You ng children tend 
to metabolize drugs more rapidl y than 
adult s [21. resul ting in lower serum con-
centrations foUowing like-for- like 
dosing. pec ific fo rms of tuberculosis. 
such as tuberculous meningitis. are mOre 
common in children; specific drug prop-
erties. for example. cerebrospinal fluid 
Drug-resistant tuberculosis in children 
penetration 
considered 
should therefore be 
The discussion regarding retooli ng of 
existing tuberculosis drugs should st imu-
late consideration of th e appropriate 
timing to include child ren in drug trials 
of both novd and existi ng agents. Given 
the paucibaciUary nature of mo.'" form 
of pediatric tuberculos i at least equal 
efficacy can be <XptCted for the t reat -
men t of drug-reSistan t disea e In chil -
dren compared to adults. However. the 
high frequency of adverse drug effects, 
for example. thyroid toxidty in de\-dop-
ing children [31. make the urgent evalua-
tion of shorter and less toxic oombinatioo 
regimens mandatory. 
Knowledge of the pharmacokinetics 
of existing and novel drugs in children, 
drug-d rug interaction and the develop -
ment of chUd-friendly formulation are 
also prio rities. The effect of hu man im-
munodeficien cy virus (HIV) oinfection 
and the intera lion between tuberculosl 
drugs and antiretroviral therapy is a 
fu rther important pediatric onsider-
ation. giVt.'I1 the high preVlllence of 
pediatric HIV infection in tting 
where drug- resistan t tuberc\~ O i i In-
creasing [41. 
There is an Incrca ing awarene of 
the importance of includ ing children In 
clinical re earch on new and existing 
drugs [51. Regulatory au th orities have 
now made pediatric eVll luation of novel 
drugs a prerequisite for regulatory ap-
proval in Europe and the United State 
[6-71. However. major gaps remain in 
our knowledge of existing tuberculos is 
drugs and drug regi mens in children 
and fo r the retooling of these drug.o wilh 
new drug candidate As researcMrs, In-
ternational policymakers. implen~nter. 
James Seddon 
and civil sotiety we hould be advo t-
ing for the needs of children. the most 
v\~nerab lc member of our ociety. 
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The evolving epidemic of drug-resistant tuberculosis 
among children in Cape Town, South Africa 
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- _________________________________ S UM MARY 
SETTING: Tyg<' rbcrg hildron', HO<I il.ll. ~pc Town, 
uUlh Afric.1. 
OBJECTIVE: To del rminc Ihe prevalencc and [rend of 
drug resistance and hlllllan imlllunodeficiency virlls (HI V) 
co-infc:clion .Hllong chil dren wilh cullurl'-confinned 1lI -
berc ulosis (TB ). 
METHOD: Pros pc li\'c urwilbncc frOIll ~br h 2007 
10 FebruolrY 2009, COlliI'M d 10 Ihree prc"ious survey 
( I <l94- 199S, 2003-2005 , 2005-200 ). Drug u ('cpli-
hilily ICSling (DST) again I isonidzid (lNH ) and riblll-
picin ( R~lPJ was performed u ing genolypic and pheno-
Iypic lesting. If Illullidrug-r sist.11l! TB (MDR -TB ) "'.1 
dcrecled. furrh ('r DST aga inst ('I halnbulol (EM B) (l nd 
second-I inc drug \\'.IS performed. 
RESULTS: A IO I~1 of 294 children wilh ~ Illcdi .11l agc of 
26 lIIonths (range 3 d.lys-13 years) wcr di3gno cd wilh 
l'l,lrurc-collfirmed TB. D T resulls were avai labl .. for 
THE WORLD HEALTH Organiz3rion (WH ) e ti-
m:!led Ihat there were 440000 new case of multi-
drug-resistant nlberculo is (MDR-TB; i.e., Mycobac-
terilllll tllberclliosis resi tant ro isoniazid rlNH I and 
rifampicin lRMPj) worldwide in 2008. 1 Children wi lh 
drug- resistant TB usually have rransmirred resi rance, 
whereby the chi ld is infected by an organism with es-
tab lished resisrance.2-S Thi c ntrasrs wi lh adulr , in 
whom drug resi tance i a result of bOlh lransmissi n 
and acquisilion, the latter due to a susceptible o rgan-
ism deve lopi ng rcsi rance due 10 inadequate Ireat-
melll.6 hildren rarely have acquired resistance, a 
paediatric TB i usually paucibacillary; with mall or-
ga nism loads, it is unlikely Ihar re istant Illutant will 
occur and be elected. This is supporred by snldic 
comparing Ihe genetic DNA fingerprint (restriction 
fragment length polymorphism [RFLPJ), as well as 
Corresponden e t : Jam S Alexander Seddon, Paediarri 
Tyge rberg, 'IfX' Town, \X' st rn j<eddon@sun.lI .za 
292 (<)9.J %); 4 1 (14 0'0) w re INH-rc, i,t.III1, includin T 
_ (.9%) wilh ~IDR -TiJ. Four childrell ( 1.4 ~0) had 
Rj\lP 11101101' i IJII I: . EMB rc i'IJII Ce WJ present 
ill 11124 (50%) t.IDR-TB c."c, te tcd. Two ;,ol.lte 
were: r('\ill .1Il1 I OOox,\(' ill; 1I0ne h;ld ('Xlell iv I . drug-
rc iSla III TB. f Ihosf I red, 290(, (6312 1 ) ,,'('rt' HI V-
infecled. II ' rc i tam'c to RMP illac.1S I b rween 
199-1 .Ind 2009 (/' < 0.00 I), .J' did R lP lIIonor i<· 
11IIlce (P = 0.009) ,\lid ,\1DR-TB (P < 0.00 I . en iliv-
il)' w~ .5°~ .111 1 spe:.ifici l)' 100·0 ~ I' ll 1I01)'pi 
pM d 10 phcnorypic te lillg for INH rC' i 1.111(' . 
CONCLUSIONS : R,\l!', lind CO il ' qllCllrly mllilidru8, re-
sisram'e is in.:r<·.lsing .,,"oull childrell wilh TB ill Ihi. 
sellin!!. Et.1B res i lance: is C Il1lllnn .lIuong children wilh 
rc iSlall .. 10 R.\IP Jlld INH. 
KEY WORDS: I'" liorri-; D. T; I' <i'r.lllt; <un' .Ibn c; 
TB 
the drug su, eptibiliry te ting (D T) p. rr rns of or-
ganisms from hildren \ ith drug- re i tJnt Ttl I gelher 
with the likely IIrce ('-.1 e.7 Bolh RFLP and D Tare 
generally con ordant in uch a es, implying rr.ln mi -
ion f resistance from .Idult to children.S As paedi-
atr ic MDR-TB case repre t' llt re fnt inf('C tion , ith a 
dnlg- re istant tnlin, D T parrern in hild ren, p.lrtic-
ularl y am ng y ung children, provide illl rt:lnt in-
formarion reg.Hding urrenr tnm mi , i n p.ltterns in a 
c I11muniry or tting, facilita ling individual C.l e man-
agement, surveillan e and public hCoilth pl.lI1nlllg. 
Tradilionally, D T ha been determined by pheno-
typic method whereby bJ illi .Ire gr wn in the prt' -
en e of an antibiotic. If more than a certain per enrJge 
(u ualiy I % or more) of bacilli grow in ompari on 
ro a OIltrol wirhout J nribioti , Ihe h.l illi dre cia i-
fi ed as being resislanr. The e re r~ Jrt! reliable bur.lre 
Arl ide slIbnlltlf!d 29 epll'lIIber 20 11 . Flllal ,'ersioll a (~/ed I Jal/l/.lry 201l. 
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D ecentralised care for the management of child 
of multidrug-re istant tuberculosi 
ontacts 
J. A. Seddon,'oZ . H~s 
P. odfrey-F.usse tt ,2 H .. 
ling,' R. Dunbar,' H. 
haJf u 
http ://dx .dol.o rgflO.5588lpha.12.0023 
Set ting : Ca~ Town, South Africa . 
Oblect ive : To determme the number of multidrug-
resistant tuberculosis (MDR-TB) child contacts routine ly 
identified by health services and whether a model of d .... 
centralised care lmprov~s acceSS. 
Met hods: All MOR-TB source cases registered in Cape 
Town from April 2010 to March 2011 were Included. All 
child contacts assessed at hosp'tal and outreach cUnio 
were recorded from May 2010 to June 2011. Electronic 
probabilistic matching was used to match sou rce cases 
with potential chUd contacts; the number of children ac-
cessing decentr hsed (KhayeUtsha) and hospital-based care 
was compared. 
Result s: Of 1221 MOR-TB source cases Identified, 189 
(15 .5%) were registered In Khayelitsha; 31 (16.4%) had 
at least one child contact assessed. In contr.st, 95 (9.2%) 
of the 1032 source cases diagnosed In Ihe other Cape 
Town subdlst rkU (hospital-based care) had at lust one 
child conlact assessed (P = 0.003). Children In Khayelltsha 
were seen al a median of 71 days (Interquanile range [IQR] 
37-121 days) after source case diagnosis compared to 90 
days (IQR 56-132 days) in ot her subdIStricts (P - 0 .15). 
Con clusion : Although decentr.Used care led to an in-
creased number of child contacts being evaluated, both 
models led to the assessment o r a small number of po. 
tentlal child MOR-TB contacts, with considerable delay In 
assessment. 
Aleord ing to \ orld lI ealth rg nizati n (\ H ) \.."Stim:lh."s, thert" were 6 0000 prevalent cases of 
l1lultl<.lrllg.res1st~lI1t tuber ulo~i (l\ (OR· ·m . defined 01 
TB resistant to rlfampidn I~IPJ a nd Isoniazid II NHl> 
worldwiue in 20 10.' .1 Patients with urug-resi tanl Tn 
IOR-TB) live a nd Interact with numer us o ther pc'o--
pie, termed Olt-TII contact s. Although th" m.Jo rlty of 
individuals infected with M,rolM terlum tuberclllo'ii.s 
w ill never dewl p 11) disease,) young children aged 
< 5 years4.S and Individua ls wi th impaired Immunit)' 
,e.g., human Immunodefi len virus IHIVI Infected) 
art" a t high rhl:. of developing disease fall wing expo--
slire and infl' tlon.6,7 
A key TO ontrol strah..ogy I .. t identify th e contact .. 
f newly diagn sed TB ca..-' and r en them f r Til 
disease, enabling early treatment. If conta s are well 
but. re at high rl .k of developmen t of dls •• se, th ey 
a n I"C considered fo r pr<.'Ventiv(" trca tnu·nt.8 INt-I 
given da il y for 6 mon ths redu 5 the rl k of progres-
sion from inf,..-tion to dise.,.. in child ('ontaclS o f 
dntg-susceptlble TIl.",'O Although oviden " regarding 
Drug-resistant tuberculosis in children 
ox,'J. Hughe ,J K. Fielding,. 
preventive treatme nt r('glmen~ for child o nt{H .. -t .. 
MDR-TR patients is limited. ex-posed ch ildren shou ld 
be luentifi('Ci and s",<.'Cned for )'IlJR-nl ulse ... and fol-
lowed lip for at least I year." 
Th" WN and the m a l rlty of natlono l n\ pro-
gr.lmJ1H.'S advise tha t child ren age I < S yea rs ::lnu I IIV-
Infected children In o ntoct with an Inf lous asc of 
OR-lll h ould be Identified and '<'en by a specialist ex-
p"rlen In the management of paediatriC DR_lll.~1l1l 
In nlolny settings with a high bllrd n of OR-TIl. o n-
ta t tracing I p lOrly Implem"nt"d, whll. spedo llst ' 
with approprlah.· expcri\.·n e are few and uSLIally based 
In a ademlc referrn l centr . TIlls r~ult In long trJ\ I 
Jistoln c for (Xltl~nts. which may be cxpt.·llSive and 
tim.-consumlng. u h obstadcs m ay r.",it In a failure 
to access appr prlo te h ea lth servicelJ, 
Khay.Ut h ,a peri-urban I wmhlp and h ea lth nat>-
distri • Is I .lted o n the outskirts f th l' Jtyof pt:' 
Town, South Afri a. MN1 ns Sans I r ntler('~ has Ix: \n 
working in parmershlp with the I "al hea lth authuritll"l 
sin e 2007 to pilot a d< ('nttaiised m dd f ,arc for 1'-'-
tt ents wi t h DR~l11 . '11" patien t-cen tred, (.'Immunity· 
Il.,,..d appr a h I almed.t In rea Ing DR--I ll a,. d -
te<tion, improving trcatm nt ou t In nd redu Ing 
DR·l13 tran'imission . l.f 
One C I11ponent of th \.· pro~rammt' in lude ... a t V~ 
f lIow.up I ( ~hilll c nt s. In Dt.: (,lnhcr ZOOM, .a \pc· 
ia li st JXwdlatric In nthly outreath scrvt e wa es t,lb-
lished t m a nage htld wn tact s f l>R-TB pall nl\. In 
the rem.lnlng ",'" n subdistrict f the It)' of up..' 
Town, the traditiona l, h us pltal·ba ('<..I ~ystcm elf (:art: 
w"," con l inuro. induoJllJ{ th.:- idl'lltlfh.:ation of child 
co nta ts by local servl (It' and routln • ref'rral to the 
hospital-b..l scd speciall t o;cl"vice. 
n,e aim of thlj stud)' WD~ to determine Ih(,.~ num-
ber of (OR- n\ hOd co ntact s luenllth . ....t and wh\.·th~·r 
decentralise I cn re o fft'f improved ace, .. (ompa(c t 
to ho~ pltal .ba~ed car .... W e al<. Ime,", to dctt"rminc 
wheth r d entralised are was a socl.1tcd wtth m rC 
rapid Identlficatl 11 of child ,ont.ct . 
STUDY POPULATION ANO METHODS 
Sett ing and population 
The study was based In the City f Cape" wn h allh 
district , o n . of ix h ealth districts In Ihe \. estern 
pe Pr vll1 e of South i\frl " with a population of 
3 .4 millio n . 'r1lc di~trlct mprl~ eight ~uhdbtrlch, 
Including Kho)' IItsh., which hn\ a population of up-
proxlmaldy 000." Khuyellt h. Is a r ubdlstrlct 
with a predominantly Xhos.J-sl",.king, ethnl all blad. 
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Why do child contacts of multi drug-resistant tuberculosis 
not come to the assessment clinic? 
K. Zimri,1 A. C. He eliflg,1 r. Godfrey-Fall et t,l H. . haaf,I.J J .. edd fl U 
http://dx.dol.orgJl0.5S881pha.12.0024 
Background: local policy advises that children exposed 
to multKfrug-reslstant tuberculosis (MDR-TBl should be 
assessed in a specialist dink. Many children, however, are 
not brought for assessment. 
Methods: Focus group discussion was used to design 
.pproprlate questionnaires. From 1 September 2011, the 
first 50 children referred to the specialist paediatric MDR-
TB clinic, Cape Town, South Afrka, and who attended 
the ir clinic appointment, were recruited. The first 50 chil-
dren who were referred but who did not attend were 
concurrently Identified, tr.ced and recruited. Differences 
In group char.cteristlcs were compared. 
Results: The median age of the children was 35 months: 
48 (48%) were boys, 4 (4%) were human Immuno-
defiCiency Virus infected and 47 (47%) were of coloured 
ethnicily. Factors Significantly associated with non-
• attendance at the DR-TB clinic were: coloured ethnidly 
(OR 2.B2, 95%CI 1.21-<5.59, P = 0.01), the mother be-
Ing the source case (OR 3.78, 95%CI 1.29-11.1, P = 
0.02), having a smoker resident In the house (OR 2.37, 
95%CI 1.01-5.57, P = 0.04), the time (P = 0.002) and 
cost (P = 0.03) required to get to (he spec.,list clink, and 
fear of Infection whilst waiting to be seen (DR 2.45, 
95%CI 1.07-5.60, P = 0 .03). 
Conclusions: Reasons for non-attendance at paediatriC 
MDR-TB cliniC appointments are complex and are Influ-
enced by demographic, socia l, logistical and cukural 
factors. 
T he Wo rld Health Organization (W I I l and her a~ende1\: re-collllllend that duld contacts of multi· 
drug-r~<istant tuberculosis (~IDR-TB) sh .Id be as-
s.., cd r TB dlsease and, if well, f lIowed up f r a pe-
riod of at least yea r .'-11 TI,e ralionale is Ihal if child 
contaclS are found to have MDR-1ll disease, treatment 
can be Initiated rapidly. If they do nol ha\' disea , 
th<y arc followed to detecl incident 1ll disease, hil-
dren at the highest risk of disease progre slon follow-
Ing infection arc the ung (aged < 5 y ars),,,1J and 
Ihe human immuna.Jefidency \1rUS (HIV) inf ed." 
Ille policy regarding preventive tIealment of hlld 
conlacts of MDR-1ll patients Is debalable, with IInle 
evidence to inform pcacti e." A wide variety of advi e 
Is provided by different ag~ncies , but in the Western 
ape Pr \1nce of South frica the policy is t give 
t'thambutol, /loxarin and h igh-dose isoniazid (lNH) 
dally (o r 6 monlhs. 
In Ihe paediatric 111 Iileratu re, few "udies have 
quantified the prop rtion of ligible child contactS 
broughl for assessnwnt following exposu re 10 a case f 
Drug-reSistant tuberculosis in children 
infectiOUS, drug-susceptible TR, I6-3l Few studil~ hu\'\.' 
examined reas n for non-altendan c. hlldren may 
not be Identified, o r Ihey may be Idenllfied bUI then 
not I roughl to linie appoimment . In other heallh 
care onlexts, Ihe reas n r failure t attend paedlat-
ri e1inl appointments are complex, but in lude logl -
tic and finan lal aspect, parent ' educational 51 (U~ 
and the attitudes f the parents loward th e child, in-
ludlng per cpt! ns rega rding Ihe Importance o f Ihe 
disease."'" The attritl n for hlld TO cO.lI en ppean 
to occu r at every Slep In the Idemlfi all n and referral 
ca cade.19 
According t Wl-IO est imates, there w~re 650000 
prevalent ase f MDR-11I worldwide In 2010." MDR-
111 I d lintd as 111 re I tan I at lea I rlfam plein nd 
INH,J Not all f Ihe esllmaled adull case or currl'ntly 
dlagno~d, hUI with th e Imminenl r II-oul of new mo-
len.1 1 diagnoSiI tests, Ihe proportion diagn "d I 
likely 10 rise." A, each MDR-1ll 'iOur C cas,' intcro N 
with multiple hildren ,~' a large number o f hildrcn 
are exposed ea h year. Th managem III f hlld n-
to IS of MDR-TB differ fr III Ihal o f drug-sll epllble 
TIl, a In mosl pr gramme. Ih~y are man ged by J 11-
nldan with spe alisl knowledg and experlen e n 
paediatric MDR-TR, ',. Thl an have further logl tl 
and financial 1mI'll ations, os thl servl e I frequently 
onlya\·.lIabl In acad ml entre., pol nllall), lading 
I long delays In obtaining appolntm /lIS, I It Ih~r 
with Impll ations for travel and Incurred co t I the 
family. Furtherm re, MI It-HI ma be pwce.ved a' 
more danger us and more difficult 10 manage, p< \1-
bly further affeolng clin. attendance. W,' ,11111 ,'(1 t 
d~tt?rminp tentlal reJSOIH for lini 11 n·atU'nddnt'e 
among hlld c ntacts of MDR-1ll a~ , 
METHODS 
St tting 
The 111 n tineal Ion rate In Ihe Weslern ape Pr vln 
of uth Africa was 976 p r 100 In 2009,'" f chil-
dren with cultur.,.. onfirmed 1ll during 2007-2009 at 
the Tygerberg hlldren 's Hospital (TOn, 8 .9'~1 were 
diagnosed with MDR-TB,21 l .1 P IIcy Is th.I, f IJ w-
Ing th. diagnosis of MDR-TB In an adult, a h me vi It 
Is performed. HI -Infected hildren and children aged 
<5 years wh have been in o ntact with Ihl' MDIt-TB 
sOllr (' case are referred to their I al Iinl (rough! 100 
e.dsl in the ity o f ape Town Health distllct), where 
they are a~scs ed by the I al din I I am before ref cral 
10 the regiona l paediatll drug-re,lstanl (DR) TB din! , 
TIlls DR-TB linl takes place at T .H, a large provin-
dal, academic ho pltal and, s an outreach ervi ,Is 
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all symploms tn patients recciving oseltamivir lrcalment. Fever 
and cough \lere reduced by 2 and 3 days. respectively. a higher 
r<!ductton Ihan Ihat reponed by sy lemalic revic\I s f scasorul 
tntluenza .' A study of chtldren 1-3 years with easona l Influenza 
A HI N I dctccled a median reduction of illncss of 3.5 days and 
an average f.ver resolution time of 1.8 days fo llowing oseltamivir 
lrealment wtthin 24 hours : Ihey proposed that the observed differ-
ence' from previous repons were rei aII'd to earlier trealment' Thi 
explanation may be valtd to the urrenl study, because 62.5% of our 
patient s were treated withm 24 h urs. 
Th. World Health Organization reported a current esti-
mated AR III household contact of HI NI of22- 33% and a sea-
sonal IIlfluenza R of 15'!-•. ' Epidemiological field studies in 5.' era I men an states tndi ated thai the AR in hou eh Id on-
taets for acute respiratory Iline s was I - 19"10 and - 12% for Ill .' 
The'c differences III ARs may be influen ed by different com-
mUllIty control measures u h as hand washing. school closures, 
quaranllne. public recommendallons, use of masks. isolatIon of 
the t/ldex cases or number of households contact by mdex Cn e . 
The overall SAR fo r our p pulation was 15%. but Ihis rate 
signtficantly differed for household contact based on whether 
o ehaml\'tr prophylaxi wa received (IO.Q% trealed versu 
3 0. unlrc.t"d~ The usc ofn<ur.mlllidase inlubilors to Itmlt the 
spread of mfluenz3 is a key component of containment strategIc 
and the prevention ofinfccttons in people at risk of complication '. 
Oscltamlvir was well tolerated in thiS series: only mI ld 
gastrollltestlO.1 symploms \\ere obser\'ed in 120 • of palienls wilh 
oseltamlVlr treatment and in only 6° ~ of contact with pr phylaxis. 
ThaI may be ~.'plalned by the double dose used for Ire tment. but a 
pOSSIble biaS I~ that the household contacts were nearly all adults. 
No neuropsyehl31nc sid~ etli ts weI\' rep rted in our senes as 
reported III United Kingdom and Japanese tudles: ncvenhe le s. 
se\'era l recent re',ew' Mve demonstrated that oseltamiVlr is nol 
assocIated WIth an mcreased risk for those events.'o 
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DISCORDANT DRUG SUSCEPTIBILITY FOR 
MYCOBACTERIUM TUBERCULOSIS WITH IN 
FAM ILIES 
James A. Seddoll, MRCPCH. *t AllltClllie M. JOIT/aall . 
Med Tech.: Thomas C. Victor. PhD,: 
alld H. Simoll Schaaf. MD·§ 
Abstmtt: Chlld«n "'''h prrsumtd tubercul I who '" 10 C nl"'l '\lth 
o multtdruy-r<' I 'Ionl source ca hauld b. l""'led accordlO Iu the iliuj; 
uscepllbilllY of the source case" lsolot. H ~"'.T. II IS im~nanl 10 obtalO 
a mlcrobiol'ltIC daa1l005IS I II I pos5lble for Ihe: hlld 10 tu\t dlfrtrt"nr 
susceptlblhty profile: 10 the Ul'C'e cast \V.: preRnt.2 such caseJ 
1\ (') \\ord : tulx:r ulosli. chdd~n. re.Sl.sranL clilltCordanl 
C luldren with nlbercul ' is (TB) u,unll h.l\c pJUClbJ'lIlJ J,,-case and consequently nllcroblologl dla~M I an be hal-
IcnglllS. Til.! dlallno I I u,u,llIy matle pre umptt\cly on th~ bJSh 
of ussestlve symptoms. sIgn .nd ... dlol I chJngc. I 
to nllcrobl logi culture and drug u epttblltty tc-ttng (D ). 
whether phenotypIc or gen typl , I often 1IIlllted wh rc th burden 
of TB is Itlghe\1. hildrcn with pre~ulllcd TD ",ho ar~ III ,nta I 
with a multldrug-rcslstallt TB IMDR-TB . .IIl col><It' I('nUnt 1II""t\~I­
losty resistant 10 both I Ont zid and n~ mptnl source a • hould be 
treated accordms to Ihe D T pattern of the , Un:.! 3M)\ l..alate 12 
As it IS a umcd that chI ldren Will h \0 the same stratn nd D T 
a~ lhe Idcnttfied lIree e,' thIS gencral trategy IS usually ,altd 
However, It I 100ponant to obtaIn a tnl roblol 'I dlagn I GS It 
i po,sible ~ r the hlld t MVII n dIfferent D T to the 'l()lI!'Cc 1'0) 
The Impllcattons for the III nagement of the Iltld rc Ignlfi aIlt. 
We presenl 2 hl ldren \lh 00,,'1 pod Til followtng c nl. t \\tlh 
parents who had MDR-TB. TIl<) study 'va~ appro, cd b) !'tcll n-
bosch UnIversIty Ethics COntntltte<' 
CASE 1 
A 50-month-old girl presented "'ith f~ ... cr. \\CI 'ht Ie ~'. ough 
nd contact WIth her father who had prcvlOU Iy bc\'n dlngnosN with 
MDR-TB. u cpltble to ethambutol. ethlOl\Jntldc. oflo til aOO 
amlkocin. h" had recei\'ed Ba IlIo! almCltc-Gucnn Intmunlbltlon 
www.pldl·comI783 
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DISPATCHES 
Drug-Resistant 
Tuberculosis 
Transmission and 
Resistance 
Amplification 
within Families 
James A. Seddon, Rob M. Warren, 
Donald A. Enarson, Nulda Beyers. 
and H. Simon Schaaf 
Drug-resistant tuberculosis is caused by transmission 
of reSistant strains of Mycobacterium tuberculosis and by 
acqu isition of reSistance through inadequate treatment. 
We investigated the clinical and molecular featu res of 
the disease in 2 fam ilies after drug-resistant tuberculosis 
was identified in 2 children . The find ings demonstrate the 
potentia l for resistance to be transmitted and amplified 
within families . 
The de\'astating effects of extensively dJllg-resistanr tuberculosis (XOR TB) ga ined intemational attention 
after the 2006 outbreak in Tuge la Fen,),. South Africa. The 
evolution of the epidemic i the result of transmission of 
resistant strains and sn'ain acquisition of resistance t1u'ough 
inadequate treatment 1). Muitidmg-resi tant (MDR) TB 
is disease caused by MycobacleriulII IIIberclI/osis that is 
resistant to isoniazid and rifampin. and XDR TB i disease 
cau ed by .~f. IIIbercu/osis that is additionally resis tant to a 
fl uoroquino\one and an injectable second-line anti-TB dJllIl. 
Becaus e children usually ha\'e trans mitted resistance (2). 
they can be seen a the end of a sequence of transmission 
e\·ents. We describe im'estillations of 2 families after the 
identification of children with dlUlI-resistant TB in teml 
of clinical features and molecula; characteristics of the 
isolates . 
The Study 
Tlus im'estigation was conducted in a suburban 
conullunity of Cape Town. South Africa . where TB 
Author affiliatIons: London School of HygIene and Tropical 
MediCine. London. UK (J A Seddon); Stellenbosch UniVerSity, 
Tygerberg. South Africa (J A. Seddon. R M Warren. N Beyers. 
H S Schaaf,); Inte rnatIOnal Union Agalnsl Tuberculosis and Lung 
Disease , Paris, France (D.A. Enarson); and Tygerberg Children's 
HospItal, Tygerberg (H S Schaaf) 
001 http IIdx dOl.OrgJl0 3201 /e ld 1808 111 650 
incidence wa 978/ 100.000 popUlation in 2009 (HealtJl 
Systems Ttust). Since 1994. nuct'obiologica l SAmples from 
all patients treated fat' TB in this area have been sent to 
the re carch laboratory at Tygerberg Ho pital. Stellenbo h 
University. From 2008 through 2010. two children from 
this community receind a diagnosis ofMDR TB . 
lllfonllation was obtained from ~e\' ral oltrCe to 
document tile sequence of event that cnlmu13ted in the 
de\'elopment of MDR TB in ea h child. A horne \ 'i it wa 
made. and the family was inter; iewed after \\Tinen ulfomled 
consent was obtained. Family members were included if 
they either li"ed with 01' pent ubstalltial amount of time 
with the child (3). Infomlation on TB diagno i . treatment. 
and outcome was obtained at illterview. If a family member 
was identified as ha\' ing had TB. family OOla ts of that 
person were included. Searche for case no te for tho e 
included were made at the loca l linic. the n ademi 
ho pita Is. and the regional TB ho pital re pon ible for 
dmg-resis tam TB management . Al o. the local lillie TB 
register was consulted. The im'esllgntion wa approved by 
the tellenbo h ni\'er ity E tlu onuuinee. 
putlUD samples from tile 2 families were identified. and 
i olates were genotyped by spoligotyping ./) and I 6//0 
D A fingetvrintillg (5). train were identified a OrdUI 
to distinct [ 6110 banding pattent by using e\compar 
II (Applied Maths. Sint-Marten -Lntelll. Belgilun) or 
characteri tic spoligotype pattem (6). Milt. tioll nfenill2 
resistance to i oniazid. rifampin. etll3l11butol. pyrozinamid;. 
oftoxa in. and amikAcul were detemuned by D A 
equencing oflhe milA prom ter, karG. IpoB. I'lIIbB p'icA. 
gyrA, and ''I'S gene . respectively (7). 
A 19-1llonth-old girl (A3) receh'ed a diagno i of TB 
Ul Mal' h 200 after a 6-monlh ourse of pt e\'enti \'l~ tllerapy 
with isoluazid. he wa brought for asse, ment \\ ith a 
2-weeek hi tory of cough. re pirntol')' di li e s. and fe,·er. 
he had ontac t witll a palienl with pr XDR TB (MDR 
TB resistant to either a fllloroquinoione r ae nd-line 
injectable dmg). and Iherefore Ihe follow in antimi lobi I 
dl1lgs were ndmini tered: npre my in. elhion mide. 
ethambulol. para-amino alicyli aid. tetizid ne. 
clarittU'omy in. and lugh-do e i oniazid. Ga til n pi r te 
samples were sent to the National Hea lth L bolO! ry 
Servi e: M. I/Ibe/'c/I/osis grew in ulture nd \ 0 re i talll 
to rifampin . i oniazid. and ofloxn III and u eptible t 
amikacin and ethionamide. he re ein!d treatment Ii I' 1 
month from the time of her firs t negati\'e ulture (Ihe first 6 
month included rhe injectable medi a tion) nnd recovered. 
Patient 1 's family consi ted of 18 pe~on (Figure I ). 
The husband of her aunt (A2) had dl1lg-re i tant TB. H 
cared for the gU'1 011 a daily basis . He had re ei~ed treatment 
initially for dnlg-susceptible TB : thi wa changed to MDR 
TB therapy when res i tanee to tifampin and i oniazid wa 
detennuled and then to XDR TB trea tment when resi tan e 
1342 EmergIng Infectious DIseases ' wwwcdc gov/eld • Vol 18, No 8. August 2012 
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MAJOR ARTICLE 
Culture-Confirmed Multidrug-Resistant 
Tuberculosis in Children: Clinical Features, 
Treatment, and Outcome 
J ames A. Seddon.1.Z Anneke C. Hosseling.' Marianne Willemso.J Petor R. Donald.' and H. Simon Schaaf' ·' 
'Desmond Tutu Tuberculos IS Centre. Faculty of ftea lth $coerces. S lenbosch University. South Afr ica. 'Oepanrnent of Chmcal Research. Faculty of 
Infecuous and Tropical Diseases. wOODn School of Hygler,e iIfld TrDplcal MedIC""'. Un ited Kilgdom. ' Bra yn IIosprtal fe r Chest D.as Cape 
Town. and 'Tygerberg Child ren's Hospital. South Africa 
Backgro,,"d. Muhidrug-re is tam ( ~IDR ) tubercu losis in chi ldren is frequent I • asso ialcd with delayed 
diagnosis and treatment. There is limited evidence regarding the managemen t and out ome of hildren with 
MDR-tuber ulosis. 
"'1'1 /10" 5. All hildren < 15 years of ab'C with a diagnosis of cuhure- onfirmed MDR-tuher ulo is were in luded 
in this retrospective cohon tudy from I January 2003 to 3 1 De ember l008. with f, IIow-up documented until 
31 May 20 11. We identified children from Brooklyn Hospita l for alest Diseases and Tygerberg hildren '~ Hospit, I. 
Western Cape PrOl'ince, South Africa. Treatment outcomes were defined as 2-month ,p uturn-cuhure onver ion, 
treatment episode ou t ome. and survival. 
RrslI/ts. A total of III children (median age, 50 months) were in luded. The diagnosi wa delayed in children 
who had no identified MDR-tuberculosis index case (median delay, 123 vs 58 day.; P .001 ). ixty-two per ent f 
patients (53 of 85) were spu tum-. mear positive. and 43% of patient (43 f 1(0) were human immunodeftcien 
virus (HIV) infected. Overal l, 82% had favora ble treatment outcomes; to tal morta lity wn~ 12 n. Malnutrition 
was associated wi th failure to culture-convert at 2 months {odds ra tio {OR I, 4.49 (95% onfidcncc in t ~rV'Jl f II. 
1.32-15.21: P = .(2) and de:uh {OR. 15.0 (95% CI. 1.17-192.5 1; P - .04) in multivariate analy,is. HIV coinfeuion 
(O R. 24.7 (95% CI . 1.79-341.1 1: P = .(2) and the presence of eX lrapulmonary tuher ul sis (OR. 37.11 [95% J, 
2.78-5 13.4 J; P = .0(6) predicted death. 
CO/lell/siollS. Despite advanced disea.~e at presentation and a high prevalence of human imlllunodefi .ien 
viru oinfl'Ction. c.hildren with MOR-tuber ul sis can he t rea tt'" su,ces.~fuU y, u,ing individualized IrC'Jtmcnt under 
routine condi tions. 
Multidrug-resistant (MDR) luber ulos is is caused by 
M)'I.·obncterillln tllberculosis re islan t to isoniazid and 
riFJmpin. The \- orld Health Org'lnization (WHO) cs-
tima"'" that there were 4'10 000 new MOR-tuber ulosis 
cases worldwide during 2008 {I J. Treatment outcomes 
are generally poor in adulls, with favorab le oulcomes 
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Drug-resistant tuberculosis in children 
reportt'Cl in only 6O"A> of those rl"CCiving trC'Jtmcnt 12J. 
EVClll.hough hildhood tuberculo.."; make. up 15 , .... 20% 
of thc global tubcrculosis burden 131, MOR-tubcrcul . 
is poorly studi ed in hildren. the literature in luding 
mainly nse reports or small ,~se s~ri('S [I-I bl. 
The diagno i> or tuber ulosis in ounS hildren j, 
challenging and oftcn delay~d [ 171. Symplom, and sign 
may be nonsp if! . especially in hildren < 3 ("Jf> of 
age and in children infected with human immu nodefi-
cien y vi rus (HIV) 1181 . Brotuse of the paucihadllary 
nalure of hildhood tuberculosi" a microbi logi al 
di agnosis is rypi ally m:ldc in only 10°0-40 ,or s.. ... 
wilh radiologi al eviden e of in trathortl i di~ use 
[19J. Because drug su ep tibility testing (O T) i onl 
possible follmving bacteriological COnfinllJtion, on-
firmed MDR-tuber ulosis in chi ldren is infre<luent. In 
James Seddon P a ge 1306 
ORIGI AL STUDI ES 
Impact of Drug Resistance on Clinical Outcome in Children 
With Tuberculous Meningitis 
JlIllle5 A. eddoll. JIIRCPCH ... t DOIlII 'e H. /-'issel: MD.: Ma/'gC/l~r Ba/'leIl5./ 
AIII/emie '\/. JO/'t/lIl1l1. MTl!ch.§ Thol7ll/s . VicIOI: PhD. § A. MOIr'elille 1'1111 FII/'lh. PhD. : 
)0//(//1 F. 'c/lOem lill. MD. lIlIt! f-f. illIOII ellUl//. MD· 
B.r~~rllund : Tuberculous m.nlO~ltI .. (TBM) IS assoclalM wi th del3yed 
diagnosIs and poor outcome In children. This study Investlg3ted the Impact 
of drug resistance on cltnlca l outcome In children With TBM . 
\1l'thlH.h : All children (0-1) years) "ere Included IfadmJUed 10 Tn;erberg 
hlldrcn Ho,pItJI. CaP<' Toon. outh Afnca. from JanuarY 2003 10 Apnl 
2009 wtth a dlagnO!lI" of either contirmtXI TBM. or probable TBM with 
mycobaC1Crlo.11 Isolation from a sile other Ih:m cerebrospmal fluid . My 0-
bactcmll .sampl~s underwem drug suscepllbl lity testing (0 rifnmpm nnd Iso. 
nmzld Children ~ere treated with Isoniazid. nfampin. pyrazinamide and 
eth l ona11li~ according to loell l gUJd~lin~s , 
Itt" I1I,, : One hundred IwcllIy-three hlldren \\ere in Itlded: 13'0 ( 16 of 123) 
had any foml o f drua reSlstnn c. and ~o ... (5 of 123) had mullldrug·rcsistall1 
tU~f'('ulosls , TLme rrom stan or symptoms 10 appropriate treatment wa.s 
longer In children ",l1h any drug rtSlstance (me<lIan; 31 <L.1YS versus \) dayS; 
P - 0 ool} In muilivanabl. "nalyslS. young "~e (P - 0.0 13) and muilidrug-
resistant tuberculosIs (aUJusled odds rolio 12" [9SD o confidence inlen-al: 
I 17- 132.3]: P - O 037) rom31OM risk f,,'Iors for unfavorablo OUlcom •• and 
muilidrug-rl!sistant l'U~rculosl.s rcm:lIncd 3 r isk for death (adjusted odds 
rallO 63 9 (9~' . confiden c ,,"0"~1 : 4. +-8432]: P - 0.OO2). We did nOl 
dCl1!C1 any dlfferen(:e in out me bcf\\ccn those with Isolates resistant 10 
only lSoni:lZld and those with fully suscepllble strains (adJusled odds ratio: 
022 Iconfidence Inl.,,·ol: 003- 1.87]; P - 0.17) 
{'nnrlll, lo ll : Mullldru~-rcs"lnnl TBM 10 children h3S poor el lm . 1 out-
come and is nssocUlt~d with death. We did nOI find any difference In the 
utcomcs ~fween children wuh tsonl~ld moooresistan i TBM and tho~e 
wuh drug-suscepltblc TBf\1. One explanation cou ld be the local 1re..1 lmenl 
r~imen. Further In\eSIIg3tlon of lhls rCi:"llcn IS mdl ated, 
K,', \\ unh : pediatriC, m~ntngilis. tuberculOSIS. children. rcsisrance . 
OUlcon1e 
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Tuberculous m<.'ningills (TBM) i a "'Vere foml of ruberculo-SIS (TB) and frequently occurs in early chi ldhood. I Hem tog-
enous sprc.1d of bacilli from 3 primary pulmonary focu leads 10 the 
development of (I Rich focus in the bruin. Ruprure of this cas..'OUs 
gmnuloma illlo the subarachnoid spa c causes (he IIrucal features 
ofTBM.» This ustk111y starts insidiously with a prodromal pertod 
of nonsp...--cific symplolllS bUI as the disen e progresses. neck It lf-
ne . loss of conscIOusness. mOlor pare IS and com'Ulsl ns invaria-
bly follow. The diagnOSIS is often dela)'l.'d and only considered after 
irrevcr"ible neurologic damage has already occumd." nlre led. 
Ihe condilion is almoS! unrvers.1 l1y fain I wllh a me IIan lune 10 
dcalh of 19.5 days.' Even for Ihose Irealed TIlM I ~ as ialed with 
high rules of mOrlahly and morbidily; aboul 80". of hildren With 
advan ed di..,a<e at diasoo.is (TOM slaBe 11 and II I) Will develop 
neurologic sequelae.'- TIlM iSlhe mo I common auscofba lena I 
meningilis in th<! Weslcm Cape Pro\,,1CC (W P) f uth Arnea.' 
The World Health rgJniZlltion (WI I ) eslunated lhat tht.'re 
were -140.000 new cases ofmultidrug-rc. is! nt (MDR)TIl gloooll 
during 200 .' ~IDR-TB i caused bAIl''''''''/( Inillfn rubm ;uw ;. 
resislanl 10 both isoniazid and rifumpin .· E IcnsI'ely drug-r<!sl IMI 
Til IS adcliltoll!llly resi tanl 10 a Ouoroqurnolone and an mj('Ctable 
so ond-line antl-TB medi at ion. As TB In chlldrl'Jl IS usually paucl-
bacillary. mlcroblologi diagJlOSts occurs in only 2(i-40'. of case. 
Wllh eviden e of discasc' As drug susceptlhllity leSll118 (0 T) 
reqUirCli a microblologrc diagnOSIs, Ihe Jlagno " of MDR-TB til 
children IS oOen made preslImpuvcly. This IS based 011 SignS. symp-
toms and radiology ~uggcs li\'e of Til tn the conle:{I of ell her an 
MDR-TB ur e case or treat",ent f.1iltng III a child bemg rrCJll'd 
wllh first-hne regimen. A an MDR -TO source sc is nOI I" )'5 
Idenllfied. moSI children Wllh MDR-TD arc Ini ltally treated wllh 
3 first -line regimen unul therr culture and D T rC;lu lu are U\, lI-
able. an MDR-TB source case IS Id""Ufied or lI'ealm,'nll ' found to 
be fOl hng . TIle Inrliallon of approprlalc treaUncnl with ,~ and-line 
<lnlgs IS therefore oftcn delayed IR chi ldren "11h MDR-TIl .,. 
MDR-TBM has very poor outcome"" but I~re nre 
few data regarding chi ldren. The relatl n hip b.:twecn th<! .11 
w""re"lus/S stmm and cllmcal phenotype has been c~plor,'" U1 
bolh adu~t s and children with TBM '"'' with onn,ctlll!! rc ult 
The relallonshlp bctw,-cn strnln type and drug re"stance PJn~m 
j", complex, but a frong assoc1£l1ion c. i~18 belwcen drug re i ~ t nee 
and Ihe Beijing genotype . I .. '" The aim of Ihi siudy i to an Iyze 
whelher a rel3l ionshi p exists betwccn the drug usccptlbililY panem 
a flhe infecl ing M. I"b,'rel/lu;;s organism and the clinical outcome 
of TBM in children and (0 dClcnnine "hether this relaflon,hil' IS 
influencc<l by Ihe genotype of Ihe Slm,". 
PATIENTS AND METHODS 
Setting 
1»gerbcrg Children's lIasplla l (T Il l. tn the W. th 
Arri . provides specialized carc to half of the province's I 2 
million chi ldren. The W P had a TB notificallon (,Jle f Q7b per 
100.000 in 2009." and among all children with routlnel dlagr ~ 
The Pediatric Infectious Disease Journal . Volume 31, Number 7, July 201 2 www.pidj.com I 71 1 
Drug-resistant tuberculosis in children James Seddon P age 1307 
Jot R'IAL OF TROPtcAl PEDIATRK! , ~m I 
Multidrug-Resistant Tuberculosi of the Spine in 
Chi ldren - Characteristic from a High Burden Setting 
hI' Jam,-" . &:<lJon. ,·2 Peler R. Dona kJ.J Cen J. Vlok.4"s a"d H. imon Schaar:!.) 
I Dnlllo"d T/lIII TB Cel/lre. Depa,ylllelll 0 Poedill/rics alld Child lIeallil. Foelilry of fleallil Sci£7lces. lellellbo.,,11 Vllit"rsi" . 
Tnw rh<'l'ii . 7'IJ , SOlllil Africa 
2n' f',,,,,,wl/I a/Clill icnl Resenr II . FacII/IY o/ llIfeeliolL' a"d Tropical M edidlle . LOlldoll .<;,.11001 of III~ielle (Il1d Tropic/II AII·did" • . 
L,.,doll. JVCI E 71fT. 1\ 
JTl'gcri>erg Chilt/rm\ lIospiral. Cnpt' TOII'II. Tygt'rberg , 750) . SOI"h A;;ic/J 
'Diri,i"" o/ O"ll(Ipn{'(lic /lrger)' . FIII'IIIIY 0/ IfrClllII ·;" lIce . Slellmhoscil VI/ilw il)" Tygerb('rg . 750) . Sourll Iffri 1I 
' Tl'geri>erg flospiral. ClIpe TO'I'II . T)'gerberg , 7505. SOlllil A/riC/( 
COrreSplJlltJellce: Jallles A . eddoll . Desmolld TUII/ TB CmIT •. PO Box 19063. Frallcie " (III 2.1 1 Dri .v. T,I'gerherg . 7505 . 
CIIP~ TOtI7l , OIull If[rica. Tel: +_7 11 93 9177; Fllx : + .:'7 !I 938 9719; E'lIIllil: <j,eddoll (o SIIII.(IC.:II>. 
umm3f) 
l1a(·k:.:round: Fell sludie~ hale dr~('rihrd childrm "ilh sllinll l mll"idru:':-fl'~ i~ I U III luhermlo";, 
(.\IUR-TI1). Trealment imohes surgery :lI1d medical clIre "ith long courses of drug Ihemp). 
:\ I (' Ihods: II o~llilal and laboralory recortL~ :11 I1rooklyn (llesl :llId T~ gerherg (,hildren'~ lIo"pitul,. 
ap<' TOlin • • outh Afric:I . li ef{' an:tI~~C(1 (,J:lnu:lr~ 20U" until l)et'('mbcr 2010) "'urching for children 
lrealrd for :\ Jl)R ~pilla l Til. 
Result ': Of Ihe II children idenlified ... were excluded. Of Ihe 7 remaining, S lIere hu~ s: median age: II 
~t· al'\. mrdiull delu)' In Irealment inili:lliun: 36 IIcch, Amollg tll('m nn(' child died. file IIlIlC compleled 
Ir(':llmellt 11I1d olle i~ n(,:lr Ih(' (,lid of thenlll~. :\1('dk:lIion .. lien' lIell-lOlcrull'd alld ulthoul!h 1110 nf Ihe 
sun ilinl: childr('n IUlIe ~pilla l defonllit~. none h:l"(' sicnilicnnt neurolugical deficit . 
Cun lu,ion..: Thl.' dia l!nu,i ~ of spinal :\JI)R-TO i~ oft(,11 dd:l~ ed in cllildrcn. frr(IUenll~ lendinJ: 10 
:ld\(ln('('d <li"':ls(' and 'oe' erc H'rtebral dumugc. Children tnlt'ru tl' thenlp~ 11(' 11 und. nnce idenlified, il 
is :I condilion Ihul ClI n be lrealed succe~~rull)'. 
I ntroduclinn 
Spina l tuberculosis (TI1 ) in children can be a debili-
taling di,casc , ilh potentia l long-Ierm neurological 
scquelae. Treatment involves a combination of surgi-
ca l and medical care with long co urses or drug ther-
apy, M ult id rug-resistant (M DR )-T B occu rs when 
JI[,l'coba tefilllll tuberculosis is resistant 10 rirampicin 
and isoniazid. II was es timaled lhat therc were 
440000 new casc. or 'IDR·TB globully during 
2008 [I) and in many high.incidence sell ing' 
childho d T il make. up I 20"0 of the 10101 burd~n 
[24). Pacdial ri MDR · n i. difficu lt 10 diagno. e 
and the initiation of clTecti vc Ihcmpy i~ olien del.lyed 
[5). The drugs used are less effective und m rr to ie 
Ihan Ihe (j"l-linc medicltlions; lI'Cmtnl!nl i .. Ih l!rcforc 
longer and wi th frequent adverse elTe I., Fc\\ paedl-
alric spinal MDR-TB siud ie:. h:lvc b...~n publi hed . 
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Summary Objective : The aminoglycosldes and polypeptides are 'lital drugs for the manage· 
ment of multldrug· resistant (MDR) tlberculosls (TB) . Both classes of drug cause hearinilloss . 
We aimed to determine the extent of hearing loss in children t reated (or MDR·TB. 
Methods: In this retrospective study, children « 15 years) admitted to Brooklyn Chest Hospital, 
Cape Town , South Africa , from January 2009 until December 2010, were Included If treated for 
MDR·TB with Injectable drugs. Hearing was assessed and classified using audiometry and otOil ' 
coustic emissions. 
Results: Nlnety·four children were Included (median age: 43 mCJ1ths) . Of 93 tested . 28 (30\) 
were HIV·infected . Twenty · three (24%) chi ldren had hearinilloss . Culture,cCJ1f1rmed. as op· 
posed to presumed. diagnosiS o f TB was a risk factor for hearing loss (OR: 4 . 12 ; 95% CI : 
1.13- 15.0; p = 0.02) . Seven of 11 (64%) children classified as ha ving hearing loss using udl· 
ometry had progression of hearing loss after finishing the injectable drug. 
Cone/us/OtIS: Hearing loss is common In child ren treated for MDR ·TB. Alternative drugs are re o 
qulred (or the treatment o( paediatric MDR·TB. 
~ 2012 The British Infection Association . Published by Elsevier Ltd . All rlllhts reserved. 
Abbrevlatlans: /.'DR, multidrus· resistant; DR, drug-resistant; TB . tLi>erculosis ; WHO. World Health Oraanlzatlon ; PTA. pure tone audiome-
try ; OAE , otoacoustic emission; OPOAE, distortion product otoacoustic emission ; BCH. Brooklyn Chest HospIUI; 1M, Intramuscu lar; ASHA, 
American Speech and Hearing Association; OR , odds ratio; CI , confldence Intervals ; IQR, Inter·quartlle range . 
• Correspondini author. Desmond Tutu TB Centre, Department of Paediatrics and Child Health , Clinical Bulldina, Room 0085. Faculty of 
Health Sciences. Stellenbosch University, PO Box 19063. Tygerbera. South Africa . Tel. : 2721 378 91n; (ax: 2721 9389792 . 
( ·mail address: jseddon@sun.ac.za (J .A. Seddon). 
0163-4453 / $36 ~ 2012 The British In (ectlon Association. Published by Elsevier Ltd. All rights reserved. 
http://dx .dol.org / l0. 10161j .jlnf.2012.09.oo2 
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Pharmacokinetics of Isoniazid, Rifampin, and Pyrazinamide in hildren 
Y oungcr than Two Years of A ge with Tuherculosis: Evidence 
for Implementation of Revi cd World H ealth 
Organization R ecommendation 'fl 
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D"po,I7I1('1I1 of P(/~diatric Pllellmology mId !tIl/IIIIIIOlo&\,. Charilf. Ulliversilolsmedi!ill Berlin, GenTlDlIY'; De,moold TI/ II/ TB Cell,". 
Depanlll1'llt of Paediatrics alld O,ild Heoillo, Facility of Health Sdences, telk'llboscl, UII;"l.'rsity. Tyge~rg. SOl/ lh Afrim'; 
lillical &la/Ie" Deparm'm~ Faalll)' oJ Iotfocrioo/S alld Tropical D;s..'tISeS. WldOf' School of HrgilU.' will Trvpical Medicine. 
w,dool. Uo,in'd Ki,tgdOlIl -'; Di"isioll of Phannacology, lelll!llboscl, UI/i"ersir),. Ty'~erberg, 01111, Africa·; 
Divisioll of MoleCIIla, Biology mId Hlllllan Gmerics, Faclllf)' of Healtlt Scieoo ('S, Id/fllbosc/I 
Ulli"""'iry • .,., '!,'('l'ix:rg, SOllrlt Africa'; and Io'Slilllll.' for Social Medicine, Epillemiolo ' aI/ii 
Heallio ECOIIOlllics, C/oarillf. Ulln'ersilalsmedizil/. Berli". Gmnully" 
Received 31 July 20 1 VRclurncd for modifie," ion 7 Scplemher 20 1llAc pled 27 plemher ::011 
'Ille Wor ld II callh O!,)!u ll izalion (WII O) reccm ly l" ul'(l rc 'i~l'(l fir'I -lill e II nliluhcrl'U lo,l, (u llI i-Tlll dm)! 
dO'"Il~ n'romm~ndall on. for childrcn. ' 0 pha rm arokillNIc ~ lUdics for Ihe<c rc,'l I.'d dO<IIIl' " li re " ' :1 lta hlc for 
('hildren <2 year" The aim of Ihe , Iud) ":1 ,10 documenl Ihe Ilha rmll(,Olkin clic, ol' lhe fi r' I-line 01 111 1- fII "gl'm, 
ill chil dren <2 yea rs Olf age ('Omlla rillll pre'ioll ' alld n " hcd WilD dO'"llc' of ""lI hl/ld (IN" : ~ ' cr' u, 10 
1II!!1 kj.:ldll) l. rifa mpin ( I~MI': III ver, us 15 IlIwkgldllyl. a nd p)nllinamide (l'ZA: 25 'H,U' 35 1lIl: kj!'duYI II l1d 
III inw' llgll lc Ihe ell'"I'' ' of din kll l c(lvllrlulc" IIIl'iudi nl( IIiV ('olnfr('lion, nUlrh ionul '1U Ilh. IIge. gcnd('r, nnd 
Iype or luberl'll lo,is (nl), nlld Ihe cU'('('I of An lIcelylalcor ' I II III~. SHum INII , 1'7,.;\, and RM I' Ic,eh " I'n' 
pro'pcI'I " 'el) IIs.e.sed in 20 children <2 )cars nf nil" Irelil cd fo r 'I'll fo ll" " lnll Ihe Ilrl" inu, und Ih(' n ', l,cd 
W1l0 do, age re('olllllwndalioll ' . Samples " or. wken prior 10 do,ing • lid II I O.S. L~. _' . "lid 5 h fllll o" llIl: d",IIII!. 
The maxim um d llll( COII{'r rllrnlion In ,crllill (('",",). Ihe lillie 10 C ... , (1 •• ,, 1, nnd Ih,' IIrell " ndl'r Ihe l'iJlIl'Cn-
Iralioll-lime r u.,'e ( Ut:) were ca lculated. Eleven ch ild ren hnd IJUlnHllIIl1') a nd <) had ul rll llUlmonul') I'll. Fhc 
\\ ere III V infef led, The melln Ch~" (,LWml ) foliowi nJ( Ihe udllllni , lruII" n I1r prcvIOl" lrf , I'NI do,uJ(c, \\,'re II' 
f" lI o" .: I II. J, I 9/R, I I : Rr. II' . 6 . .16/ 11.69: l' lA. 29.9~/~7, 11 . The lll oun Alit: (Jolt: . hlml ) \\ ~r.'l> foll 'I''': INII . 
K.I~J/2Il . .I6: R~II'. 17.7K . 6.')S: I'ZA, I lK_Oi l 7S.2. '111e III I' a li CIII" a nd AU . dlll'~n'<l ,i llnifil'a UlI~ 1" 'I,\('t'n dfl, ",. 
°n,en ' "as nu d ifference in th ... · ' min. , a l ue~ lu'hie\'l-l{!. hildren h.~~~ Ihun 2 ~ ~ur4io fir 1IJ.!~ 1u'hiCH' tur~CI f'o nCl'n· 
lrallon, of fi r' I-line anll -TIl agl'lIl ;, u. lng n " ised WIIO dlN'I((' rCl'ommcnda liun \, O ur da lll prl/' IdNI '''p-
po rl i\'(' I" id('m'e for II ... implelllenlillion Ilr Ih c rC"lsed wlln ~u ld(· l i n ' ... fllr fir' l-tine tHII I -Tlll henop~ In ~ lIlm t: 
dlildr~n , 
lson ~lzid ( I H ). rifa mpin ( RMP). and pyTazinamidc (PZA) 
a re rou line ly used to Irea l luberculos is (TB) in children (23. 
+4) , Rccomme ndali n f r pcdia lric dosages li re based on " 
small number of pharmacokinelic sludies, few o f which in-
cluded children younger th an 2 years of age, D uring early life. 
children experience Slgnificum changes in the re lal ive sizes of 
Iheir body comparlmenlS and Iheir ubil ity 10 absorb. melabo-
lizc. a nd excrele drugs (5, 17), The e change a re greatesl 
wilhin Ihe first 2 yea rs of life (4), Most published siudies on 
fir' l-line atlli-TB drug in children have nol analyzed diffe r-
ences belween older and younge r children or Ihe effect of HI 
coinfeclio n, The pharmacokinel ics of INH are further compli-
cated by ge nelic polymorphlsms of -acerylrransfe ra'IC type 2 
(NAT2) in Ihe melabolic palhway of INH, which inOuences 
INH concenlra l ions ( 18.26. 46), 
• Corrc~pondins au thor. Mailing addn ... ·~,s : Department ,:)r Pacdtat-
roc, and hikl Health. P,O, Bo., I~. Tygcrherg 7505, South Africa , 
Phone: 27,21.9.\89 11 2, Fa." 27,21.939 1 . E-mail: h (/'un,ae,Z(I , 
In Ihe nb;cn c f ph nnn od muuie d,IIU lor children ~nJ 
Iher.fore dala Ihal demonslrJIC an a~ .. oda l ion b~"'een ,Num 
drugconcenlr:lllon and lini nioul me. oplimul fimi- I3 l h~r­
apy should ailll 10 produce the large lcd .en'lll drug con en-
Ir:llions Ih ll l have been del'rmincd in ndu ll phurmuo.,kincli 
an<! pharma oo:lynamic sllIdies, For INH. the pmJXl",d opUmal 
maximum ",rum In'g ,"cenlrntion ( m, .. ) for Ihemp i 3 10 
5 J.l.g/ml ( 15. 27 ), T argel se n,m RMP cOnCCnlrlllion in uduh, 
aft e r a slandard ral dose r 600 mg a rc inlhe range f 102-1 
Ilg/ml; se rum RMP eonee nmll ion below 8 Ilglml lire n,id-
ered low. and Ihose be low -I11g11l11 are con;ide red ,ery low (2 . 
29). There is more un 1111illlY regarding Ih e oplinlal Ihera-
peulle serum PZA conee nlrat ion, In adull, • • e rum P 'It 1-
ce l1lral ions are largeled (I I 20 1060 Ifoglml ( II. ), Howe'er. U1 
a rece", siudy o f adull . poor Iren tmenl OUI Jme of pUhlIL~'ar}' 
TB was msoeiOlcd wllh se rum PZA oonccnl ru li n, I,r r ~ 
Ilg/ml ( ) , 
• Publi'hed ahead of prinl cn 3 October 2fJ1 I. 
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Oplimal ami-TB Ihe rapy Is impon (l nl in a lt hildrcn bUI 
particu larly in young chi ldren « _ years of age) a nd IhtbC HI 
infecled. whe re Ihe re is a high rl k f progrc ion to "ere 
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Linezolid-containing regimens for the treatment of 
drug-resistant tuberculosis in South African children 
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__________________________________ S U M MA RY 
BACKGROUND : Tre.ltnlent options for dru ·resismnt ru · 
berculosis (DR-Til ) Jre limited. Linezolid 113 be n uc-
cessfull ) u cd to tren t DR-TIl in "dults, but th re M 
fe w c:lse report o f its use in childrcn for Til. The rc-
ported rate o f ad' crse el cllt5 in adulrs is high. 
METHODS : \ C cOllducted a retrospecti , c rel ic" of chil-
dren with DR-TB trented "ith linezolid·conraining regi-
mens from FebruMY 200 to March 20 i2 at two uth 
Afri an hospita ls. 
RESULTS : evell children (three hllman intmllno-
defi cienc) viru < IHI I infectcd) receil cd a linezolid-
,omaining reg imcn. All had culture-co nfirm d DR-TB; 
fi, e had preliOIlSi) f" i1ed second-line " nri-rube rcul osi~ 
trea tmcnt. Fo ur d .ildrcn lI ere ured Jnd three were . till 
r{',{'iving "nti-tuberculos is treatment, bur had ultu rc 
om erted. one of the non-HiV-i nfc ted child ren cxpe-
T H E N UMBEIl OF PEOPLE w ith drug- resistant tu -
berculo i (DR-TB) is increasing world wide; the World 
H eal th Orga niza tion (WHO) es tima ted that there 
' ere approximately 650000 preva lent ca e of 
mu ltidrug-resi tant TB (MDR-TB) globa lly in 20 I 0. 1 
The trea tment of MDR-TB (i. e., Mycobacterium tu-
berculosis res i tant to a t least i oniazid [INHJ a nd ri-
fam picin [RMPJ) a nd e>..1:en ive ly drug-re iSlant TB 
(XDR-TB; i.e. , MDR-TB with additio na l resi tance 
to the tl uoroqu ino lone and a t lea t o ne eeond-line 
injectable agent) i compl i a ted by limited trea tment 
o pt ions, long trea tment duration a nd a high risk of 
ad ver e events.2 
Linezolid i an oxazolidinone antibiotic u ed pri-
marily in the trea tment of DR gra m-po irive ba reria l 
in fect ions, w ith bo th in vitro a nd in vivo activity 
aga inst M. tl/bercl//osis. It inhibits protein ynrhesi 
a t an early stage o f tran lation by binding to the 23 
rRNA. Th is un ique mecha nism o f action means that 
ro s-re i ta n e with other anti -tu berculosi drugs i 
rre pondence to: Pendope 
ri necd .Idv rs el nt. ",hil r c ivins line1.Olid. Thr 
HI -infect d children h.1 I .Id, r. I nts, on of IIh ich 
\\'.1' life-threat ning; linczolid II .• perm an ntl ) dismn-
tinucd in this C.I e. Adv rsc c'Cnts indud d lactic ac id -
is (II = I ), pan rea tilis (II = 2) , periphera l neuropath) 
(II = I ) and a'YllIptomari hone marroll h popla\ia 
(,,= i ). 
CONCLUS ION : Linezolid a nl.l ining regim n .In be f-
f li,e in trc •• tin childr n II ith DIl-TB CI n afrer fai ling 
,eeond-l in tr ·" tm nt . d' crs >ent, .!lOuld be 1II0ni-
ta red, <p da lly in o mhi n.uion with III di .n ion that 
h.lw illli"'r ad.cr e cHe ts. Lin za lid remni n c tI ), 
.lIId n reduced do ••• S' .lIId dut'..tion III •• ) rcsult in fe" cr 
ad, rIc el ent' .mel lo" cr (H r. 
KEY WORDS : pacdiatri ; TB; I ng-term; li n lolid 
rnent outcom 
trea ted wi th Iinezolid- o ntaini ng regime n , de pite 
signifi ant ad ver e e enl • in patti u l. r neuropathies 
and myelo upprl' ion.'-7 F ur ca c rc rr o f line-
zolid use in child ren with MDR-TB and DR-TB d -
ri be the outcomes fo r a tota l or seven hild r n 
trea ted with linezolid o ntain ing regimen . -\I Three 
hildren e peri en ed adver e event. Linezolid w'a 
sto pped in ne pa tient ~ ho developed 13 t i a ido i • 
and the dosage wa redu ed in a nother t\ 0 hildren. 
onc o f who m developed anaemia and neuropa thy 
and the other an urti aria l ra h. All hildren had a a-
vourable out me, either ure o r lini, I re p n e, 
and were a ymptomati at trea tment omplction. 
Two revie\ have de ribed thc u c f linczolid in 
hildren , mai nly documenting ho rr- our rreatment 
ArliC/1' slIbmiltl'd I May 2012. Final II('TSIOIl QCCI'pied 1 filly 20 /2. 
Drug-reSistant tuberculosis in children James Seddon P age 1311 
References 
1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione Me. Consensus statement. Global burden of 
tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global 
Surveillance and Monitoring Project. JAMA. 1999;282:677-686. 
2. World Health Organization, Geneva, Switzerland. Global Tuberculosis Control Report -
surveillance, planning, financing. 2008. 
3. Dye e. Global epidemiology of tuberculosis. Lancet. 2006;367:938-940. 
4. Mandalakas AM, Detjen AK, Hesseling AC, Benedetti A, Menzies D. Interferon-gamma release 
assays and childhood tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis. 
2011; 15: 1018-1032. 
5. Zar HJ, Hanslo 0, Apolles P, Swingler G, Hussey G. Induced sputum versus gastric lavage for 
microbiological confirmation of pulmonary tuberculosis in infants and young children: a 
prospective study. Lancet. 2005;365:130-134. 
6. Marais BJ, Gie RP, Schaaf HS, Beyers N, Donald PR, Starke JR. Childhood pulmonary 
tuberculosis: old wisdom and new challenges. Am J Respir Crit Care Med. 2006;173:1078-1090. 
7. Du Preez K, Schaaf HS, Dunbar R, et al. Incomplete registration and reporting of culture-
confirmed childhood tuberculosis diagnosed in hospital. Public Health Action. 2011;1 :19-24. 
8. Petrini B, Hoffner S. Drug-resistant and multidrug-resistant tubercle bacilli. Int J An tim icrob 
Agents. 1999;13:93-97. 
9. Pablos-Mendez A, Raviglione MC, Laszlo A, et al. Global surveillance for antituberculosis-drug 
resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and 
Lung Disease Working Group on Anti -Tuberculosis Drug Resistance Surveillance. N Eng/) Med. 
1998;338: 1641-1649. 
10. Cohn DL, Bustreo F, Raviglione Me. Drug-resistant tuberculosis : review of the worldwide 
situation and the WHO/IUATLD Global Surveillance Project. International Union Against 
Tuberculosis and Lung Disease. Clin Infect Dis. 1997;24 5uppll:S121-130. 
11. Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-resistant 
tuberculosis. N Eng/ J Med. 2008;359:563-574. 
12. Keshavjee S, Gelmanova IV, Farmer PE, et al. Treatment of extensively drug-resistant 
tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet. 2008;372:1403-1409. 
13. World Health Organization, Geneva, Switzerland. Global tuberculosis control. 
WHO/HTM/TB/2011 .16.2011. 
14. World Health Organization, Geneva, Switzerland. Anti -tuberculosis drug resistance in the world 
- report no. 4. 2008; (WHO/HTM/TB/2008.394). 
15. Department of Health, Republic of South Africa. Management of Drug-resistant Tuberculosis. 
Policy Guidelines. Available at: http://www.doh.gov.za/docs/policy/2011/pollcy TB.pdf 
(accessed 17 July 2012). 2011. 
16. World Health Organization, Geneva, Switzerland. Guidance for National Tuberculosis 
Programmes on the management of tuberculosis in children. WHO/HTM/TB/2006.371, 
WHO/FCH/CAH/2006.7. 2006. 
17. van Rie A, Beyers N, Gie RP, Kunneke M, Zietsman L, Donald PRo Childhood tuberculosis in an 
urban population in South Africa : burden and risk factor. Arch Dis Child. 1999;80:433-437. 
18. Marais BJ, Hesseling AC, Gie RP, Schaaf HS, Beyers N. The burden of childhood tuberculosis and 
the accuracy of community-based surveillance data. Int J Tuberc Lung Dis. 2006;10 :259-263. 
19. Lin Pl, Flynn Jl. Understanding latent tuberculosis : a moving target. J Immunol. 2010;185 :15-
22. 
20. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official 
statement of the American Thoracic Society and the Centers for Disease Control and Prevention 
was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the 
Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care 
Med. 2000;161:1376-1395. 
Drug-reSistant tuberculosis in children James Seddon P (\ ge l 312 
21. Schaaf HS, Gie RP, Kennedy M, Beyers N, Hesseling PB, Donald PRo Evaluation of young children 
in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. 
Pediatrics. 2002;109:765-77l. 
22. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the 
absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis. 2006;10:1192-
1204. 
23. Graham NM, Nelson KE, Solomon L, et al. Prevalence of tuberculin positivity and skin test 
anergy in HIV-1-seropositive and -seronegative intravenous drug users. JAMA. 1992;267:369-
373. 
24. Hesseling AC, Mandalakas AM, Kirchner HL, et al. Highly discordant T cell responses in 
individuals with recent exposure to household tuberculosis. Thorax. 2009;64:840-846. 
25. Pai M, Zwerling A, Menzies D. Systematic review: T -cell-based assays for the diagnosis of latent 
tuberculosis infection: an update. Ann Intern Med. 2008;149:177-184. 
26. Machingaidze S, Wiysonge CS, GonzaleZ-Angulo V, et al. The utility of an interferon gamma 
release assay for diagnosis of latent tuberculosis infection and disease in children: a systematic 
review and meta-analysis. Pediatr Infect Dis J. 2011. 
27. Huang VW, Shen GH, Lee JJ, Vang WT. Latent tuberculosis infection among close contacts of 
multidrug-resistant tuberculosis patients in central Taiwan. Int J Tuberc Lung Dis. 2010;14:1430-
1435. 
28. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using 
Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United 
States, 2010. MMWR Recomm Rep. 2010;59:1-25. 
29. European Centre for Disease Prevention and Control, Stockholm, Sweden. Use of interferon-
gamma release assays in support ofTB diagnosis. 2011. 
30. World Health Organization, Geneva, Switzerland. Strategic and technical advisory group for 
tuberculosis (STAG-TB). Report of the tenth meeting. 2010. 
31. Rieder HL. Epidemiologic Basis of Tuberculosis Control. First Edition. International Union 
Against Tuberculosis and Lung Disease. 1999. 
32. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in 
childhood and adolescence. Am J Epidemiol. 1974;99:131-138. 
33. Mitchison OA, Wallace JG, Bhatia AL, Selkon JB, Subbaiah TV, Lancaster MC. A comparison of 
the virulence in guinea-pigs of South Indian and British tubercle bacilli. Tubercle. 1960;41:1-22. 
34. Middlebrook G, Cohn ML. Some observations on the pathogenicity of isoniazid-resistant 
variants of tubercle bacilli. Science. 1953;118:297-299. 
35. Barroso E, Mota R, Pinheiro V, Campelo C, Rodrigues J. Occurence of active tuberculosis in 
households inhabited by patients with susceptible and mulidrug-resistant tuberculosis. Jornal 
Brasileiro de Pneumologia. 2004;30:401-408. 
36. Snider DE, Jr., Kelly GO, Cauthen GM, Thompson NJ, Kilburn JO. Infection and disease among 
contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli. Am Rev Respir 
Dis. 1985;132:125-132. 
37. Teixeira L, Perkins MD, Johnson JL, et al. Infection and disease among household contacts of 
patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2001;5:321-328. 
38. Risk of tuberculosis among contacts of isoniazid-resistant and isoniazid-susceptible cases. Int J 
Tuberc Lung Dis. 2011;15:782-788. 
39. Johnson R, Warren RM, van der Spuy GO, et al. Drug-resistant tuberculosis epidemic in the 
Western Cape driven by a virulent Beijing genotype strain. Int J Tuberc Lung Dis. 2010;14:119-
12l. 
40. Hanekom M, van der Spuy GO, Streicher E, et al. A recently evolved sublineage of the 
Mycobacterium tuberculosis Beijing strain family is associated with an increased ability to 
spread and cause disease. J Clin Microbiol. 2007;45:1483-1490. 
41. Thwaites G, Caws M, Chau TI, et al. Relationship between Mycobacterium tuberculosis 
genotype and the clinical phenotype of pulmonary and meningeal tuberculosis. J Clin Microbial. 
2008;46:1363-1368. 
42. Gessner BD, Weiss NS, Nolan CM. Risk factors for pediatric tuberculosis infection and disease 
after household exposure to adult index cases in Alaska. J Pediatr. 1998;132:509-513. 
43. Singh M, Mynak ML, Kumar L, Mathew JL, Jindal SK. Prevalence and risk factors for transmission 
of infection among children in household contact with adults having pulmonary tuberculosis. 
Arch Dis Child. 2005;90:624-628. 
Drug-resistant tuberculosis in children James Seddon P age 1313 
44. Shaw JB, Wynn-Williams N. Infectivity of pulmonary tuberculosis in relation to sputum status. 
Am Rev Tuberc. 1954;69:724-732. 
45. Kenyon TA, Creek T, Laserson K, et al. Risk factors for transmission of Mycobacterium 
tuberculosis from HIV-infected tuberculosis patients, Botswana. tnt J Tuberc Lung Dis. 
2002;6:843-850. 
46. Siddiqi K, Lambert ML, Walley J. Clinical diagnosis of smear-negative pulmonary tuberculosis in 
low-income countries: the current evidence. Lancet Infect Dis. 2003;3:288-296. 
47. Cruciani M, Malena M, Bosco 0, Gatti G, Serpelloni G. The impact of human immunodeficiency 
virus type 1 on infectiousness of tuberculosis: A meta-analysis. Clin Infect Dis. 2001;33:1922-
1930. 
48. Escombe AR, Moore DA, Gilman RH, et al. The infectiousness of tuberculosis patients 
coinfected with HIV. PLoS Med. 2008;5:eI88. 
49. Lienhardt C, Fielding K, Sillah J, et al. Risk factors for tuberculosis infection in sub-Saharan 
Africa: a contact study in The Gambia. Am J Respir Crit Care Med. 2003;168:448-455. 
50. Lienhardt C, Sillah J, Fielding K, et al. Risk factors for tuberculosis infection In children in contact 
with infectious tuberculosis cases in the Gambia, West Africa. Pediatrics. 2003;111:e608-614. 
51. Lienhardt C. From exposure to disease: the role of environmental factors in susceptibility to and 
development of tuberculosis. Epidemiot Rev. 2001;23:288-301. 
52. Rouillon A, Perdrizet S, Parrot R. Transmission of tubercle bacilli: The effects of chemotherapy. 
Tubercle. 1976;57:275-299. 
53. Andersen S, Geser A. The distribution of tuberculous infection among households in African 
communities. Bul/ World Health Organ. 1960;22:39-60. 
54. Narain R, Nair SS, Rao GR, Chandrasekhar P. Distribution of tuberculous infection and disease 
among households in a rural community. Bul/ World Health Organ. 1966;34:639-654. 
55. den Boon S, Verver S, Marais BJ, et al. Association between passive smoking and infection with 
Mycobacterium tuberculosis in children. Pediatrics. 2007;119:734-739. 
56. Wood R, Johnstone-Robertson S, Uys P, et al. Tuberculosis transmission to young children In a 
South African community: modeling household and community infection risks. Clin Infect Dis. 
2010;51:401-408. 
57. Loudon RG, Spohn SK. Cough frequency and infectivity in patients with pulmonary tuberculosis. 
Am Rev Respir Dis. 1969;99:109-111. 
58. Schaaf HS, Shean K, Donald PRo Culture-confirmed multidrug-resistant tuberculosis: diagnostic 
delay, clinical features, and outcome. Arch Dis Child. 2003;88:1106-1111. 
59. Nathanson E, Lambregts-van Weezenbeek C, Rich ML, et al. Multidrug-resistant tuberculosis 
management in resource-limited settings. Emerg Infect Dis. 2006;12:1389-1397. 
60. Marais 8J, Gie RP, Schaaf HS, et al. The clinical epidemiology of childhood pulmonary 
tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung 
Dis. 2004;8:278-285. 
61. Marais 8J, Gie RP, Schaaf HS, et al. The natural history of childhood intra-thoracic tuberculosis: 
a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis. 2004;8:392-
402. 
62. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among 
intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 
1989;320:545-550. 
63. Hesseling AC, Cotton MF, Jennings T, et al. High incidence of tuberculosis among HIV-infected 
infants: evidence from a South African population-based study highlights the need for 
improved tuberculosis control strategies. Clin Infect Dis. 2009;48:108-114. 
64. Schaaf HS, Van Rie A, Gie RP, et al. Transmission of multidrug-resistant tuberculosis. Pediatr 
Infect Dis J. 2000;19:695-699. 
65. Kritski AL, Marques MJ, Rabahi MF, et al. Transmission of tuberculosis to close contacts of 
patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 1996;153:331-335. 
66. Schaaf HS, Michaelis lA, Richardson M, et al. Adult-to-child transmission of tuberculosis: 
household or community contact? Int J Tuberc Lung Dis. 2003;7:426-431. 
67. Bayona J, Chavez-Pachas AM, Palacios E, L1aro K, Sapag R, Becerra MC. Contact investigations as 
a means of detection and timely treatment of persons with infectious multidrug-resistant 
tuberculosis. Int J Tuberc Lung Dis. 2003;7:S501-509. 
68. Steiner P, Rao M, Mitchell M, Steiner M. Primary drug-resistant tuberculosis in children. 
Correlation of drug-susceptibility patterns of matched patient and source case strains of 
Mycobacterium tuberculosis. Am J Dis Child. 1985;139:780-782. 
Drug-resistant tuberculosis in children James Seddon P age 1314 
69. Verver S, Warren RM, Munch Z, et al. Proportion of tuberculosis transmission that takes place 
in households in a high-incidence area. Lancet. 2004;363:212-214. 
70. Madico G, Gilman RH, Checkley W, et al. Community infection ratio as an indicator for 
tuberculosis control. Lancet. 1995;345:416-419. 
71. van Rie A, Victor TC, Richardson M, et al. Reinfection and mixed infection cause changing 
Mycobacterium tuberculosis drug-resistance patterns. Am J Respir Crit Care Med. 
2005;172:636-642. 
72. Warren RM, Victor TC, Streicher EM, et al. Patients with active tuberculosis often have different 
strains in the same sputum specimen. Am J Respir Crit Care Med. 2004;169:610-614. 
73. Wootton SH, Gonzalez BE, Pawlak R, et al. Epidemiology of pediatric tuberculosis using 
traditional and molecular techniques: Houston, Texas. Pediatrics. 2005;116:1141-1147. 
74. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc 
Lung Dis. 2009;13:1320-1330. 
75. Caws M, Thwaites G, Stepniewska K, et al. Beijing genotype of Mycobacterium tuberculosis is 
significantly associated with human immunodeficiency virus infection and multidrug resistance 
in cases of tuberculous meningitis. J Clin Microbiol. 2006;44:3934-3939. 
76. Maree F, Hesseling AC, Schaaf HS, et al. Absence of an association between Mycobacterium 
tuberculosis genotype and clinical features in children with tuberculous meningitis. Pediatr 
Infect Dis J. 2007;26:13-18. 
77. Hesseling AC, Marais BJ, Kirchner Hl, et al. Mycobacterial genotype is associated with disease 
phenotype in children. Int J Tuberc Lung Dis. 2010;14:1252-1258. 
78. Kong Y, Cave MO, Zhang l, et al. Association between Mycobacterium tuberculosis Beijing/W 
lineage strain infection and extrathoracic tuberculosis: Insights from epidemiologic and clinical 
characterization of the three principal genetic groups of M. tuberculosis clinical isolates. J Clin 
Microbiol. 2007;45:409-414. 
79. Johnson R, Warren R, Strauss OJ, et al. An outbreak of drug-resistant tuberculosis caused by a 
Beijing strain in the western Cape, South Africa. Int J Tuberc Lung Dis. 2006;10:1412-1414. 
80. Marais BJ, Victor TC, Hesseling AC, et al. Beijing and Haarlem genotypes are overrepresented 
among children with drug-resistant tuberculosis in the Western Cape Province of South Africa. J 
Clin Microbiol. 2006;44:3539-3543. 
81. Nodieva A, Jansone I, Broka l, Pole I, Skenders G, Baumanis V. Recent nosocomial transmission 
and genotypes of multidrug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 
2010;14:427-433. 
82. Marais BJ, Gie RP, Hesseling AH, Beyers N. AdUlt-type pulmonary tuberculosis in children 10-14 
years of age. Pediatr Infect Dis J. 2005;24:743-744. 
83. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc. 
1970;26:28-106. 
84. Gray OM, Zar H, Cotton M. Impact of tuberculosis preventive therapy on tuberculosis and 
mortality in HIV-infected children. Cochrane Database Syst Rev. 2009:C0006418. 
85. Smieja MJ, Marchetti CA, Cook OJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV 
infected persons. Cochrane Database Syst Rev. 2000:CD001363. 
86. Hsu KH. Thirty years after isoniazid. Its impact on tuberculosis in children and adolescents. 
JAMA. 1984;251:1283-1285. 
87. Seddon JA, Godfrey-Faussett P, Hesseling AC, Gie RP, Beyers N, Schaaf HS. Management of 
children exposed to multidrug-resistant Mycobacterium tuberculosis. Lancet Infect Dis. 
2012;12:469-479. 
88. Sneag DB, Schaaf HS, Cotton MF, Zar HJ. Failure of chemoprophylaxis with standard 
antituberculosis agents in child contacts of multidrug-resistant tuberculosis cases. Pediatr Infect 
Dis J. 2007;26:1142-1146. 
89. Tochon M, Bosdure E, Salles M, et al. Management of young children in contact with an adult 
with drug-resistant tuberculosis, France, 2004-2008. Int J Tuberc Lung Dis. 2011;15:326-330. 
90. Schaaf HS, Victor TC, Engelke E, et al. Minimal inhibitory concentration of isoniazid in isoniazid-
resistant Mycobacterium tuberculosis isolates from children. Eur J Clin Microbiollnfect Dis. 
2007;26:203-205. 
91. Schaaf HS, Victor TC, Venter A, et al. Ethionamide cross- and co-resistance in children with 
isoniazid-resistant tuberculosis. Int J Tuberc Lung Dis. 2009;13:1355-1359. 
92. Muller B, Streicher EM, Hoek KG, et al. inhA promoter mutations: a gateway to extensively 
drug-resistant tuberculosis in South Africa? Int J Tuberc Lung Dis. 2011;15:344-351. 
Drug-resistant tuberculosis in children James Seddon Page 1315 
93. Centres for Disease Control, Atlanta, Georgia, USA. Management of persons exposed to 
multidrug-resistant tuberculosis. MMWR Recomm Rep. 1992;41:61-71. 
94. European Centre for Disease Prevention and Control. Management of contacts of MDR TB and 
XDR TB patients. Available at: http://ecdc.europa.eu/en/publications/Publications/201203-
Guidance-MDR-TB-contacts.pdf (accessed 15 May 2012).2012. 
95. Graham SM, Gie RP, Schaaf HS, Coulter JB, Espinal MA, Beyers N. Childhood tuberculosis: 
clinical research needs. Int J Tuberc Lung Dis. 2004;8:648-657. 
96. Cobelens FG, Heldal E, Kimerling ME, et al. Scaling up programmatic management of drug-
resistant tuberculosis: a prioritized research agenda. PLoS medicine. 2008;5:e150. 
97. Scano F, Vitoria M, Burman W, Harries AD, Gilks CF, Havlir D. Management of HIV-infected 
patients with MDR- and XDR-TB in resource-limited settings. Int J Tuberc Lung Dis. 
2008;12:1370-1375. 
98. RESIST-TB. Report on the RESIST-TB Protocol Workshop, 5-6 October. Available at: 
http://www.resisttb.orq/uploads/RESIST-TB Protocol Workshop summary. pdf (accessed 29-5-
11).2009. 
99. Marais BJ, Hesseling AC, Gie RP, Schaaf HS, Enarson DA, Beyers N. The bacteriologic yield in 
children with intrathoracic tuberculosis. Clin Infect Dis. 2006;42:e69-71. 
100. World Health Organization, Geneva, Switzerland. Guidelines for the programmatic 
management of drug-resistant tuberculosis. 2011 update.WHO/HTM/TB/2011.6. 
101. Marais BJ, Gie RP, Hesseling AC, Schaaf HS, Enarson DA, Beyers N. Radiographic signs and 
symptoms in children treated for tuberculosis: possible implications for symptom-based 
screening in resource-limited settings. Pediatr Infect Dis J. 2006;25:237-240. 
102. Schaaf HS, Marais BJ. Management of multidrug-resistant tuberculosis in children: a survival 
guide for paediatricians. Paediatr Respir Rev. 2011;12:31-38. 
103. AI-Dabbagh M, Lapphra K, McGloin R, et al. Drug-resistant tuberculosis: pediatric guidelines. 
Pediatr Infect Dis J. 2011;30:501-505. 
104. Burman WJ, Cotton MF, Gibb DM, Walker AS, Vernon AA, Donald PRo Ensuring the involvement 
of children in the evaluation of new tuberculosis treatment regimens. PLoS Med. 2008;5:e176. 
105. Schaaf HS, Willemse M, Cilliers K, et al. Rifampin pharmacokinetics in children, with and 
without human immunodeficiency virus infection, hospitalized for the management of severe 
forms of tuberculosis. BMC Med. 2009;7:19. 
106. Schaaf HS, Parkin DP, Seifart HI, et al. Isoniazid pharmacokinetics in children treated for 
respiratory tuberculosis. Arch Dis Child. 2005;90:614-618. 
107. Mcilieron H, Willemse M, Werely 0, et al. Isoniazid plasma concentrations In a cohort of South 
African children with tuberculosis: implications for international pediatric dosing guidelines. 
Clin Infect Dis. 2009;48:1547-1553. 
108. Holdiness MR. Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet. 
1984;9:511-544. 
109. Peloquin CA, Nitta AT, Burman WJ, et al. Low antituberculosis drug concentrations in patients 
with AIDS. Ann Pharmacother. 1996;30:919-925. 
110. Graham SM, Bell DJ, Nyirongo S, Hartkoorn R, Ward SA, Molyneux EM. Low levels of 
pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional 
status, and human immunodeficiency virus infection. Antimicrob Agents Chemother. 
2006;50:407-413. 
111. Roy V, Gupta D, Gupta P, Sethi GR, Mishra TK. Pharmacokinetics of isoniazid in moderately 
malnourished children with tuberculosis. Int J Tuberc Lung Dis. 2010;14:374-376. 
112. Donald PR, Parkin DP, Seifart HI, et al. The influence of dose and N-acetyltransferase-2 (NAT2) 
genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. fur J 
Clin Pharmacol. 2007;63:633-639. 
113. World Health Organization, Geneva, Switzerland. Rapid Advice. Treatment of tuberculosis in 
children. WHO/HTM/TB/201 O.13. 2010. 
114. Lonnroth K, Williams BG, Stadlin S, Jaramillo E, Dye C. Alcohol use as a risk factor for 
tuberculosis - a systematic review. BMC Public Health. 2008;8:289. 
115. Franke MF, Appleton SC, Bayona J, et al. Risk factors and mortality associated with default from 
multidrug-resistant tuberculosis treatment. Clin Infect Dis. 2008;46:1844-1851. 
116. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-
resistant tuberculosis: a systematic review and meta-analysis. PLoS One. 2009;4:e6914. 
117. SouthAfrica.info. South Africa's population. Available at: 
http://www.southafrica.info/about/people/population.htm (accessed 20 August 2012). 2011. 
Drug-resistant tuberculosis in children James Seddon P age 1316 
118. South African Health Review 2010. Health and related indicators. Available at: 
http://www.hst.org.za/sites/default/files/sahr10 21.pdf (accessed 17 April 2012). 
119. South African HIV & AIDS Statistics. Available at: http://www.avert.org/safricastats.htm 
(accessed 24 August 2011). 
120. City of Cape Town - Census 2001 - Khayelitsha 2001. Available at: 
http://www.capetown.gov.za/en/stats/2001census/Documents/Khayelitsha.htm (accessed 15 
May 2012). 
121. Medecins Sans Frontieres, Western Cape Province Department of Health, City of Cape Town 
Department of Health, University of Cape Town Centre for Infectious Disease Epidemiology and 
Research. Providing HIV ITB Care At The Primary Health Care Level. Khayelitsha Annual Activity 
Report 2008-2009. Available at: http://www.health-
e.org.za/documents/cllOaf046ff02d6d4d032755b5ca7e06.pdf (accessed 22 July 2012). 
122. Medecins Sans Frontieres. Scaling up diagnosis and treatment of drug-resistant tuberculosis in 
Khayelitsha, South Africa: an integrated, community-based approach. Available at 
http://www.msf.org.za/publication/scaling-diagnosis-and-treatment-drug-resistant-
tuberculosis-khayelitsha-south-africa (accessed on 5.9.11). 2011. 
123. Blumberg HM, Leonard MK, Jr., Jasmer RM. Update on the treatment of tuberculosis and latent 
tuberculosis infection. JAMA. 2005;293:2776-2784. 
124. Leung CC, Rieder HL, Lange C, Yew WW. Treatment of latent infection with m. tuberculosis: 
update 2010. fur Respir J. 2010. 
125. World Health Organization, Geneva, Switzerland. Chapter 4: childhood contact screening and 
management. Int) Tuberc Lung Dis. 2007;11:12-15. 
126. Halsey NA, Coberly JS, Desormeaux J, et al. Randomised trial of isoniazid versus rifampicin and 
pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet. 1998;351:786-792. 
127. Mwinga A, Hosp M, Godfrey-Faussett P, et al. Twice weekly tuberculosis preventive therapy in 
HIV infection in Zambia. AIDS. 1998;12:2447-2457. 
128. Ormerod LP. Reduced incidence of tuberculosis by prophylactic chemotherapy in subjects 
showing strong reactions to tuberculin testing. Arch Dis Child. 1987;62:1005-1008. 
129. Hong Kong Chest Service, Tuberculosis Research Centre Madras, British Medical Research 
Council. A double-blind placebo-controlled clinical trial of three antituberculosis 
chemoprophylaxis regimens in patients with silicosis in Hong Kong .• Am Rev Respir Dis. 
1992;145:36-41. 
130. CDC/ATA/IDSA. Targeted tuberculin testing and treatment of latent tuberculosis infection. This 
official statement of the American Thoracic Society was adopted by the ATS Board of Directors, 
July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for 
Disease Control and Prevention (CDC). This statement was endorsed by the Council of the 
Infectious Diseases Society of America. (IDSA), September 1999, and the sections ofthis 
statement. Am J Respir Crit Care Med. 2000;161:S221-247. 
131. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of 
follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. 
Bul/ World Health Organ. 1982;60:555-564. 
132. Zar HJ, Cotton MF, Strauss S, et al. Effect of isoniazid prophylaxis on mortality and incidence of 
tuberculosis in children with HIV: randomised controlled trial. BM). 2007;334:136. 
133. Madhi SA, Nachman S, Violari A, et al. Primary isoniazid prophylaxis against tuberculosis in HIV-
exposed children. N Engl J Med. 2011;365:21-31. 
134. World Health Organization, Geneva, Switzerland. Guidelines for intensified tuberculosis case-
finding and isoniazid preventive therapy for people living with HIV in resource constrained 
settings. ISBN 978 92 4 1500708. 2010. 
135. Fraser A, Paul M, Attamna A, Leibovici l. Drugs for preventing tuberculosis in people at risk of 
multiple-drug-resistant pulmonary tuberculosis. Cochrane database 0/ systematic reviews 
(Online). 2006:CD005435. 
136. Bamrah S, Brostrom R, Setik l, Fred 0, Kawamura M, Mase S. An ounce of prevention: treating 
MDR-TB contacts in a resource-limited setting. Abstract. International Union o/Tuberculosis 
and Lung Disease Conference, Berlin, Germany 11-15 November. 2010;FA-1--656-14:S180. 
137. National Institute for Health and Clinical Excellence. Tuberculosis. Clinical diagnosis and 
management of tuberculosis, and measures for its prevention and control. NICE clinical 
guideline 117.2011. 
138. Department of Health, Republic of South Africa. Management of Drug-resistant Tuberculosis. 
Policy Guidelines. 2010. 
Drug-resistant tuberculosis in children James Seddon Page 1317 
139. Passannante MR, Gallagher CT, Reichman LB. Preventive therapy for contacts of multidrug-
resistant tuberculosis. A Delphi survey. Chest. 1994;106:431-434. 
140. American Academy of Pediatrics. Tuberculosis. In: Pickering LK, ed. Red Book: Report of the 
Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL: American Academy of 
Pediatrics. 2009:680-701. 
141. Partners in Health. The Partners in Health Guide to the Medical Management of Multidrug-
Resistant Tuberculosis. 2003. 
142. Francis J Curry National Tuberculosis Center. Drug-Resistant Tuberculosis: A Survival Guide for 
Clinicians, Second Edition. 2008. 
143. Attamna A, Chemtob 0, Attamna S, et al. Risk of tuberculosis in close contacts of patients with 
multidrug resistant tuberculosis: A nationwide cohort. Thorax. 2009;64:271. 
144. Feja K, McNelley E, Tran CS, Burzynski J, Saiman l. Management of pediatric multidrug-resistant 
tuberculosis and latent tuberculosis infections in New York City from 1995 to 2003. Pediatr 
Infect Dis J. 2008;27:907-912. 
145. Sasaki V, Vamagishi F, Vagi T. The current situation of contacts examination and 
chemoprophylaxis for persons exposed to multi-drug resistant tuberculosis In ordinance-
designated cities in Japan. Kekkaku. 2005;80:637-642. 
146. Papastavros T, Dolovich LR, Holbrook A, Whitehead L, Loeb M. Adverse events associated with 
pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. 
CMAJ. 2002;167:131-136. 
147. Cain KP, Nelson U, Cegielski JP. Global policies and practices for managing persons exposed to 
multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2010;14:269-274. 
148. Pineiro Perez R, Mellado Pena MJ, Mendez Echevarria A, et al. Exposure to multiresisant 
tuberculosis: Study and follow-up of nine children. Anales de Pediatria. 2008;68:490-495. 
149. Chopra I, Brennan P. Molecular action of anti-mycobacterial agents. Tuber Lung Dis. 
1997;78:89-98. 
150. Loebstein R, Koren G. Clinical pharmacology and therapeutic drug monitoring in neonates and 
children. Pediatr Rev. 1998;19:423-428. 
151. Rey E, Gendrel D, Treluyer JM, et al. Isoniazid pharmacokinetics in children according to 
acetylator phenotype. Fundam Clin Pharmacal. 2001;15:355-359. 
152. Sirgel FA, Donald PR, Odhiambo J, et al. A multicentre study of the early bactericidal activity of 
anti-tuberculosis drugs. J Antimicrob Chemather. 2000;45:859-870. 
153. Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid preventive therapy and risk for 
resistant tuberculosis. fmerg Infect Dis. 2006;12:744-751. 
154. Banerjee A, Dubnau E, Quemard A, et al. inhA, a gene encoding a target for isoniazid and 
ethionamide in Mycobacterium tuberculosis. Science. 1994;263:227-230. 
155. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung 
Dis. 2000;4:796-806. 
156. Ijaz K, Jereb JA, Lambert LA, et al. Severe or fatal liver injury in 50 patients In the United States 
taking rifampin and pyrazinamide for latent tuberculosis infection. Cfin Infect Dis. 2006;42:346-
355. 
157. Vounossian AB, Rochat T, Ketterer JP, Wacker J, Janssens JP. High hepatotoxicity of 
pyrazinamide and ethambutol for treatment of latent tuberculosis. fur Respir J. 2005;26:462-
464. 
158. American Thoracic Society/Centres for Disease Control. Update: adverse event data and revised 
American Thoracic Society/CDC recommendations against the use of rifampin and 
pyrazinamide for treatment of latent tuberculosis infection--United States, 2003. MMWR. 
2003;52:735-739. 
159. Ie Bourgeois M, de Blic J, Paupe J, Schein mann P. Good tolerance of pyrazinamide in children 
with pulmonary tuberculosis. Arch Dis Child. 1989;64:177-178. 
160. Sanchez-Albisua I, Vidal ML, Joya-Verde G, del Castillo F, de Jose MI, Garcia-Hortelano J. 
Tolerance of pyrazinamide in short course chemotherapy for pulmonary tuberculosis in 
children. Pediatr Infect Dis J. 1997;16:760-763. 
161. Hoek KG, Schaaf HS, Gey van Pittius NC, van Heiden PO, Warren RM. Resistance to 
pyrazinamide and ethambutol compromises MDR/XDR-TB treatment. S Afr Med J. 2009;99:785-
787. 
162. Mphahlele M, Syre H, Valvatne H, et al. Pyrazinamide resistance among South African 
multidrug-resistant Mycobacterium tuberculosis isolates. Journal of clinical microbiology. 
2008;46:3459-3464. 
Drug-resistant tuberculosis in children James Seddon Page 1318 
163. Yu MC, Suo J, lin TP, luh KT. In vitro activity of ofloxacin against Mycobacterium tuberculosis. J 
Formos Med Assoc. 1997;96:13-16. 
164. Ingham B, Brentnall 0, Dale E, McFadzean J. Arthropathy induced by antibacerial fused N-Alkyl-
4-pyridone-3-carboxylic acids. Toxicology Letters. 1977;1:21-26. 
165. Burkhardt JE, Walterspiel IN, Schaad UB. Quinolone arthropathy in animals versus children. Clin 
Infect Dis. 1997;25:1196-1204. 
166. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet 
Infect Dis. 2003;3:432-442. 
167. World Health Organization, Geneva, Switzerland. Ethambutol efficacy and toxicity: literature 
review and recommendations for daily and intermittent dosage in children. 
(WHO/HTM/TB/2006.365; WHO/FCH/CAH/2006.3). 2006. 
168. Victor TC, Warren R, Butt Jl, et al. Genome and MIC stability in Mycobacterium tuberculosis 
and indications for continuation of use of isoniazid in multidrug-resistant tuberculosis. J Med 
Microbiol. 1997;46:847-857. 
169. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant 
tuberculosis. N Engl J Med. 2009;360:2397-2405. 
170. Stevens JP, Daniel TM. Chemoprophylaxis of multidrug-resistant tuberculous infection in HIV-
uninfected individuals using ciprofloxacin and pyrazinamide. A decision analysis. Chest. 
1995;108:712-717. 
171. Parsyan AE, Saukkonen J, Barry MA, Sharnprapai S, Horsburgh CR, Jr. Predictors of failure to 
complete treatment for latent tuberculosis infection. J Infect. 2007;54:262-266. 
172. Bock NN, Metzger BS, Tapia JR, Blumberg HM. A tuberculin screening and isoniazid preventive 
therapy program in an inner-city population. Am J Respir Crit Care Med. 1999;159:295-300. 
173. van lyl 5, Marais BJ, Hesseling AC, Gie RP, Beyers N, Schaaf HS. Adherence to anti-tuberculosis 
chemoprophylaxis and treatment in children. Int J Tuberc Lung Dis. 2006;10:13-18. 
174. Barker RD, Millard FJ, Nthangeni ME. Unpaid community volunteers-effective providers of 
directly observed therapy (DOT) in rural South Africa. S Afr Med J. 2002;92:291-294. 
175. Economist. Taken your medicine? The Economist Technology Quarterly (June 6th). 2009:7-8. 
176. Marais BJ, van lyl 5, Schaaf HS, van Aardt M, Gie RP, Beyers N. Adherence to isoniazid 
preventive chemotherapy: a prospective community based study. Arch Dis Child. 2006;91:762-
765. 
177. Coyne KM, Pozniak Al, lamorde M, Boffito M. Pharmacology of second-line antituberculosis 
drugs and potential for interactions with antiretroviral agents. AIDS. 2009;23:437-446. 
178. Peloquin CA, Berning SE, Huitt GA, Iseman MD. AIDS and TB drug absorption. Int J Tuberc Lung 
Dis. 1999;3:1143-1144. 
179. World Health Organization, Geneva, Switzerland. Antiretroviral therapy of HIV infection in 
infants and children: towards universal access. Recommendations for a public health approach. 
2006. 
180. Welch SB, Gibb D. When should children with HIV infection be started on antiretroviral 
therapy? PLoS Med. 2008;5:e73. 
181. Violari A, Cotton MF, Gibb OM, et al. Early antiretroviral therapy and mortality among HIV-
infected infants. N Engl J Med. 2008;359:2233-2244. 
182. World Health Organization, Geneva, Switzerland. Guidelines on co-trimoxazole prophylaxis for 
HIV-related infections among children, adolescents and adults. Recommendations for a public 
health approach. 2006 
183. International Network of the Study of HIV-associated IRIS. Case definition: consensus criteria 
for diagnosis of paediatric TB IRIS. 2008 
(http://www.inshLumn.edu/definitions/PedsTBIRIS/home.html-accessedon29.5.11). 
184. Boulware DR, Callens 5, Pahwa S. Pediatric HIV immune reconstitution inflammatory syndrome. 
Curr Opin HIV AIDS. 2008;3:461-467. 
185. lampoli M, Kilborn T, Eley B. Tuberculosis during early antiretroviral-induced immune 
reconstitution in HIV-infected children.lnt J Tuberc Lung Dis. 2007;11:417-423. 
186. Muller M, Wandel 5, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution 
inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a 
systematic review and meta-analysis. Lancet Infect Dis. 2010;10:251-261. 
187. Becerra MC, Appleton SC, Franke MF, et al. Tuberculosis burden in households of patients with 
multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. 
Lancet. 2011;377:147-152. 
Drug-resistant tuberculosis in children James Seddon P age 1319 
188. Resch SC, Salomon JA, Murray M, Weinstein MC. Cost-effectiveness of treating multidrug-
resistant tuberculosis. PLoS Med. 2006;3:e241. 
189. Tupasi TE, Gupta R, Quelapio MI, et al. Feasibility and cost-effectiveness of treating multidrug-
resistant tuberculosis: a cohort study in the Philippines. PLoS Med. 2006;3:e352. 
190. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-
resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9:153-161. 
191. Fairlie L, Beylis NC, Reubenson G, Moore DP, Madhi SA. High prevalence of childhood multi-
drug resistant tuberculosis in Johannesburg, South Africa: a cross sectional study. BMC 
infectious diseases. 2011;11:28. 
192. Seddon JA, Hesseling AC, Willemse M, Donald PR, Schaaf HS. Culture-confirmed multidrug-
resistant tuberculosis in children: clinical features, treatment, and outcome. Clin Infect Dis. 
2012;54:157-166. 
193. Padayatchi N, Bamber S, Dawood H, Bobat R. Multidrug-resistant tuberculous meningitis in 
children in Durban, South Africa. Pediatr Infect Dis J. 2006;25:147-150. 
194. Schluger NW, Lawrence RM, McGuiness G, Park M, Rom WN. Multidrug-resistant tuberculosis 
in children: two cases and a review of the literature. Pediatr Pulmonol. 1996;21:138-142. 
195. Suessmuth S, Bange FC, Gappa M. Multidrug resistant tuberculosis in a 6 year old child. 
Paediatr Respir Rev. 2007;8:265-268. 
196. Kjollerstrom P, Brito MJ, Gouveia C, Ferreira G, Varandas l. Linezolid in the treatment of 
multidrug-resistant/extensively drug-resistant tuberculosis in paediatric patients: Experience of 
a paediatric infectious diseases unit. Scand J Infect Dis. 2011. 
197. World Health Organization, Geneva, Switzerland. Guidlelines for the programmatic 
management of drug-resistant tuberculosis - Emergency update. WHO/HTM/TB/200B.402. 
2008. 
198. Wright CA, Hesseling AC, Bamford C, Burgess SM, Warren R, Marais BJ. Fine-needle aspiration 
biopsy: a first-line diagnostic procedure in paediatric tuberculosis suspects with peripheral 
lymphadenopathy? Int J Tuberc Lung Dis. 2009;13:1373-1379. 
199. Oberhelman RA, Soto-Castellares G, Gilman RH, et al. Diagnostic approaches for paediatric 
tuberculosis by use of different specimen types, culture methods, and peR: a prospective case-
control study. Lancet Infect Dis. 2010;10:612-620. 
200. Zar HJ, Workman L, Isaacs W, et al. Rapid molecular diagnosis of pulmonary tuberculosis in 
children using nasopharyngeal specimens. Clin Infect Dis. 2012. 
201. Nicol MP, Zar Hl New specimens and laboratory diagnostics for childhood pulmonary TB: 
progress and prospects. Paediatr Respir Rev. 2011;12:16-21. 
202. Goussard P, Gie RP, Kling S, et al. The diagnostic value and safety of transbronchial needle 
aspiration biopsy in children with mediastinal lymphadenopathy. Pediatr Pulmonol. 
2010;45:1173-1179. 
203. Seddon JA, Hesseling AC, Marais BJ, et al. Paediatric use of second-line anti-tuberculosis agents: 
A review. Tuberculosis (Edinb). 2012;92:9-17. 
204. Drobac PC, Mukherjee JS, Joseph JK, et al. Community-based therapy for children with 
multidrug-resistant tuberculosis. Pediatrics. 2006;117:2022-2029. 
205. Mendez Echevarria A, Baquero Artigao F, Garcia Miguel MJ, et al. Multidrug-resistant 
tuberculosis in the pediatric age group. Anales de Pediatria. 2007;67:206-211. 
206. Swanson OS, Starke JR. Drug-resistant tuberculosis in pediatrics. Pediatr Clin North Am. 
1995;42:553-581. 
207. Ren V, Nuttall JJ, Egbers C, et al. Effect of rifampicin on lopinavir pharmacokinetics in HIV-
infected children with tuberculosis. J Acquir Immune Deftc Syndr. 2008;47:566-569. 
208. Louw GE, Warren RM, Gey van Pittius NC, et al. Rifampicin Reduces Susceptibility to Ofloxacin 
in Rifampicin-resistant Mycobacterium tuberculosis through Efflux. Am J Respir Crit Care Med. 
2011;184:269-276. 
209. Weiner M, Burman W, Luo ee, et al. Effects of rifampin and multidrug resistance gene 
polymorphism on concentrations of moxifloxacin. An tim icrob Agents Chemother. 
2007;51:2861-2866. 
210. Frydenberg AR, Graham SM. Toxicity of first-line drugs for treatment of tuberculosis in children: 
review. Trop Med Int Health. 2009;14:1329-1337. 
211. Johnson R, Streicher EM, Louw GE, Warren RM, van Heiden PO, Victor Te. Drug resistance in 
Mycobacterium tuberculosis. Curr Issues Mol Bioi. 2006;8:97-111. 
212. Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. Tuberculosis 
drug resistance mutation database. PLoS Med. 2009;6:e2. 
Drug·resistant tuberculosis in children James Seddon P age 1320 
213. Hu V, Coates AR, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-
tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 
2003;47:653-657. 
214. Handbook of Anti-Tuberculosis Agents. Tuberculosis (Edinb). 2008;88:1-169. 
215. Rodriguez JC, Cebrian l, Lopez M, Ruiz M, Jimenez I, Royo G. Mutant prevention concentration: 
comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis. J Antimicrob 
Chemother. 2004;53:441-444. 
216. Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a 
systematic review and meta-analysis [Review article). Int J Tuberc Lung Dis. 2012. 
217. Van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized 
treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182:684-692. 
218. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant 
pulmonary tuberculosis. N Engl J Med. 2012;366:2151-2160. 
219. Diacon AH, Dawson R, du Bois J, et al. Phase II dose-ranging trial of the early bactericidal 
activity of PA-824. Antimicrob Agents Chemother. 2012;56:3027-3031. 
220. Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline 
(TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and 
effect on emergence of drug resistance. Antimicrob Agents Chemother. 2012;56:3271-3276. 
221. Ettehad D, Schaaf HS, Seddon JA, Cooke GS, Ford N. Treatment outcomes for children with 
multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 
2012;12:449-456. 
222. Leimane V, Ozere I. Challengest of managing a child with MDR-TB: 41st World Conference on 
Lung Health of the International Union Against Tuberculosis and Lung Diseae (The Union), 
Cancun, Mexico, 3-7 December. 2009. 
223. Schaaf HS, Seddon JA, Caminero JA. Second-line antituberclosis drugs: current knowledge and 
controversies. Prog Respir Res. 2011;40:81-95. 
224. Steiner P, Rao M, Victoria M, Steiner M. Primary isoniazid-resistant tuberculosis in children. 
Clinical features, strain resistance, treatment, and outcome in 26 children treated at Kings 
County Medical Center of Brooklyn between the years 1961 and 1972. Am Rev Respir Dis. 
1974;110:306-311. 
225. Dramowski A, Morsheimer MM, Jordaan AM, Victor Te, Donald PR, Schaaf HS. Rifampicin-
monoresistant Mycobacterium tuberculosis disease among children In Cape Town, South 
Africa. Int J Tuberc Lung Dis. 2012;16:76-81. 
226. Hazbon MH, Brimacombe M, Bobadilla del Valle M, et al. Population genetics study of isoniazid 
resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. 
Antimicrob Agents Chemother. 2006;50:2640-2649. 
227. Cilliers K, Labadarios D, Schaaf HS, et al. Pyridoxal-5-phosphate plasma concentrations in 
children receiving tuberculosis chemotherapy including isoniazid. Acta Paediatr. 2010;99:705-
710. 
228. Thwaites G, Fisher M, Hemingway C, Scott G, Solomon T, Innes J. British Infection Society 
guidelines for the diagnosis and treatment of tuberculosis of the central nervous system In 
adults and children. J Infect. 2009;59:167-187. 
229. Prasad K, Singh MB. Corticosteroids for managing tuberculous meningitis. Cochrane Database 
Syst Rev. 2008:CD002244. 
230. Schoeman JF, Van Zyl LE, Laubscher JA, Donald PRo Effect of corticosteroids on intracranial 
pressure, computed tomographic findings, and clinical outcome in young children with 
tuberculous meningitis. Pediatrics. 1997;99:226-231. 
231. Goussard P, Gie R. Airway involvement in pulmonary tuberculosis. Paediatr Respir Rev. 
2007;8:118-123. 
232. du Plessis J, Goussard P, Andronikou S, Gie R, George R. Comparing three-dimensional volume-
rendered CT images with fibreoptic tracheobronchoscopy in the evaluation of airway 
compression caused by tuberculous lymphadenopathy in children. Pediatr Radiol. 2009;39:694-
702. 
233. Maydell A, Goussard P, Andronikou S, Bezuidenhout F, Ackermann C, Gie R. Radiological 
changes post-lymph node enucleation for airway obstruction in children with pulmonary 
tuberculosis. Eur J Cardiothorac Surg. 2010;38:478-483. 
234. Webb EA, Hesseling AC, Schaaf HS, et al. High prevalence of Mycobacterium tuberculosis 
Infection and disease in children and adolescents with type 1 diabetes mellitus. Int J Tuberc 
Lung Dis. 2009;13:868-874. 
Drug-resistant tuberculosis in children James Seddon Page 1321 
235. World Health Organization, Geneva, Switzerland. Antiretroviral therapy for HIV infection in 
infancts and children: towards universal access. Recommendations for a public health 
approach .• 2010. 
236. Torok ME, Yen NT, Chau TT, et al. Timing of Initiation of Antiretroviral Therapy in Human 
Immunodeficiency Virus (HIV)-Associated Tuberculous Meningitis. Clin Infect Dis. 2011;52:1374-
1383. 
237. Collins S, Dent N, Binns P, Bahwere P, Sadler K, Hallam A. Management of severe acute 
malnutrition in children. Lancet. 2006;368:1992-2000. 
238. Pawar UM, Kundnani V, Agashe V, Nene A. Multidrug-resistant tuberculosis of the spine--is it 
the beginning of the end? A study of twenty-five culture proven multidrug-resistant 
tuberculosis spine patients. Spine. 2009;34:E806-810. 
239. Seddon JA, Donald PR, Vlok GJ, Schaaf HS. Multidrug-Resistant Tuberculosis of the Spine in 
Children - Characteristics from a High Burden Setting.) Trop Pediatr. 2011. 
240. Seddon JA, Visser DH, Bartens M, et al. Impact of drug resistance on clinical outcome in children 
with tuberculous meningitis. Pediatr Infect Dis J. 2012;31:711-716. 
241. McCracken GH, Jr. Aminoglycoside toxicity in infants and children. Am J Med. 1986;80:172-178. 
242. Stelmachowicz PG, Pittman Al, Hoover BM, lewis DE, Moeller MP. The importance of high-
frequency audibility in the speech and language development of children with hearing loss. 
Arch Otolaryngol Head Neck Surg. 2004;130:556-562. 
243. Livingstone N, McPhillips M. Motor skill deficits in children with partial hearing. Dev Med Child 
Neurol. 2011. 
244. Seddon JA, Godfrey-Faussett P, Jacobs K, Ebrahim A, Hesseling AC, Schaaf HS. Hearing loss in 
patients on treatment for drug-resistant tuberculosis Jun 27. [Epub ahead of print]. fur Respir). 
2012. 
245. Seddon JA, Thee S, Hesseling AC, Schaaf HS. Hearing and renal impairment in children treated 
for drug-resistant tuberculosis (abstract). 43rd Union World Conference on Lung Health, 13-17 
November 2012, Kuala Lumpur, Malaysia. 2012. 
246. Dubo S. Psychiatric study of children with pulmonary tuberculosis. Am J Orthopsychiatry. 
1950;20:520-528. 
247. World Health Organization, Geneva, Switzerland. 2009 WHO child growth standards and the 
identification of severe acute malnutrition in infants and children: A Joint Statement by the 
World Health Organization and the United Nations Children's Fund. Available at: 
http://www.who.int/nutrition/publications/severemalnutrition/9789241598163 eng. pdf 
(accessed 11 July 2012). 
248. American Speech-language-Hearing Association. Audiologic Management of Inidividuals 
Receiving Cochleotoxic Drug Therapy (Guideline). 1994;Available from 
http://www.asha.org/docs/pdf/GL1994-00003.pdf (accessed August 2012). 
249. Donald PR, Maher 0, Maritz JS, Qazi S. Ethambutol dosage for the treatment of children: 
literature review and recommendations. Int) Tuberc Lung Dis. 2006;10:1318-1330. 
250. Garazzino S, Tovo PA. Clinical experience with linezolid in infants and children. ) Antimicrob 
Chemother. 2011;66 Suppl 4:iv23-iv41. 
251. Clarke M, Dick J, Zwarenstein M, lombard CJ, Diwan VK. Lay health worker intervention with 
choice of DOT superior to standard TB care for farm dwellers in South Africa: a cluster 
randomised control trial. Int J Tuberc Lung Dis. 2005;9:673-679. 
252. Farmer P, Kim JY. Community based approaches to the control of multidrug resistant 
tuberculosis: introducing "DOTS-plus". 8M). 1998;317:671-674. 
253. Weber HC, Beyers N, Gie RP, Schaaf HS, Fish T, Donald PRo The clinical and radiological features 
of tuberculosis in adolescents. Annals of tropical paediatrics. 2000;20:5-10. 
254. Schaaf HS, Marais BJ, Hesseling AC, Brittle W, Donald PRo Surveillance of antituberculosis drug 
resistance among children from the Western Cape Province of South Africa--an upward trend. 
Am) Public Health. 2009;99:1486-1490. 
255. Schaaf HS, Marais BJ, Hesseling AC, Gie RP, Beyers N, Donald PRo Childhood drug-resistant 
tuberculosis in the Western Cape Province of South Africa. Acta Paediatr. 2006;95:523-528. 
256. Matlow A, Robb M, Goldman C. Infection control and paediatric tuberculosis: A practical guide 
for the practicing paediatrician. Paediatr Child Health. 2003;8:624-626. 
257. Centers for Disease Control and Prevention. Guidelines for Preventing the Transmission of 
Mycobacterium tuberculosis in Health-Care Settings, 2005. MMWR 2005;54(No. RR-17). 
258. World Health Organization, Geneva, Switzerland. WHO policy on TB infection control in health-
care facilities, congregate settings and households. Available at: 
Drug-resistant tuberculosis in children James Seddon P age 1322 
http://whqlibdoc.who.int/publications/2009/9789241598323 eng. pdf (accessed 12 July 2012). 
2009;WHO/HTM/TB/2009.419. 
259. Granich RM, Oh P, Lewis B, Porco TC, Flood J. Multidrug resistance among persons with 
tuberculosis in California, 1994-2003. JAMA. 2005;293:2732-2739. 
260. Pinon M, Scolfaro C, Bignamini E, et al. Two pediatric cases of multidrug-resistant tuberculosis 
treated with linezolid and moxifloxacin. Pediatrics. 2010;126:e1253-1256. 
261. Smith KC, Seaworth BJ. Drug-resistant tuberculosis: controversies and challenges in pediatrics. 
Expert review of anti-infective therapy. 2005;3:995-1010. 
262. Thee S, Zollner EW, Willemse M, C. HA, Magdorf K, Schaaf HS. Abnormal thyroid function tests 
in children on ethionamide treatement (short communication). Int J Tuberc Lung Dis. 
2011;15:1191-1193. 
263. van der Watt JJ, Harrison TB, Benatar M, Heckmann JM. Polyneuropathy, anti-tuberculosis 
treatment and the role of pyridoxine in the HIV/AID5 era: a systematic review. Int J Tuberc Lung 
Dis. 2011;15:722-728. 
264. Vega P, Sweetland A, Acha J, et al. Psychiatric issues in the management of patients with 
multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2004;8:749-759. 
265. Ziganshina LE, Squire SB. Fluoroquinolones for treating tuberculosis. Cochrane Database Syst 
Rev. 2008. 
266. Meissner HC, Townsend T, Wenman W, et al. Hematologic effects of linezolid in young children. 
Pediatr Infect Dis J. 2003;22:5186-192. 
267. Allen BW, Mitchison DA, Chan VC, VeWWW.AllanWG.GirlingDJ.Amikacin in the treatment of 
pulmonary tuberculosis. Tubercle. 1983;64:111-118. 
268. Caminero JA, Sotgiu G, Zumla A, Migliorl GB. Best drug treatment for multidrug-resistant and 
extensively drug-resistant tuberculosis. Lancet Infect Dis. 2010;10:621-629. 
269. Maus CE, Plikaytis BB, Shinnick TM. Molecular analysis of cross-resistance to capreomycin, 
kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents 
Chemother. 2005;49:3192-3197. 
270. Jureen P, Angeby K, Sturegard E, et al. Wild-type MIC distributions for aminoglycoside and 
cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections. J 
Clin Microbial. 2010;48:1853-1858. 
271. Rastogi N, Labrousse V, Goh KS. In vitro activities of fourteen antimicrobial agents against drug 
susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative 
intracellular activities against the virulent H37Rv strain in human macrophages. CUff Microbiol. 
1996;33:167-175. 
272. Treluyer JM, Merle V, Tonnelier S, Rey E, Pons G. Nonparametric population pharmacokinetic 
analysis of amikacin in neonates, infants, and children. Antimicrob Agents Chemother. 
2002;46:1381-1387. 
273. Peloquin CA, Berning SE, Nitta AT, et al. Aminoglycoside toxicity: daily versus thrice-weekly 
dosing for treatment of mycobacterial diseases. Clin Infect Dis. 2004;38:1538-1544. 
274. Kam KM, Yip CW, Cheung Tl, Tang H5, Leung DC, Chan MY. Stepwise decrease in moxifloxacin 
susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: 
correlation with ofloxacin susceptibility. Microb Drug Resist. 2006;12:7-11. 
275. Schaefer HG, Stass H, Wedgwood J, et al. Pharmacokinetics of ciprofloxacin In pediatric cystic 
fibrosis patients. Antimicrob Agents Chemother. 1996;40:29-34. 
276. Peltola H, Vaarala M, Renkonen OV, Neuvonen PJ. Pharmacokinetics of single-dose oral 
ciprofloxacin in infants and small children. Antimicrob Agents Chemother. 1992;36:1086-1090. 
277. Bethell DB, Day NP, Dung NM, et al. Pharmacokinetics of oral and intravenous ofloxacin in 
children with multidrug-resistant typhoid fever. Antimicrob Agents Chemother. 1996;40:2167-
2172. 
278. Gendrel D, Chalumeau M, Moulin F, Raymond J. Fluoroquinolones in paediatrics: a risk for the 
patient or for the community? Lancet Infect Dis. 2003;3:537-546. 
279. Capparelli EV, Reed MD, Bradley JS, et al. Pharmacokinetics of gatifloxacin in infants and 
children. Antimicrob Agents Chemother. 2005;49:1106-1112. 
280. Chien S, Wells TG, Blumer JL, et al. Levofloxacin pharmacokinetics in children. J Clin Pharmacol. 
2005;45:153-160. 
281. Johnson JL, Hadad DJ, Boom WH, et al. Early and extended early bactericidal activity of 
levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 
2006;10:605-612. 
Drug-resistant tuberculosis in children James Seddon P age 1323 
282. Auclair B, Nix DE, Adam RD, James GT, Peloquin CA. Pharmacokinetics of ethionamide 
administered under fasting conditions or with orange juice, food, or antacids. Antimicrob 
Agents Chemother. 2001;45:810-814. 
283. Dover LG, Corsino PE, Daniels IR, et al. Crystal structure of the TetR/CamR family repressor 
Mycobacterium tuberculosis EthR implicated in ethionamide resistance. J Mol BioI. 
2004;340:1095-1105. 
284. Zhu M, Namdar R, Stambaugh JJ, et al. Population pharmacokinetics of ethionamide in patients 
with tuberculosis. Tuberculosis (Edinb). 2002;82:91-96. 
285. Eule H. [Ethionamide concentration in the blood and urine of healthy persons and lung 
patients]. Beitr Klin Erforsch Tuberk Lungenkr. 1965;132:339-342. 
286. Donald PR, Seifart HI. Cerebrospinal fluid concentrations of ethionamide in children with 
tuberculous meningitis. J Pediatr. 1989;115:483-486. 
287. Thee S, Seifart HI, Rosenkranz B, et al. Pharmacokinetics of ethionamide in children. Antimicrob 
Agents Chemother. 2011;55:4594-4600. 
288. Vora A. Terizidone (Drug Review). J Assoc Physician India. 2010;58:267-268. 
289. Zitkova L, Tousek J. Pharmacokinetics of cycloserine and terizidone. A comparative study. 
Chemotherapy. 1974;20: 18-28. 
290. Zhu M, Nix DE, Adam RD, Childs JM, Peloquin CA. Pharmacokinetics of cycloserine under fasting 
conditions and with high-fat meal, orange juice, and antacids. Pharmacotherapy. 2001;21:891-
897. 
291. Nopponpunth V, Sirawaraporn W, Greene PJ, Santi DV. Cloning and expression of 
Mycobacterium tuberculosis and Mycobacterium leprae dihydropteroate synthase in 
Escherichia coli. J Bacteriol. 1999;181:6814-6821. 
292. Peloquin CA, Berning SE, Huitt GA, Childs JM, Singleton MD, James GT. Once-daily and twice-
daily dosing of p-aminosalicylic acid granules. Am J Respir Crit Care Med. 1999;159:932-934. 
293. Soderhjelm L. Serum para-aminosalicylic acid following oral ingestion In children. Tex Rep BioI 
Med. 1949;7:471-479. 
294. Clofazimine. Tuberculosis (Edinb). 2008;88:96-99. 
295. Shen GH, Wu BD, Hu ST, Lin CF, Wu KM, Chen JH. High efficacy of clofazimine and its synergistic 
effect with amikacin against rapidly growing mycobacteria. Int J Antimicrob Agents. 
2010;35:400-404. 
296. Nix DE, Adam RD, Auclair B, Krueger TS, Godo PG, Peloquin CA. Pharmacokinetics and relative 
bioavailability of clofazimine in relation to food, orange juice and antacid. Tuberculosis (Edinb). 
2004;84:365-373. 
297. Jungbluth GL, Welshman IR, Hopkins NK. Linezolid pharmacokinetics in pediatric patients: an 
overview. Pediatr Infect Dis J. 2003;22:S153-157. 
298. Chiappini E, Conti C, Galli L, de Martino M. Clinical efficacy and tolerability of linezolid in 
pediatric patients: a systematic review. Clin Ther. 2010;32:66-88. 
299. Hachem R, Afif C, Gokaslan Z, Raad I. Successful treatment of vancomycin-resistant 
Enterococcus meningitis with linezolid. Eur J Clin Microbiollnfect Dis. 2001;20:432-434. 
300. Dietze R, Hadad OJ, McGee B, et al. Early and extended early bactericidal activity of linezolid in 
pulmonary tuberculosis. Am J Respir Crit Care Med. 2008;178:1180-1185. 
301. Dauby N, Muylle I, Mouchet F, Sergysels R, Payen MC. Meropenem/Clavulanate and Linezolid 
Treatment for Extensively Drug-Resistant Tuberculosis. Pediatr Infect Dis J. 2011. 
302. Schaaf HS, Willemse M, Donald PRo Long-term linezolid treatment in a young child with 
extensively drug-resistant tuberculosis. Pediatr Infect Dis J. 2009;28:748-750. 
303. Ellard GA, Dickinson JM, Gammon PT, Mitchison DA. Serum concentrations and antituberculosis 
activity of thiacetazone. Tubercle. 1974;55:41-54. 
304. Peloquin CA, Nitta AT, Berning SE, Iseman MD, James GT. Pharmacokinetic evaluation of 
thiacetazone. Pharmacotherapy. 1996;16:735-741. 
305. Hugonnet JE, Tremblay LW, Boshoff HI, Barry CE, 3rd, Blanchard JS. Meropenem-clavulanate is 
effective against extensively drug-resistant Mycobacterium tuberculosis. Science. 
2009;323:1215-1218. 
306. Chambers HF, Moreau 0, Yajko 0, et a!. Can penicillins and other beta-Iactam antibiotics be 
used to treat tuberculosis? Antimicrob Agents Chemother. 1995;39:2620-2624. 
307. Segura C, Salvado M, Collado I, Chaves J, Coira A. Contribution of beta-Iactamases to beta-
lactam susceptibilities of susceptible and multidrug-resistant Mycobacterium tuberculosis 
clinical isolates. Antimicrob Agents Chemother. 1998;42:1524-1526. 
Drug-resistant tuberculosis in children James Seddon Page 1324 
308. Abate G, Miorner H. Susceptibility of multidrug-resistant strains of Mycobacterium tuberculosis 
to amoxycillin in combination with clavulanic acid and ethambutol. J Antimicrob Chemother. 
1998;42:735-740. 
309. Gorzynski EA, Gutman SI, Allen W. Comparative antimycobacterial activities of difloxacin, 
temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, 
clarithromycin. Antimicrob Agents Chemother. 1989;33:591-592. 
310. Luna-Herrera J, Reddy VM, Daneluzzi 0, Gangadharam PRo Antituberculosis activity of 
clarithromycin. Antimicrob Agents Chemother. 1995;39:2692-2695. 
311. Cavalieri SJ, Biehle JR, Sanders WE, Jr. Synergistic activities of clarithromycin and 
antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis. Antimicrob 
Agents Chemother. 1995;39:1542-1545. 
312. Mor N, Esfandiari A. Synergistic activities of clarithromycin and pyrazinamide against 
Mycobacterium tuberculosis in human macrophages. Antimicrob Agents Chemother. 
1997;41:2035-2036. 
313. Gan VN, Chu SY, Kusmiesz HT, Craft JC. Pharmacokinetics of a clarithromycin suspension in 
infants and children. Antimicrob Agents Chemother. 1992;36:2478-2480. 
314. Donald PRo Childhood tuberculosis. Curr Opin Pulm Med. 2000;6:187-192. 
315. Schaaf HS, Nelson U. Tuberculosis drug therapy in children. In: Schaaf HS, Zumla A, eds. 
Tuberculosis. A comprehensive clinical reference. Europe: Saunders Elsevier; 2009:627-638. 
316. Donald PR, Schaaf HS. Old and new drugs for the treatment of tuberculosis in children. Paediatr 
Respir Rev. 2007;8:134-141. 
317. World Health Organization, Geneva, Switzerland. Guidance for national tuberculosis 
programmes on the management of tuberculosis in children. Chapter 2: anti-tuberculosis 
treatment in children. tnt J Tuberc Lung Dis. 2006;10:1205-1211. 
318. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with 
extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 
2010;375: 1798-1807. 
319. Rao SC, Ahmed M, Hagan R. One dose per day compared to multiple doses per day of 
gentamicin for treatment of suspected or proven sepsis in neonates. Cochrane Database Syst 
Rev. 2006:C0005091. 
320. Smyth AR, Bhatt J. Once-daily versus multiple-daily dosing with intravenous aminoglycosides 
for cystic fibrosis. Cochrane Database Syst Rev. 2010:C0002009. 
321. Deutsch ES, Bartling V, lawenda B, Schwegler J, Falkenstein K, Dunn S. Sensorineural hearing 
loss in children after liver transplantation. Arch Otolaryngol Head Neck Surg. 1998;124:529-533. 
322. Selimoglu E. Aminoglycoside-induced ototoxicity. Curr Pharm Des. 2007;13:119-126. 
323. Guthrie OW. Aminoglycoside induced ototoxicity. Toxicology. 2008;249:91-96. 
324. Brummett RE, Fox KE. Aminoglycoside-induced hearing loss in humans. Antimicrob Agents 
Chemother. 1989;33:797-800. 
325. Bardien S, de Jong G, Schaaf HS, Harris T, Fagan J, Petersen L. Aminoglycoside-induced hearing 
loss: South Africans at risk. S Afr Med J. 2009;99:440-441. 
326. Bardien S, Human H, Harris T, et al. A rapid method for detection of five known mutations 
associated with aminoglycoside-induced deafness. BMC Med Genet. 2009;10:2. 
327. Cortopassi G, Hutchin T. A molecular and cellular hypothesis for aminoglycoside-induced 
deafness. Hear Res. 1994;78:27-30. 
328. Hutchin T, Haworth I, Higashi K, et al. A molecular basis for human hypersensitivity to 
aminoglycoside antibiotics. Nucleic Acids Res. 1993;21:4174-4179. 
329. Hampel B, HUlimann R, Schmidt H. Ciprofloxacin in pediatrics: worldwide clinical experience 
based on compassionate use--safety report. Pediatr Infect Dis J. 1997;16:127-129. 
330. Berning SE, Madsen L, Iseman MD, Peloquin CA. long-term safety of ofloxacin and ciprofloxacin 
in the treatment of mycobacterial infections. Am J Respir Crit Care Med. 1995;151:2006-2009. 
331. Kubin R. Safety and efficacy of ciprofloxacin in paediatric patients--review.tnfection. 
1993;21:413-421. . 
332. Davis R, Markham A, Balfour JA. Ciprofloxacin. An updated review of its pharmacology, 
therapeutic efficacy and tolerability. Drugs. 1996;51:1019-1074. 
333. Schaad UB. Fluoroquinolone antibiotics in infants and children. Infect Dis Clin North Am. 
2005;19:617-628. 
334. Forsythe CT, Ernst ME. Do fluoroquinolones commonly cause arthropathy in children? ClEM. 
2007;9:459-462. 
335. Leibovitz E. The use of fluoroquinolones in children. Curr Opin Pediatr. 2006;18:64-70. 
Drug-resistant tuberculosis in children James Seddon Page 1325 
336. European Medicines Agency. Fluoroquinolones - Risk of QT interval prolongation. 
Pharmacovigilance Working Party (PhVWP) Montly Report - December 2010 plenary meeting. 
fMA/CHMP/PhVWP/810358/2010. Available at: 
http://www.ema.europa.eu/docs/en GB/document Iibrarv/Report12011/01/WC500100459 
.:.P!!f accessed on 20-9-11. 
337. Ridzon R, Meador J, Maxwell R, Higgins K, Weismuller P, Onorato 1M. Asymptomatic hepatitis in 
persons who received alternative preventive therapy with pyrazinamide and ofloxacin. Clin 
Infect Dis. 1997;24:1264-1265. 
338. Gupta OK. Acceptability of thioamides.1. Ethionamide. J Postgrad Med. 1977;23:175-180. 
339. Gupta OK. Acceptability of thioamides. II. Prothionamide. J Postgrad Med. 1977;23:181-185. 
340. lees AW. Toxicity in Newly Diagnosed Cases of Pulmonary Tuberculosis Treated with 
Ethionamide. Am Rev Respir Dis. 1963;88:347-354. 
341. Becks GP, Eggo MC, Burrow GN. Organic iodine inhibits deoxyribonucleic acid synthesis and 
growth in FRTL-5 thyroid cells. Endocrinology. 1988;123:545-55l. 
342. McDonnell ME, Braverman LE, Bernardo J. Hypothyroidism due to ethionamide. N Engl J Med. 
2005;352:2757-2759. 
343. Moulding T, Fraser R. Hypothyroidism related to ethionamide. Am Rev Respir Dis. 1970;101:90-
94. 
344. Marmorstein Bl, Scheinhorn OJ. Effect of ethionamide on thyroid function. Curr Ther Res Clin 
Exp. 1976;19:483-486. 
345. Drucker D, Eggo MC, Salit IE, Burrow GN. Ethionamide-induced goitrous hypothyroidism. Annals 
of internal medicine. 1984;100:837-839. 
346. Hallbauer UM, Schaaf HS. Ethionamide-induced hypothyroidism in children. South Afr J 
Epidemiollnfect. 2011;26:161-163. 
347. Swash M, Roberts AH, Murnaghan OJ. Reversible pellagra-like encephalopathy with 
ethionamide and cycloserine. Tubercle. 1972;53:132-136. 
348. Gupta OK, Mital OP, Agarwala MC. Hepatic injury due to ethionamide (1314-TH) and 
prothionamide (1321-TH). J Assoc Physicians India. 1975;23:147-151. 
349. Somner AR, Brace AA. Changes in serum transaminase due to prothionamide. Tubercle. 
1967;48:137-143. 
350. EI-Khoury SA, Dunmore LA, Jr. Ethionamide and Hepatotoxicity: A Clinical Study. Med Ann Dist 
Columbia. 1964;33:15-17. 
351. Lees AW. Jaundice Due to Ethionamide. Br J Dis Chest. 1963;57:158-161. 
352. Phillips S, Tashman H. Ethionamide jaundice. Am Rev Respir Dis. 1963;87:896-898. 
353. Conn HO, Binder HJ, Orr HO. Ethionamide-Induced Hepatitis. A Review with a Report of an 
Additional Case. Am Rev Respir Dis. 1964;90:542-552. 
354. Phillips S, Trevathan RD. Serum glutamic oxaloacetic transaminase elevation and possible 
hepatotoxicity accompanying the administration of ethionamide. Am Rev Respir Dis. 
1962;86:268-269. 
355. Cameron SJ, Crompton GK. Severe hypoglycaemia in the course of treatment with 
streptomycin, isoniazid and ethionamide. Tubercle. 1967;48:307-310. 
356. A comparison of the toxicity of prothionamide and ethionamide: a report from the research 
committee of the British Tuberculosis Association. Tubercle. 1968;49:125-135. 
357. Yew WW, Wong CF, Wong PC, lee J, Chau CH. Adverse neurological reactions in patients with 
multidrug-resistant pulmonary tuberculosis after coadministration of cycloserine and ofloxacin. 
Clin Infect Dis. 1993;17:288-289. 
358. Walker WC, Murdoch JM. Cycloserine in the treatment of pulmonary tuberculosis; a report on 
toxicity. Tubercle. 1957;38:297-302. 
359. Ritchie JA, Campbell AE, Cuthbert J, Bruce LG. Treatment of drug-resistant cases of pulmonary 
tuberculosis with cycloserine and pyrazinamide. Tubercle. 1958;39:289-295. 
360. Akula SK, Aruna AS, Johnson JE, Anderson OS. Cycloserine-induced Stevens-Johnson syndrome 
in an AIDS patient with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 1997;1:187-190. 
361. Kwon HM, Kim HK, Cho J, Hong YH, Nam H. Cycloserine-induced encephalopathy: evidence on 
brain MRI. fur J Neurol. 2008;15:e60-61. 
362. Weyer K. Annexure 2. DOTS-Plus for multidrug resistant tuberculosis patients in South Africa. 
Systematic evaluation of a standardised treatment regimen applied under tuberculosis control 
program me conditions. http://www.sahealthinfo. orq!tblannexuresl-4.pdf (accessed 
30/10/10). 2004. 
Drug-resistant tuberculosis in children James Seddon P age 1326 
363. Soumakis SA, Berg 0, Harris HW. Hypothyroidism in a patient receiving treatment for 
multidrug-resistant tuberculosis. Clin Infect Dis. 1998;27:910-911. 
364. Mizutani H, Horiba M, Shindoh J, Kimura T, Son M, Wakahara K. [Two cases of multi-drug-
resistant pulmonary tuberculosis with para-aminosalicylic acid (PAS)-induced hypothyroidism). 
Kekkaku. 2001;76:667-672. 
365. Joules FE, Nassau E. Para-aminosalicylic acid; a clinical trial in 10 patients with pulmonary 
tuberculosis. Tubercle. 1949;30:98-102. 
366. Co-operative controlled trial of a standard regimen of streptomycin, PAS and isoniazid and 
three alternative regimens of chemotherapy in Britain. A report from the British Medical 
Research Council. Tubercle. 1973;54:99-129. 
367. Bower G. Skin Rash, Hepatitis, and Hemolytic Anemia Caused by Para-Aminosalicylic Acid. Am 
Rev Respir Dis. 1964;89:440-443. 
368. Eisner EV, Kasper K. Immune thrombocytopenia due to a metabolite of para-aminosalicylic acid. 
Am J Med. 1972;53:790-796. 
369. Feigin RD, Zarkowsky HF, Shearer W, Anderson DC. Thrombocytopenia following administration 
of para-aminosalicylic acid. J Pediatr. 1973;83:502-503. 
370. Wurzel HA, Mayock RL. Thrombocytopenia induced by sodium para-aminosalicylic acid: report 
of a case. JAm Med Assoc. 1953;153:1094-1095. 
371. Dandona P, Greenbury E, Beckett AG. Para-aminosalicylic acid-induced hypoglycaemia in a 
patient with diabetic nephropathy. Postgraduate medical journal. 1980;56:135-136. 
372. Longstreth GF, Newcomer AD, Westbrook PRo Para-aminosalicylic acid-induced malabsorption. 
Am J Dig Dis. 1972;17:731-734. 
373. Akhtar AJ, Crompton GK, Schonell ME. Para-aminosalicylic acid as a cause of intestinal 
malabsorption. Tubercle. 1968;49:328-331. 
374. Nagaratnam N, Bhuvanendran N, Jiffry AJ, Ramachandra V. Lymphoma-like syndrome following 
para-aminosalicylic acid. Postgraduate medical journal. 1982;58:729-730. 
375. McEvoy GK. AHFS drug information. American Society of Health-System Pharmacists, Inc. 
Bethesda, MD. 1996:399-401. 
376. Kucers A, Bennett NM. The use of antibiotics, 4th ed. Philadelphia: Lippincott Williams & 
Wilkins; 1987. 
377. Peloquin CA. Para-aminosalicylic acid. In: Yu VL, Edwards G, McKinnon PS, Peloquin CA, Morse 
GO, eds. Antimicrobial Chemotherapy and Vaccines, 2nd edition, Volume II: Antimicrobial 
Agents: Esun Technologies, LLC; 2005:551-558. 
378. Wilson JW, Kelkar P, Frigas E. Para-aminosalicylic acid (PAS) desensitization review in a case of 
multidrug-resistant pulmonary tuberculosis. Int J Tuberc Lung Dis. 2003;7:493-497. 
379. Kroger A, Pannikar V, Htoon MT, et al. International open trial of uniform multi-drug therapy 
regimen for 6 months for all types of leprosy patients: rationale, design and preliminary results. 
Trop Med Int Health. 2008;13:594-602. 
380. Tan TQ. Update on the use of linezolid: a pediatric perspective. Pediatr Infect Dis J. 
2004;23:955-956. 
381. Kaplan SL. Use of linezolid in children. Pediatr Infect Dis J. 2002;21:870-872. 
382. Saiman L, Goldfarb J, Kaplan SA, et al. Safety and tolerability of linezolid in children. Pediatr 
Infect Dis J. 2003;22:S193-200. 
383. Condos R, Hadgiangelis N, Leibert E, Jacquette G, Harkin T, Rom WN. Case series report of a 
linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest. 2008;134:187-
192. 
384. Anger HA, Dworkin F, Sharma S, Munsiff SS, Nilsen OM, Ahuja SO. Linezolid use for treatment of 
multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06. J 
Antimicrob Chemother. 2010;65:775-783. 
385. von der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug resistant 
tuberculosis (MDR-TB)--a report of ten cases. J Infect. 2006;52:92-96. 
386. Fortun J, Martin-Davila P, Navas E, et al. Linezolid for the treatment of multidrug-resistant 
tuberculosis. J Antimicrob Chemother. 2005;56:180-185. 
387. Schecter GF, Scott C, True L, Raftery A, Flood J, Mase S. Linezolid in the treatment of multidrug-
resistant tuberculosis. Clin Infect Dis. 2010;50:49-55. 
388. Udwadia ZF, Sen T, Moharil G. Assessment of linezolid efficacy and safety in MDR- and XDR-TB: 
an Indian perspective. fur Respir J. 2010;35:936-938; author reply 938-940. 
389. Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, 
tolerability and efficacy in multidrug-resistant tuberculosis. fur Respir J. 2009;34:387-393. 
Drug-resistant tuberculosis in children James Seddon P age 1327 
390. Nunn P, Kibuga D, Gathua S, et al. Cutaneous hypersensitivity reactions due to thiacetazone in 
HIV-1 seropositive patients treated for tuberculosis. Lancet. 1991;337:627-630. 
391. Okwera A, Whalen C, Byekwaso F, et al. Randomised trial of thiacetazone and rifampicin-
containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. The Makerere 
University-Case Western University Research Collaboration. Lancet. 1994;344:1323-1328. 
392. Chintu C, Luo C, Bhat G, Raviglione M, DuPont H, Zumla A. Cutaneous hypersensitivity reactions 
due to thiacetazone in the treatment of tuberculosis in Zambian children infected with HIV-1. 
Arch Dis Child. 1993;68:665-668. 
393. Miller AB. Thiacetazone toxicity: a general review. Tubercle. 1968;49:Suppl:54-56. 
394. Pozniak A. Multidrug-resistant tuberculosis and HIV infection. Ann N Y Acad ScI. 2001;953:192-
198. 
395. Andrews JR, Shah NS, Gandhi N, Moll T, Friedland G. Multidrug-resistant and extensively drug-
resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in 
South Africa. J Infect Dis. 2007;196 SuppI3:S482-490. 
396. Di Perri G, Aguilar Marucco D, Mondo A, et al. Drug-drug interactions and tolerance in 
combining antituberculosis and antiretroviral therapy. Expert Opin Drug Sa/. 2005;4:821-836. 
397. Mclileron H, Khoo SH. Interactions between antituberculosis and antiretroviral agents. Progress 
in Respiratory Research (in press). 2011;40. 
398. Seung KJ, Omatayo DB, Keshavjee S, Furin JJ, Farmer PE, Satti H. Early outcomes of MDR-TB 
treatment in a high HIV-prevalence setting in Southern Africa. PLoS One. 2009;4:e7186. 
399. Huerga H, Arnold A, Chikwanha I, et al. MDR-TB treatment in Kenya: cohort description from 
the first program. 41st Union World Conference on Lung Health, 11-15 Nov 2010, Berlin. 
Abstract PC-l00347-14. 
400. The Sentinel Project on Pediatric Drug-Resistant Tuberculosis . . Available at: www.sentinel-
project.org. (accessed 22.3.12) 
401. Mandalakas AM, Kirchner HL, Lombard C, et al. Well-quantified tuberculosis exposure is a 
reliable surrogate measure of tuberculosis infection. Int J Tuberc Lung Dis. 2012;16:1033-1039. 
402. Davies PD. The natural history of tuberculosis in children. A study of child contacts in the 
Brompton Hospital Child Contact Clinic from 1930 to 1952. Tubercle. 1961;42(Suppl):1-40. 
403. Gedde-Dahl T. Tuberculous infection in the light of tuberculin matriculation. Am J Hyg. 
1952;56:139-214. 
404. Van Wyk SS, Mandalakas AM, Enarson DA, Gie RP, Beyers N, Hesseling AC. Tuberculosis contact 
investigation in a high-burden setting: house or household? Int J Tuberc Lung Dis. 2012;16:157-
162. 
405. Graham SM, Ahmed T, Amanullah F, et al. Evaluation of tuberculosis diagnostics in children: 1. 
Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. 
Consensus from an expert panel. J Infect Dis. 2012;205 Suppl 2:5199-208. 
406. Clinical and Laboratory Standards Institute (CLSI). Susceptibility Testing of Mycobocteria, 
Nocardiae, and Other Aerobic Actinomycetes; Approved Standard - Second Edition: CLSI 
document M24-A2 (ISBN 1-56238-746-4). Clinical and Laboratory Standards Insitutue, 940 West 
Valley Road, Suite 1400, Wayne, Pennsylvania 19087 USA, 2011. 
407. World Health Organization, Geneva, Switzerland. Automated real-time nucleic acid 
amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin 
resistance: Xpert MTB/RIF system. Policy statement. 2011. Available at: 
http:Uwhqlibdoc.who.int!publications!2011!9789241501545 eng.pdf (accessed August 2012). 
408. Mukinda FK, Theron D, van der Spuy GD, et al. Rise in rifampicin-monoresistant tuberculosis In 
Western Cape, South Africa. Int J Tuberc Lung Dis. 2012;16:196-202. 
409. World Health Organization, Geneva, Switzerland. Provisional guidelines for the diagnosis and 
classification of the EPI target diseases for primary health care, surveillance and special studies. 
EPI/GEN/83/4.1986. 
410. Marais S, Thwaites G, Schoeman JF, et al. Tuberculous meningitis: a uniform case definition for 
use in clinical research. Lancet Infect Dis. 2010;10:803-812. 
411. Wiseman CA, Gie RP, Starke JR, et al. A Proposed Comprehensive Classification of Tuberculosis 
Disease Severity in Children. Pediatr Infect Dis J. 2012. 
412. World Health Organization, Geneva, Switzerland. International Statistical Classification of 
Diseases and Related Health Problems. 10th Revision. Available at: 
http:Uapps.who.int!classifications!icdl0/browse!2010!en (accessed 15 March 2012). 2010. 
413. Marais BJ, Gie RP, Schaaf HS, et al. A proposed radiological classification of childhood intra-
thoracic tuberculosis. Pediatr Radiol. 2004;34:886-894. 
Drug-resistant tuberculosis in children James Seddon Page 1328 
414. Bloss E, Kuksa L, Holtz TH, et al. Adverse events related to multidrug-resistant tuberculosis 
treatment, Latvia, 2000-2004. Int 1 Tuberc Lung Dis. 2010;14:275-281. 
415. Division of Microbiology and Infectious Diseases. Pediatric Toxicity Tables. November 2007 
DRAFT. 
http://www.niaid.nih.gov/LabsAndResources/resources/OMIOClinRsrch/Oocuments/dmidpedt 
ox. pdf. Accessed February 6,2012. 
416. Marra F, Marra CA, Moadebi S, et al. Levofloxacin treatment of active tuberculosis and the risk 
of adverse events. Chest. 2005;128:1406-1413. 
417. Laserson KF, Thorpe LE, Leimane V, et al. Speaking the same language: treatment outcome 
definitions for multidrug-resistant tuberculosis. Int 1 Tuberc Lung Dis. 2005;9:640-645. 
418. Starke JR. Pediatric tuberculosis: time for a new approach. Tuberculosis (Edinb). 2003;83:208-
212. 
419. Chisti MJ, Tebruegge M, La Vincente S, Graham SM, Duke T. Pneumonia in severely 
malnourished children in developing countries - mortality risk, aetiology and validity of WHO 
clinical signs: a systematic review. Trop Med Int Health. 2009;14:1173-1189. 
420. Cegielski JP, McMurray ON. The relationship between malnutrition and tuberculosis: evidence 
from studies in humans and experimental animals. Int 1 Tuberc Lung Dis. 2004;8:286-298. 
421. Hesseling AC, Westra AE, Werschkull H, et al. Outcome of HIV infected children with culture 
confirmed tuberculosis. Arch Dis Child. 2005;90:1171-1174. 
422. Soeters M, de Vries AM, Kimpen JL, Donald PR, Schaaf HS. Clinical features and outcome in 
children admitted to a TB hospital in the Western Cape-the influence of HIV infection and drug 
resistance. S Afr Med 1. 2005;95:602-606. 
423. Walters E, Cotton MF, Rabie H, Schaaf HS, Walters LO, Marais BJ. Clinical presentation and 
outcome of tuberculosis in human immunodeficiency virus infected children on antl-retroviral 
therapy. BMC Pediatr. 2008;8:1. 
424. Orikiiriza J, Bakeera-Kitaka S, Musiime V, Mworozi EA, Mugyenyi P, Boulware DR. The clinical 
pattern, prevalence, and factors associated with immune reconstitution inflammatory 
syndrome in Ugandan children. AIDS. 2010;24:2009-2017. 
425. American Speech-Language-Hearing Association. Guidelines for Audiologic Screening 
(Guideline). 1997;Available at http://www.asha.org/docs/pdf/GL1997-00199.pdf (accessed 
August 2012). 
426. American Speech-language-Hearing Association. Audiologic Screening (Technical Report). 
1994;Available at http://www.asha.org/docs/pdf/TR1994-00238.pdf (accessed August 2012). 
427. van Rie A, Warren R, Richardson M, et al. Exogenous reinfection as a cause of recurrent 
tuberculosis after curative treatment. N EnglJ Med. 1999;341:1174-1179. 
428. Schaaf HS, Gie RP, Beyers N, Sirgel FA, de Klerk PJ, Donald PRo Primary drug-resistant 
tuberculosis in children. Int 1 Tuberc Lung Dis. 2000;4:1149-1155. 
429. Kassa-Kelembho E, Bobossi-Serengbe G, Takeng EC, Nambea-Koisse TB, Yapou F, Talarmin A. 
Surveillance of drug-resistant childhood tuberculosis in Bangui, Central African Republic. Int 1 
Tuberc Lung Dis. 2004;8:574-578. 
430. Warren RM, Gey van Pittius NC, Barnard M, et al. Differentiation of Mycobacterium 
tuberculosis complex by PCR amplification of genomic regions of difference. Int 1 Tuberc Lung 
Dis. 2006;10:818-822. 
431. NCCLS. Susceptibility testing oj mycobacteria, nocardiae and other aerobic actinomycetes: 
approved standard: NCCLS document M24-A. 2003. NCCLS, 940 West Valley Road, Wayne, 
Pennysylvania, USA. 
432. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. Rapid molecular screening for 
multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am 1 
Respir Crit Care Med. 2008;177:787-792. 
433. AI-Dabbagh M, Lapphra K, McGloin R, et al. Drug-resistant Tuberculosis: Pediatric Guidelines. 
Pediatr Inject Dis 1. 2011. 
434. Louw GE, Warren RM, Donald PR, et al. Frequency and implications of pyrazinamide resistance 
in managing previously treated tuberculosis patients. Int 1 Tuberc Lung Dis. 2006;10:802-807. 
435. Johnson R, Jordaan AM, Pretorius L, et al. Ethambutol resistance testing by mutation detection. 
Int 1 Tuberc Lung Dis. 2006;10:68-73. 
436. Vilcheze C, Weisbrod TR, Chen B, et al. Altered NADH/NAD+ ratio mediates coresistance to 
isoniazid and ethionamide in mycobacteria. Antimicrob Agents Chemother. 2005;49:708-720. 
Drug-resistant tuberculosis in children James Seddon Page 1329 
437. Hesseling AC, Schaaf HS, Victor T, et al. Resistant Mycobacterium bovis Bacillus Calmette-
Guerin disease: implications for management of Bacillus Cal mette-Guerin Disease in human 
immunodeficiency virus-infected children. Pediatr Infect Dis J. 2004;23:476-479. 
438. Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smear-negative pulmonary 
tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing 
urgent policy changes. Lancet. 2007;369:2042-2049. 
439. Suarez-Garcia I, Rodriguez-Blanco A, Vidal-Perez JL, et al. Risk factors for multidrug-resistant 
tuberculosis in a tuberculosis unit in Madrid, Spain. European Journal of Clinical Microbiology 
and Infectious Diseases. 2009;28:325-330. 
440. Marais BJ, Hesseling AC, Schaaf HS, Gie RP, van Heiden PD, Warren RM. Mycobacterium 
tuberculosis transmission is not related to household genotype in a setting of high endemicity. 
Journal of clinical microbiology. 2009;47:1338-1343. 
441. Health Systems Trust. Incidence ofTB (all types) per 100000. 2009. [cited 2011 Feb 24] 
http://www.hst.org.za/healthstats/16/data. 
442. Driver CR, Cordova 1M, Munsiff SS. Targeting tuberculosis testing: the yield of source case 
investigations for young children with reactive tuberculin skin tests. Public Health Rep. 
2002;117:366-372. 
443. Kamerbeek J, Schouls L, Kolk A, et al. Simultaneous detection and strain differentiation of 
Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol. 1997;35:907-914. 
444. van Embden JD, Cave MD, Crawford JT, et al. Strain identification of Mycobacterium 
tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin 
Microbiol. 1993;31:406-409. 
445. Streicher EM, Victor TC, van der Spuy G, et al. Spoligotype signatures in the Mycobacterium 
tuberculosis complex. J Clin Microbiol. 2007;45:237-240. 
446. Streicher EM, Muller B, Chihota V, et al. Emergence and treatment of multidrug resistant (MDR) 
and extensively drug-resistant (XDR) tuberculosis in South Africa. Infect Genet Evol. 2011. 
447. Furin JJ, Becerra MC, Shin SS, Kim JV, Bayona J, Farmer PE. Effect of administering short-course, 
standardized regimens in individuals infected with drug-resistant Mycobacterium tuberculosis 
strains. Eur J Clin Microbiollnfect Dis. 2000;19:132-136. 
448. Warren RM, Streicher EM, Gey van Pittius NC, et al. The clinical relevance of Mycobacterial 
pharmacogenetics. Tuberculosis (Edinb). 2009;89:199-202. 
449. World Health Organization, Geneva, Switzerland. Molecular Line Probe Assays for the rapid 
screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Policy Statement. 
2008:Available at: http://www.who.int/tb/features archive/policy statement.pdf (accessed 
August 2012). 
450. Fair M, Cyr M, Allen AC, Wen SW, Guyon G, MacDonald RC. An assessment of the validity of a 
computer system for probabilistic record linkage of birth and infant death records in Canada. 
The Fetal and Infant Health Study Group. Chronic Dis Can. 2000;21:8-13. 
451. Meray N, Reitsma JB, Ravelli AC, Bonsel GJ. Probabilistic record linkage is a valid and 
transparent tool to combine databases without a patient identification number. J Clin 
Epidemiol. 2007;60:883-891. 
452. Claessens NJ, Gausi FF, Meijnen S, Weismuller MM, Salaniponi FM, Harries AD. Screening 
childhood contacts of patients with smear-positive pulmonary tuberculosis In Malawi. Int J 
Tuberc Lung Dis. 2002;6:362-364. 
453. van Wyk SS, Reid AJ, Mandalakas AM, et al. Operational challenges in managing Isoniazid 
Preventive Therapy in child contacts: a high-burden setting perspective. BMC Public Health. 
2011;11:544. 
454. Storla DG, Vimer S, Bjune GA. A systematic review of delay in the diagnosis and treatment of 
tuberculosis. BMC Public Health. 2008;8:15. 
455. Sreeramareddy CT, Panduru KV, Menten J, Van den Ende J. Time delays in diagnosiS of 
pulmonary tuberculosis: a systematic review of literature. BMC infectious diseases. 2009;9:91. 
456. Finnie RK, Khoza LB, van den Borne B, Mabunda T, Abotchie P, Mullen PD. Factors associated 
with patient and health care system delay in diagnosis and treatment for TB in sub-Saharan 
African countries with high burdens of TB and HIV. Trop Med Int Health. 2011;16:394-411. 
457. Nyirenda M, Sinfield R, Haves S, Molyneux EM, Graham SM. Poor attendance at a child TB 
contact clinic in Malawi. Int J Tuberc Lung Dis. 2006;10:585-587. 
458. Zachariah R, Spielmann MP, Harries AD, et al. Passive versus active tuberculosis case finding 
and isoniazid preventive therapy among household contacts in a rural district of Malawi. Int J 
Tuberc Lung Dis. 2003;7:1033-1039. 
Drug-resistant tuberculosis in children James Seddon Page 1330 
459. Banu Rekha W, Jagarajamma K, Wares F, Chandrasekaran V, Swaminathan S. Contact screening 
and chemoprophylaxis in India's Revised Tuberculosis Control Programme: a situational 
analysis.lnt J Tuberc Lung Dis. 2009;13:1507-1512. 
460. Andrews R, Morgan JO, Addy DP, McNeish AS. Understanding non-attendance in outpatient 
paediatric clinics. Arch Dis Child. 1990;65:192-195. 
461. McClure RJ, Newell SJ, Edwards S. Patient characteristics affecting attendance at general 
outpatient clinics. Arch Dis Child. 1996;74:121-125. 
462. Kitzinger J. Qualitative research. Introducing focus groups. BMJ. 1995;311:299-302. 
463. Patton MQ. Qualitative research and evaluation methods. Third edition. Sage Publications, Inc., 
Thousand Oaks, California, USA. 2001. 
464. Jones RG, Trivedi AN, Ayanian JZ. Factors influencing the effectiveness of interventions to 
reduce racial and ethnic disparities in health care. Soc Sci Med. 2010;70:337-341. 
465. South African Advertising Research Foundation. Universal Living Standards Measure. Available 
at: http://www.saarf.co.za/LSM/lsms.asp (accessed 7th May 2012). 2004. 
466. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death 
in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 
2006;368:1575-1580. 
467. Ethionamide. Tuberculosis (Edinb). 2008;88:106-108. 
468. Donald PR, Schoeman JF, Van Zyl LE, De Villiers IN, Pretorius M, Springer P. Intensive short 
course chemotherapy in the management of tuberculous meningitis. Int J Tuberc Lung Dis. 
1998;2:704-711. 
469. Oyugi JH, Byakika-Tusiime J, Charlebois ED, et al. Multiple validated measures of adherence 
indicate high levels of adherence to generiC HIV antiretroviral therapy in a resource-limited 
setting. J Acquir Immune Deftc Syndr. 2004;36:1100-1102. 
470. Vreeman Re, Wiehe SE, Pearce Ee, Nyandiko WM. A systematic review of pediatric adherence 
to antiretroviral therapy in low- and middle-income countries. Pediatr Infect Dis J. 2008;27:686-
691. 
471. Simoni JM, Montgomery A, Martin E, New M, Demas PA, Rana S. Adherence to antiretroviral 
therapy for pediatric HIV infection: a qualitative systematic review with recommendations for 
research and clinical management. Pediatrics. 2007;119:e1371-1383. 
472. Giordano TP, Guzman D, Clark R, Charlebois ED, Bangsberg DR. Measuring adherence to 
antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials. 
2004;5:74-79. 
473. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment 
outcomes: a meta-analysis. Med Care. 2002;40:794-811. 
474. Thomas TA, Shenoi SV, Heysell SK, et al. Extensively drug-resistant tuberculosis in children with 
human immunodeficiency virus in rural South Africa. Int J Tuberc Lung Dis. 2010;14:1244-1251. 
475. Mukherjee JS, Joseph JK, Rich ML, et al. Clinical and programmatic considerations In the 
treatment of MDR-TB in children: a series of 16 patients from Lima, Peru. Int J Tuberc Lung Dis. 
2003;7:637-644. 
476. Beyers N, Gie RP, Schaaf HS, et al. Delay in the diagnosis, notification and initiation of 
treatment and compliance in children with tuberculosis. Tuber Lung Dis. 1994;75:260-265. 
417. Marais BJ, Gie RP, Hesseling AC, et al. A refined symptom-based approach to diagnose 
pulmonary tuberculosis in children. Pediatrics. 2006;118:e1350-1359. 
478. Schaaf HS, Marais BJ, Whitelaw A, et al. Culture-confirmed childhood tuberculosis in Cape 
Town, South Africa: a review of 596 cases. BMC infectious diseases. 2007;7:140. 
479. Schaaf HS, Krook S, Hollemans DW, Warren RM, Donald PR, Hesseling AC. Recurrent culture-
confirmed tuberculosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 
200S;24:685-691. 
480. Chiang CY, Schaaf HS. Management of drug-resistant tuberculosis. Int J Tuberc Lung Dis. 
2010;14:672-682. 
481. Grant A, Gothard P, Thwaites G. Managing drug resistant tuberculosis. 8MJ. 2008;337:a1110. 
482. Schaaf HS, Donald PRo The epidemiology and management of drug-resistant tuberculosis in 
childhood. In: Spiegelburg DO, ed. New topics in tuberculosis research. New York: Nova Science 
Publishers, Inc.; 200771-102. 
483. World Health Organization, Geneva, Switzerland. WHO case definitions of HIV for surveillance 
and revised clinical staging and immunological classification of HIV-related disease in adults and 
children. 2007; (ISBN: 97892 4 159562 9). 
Drug-resistant tuberculosis in children James Seddon Page 1331 
484. Hesseling AC, Walzl G, Enarson DA, et al. Baseline sputum time to detection predicts month two 
culture conversion and relapse in non-HIV-infected patients. Int J Tuberc Lung Dis. 2010;14:560-
570. 
485. Schaaf HS, Beyers N, Gie RP, et al. Respiratory tuberculosis in childhood: the diagnostic value of 
clinical features and special investigations. Pediatr Infect Dis J. 1995;14:189-194. 
486. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Enarson DA, Beyers N. The spectrum of disease in 
children treated for tuberculosis in a highly endemic area. Int J Tuberc Lung Dis. 2006;10:732-
738. 
487. Donald PR, Schoeman JF. Tuberculous meningitis. N Engl J Med. 2004;351:1719-1720. 
488. Donald PR, Schaaf HS, Schoeman JF. Tuberculous meningitis and miliary tuberculosis: the Rich 
focus revisited. J Infect. 2005;50:193-195. 
489. Rich AR, McCordock HA. The pathogenesis of tuberculous meningitis. Bull Johns Hopkins 
Hospital. 1933;52:5-37. 
490. van Well GT, Paes BF, Terwee CB, et al. Twenty years of pediatric tuberculous meningitis: a 
retrospective cohort study in the western cape of South Africa. Pediatrics. 2009;123:e1-8. 
491. Lincoln EM. Tuberculous meningitis in children; with special reference to serous meningitis; 
tuberculous meningitis. Am Rev Tuberc. 1947;56:75-94. 
492. Donald PR, Cotton MF, Hendricks MK, Schaaf HS, de Villiers IN, Willemse TE. Pediatric 
meningitis in the Western Cape Province of South Africa. J Trap Pediatr. 1996;42:256-261. 
493. Patel VB, Padayatchi N, Bhigjee AI, et al. Multidrug-resistant tuberculous meningitis in KwaZulu-
Natal, South Africa. Clin Infect Dis. 2004;38:851-856. 
494. Thwaites GE, Lan NT, Dung NH, et al. Effect of antituberculosis drug resistance on response to 
treatment and outcome in adults with tuberculous meningitis. J Infect Dis. 2005;192:79-88. 
495. Daikos GL, Cleary T, Rodriguez A, Fischl MA. Multidrug-resistant tuberculous meningitis In 
patients with AIDS. Int J Tuberc Lung Dis. 2003;7:394-398. 
496. Sofia M, Maniscalco M, Honore N, et al. Familial outbreak of disseminated multidrug-resistant 
tuberculosis and meningitis. Int J Tuberc Lung Dis. 2001;5:551-558. 
497. Thwaites GE, Chau TT, Caws M, et al. Isoniazid resistance, mycobacterial genotype and 
outcome in Vietnamese adults with tuberculous meningitis. Int J Tuberc Lung Dis. 2002;6:865-
871. 
498. Warren RM, Streicher EM, Sampson SL, et al. Microevolution of the direct repeat region of 
Mycobacterium tuberculosis: implications for interpretation of spoligotyping data. J Clin 
Microbial. 2002;40:4457-4465. 
499. Brudey K, Driscoll JR, Rigouts L, et al. Mycobacterium tuberculosis complex genetic diversity: 
mining the fourth international spoligotyping database (SpoIDB4) for classification, population 
genetics and epidemiology. BMC Microbiol. 2006;6:23. 
500. Thwaites GE, Due Bang N, Huy Dung N, et al. The influence of HIV infection on clinical 
presentation, response to treatment, and outcome in adults with Tuberculous meningitis. J 
Infect Dis. 2005;192:2134-214l. 
501. Thwaites GE, Simmons CP, Than Ha Quyen N, et al. Pathophysiology and prognosis In 
vietnamese adults with tuberculous meningitis. J Infect Dis. 2003;188:1105-1115. 
502. Donald PRo Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. 
Tuberculosis (fdinb). 2010;90:279-292. 
503. Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant 
tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis. 2004;8:1382-1384. 
504. Baquero-Artigao F, Garcia-Miguel MJ, Merino R, Garcia-Consuegra J, del Castillo F. Multidrug-
resistant tuberculosis of the ankle: Case report. Foot & Ankle International. 2006;27:642-644. 
505. Pavlopoulou ID, Theodoridou M, Daikos GL, et al. Drug-resistant tuberculous mastoiditis in 2 
children. Scand J Infect Dis. 2000;32:436-438. 
506. Rodriguez L, Weinberg B, Benaroya A, Gertner M. Multidrug-resistant tuberculous 
osteomyelitis. Pediatr Infect Dis J. 1997;16:1096-1096. 
507. Inselman LS, DelaVega CE, Evans HE. Drug-resistant tuberculosis ofthe hip in a child. New York 
State Journal of Medicine. 1984;84:84-85. 
508. Khan SA, Varshney MK, Hasan AS, Kumar A, Trikha V. Tuberculosis of the sternum. J Bone Joint 
Surg Br. 2007;89:817-820. 
509. Polley P, Dunn R. Noncontiguous spinal tuberculosis: Incidence and management. fur Spine J. 
2009;18:1096-1101. 
510. Sandher DS, AI-Jibury M, Paton RW, Ormerod LP. Bone and joint tuberculosis. J Bone Joint Surg 
Br. 2007;89:1379-1381. 
Drug-resistant tuberculosis in children James Seddon Page 1332 
511. Peto HM, Pratt RH, Harrington TA, LoBue PA, Armstrong LR. Epidemiology of extrapulmonary 
tuberculosis in the United States, 1993-2006. Clin Infect Dis. 2009;49:1350-1357. 
512. Lindquist SW, Steinmetz BA, Starke JR. Multidrug-resistant tuberculosis of the first cervical 
vertebra in an immunocompetent adolescent. Pediatr Infect Dis J. 1997;16:333-336. 
513. Hussey G, Kibei M, Parker N. Ciprofloxacin treatment of multiply drug-resistant extrapulmonary 
tuberculosis in a child. Pediatr Infect Dis J. 1992;11:408-409. 
514. Agashe V, Shenai 5, Mohrir G, et al. Osteoarticular tuberculosis--diagnostic solutions in a 
disease endemic region. J Infect Dev Ctries. 2009;3:511-516. 
515. Bailey HL, Gabriel M, Hodgson AR, Shin JS. Tuberculosis of the spine in children. Operative 
findings and results in one hundred consecutive patients treated by removal of the lesion and 
anterior grafting. J Bone Joint Surg Am. 1972;54:1633-1657. 
516. Luk KD. Tuberculosis of the spine in the new millennium. fur Spine J. 1999;8:338-345. 
517. Hodgson AR, Skinsnes OK, Leong CY. The pathogenesis of Pott's paraplegia. J Bone Joint Surg 
Am. 1967;49:1147-1156. 
518. Leong Jc. Tuberculosis of the spine. J Bone Joint Surg Br. 1993;75:173-175. 
519. Hsu LC, Cheng CL, Leong JC. Pott's paraplegia of late onset. The cause of compression and 
results after anterior decompression. J Bone Joint Surg Br. 1988;70:534-538. 
520. Hazra A, Laha B. Chemotherapy of osteoarticular tuberculosis. Indian J Pharmacal. 2005;37:5-
12. 
521. Ramachandran 5, Clifton IJ, Collyns TA, Watson JP, Pearson SB. The treatment of spinal 
tuberculosis: a retrospective study. Int J Tuberc Lung Dis. 2005;9:541-544. 
522. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 
1998. Joint Tuberculosis Committee of the British Thoracic Society. Thorax. 1998;53:536-548. 
523. ATS, CDC, IDSA. Treatmet of Tuberculosis. MMRW June 20,2003/ Vol. 52/ No. RR-l1. 2003;52. 
524. American Academy of Pediatrics. Tuberculosis. In Pickering, LK ed. Red Book: 2006 Report of the 
Committee on Infectious Dieseases 2006;26th Ed:678-698. 
525. Ge Z, Wang Z, Wei M. Measurement of the concentration of three antituberculosis drugs in the 
focus of spinal tuberculosis. fur Spine J. 2008;17:1482-1487. 
526. Meissner A, Borner K, Koeppe P. Concentrations of ofloxacin in human bone and in cartilage. J 
Antimicrob Chemother. 1990;26 Suppl 0:69-74. 
527. Tuli SM, Kumar K, Sen PC. Penetration of antitubercular drugs in clinical osteoarticular 
tubercular lesions. Acta Orthop Scand. 1977;48:362-368. 
528. Liu P, Zhu Q, Jiang J. Distribution of Three Anti-tuberculous Drugs and Their Metabolites In 
Different Parts of Pathological Vertebrae with Spinal Tuberculosis. Spine (Phila Pa 1976). 
2011;36:E1290-1295. 
529. Nicol MP, Workman L, Isaacs W, et al. Accuracy of the Xpert MTB/RIF test for the diagnosis of 
pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a 
descriptive study. Lancet Infect Dis. 2011;11:819-824. 
530. Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents 
Chemother. 1999;43:1003-1012. 
531. Moeller MP. Current state of knowledge: psychosocial development in children with hearing 
impairment. far Hear. 2007;28:729-739. 
532. Moeller MP, Tomblin JB, Yoshinaga-Itano C, Connor CM, Jerger S. Current state of knowledge: 
language and literacy of children with hearing impairment. far Hear. 2007;28:740-753. 
533. American Speech-language-Hearing Association. Guidelines for the Audiologic Assessment of 
Children From Birth to 5 Years of Age. Available at: http://www.asha.org/docs/pdf!GL2004-
00002.pdf (accessed August 2012). 2004. 
534. Prayle A, Watson A, Fortnum H, Smyth A. Side effects of aminoglycosides on the kidney, ear 
and balance in cystic fibrosis. Thorax. 2010;65:654-658. 
535. Seddon JA, Hesseling AC, Marais BJ, Jordaan A, Victor T, Schaaf HS. The evolving epidemic of 
drug-resistant tuberculosis among children in Cape Town, South Africa. Int J Tuberc Lung Dis. 
2012;16:928-933. 
536. Carhart R, Jerger JF. Preferred Methods for Clinical Determination of Pure-Tone Thresholds. J 
Speech Hear Res. 1959;24:330-345. 
537. Goodman A. Reference zero levels for pure tone audiometer. ASHA. 1965;7:262-263. 
538. Katz J, Medwetsky L, Burkard R, Hood U. Handbook of Clinical Audiology. Sixth ed: Lippincott 
Williams & Wilkins; 2009. 
539. de Jager P, van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside 
treatment in patients with tuberculosis.lnt J Tuberc Lung Dis. 2002;6:622-627. 
Drug-resistant tuberculosis in children James Seddon Page 1333 
540. Sturdy A, Goodman A, Jose RJ, et al. Multidrug-resistant tuberculosis (MDR-TB) treatment in 
the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother. 
2011;66:1815-1820. 
541. Bess FH, Dodd-Murphy J, Parker RA. Children with minimal sensorineural hearing loss: 
prevalence, educational performance, and functional status. Ear Hear. 1998;19:339-354. 
542. Eisenberg LS. Current state of knowledge: speech recognition and production in children with 
hearing impairment. Ear Hear. 2007;28:766-772. 
543. Jerger S. Current state of knowledge: perceptual processing by children with hearing 
impairment. Ear Hear. 2007;28:754-765. 
544. Yoshinaga-Itano C, Sedey AL, Coulter OK, Mehl AL. language of early- and later-identjfied 
children with hearing loss. Pediatrics. 1998;102:1161-1171. 
545. Moeller MP. Early intervention and language development in children who are deaf and hard of 
hearing. Pediatrics. 2000;106:E43. 
546. Nelson U, Wells CD. Global epidemiology of childhood tuberculosis. Int J Tuberc Lung Dis. 
2004;8 :636-647. 
547. Walls T, Shingadia D. Global epidemiology of paediatric tuberculosis. J Infect. 2004;48:13-22. 
548. Brent AJ, Anderson ST, Kampmann B. Childhood tuberculosis: out of sight, out of mind? Trans R 
Soc Trop Med Hyg. 2008;102:217-218. 
Drug-resistant tuberculosis in children James Seddon Page 1334 
